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Prostate cancer is the second deadliest cancer in men in Western countries, being 
only surpassed by lung cancer.1 Prostate tumors initially respond to hormonal therapy, 
radiotherapy and/or surgery, therefore, patients in early stages of disease have a five year 
overall survival rate of nearly 100%.2 However, once the tumor becomes castrate-resistant 
and metastasizes, overall survival decreases, and treatment options are limited though 
expanding. Currently, first-line therapy in the Netherlands for patients with metastatic 
castrate-resistant prostate cancer (mCRPC) consists of docetaxel with prednisone.3 Second-
line therapies consist of cabazitaxel (with prednisone), abiraterone acetate (with prednisone) 
and enzalutamide.4-7 Other therapies, such as tasquinimod, are in advanced stages of clinical 
development.8 These improved therapies have contributed to the steady increase in the five 
year overall survival rate of prostate cancer patients from 63% to 86% in the Netherlands 
over the past two decades.9 Nevertheless, the incidence and absolute mortality of prostate 
cancer are rising, attributed to ageing of the population and the introduction of PSA 
screenings.10, 11 Therefore, research aimed at further improving mCRPC treatment in order 
to increase survival and/or quality of life for mCRPC patients, remains of crucial importance.
The mCRPC population is viewed as a homogenous population; all patients receive similar 
treatment. However, patient and/or disease characteristics, such as race, may influence 
the patient’s response to mCRPC treatment.12 Until such determinants are identified, 
it is important that clinical trials assessing novel prostate cancer treatment recruit 
participants who adequately reflect the population that will receive this therapy in clinical 
practice. Chapter 2 addresses whether enrollment of racial minorities in prostate cancer 
studies reflects the racial distribution in the average prostate cancer population. Under-
representation of racial minorities may question the scientific justification of use of studied 
therapies in minorities.
Despite the introduction of various targeted therapies, taxane chemotherapy remains 
crucial in the palliative treatment of mCRPC. Taxanes consist of docetaxel or cabazitaxel, 
and act on cancer cells by targeting and stabilizing microtubules.13 The incorrect formation 
of microtubules leads to mitotic arrest in cancer cells, as mitotic spindles cannot be formed 
correctly.14 Taxanes have other antitumor functions as well, such as a nuclear accumulation 
of p53, resulting in enhanced p53-induced apoptosis.15 
Cabazitaxel has been used in Dutch clinics for mCRPC patients who progressed during or after 
docetaxel treatment since June 2011. Between June 2010, when the drug received approval 
from the United States (US) Food and Drug Administration (FDA), and May 2011, 51 patients 
were treated with cabazitaxel in the Netherlands via a compassionate use program. Such 
programs enable patients, for whom no good treatment alternative is currently available, to 
receive therapy when it is not yet reimbursed by insurance companies, but expected to be 
in the near future. Patients included in the compassionate use program are being monitored 
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1to assess efficacy and safety of the therapy. These results were collected, analyzed and reported, and it was tested whether certain subgroups of mCRPC patients have a better 
outcome (Chapter 3). 
In addition to cabazitaxel, abiraterone was recently approved as a second-line therapy in 
mCRPC patients after docetaxel treatment. The optimal treatment sequence has not been 
studied. Therefore, treatment decisions are currently based on the preference of physicians 
and/or patients.16 In the CAST-study, the clinical outcome of mCRPC patients treated 
sequentially with cabazitaxel and abiraterone after docetaxel was retrospectively evaluated 
(Chapter 4). 
The success of taxanes spurred the search for other compounds that target cancer cells in 
mitosis. As reviewed in Chapter 5 section A, this resulted amongst others in the development 
of Eg5-inhibitors, polo-like kinase 1 (Plk1-)inhibitors and aurora kinase (AK-)inhibitors. Early 
clinical studies with such inhibitors did not show significant antitumor activity, resulting 
in skeptical views from some researchers. However, improved inhibitors do show clinical 
potential, and are currently being tested in clinical trials involving mCRPC patients (Chapter 
5 section B).
Similar to other cancers, the concept that prostate cancer can be controlled or even cured 
by a single agent is being abandoned. This idea is being replaced by the hypothesis that it 
requires targeting of multiple cancer-related pathways with multiple therapies to control 
prostate cancer disease. Although testing of combination therapies in prostate cancer 
patients has steadily been growing, results of these studies have been disappointing.17, 
18 Most combination therapies were tested based on trial-and-error, and lacked a solid 
rationale. In Chapter 6, Analysis of Functional Annotation (AFA) was used to provide a 
rational combination strategy with histone deacetylase inhibitors (HDACIs) in prostate 
cancer. Histone deacetylases deacetylate lysine residues in N-terminal tails of histones, and 
overexpression of these enzymes results amongst others in decreased expression of tumor-
suppressor genes and increased expression of oncogenes in prostate cancer.19 Two HDACIs 
have been approved for their use in cutaneous T cell lymphomas, vorinostat (SAHA) and 
romidepsin; in solid tumors, HDACIs are not used outside the research setting yet. As HDACIs 
target many important cancer-related pathways, such as the DNA damage pathway,20 this 
group of drugs has high potential for combination therapy. Therefore, HDACIs were used to 
identify potential novel combination therapies in the AFA study.
Based on the AFA results, it was hypothesized that combining HDACIs with agents that target 
mitotic enzymes such as Plk1- and AK-inhibitors may result in enhanced antitumor efficacy. 
Considering the potential of mitotic inhibitors in prostate cancer, combinations of HDACIs 




The development of inhibitors of the mitotic enzyme Eg5 was halted for prostate cancer 
treatment after a phase II trial with the Eg5-inhibitor ispinesib did not have significant 
effects on mCRPC patients.21 Immunohistochemistry of tumor samples from these patients, 
who all had disease progression during or after docetaxel treatment, revealed that 15 out 
of 16 included patients did not have overexpression of Eg5 in the tumor. Therefore, it was 
concluded that Eg5-inhibitors would not be effective in mCRPC patients due to the lack of 
Eg5 overexpression. 
However, a more recent study found that Eg5 is overexpressed in about 50% of all prostate 
cancers.22 These results and the fact that Eg5 is mainly responsible for the separation of 
microtubules,23 led to the rationale that Eg5 expression may be decreased upon docetaxel 
resistance, and may therefore be a marker for docetaxel response. This rationale is explored 
in Chapter 9.
Most prostate cancer-related deaths are contributed to cancer metastases.2 Hence, treating 
metastases may be beneficial for mCRPC patients, reducing both morbidity and mortality of 
the disease. Radium-223 chloride is the first agent that has been shown to extend overall 
survival in cancer patients by exclusively targeting bone metastases.24 It has been approved 
for the treatment of mCRPC patients with bone metastases by the US FDA, and has recently 
been introduced in Dutch clinical practice. In Chapter 10, the results leading to FDA approval 
of radium-223 are discussed, as well as the radionuclide’s limitations.
Due to the clinical relevance of metastases, targeting genes involved in the formation 
and/or growth of prostate tumor metastases may result in significant clinical benefit for 
mCRPC patients. Two genes that play a crucial role in the formation, maintenance and/
or growth of metastases, are N-myc downregulated gene 1 (NDRG1) and cyclin-dependent 
kinase 5 (CDK5). While NDRG1 is a metastasis suppressor gene in amongst others prostate 
cancer (Chapter 11 section A),25 CDK5 is necessary for metastasis formation in prostate 
and pancreatic cancer.26, 27 In the final two chapters of this thesis, the Johns Hopkins Drug 
Library (JHDL) was used to perform a synthetically lethal high-throughput screen, thereby 
identifying small molecules that may target cancer cells based on the expression of NDRG1 
(Chapter 11 section B) or CDK5 (Chapter 12). 
In conclusion, this thesis handles various aspects of research involved in the development 
of novel therapies to treat mCRPC patients. The scope of drug development ranges from 
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Under-representation of racial minorities in 
prostate cancer studies submitted to the FDA to 
support potential marketing approval, 1993-2013 
Michel D. Wissing, Paul Kluetz, Yang-Min Ning, Jonca Bull, Christine Merenda, Anthony J. 
Murgo, Richard Pazdur




Background: United States (US) Food and Drug Administration (FDA) approval of new 
drugs depends on results from clinical trials that must be generalized to the US population. 
However, racial minorities are frequently under-represented in clinical studies. Enrollment 
of racial minorities was compared in key clinical studies submitted to the FDA in the last 10 
years in support of potential marketing approval for prostate cancer (PCa) prevention or 
treatment.
Methods: Patient demographic data were obtained from archival datasets of large registration 
trials submitted to the FDA to support proposed PCa indications. Six countries/regions were 
analyzed: US, Canada, Australia, “Europe”, United Kingdom and Eastern Europe. Background 
racial demographics were collected from national census data.
Results: Seventeen key PCa clinical trials were analyzed. These trials were conducted in the 
past twenty years, comprising 39,574 patients with known racial information. A majority of 
patients were enrolled in the US, but there appears to be a trend towards increased non-
US enrollment over time. In all countries/regions, racial minorities were generally under-
represented. There was no significant improvement in racial minority enrollment over time. 
The US enrolled the largest non-white population (7.1%).
Conclusions: Over the past twenty years, racial minorities were consistently under-
represented in key PCa trials. There is a need for effective measures that will improve 
enrollment of racial minorities. With increased global enrollment, drug developers should 
aim to recruit a patient population which resembles the racial demographics of the patient 
population to which drug use will be generalized upon approval.




Prostate cancer (PCa) incidence and mortality rates vary among races. Between 2006 and 
2010, the age-adjusted PCa incidence rates were 144.9, 228.5, 81.8 and 77.8 per 100,000 
men in white, black, Asian and Native American men in the United States (US), respectively.1 
The age-adjusted PCa mortality rates were 21.2, 50.9, 10.1 and 20.7 per 100,000 men 
in the respective racial groups.1 These results indicate that black people are most prone 
to PCa disease and death.  In contrast, Asians are least likely to be diagnosed with and 
die from PCa. Comparing incidence rates to mortality rates, relative mortality is strikingly 
higher in black and Native American populations. In general, these patient groups present 
with more advanced disease and receive less aggressive treatment.2-6 Furthermore, black 
patients diagnosed with very low-risk PCa may have more advanced PCa than white patients 
with the same diagnosis.7 Multiple underlying factors may contribute to aforementioned 
epidemiological findings, such as genetic tumor alterations, differences in lifestyle, cultural 
and socioeconomic factors, distances needed to travel to the nearest hospital for treatment 
(which for multiple American Indian tribes can exceed 100 miles), variations in participation 
in population-based PSA screening, and non-conformity in clinical trial participation between 
racial groups.6, 8-15
Because the presentation of PCa disease differs amongst racial groups, the response 
to PCa therapies may also differ. Therefore, the US Food and Drug Administration (FDA) 
strongly recommends conducting clinical trials testing novel PCa drugs in a population that 
adequately represents the racial distribution of the US population that would receive the 
drug in a clinical setting. Nevertheless, minority accrual in clinical trials has been a challenge, 
as minorities are traditionally under-represented in clinical trials.14, 15 Disparity between 
racial distribution in clinical trial populations compared to the average US population has 
been a factor in FDA decisions in the past. For example, during the Oncology Drug Advisory 
Committee meeting discussing finasteride and dutasteride for the chemoprevention of PCa 
in December 2010, the FDA noted that these studies lacked adequate enrollment of black 
patients, questioning how well the studies represented the average US PCa population. 
Therefore, minority accrual is of high importance in clinical studies with PCa patients. 
In the current study, we report the enrollment of racial minorities in key clinical trials 
conducted in PCa patients submitted for FDA review in the past two decades. Minority 
accrual was compared across various countries/regions in the world. We further investigated 
whether minority accrual has changed over time. 
Methods
Data collection
For the collection of demographic data, various statistical government resources, publicly 
available on the internet, were used. These included US 2010 census data, Canadian 2011 
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national household survey data, Australian 2011 census data, United Kingdom Census 
2001 data, data from Institut Montaigne (French demographics) and data from the Czech 
Statistical Office (Český statistický úřad). 
Key clinical trials submitted for FDA review in which patients were recruited between 1993 
and 2013 were analyzed regardless of the marketing approval outcome. The proposed 
therapeutic indications were specific to PCa patients, i.e. drug or biologic products that 
sought approval for the treatment of bone metastases in cancer patients in general were 
not included in this study. Datasets from selected clinical trials were retrieved from FDA’s 
archives. Anonymity was applied to non-public data.
Data analyses
Data were analyzed for the following regions: globally, US, Canada, Australia, “Europe”, 
United Kingdom and Eastern Europe. Countries in “Europe” included the 27 countries in 
the European Union (excluding Croatia) and the 4 countries forming the European Free 
Trade Association. Eastern European countries consisted of all countries in Europe east of 
the former Berlin wall, including Russia, but excluding Turkey. Turkey was considered part of 
West-Asia (the Middle East).
Eighteen key, or “pivotal”, PCa clinical trials were identified during the time period specified 
in our analysis, 1993-2013. Of these, the key study supporting FDA approval of mitoxantrone 
was excluded from our analysis, as racial demographics of these patients had not been 
collected. The remaining 17 clinical trials, all included in our analysis, included key studies for 
review of abiraterone acetate, atrasentan hydrochloride, cabazitaxel, degarelix, denosumab, 
docetaxel, dutasteride, enzalutamide, finasteride, leuprorelin (six-month formulation), 
radium-223 dichloride, satraplatin, sipuleucel-T and triptorelin (six-month formulation). 
On the basis of the initiation of patient enrollment, the 17 selected clinical trials were 
divided into two major time periods. In group 1, clinical trials were included that initiated 
enrollment between 1993 and 2004 (n=7); trials that initiated enrollment after 2004 were 
included in group 2 (n=10). Group 1 marks clinical trials that were designed before FDA 
approval of docetaxel, while clinical trials in group 2 were designed after docetaxel had been 
approved for its use in patients with castrate-resistant PCa.
US FDA guidelines recommend that investigators separately collect demographics regarding 
race and ethnicity in clinical trials.16 In these guidelines, racial groups are divided into white, 
black, Asian, American Indian/Alaska Native, Pacific Islander, or other. Ethnicity is divided into 
Hispanic/Latino or non-Hispanic/Latino. In line with these guidelines, we divided race into 
white, black, Asian, native or other. White patients included people with European descent, 
the Middle East and Africa north of the Sahara. Black patients descended from sub-Saharan 
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Africa. Asian patients included all patients from Asian descent except for the Middle East 
and Russia. Natives were considered American Indians, Alaska Natives, Canadian Indians, 
Pacific Islanders and Aboriginals. The race “other” primarily consisted of patients with a 
multiracial background. 
A majority of studies in our analysis did not report Hispanics as a separate ethnicity, but 
as a race. All patients whose registered race was “Hispanic” were excluded from analyses, 
as only their ethnicity, but not their self-reported race, was known. Patients who did not 
have their race reported were also excluded from our analyses. In total, the race of ≥90% of 
patients was retrieved for analysis.
We calculated enrollment estimates for racial minorities that reflect the incidence and 
mortality of PCa amongst racial populations in the US to further explore whether minority 
representation was adequate in the clinical trials analyzed. To estimate projected patient 
enrollment in the US based on PCa incidence, we multiplied the age-adjusted incidence 
of PCa in each racial group by their proportion in the US population based on 2010 US 
census data. For each race, the calculated number was divided by the sum of all calculated 
numbers. This resulted in estimates of the percentage of each racial group needed in a 
PCa clinical trial to reflect the racial distribution of patients diagnosed with PCa. A similar 
procedure was used to estimate the projected patient minority enrollment in the US based 
on PCa mortality, which would approximately represent the racial distribution of patients 
who die from PCa.
Results
In total, 40,912 patients had been enrolled in selected clinical trials between October 1993 
and February 2011. The race of 1,338 patients was unknown and were excluded. Of the 
remaining 39,574 patients, 60.2% were enrolled in the US, 26.5% in “Europe” (4.6% in the 
United Kingdom), 6.6% in Eastern Europe, 4.8% in Canada and 1.6% in Australia (Table 1). 







Patients from the 17 trials were pooled together. Note that not all percentages add up to 100% because some studies enrolled 
patients in other countries/regions than listed, and because patients from the United Kingdom and parts of Eastern Europe are 
also counted in “Europe”.




The percentage of patients enrolled in each analyzed country/region is displayed for all 
individual studies as shown in Figure 1, sorted by time of enrollment initiation. Patient 
enrollment varied widely between different studies: some studies completely enrolled 
patients in the US, while one recruited patients outside the US only. 
Next we studied whether there was a difference in enrollment in countries between 
key PCa clinical trials initiated before or after 2005 (Table 2). Patient enrollment in the 
US had decreased. Enrollment in Canada was relatively low and slightly decreased post-
2005. In contrast, patient enrollment in European countries was higher post-2005. Patient 
enrollment in Australia was also higher; however, this increase was driven mostly by the 
four most recent studies, in which up to 12% of patients were enrolled in Australia (Table 2, 
Fig. 1C). Although Eastern European enrollment was higher in group 2 compared to group 
1, enrollment of Eastern Europeans decreased again in the most recent studies of group 2 
(Fig. 1F).
Figure 1. Percentages of patients enrolled from selected nations/regions in key prostate cancer clinical trials. 
Country/region 1993-2004 2005-2013




United Kingdom 5.6% 7.4%
Eastern Europe 9.5% 13.5%
Percentages were calculated by dividing the sum of percentage enrollment in each individual study by the number of studies. Note 
that not all percentages add up to 100% because some studies enrolled patients in other countries/regions than listed, and because 
patients from the United Kingdom and parts of Eastern Europe are also counted in “Europe”.
Table 2. Average percentage of patients enrolled in key PCa clinical trials initiated before and after FDA docetaxel 
approval per analyzed nation/region. 
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Our analyses further focused on enrollment of racial minorities in the selected PCa clinical 
trials in relation to national/regional racial minority population statistics. Studying national 
census data across the various countries, the non-white population was largest in the US 
(27.6%), while in Eastern European countries such as the Czech Republic less than 1% of 
the population consisted of non-whites (Fig. 2A). Pooling racial demographic data from all 
17 studies and comparing enrollment between different nations/regions, enrollment of 
racial minorities was largest in the US (7.1%) (Fig. 2B); this population primarily consisted 
of black patients (5.3%). In other countries/regions, enrollment of racial minorities did not 
exceed 5%; minority accrual was virtually non-existent in Eastern Europe. Hence, comparing 
enrollment of racial minorities (Fig. 2B) to the expected pool of eligible patients based 
on census data (Fig. 2A), enrollment of racial minorities was appreciably lower across all 
nations/regions. Comparing global enrollment of racial minorities over time, enrollment of 
non-whites seemed to be consistent at approximately 5-10% (Fig. 2C). Exceptions were study 
10, 12 and 13, which enrolled more than 15% of racial minorities. Study 10 was performed 
entirely outside the US. As this was a non-Western nation, it was not further analyzed. Study 
13 was conducted completely in the US; study 12 had a large Asian population as this study 
had a higher enrollment in Asia compared to the other studies.
In the US, enrollment of racial minorities was higher across all studies as compared to 
global minority enrollment (compare Fig. 3A to Fig. 2C), possibly due to the large minority 
population in the US in general (Fig. 2A). Notably, enrollment of racial minorities was more 
than 20% in studies 9, 12 and 13 (Fig. 3A). In studies 12 and 13, Hispanic/Latino ethnicity 
was not collected as a separate category. Therefore, these patients may have been included 
in the racial groups ‘black’ and ‘other’, increasing minority enrollment as measured in 
this study compared to clinical trials in which the Hispanic population was excluded from 
analysis. The reported minority enrollment in study 9 excluded the 9% Hispanics from the 
analysis, as their race had not been collected separately from ethnicity. 
Figure 2. Racial minority demographics in Western nations/regions and enrollment of racial minorities in key PCa 
trials. A) Demographic distribution of racial minorities in a selection of Western nations. B) Global racial minority 
enrollment and racial minority enrollment in selected nations/regions. C) Global enrollment of racial minorities for 
each key PCa clinical trial.
In B), data was pooled from all 17 key PCa studies.  
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Racial minority enrollment did not exceed 15% in any Canadian (Fig. 3B) or Australian (Fig. 
3C) study population. Comparing enrollment of racial minorities between Canada and 
Australia, which have a similar proportion of racial minorities in the population (Fig. 2A), 
Australia enrolled markedly fewer racial minorities.
In “Europe”, enrollment of racial minorities was relatively low (Fig. 4A). We further specified 
enrollment in the United Kingdom (Fig. 4B), a Western European country with an extensive 
colonial history, and in Eastern European countries (Fig. 4C). As one would expect based on 
the demographics (Fig. 2A), enrollment of racial minorities was higher in the United Kingdom, 
while virtually all patients enrolled in Eastern Europe were white. Similar results were found 
when analyzing minority enrollment of France separately: in line with its demographics, 
racial minority enrollment was higher in France compared to Eastern Europe, but slightly 
lower compared to the United Kingdom (data not shown).
Discussion
Data from our study indicate that racial minorities are consistently under-represented in 
major clinical trials assessing novel PCa therapies, also relative to differences in population 
demographics by country. This finding is consistent with previous reports regarding PCa and 
other diseases.14, 15 Treatment benefit may differ between racial groups due to variations 
Figure 3. Enrollment of racial minorities in key PCa clinical trials in A) the United States, B) Canada and C) Australia. 
Figure 4. Enrollment of racial minorities in key PCa clinical trials in “Europe” (all countries of the European Union 
plus the European Free Trade Association), the United Kingdom, and Eastern Europe (all countries east of the 
former Berlin wall, including Russia but excluding Turkey). 
Studies were excluded from graphs if no patient had been enrolled in the analyzed nation/region for that particular study. The total 
number of patients enrolled from the analyzed country/region (including white patients) is listed above each bar.
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in tumor characteristics.9 Therefore, the US FDA and other regulatory authorities strongly 
recommend registration of racial demographics for clinical studies.16 Furthermore, studies 
have indicated that oncology patients who participated in clinical trials had better survival 
compared to non-participants.14, 17, 18 These results may have been biased: patients with a 
worse prognosis may have been excluded from clinical trials, and physicians treating patients 
in a clinical trial may adhere more strictly to provided study protocols. For adjuvant breast 
cancer treatment, protocol adherence was strongly associated with improved survival.17 
Therefore, PCa survival may improve among minorities with increased participation in 
clinical trials.
In this study, we compared racial minority enrollment in PCa studies to the expected accrual 
based on census data. Our analysis has several important limitations. First, census data are 
self-reported and are only representative of people who respond to the questionnaires. 
Second, demographics were collected inconsistently: while in some studies Hispanics were 
reported under a separate category for ethnicity as recommended by US FDA guidelines,16 
in a majority of studies Hispanics were reported as a separate race. Third, to be able to 
adequately study the treatment effect in racial minorities, one could argue that enrollment 
of racial minorities should be increased even further. Fourth, data from the SEER database 
indicate that the incidence and mortality of PCa is higher in the black population than in the 
white population in the US.1 Therefore, one could argue that adequate representation of 
the US PCa patients should include a higher percentage of black patients than reported in 
the census (12.6%). For example, we estimated that in studies performed in the general PCa 
population, evaluating a treatment in early stage disease (such as finasteride and dutasteride 
for PCa risk reduction), a representation of the US population would include 31.1% non-
whites, and 18.9% black patients specifically. For therapies aimed at patients with late stage 
disease (such as enzalutamide for metastatic castrate-resistant PCa patients after docetaxel 
treatment), a stage at which most patients will eventually die from PCa, should include an 
estimated 26.1% black population due to the higher mortality rate in this racial group. The 
latter two examples further demonstrate that enrollment of racial minorities needs to be 
improved compared to current enrollment.
There are obvious limitations to grouping patients into broad phenotypic categories 
(white, black, Asian, native and other minorities). These racial groups are only very general 
predictors of biologic variations that may result in differences in PCa growth and therapy 
response. These biologic differences, in addition to environmental, socioeconomic and 
dietary variability, may be substantial between two populations categorized as the same 
race but from differing countries. E.g., while people from the Arabian Peninsula and North 
Africa are by consensus considered white in epidemiological studies, it is highly likely that 
substantial differences in environmental and genetic factors exist between these two 
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subgroups and Europeans within the same racial category. Similarly, significant differences 
may exist between Japanese patients living in Japan compared to those of Japanese ancestry 
who reside in the US. Despite these limitations, capturing racial demographics in clinical 
trials remains an important tool to ensure that the population enrolled more accurately 
approaches the general PCa population within a country. Furthermore, racial demographic 
data can identify potential challenges in clinical trial access, and reveal differences in the 
safety and efficacy of a therapy between racial subgroups, potentially aiding in the discovery 
of predictive biomarkers.
Although the need to increase minority accrual has universally been acknowledged, it 
remains a challenge as to how this goal can be achieved. Various efforts have had limited 
success in the past; for instance, efforts to increase enrollment of racial minorities in the 
PCPT study were fruitless.19 The limited success of efforts to improve enrollment of racial 
minorities is reflected in our study results, as no significant improvement in minority 
recruitment has been made over the past two decades. 
Previous research indicated that white and non-white patients have an equal interest in 
learning about clinical trials.20 However, the investigators also found that the media used 
to collect information about clinical trials differed between racial groups in the US. While 
white patients used the internet and physicians more often as an information source, racial 
minorities more often relied on information provided by other patients. This is seemingly in 
contrast with a study by Markman et al., which suggested that the internet may be useful 
as a source to recruit minorities for participation in clinical trials.21 Other studies have 
identified additional factors that may improve minority enrollment, such as approaching 
Asian patients by a more senior doctor, informing patients by staff and/or local leaders 
from the same ethnicity, and making use of written translations.22 Furthermore, while 
most clinical trials are performed in university hospitals in major cities, rural minorities, 
particularly Native Americans in the US, would benefit if patients in community/peripheral 
hospitals would be recruited for studies too. Most importantly, studies concluded that the 
main factor influencing enrollment of racial minorities was level of trust.20, 22, 23
Despite the limited success of improving enrollment of racial minorities in oncology studies 
in general, some studies were more successful in recruiting minorities, such as study 9 in our 
analysis. Additional exploration indicated that enrollment of black patients was particularly 
high in one study site in Aventura, Florida. Here, 19 out of 29 patients enrolled in the 
study were classified as black; half of all black patients enrolled in this study were enrolled 
from this site. The population that this hospital served included a large population from 
the Caribbean, primarily indicated as “white/other, Hispanic” in the US census data. There 
seems to be discrepancy in reporting whether patients from the Caribbean are considered 
white (Hispanic), black or Native American (Puerto Rico). It is plausible that the investigator 
in that study registered patients from the Caribbean as black.
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As a final note, our study results indicate that the majority of patients in PCa registration 
trials intended for US FDA review for marketing approval were enrolled in the US. However, 
our data also suggest a potential trend towards increased non-US enrollment. One key 
advantage of global clinical trial conduct is rapid enrollment, which can decrease the time 
needed to bring an effective treatment to the market. However, it also raises the question 
whether the results acquired from treating patients abroad properly reflect the efficacy 
and safety of the treatment in the average US population who will receive the treatment 
upon FDA approval. The current study underlines the importance of this question, as 
enrollment of racial minorities was lower in all studied nations/regions compared to the US, 
in particular in Eastern Europe. On the other hand, study 10, which globally had the highest 
enrollment of racial minorities, was conducted completely outside the US, in a country with 
a considerably higher non-white population. This indicates that adequate minority accrual is 
possible and there is not necessarily an objection to recruitment of patients outside the US 
or outside Western nations, provided that the rights, safety, and well-being of the subjects 
participating in those trials are ensured, there is compliance with good clinical practices, and 
that the results can be generalized to the US population. However, it must be acknowledged 
that biologic and socioeconomic characteristics of racial populations in the US may differ 
from such characteristics in the same racial population accrued in another country.
In conclusion, investigators and drug developers should take differences in racial 
demographics into account when selecting countries for clinical trials. In accordance with 
FDA’s guidelines, sponsors are advised to classify racial demographics consistently and to 
consult the review division prior to study initiation about the estimated size of minority 
enrollment in their proposed trial.16 While acknowledging that biologic and environmental 
differences may exist within the same racial category between countries, researchers 
should aim to improve enrollment of racial minorities during international trial conduct to 
accurately reflect demographics in countries for which they seek approval of their therapy. 
Inadequate minority enrollment may prevent achieving a full understanding of the benefit-
risk profile of novel treatments in racial minorities. The trend toward increasing the number 
of non-US countries, including countries with a large white population, entails a trade-off 
of enhancing enrollment and time to trial completion versus enrolling a population that 
adequately represents the racial demographics of the average US population. Improved 
strategies to enhance minority accrual in such large multinational studies are needed.
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Background: Cabazitaxel has been reimbursed as a second-line therapy for patients with 
metastatic castrate-resistant prostate cancer (mCRPC) in the Netherlands since 2011. 
Before reimbursement was available, cabazitaxel was provided through a compassionate 
use program (CUP). We report the results of the Dutch CUP, detailing the safety and efficacy 
of cabazitaxel in a routine clinical practice setting. 
Methods: Safety and efficacy data of all five Dutch centers participating in the cabazitaxel 
CUP were collected. Safety data were collected prospectively using the National Cancer 
Institute Common Toxicity Criteria for Adverse Events version 3.0. Overall survival (OS) and 
progression-free survival (PFS), time to PSA progression (TTPP), and best clinical response 
were evaluated retrospectively.
Results: Fifty-one patients were registered in the CUP; 49 received cabazitaxel. Forty-two 
of 49 patients (85.7%) had ≥2 metastatic sites. Patients received on average 6 cabazitaxel 
cycles (range 1-21). A dose reduction or dose delay occurred in 13 (26.5%) and 20 (40.8%) 
patients, respectively. Prophylactic granulocyte colony-stimulating factor (G-CSF) was used 
in 8 patients (16.3%). Grade ≥3 adverse events were observed in 25 patients (51.0%); 16 
patients (32.7%) discontinued treatment because of treatment-emergent adverse events. 
Serious adverse events (SAEs) occurred in 16 (32.7%) patients; the most frequent SAEs 
were hematuria (4 patients (8.2%)) and urosepsis (3 patients (6.1%)). Febrile neutropenia 
occurred twice; no patient had grade ≥3 neuropathy. No toxicity-related mortality occurred. 
Median follow-up was 24.1 months. Median OS was 8.7 months (interquartile range (IQR) 
6.0-15.9 months); median TTPP was 2.8 months (IQR 1.7-5.9 months). 
Conclusion: In the Dutch CUP, patients with advanced mCRPC had delayed tumor progression 
with acceptable toxicities using cabazitaxel treatment.




Metastatic castrate-resistant prostate cancer (mCRPC) is the second deadliest cancer in 
men in the United States (US), being surpassed only by lung and bronchial carcinomas.1 A 
decade ago, the main therapy for patients with mCRPC consisted of mitoxantrone. However, 
this anthracenedione increased quality of life but not patient survival.2 Therapy options 
for patients with mCRPC evolved in 2004, when docetaxel received approval as first-line 
therapy for this group of patients, based on two phase III clinical trials which concluded 
that docetaxel improved survival in patients with advanced prostate cancer.3, 4 Although 
the introduction of docetaxel implemented a radical improvement in treatment options for 
patients with mCRPC, about 50% of these patients did not respond to docetaxel-treatment, 
and there were few objective responses.3 Furthermore, all tumors that were initially targeted 
by docetaxel eventually developed resistance against this taxane.5 Approximately 70% of 
patients with mCRPC treated with docetaxel had progressive disease during treatment or 
within 3 months after discontinuation. These observations required further development of 
therapy options for patients with docetaxel-resistant mCRPC and led to the discovery and 
approval of cabazitaxel as a second-line therapy in patients with mCRPC. 
Cabazitaxel is a tubulin-binding taxane that suppresses microtubule dynamics in mitosis, 
resulting in mitotic arrest and apoptosis.6, 7 This second-generation taxane effectively 
inhibited a wide variety of human and murine tumors in vitro and in vivo and was well 
tolerated by mice.6 Mice with established DU-145 prostate tumors had a 100% complete 
regression after treatment with cabazitaxel at the maximum tolerated dose (MTD); 5 of 
6 mice had a tumor-free survival of ≥133 days.6 Cabazitaxel has poor substrate affinity 
for the adenosine triphosphate-dependent drug efflux pump P-glycoprotein (activated by 
overexpression of multidrug-resistant protein 1), which may partly contribute to the fact 
that cabazitaxel effectively inhibits cell lines with acquired resistance against docetaxel.6, 7 In 
phase I/II studies, the recommended dose was established at 20 or 25 mg/m2 through a 1 h 
intravenous infusion once every three weeks, the dose-limiting toxicity being neutropenia.8, 
9 Of the eight patients with mCRPC who received cabazitaxel treatment at doses ≤25 mg/
m2 in the phase I study, two patients had an objective partial response for ≥6 cycles, and an 
additional patient with mCRPC had a minor reduction in tumor size.8
In the subsequent TROPIC study (an open-label randomized multicenter phase III clinical trial), 
755 patients with mCRPC were randomized to either mitoxantrone (12 mg/m2 intravenously 
over 15-30 minutes every 3 weeks) plus prednisone (10 mg oral daily) or cabazitaxel (25 
mg/m2 intravenously over 1 h every 3 weeks) plus prednisone (10 mg oral daily).10 All 
patients with mCRPC included in the study had documented disease progression during or 
after docetaxel treatment. Median overall survival (OS) was significantly increased in the 
cabazitaxel-treated group compared with the mitoxantrone-treated group (15.1 vs. 12.7 
months, respectively; p<0.0001). Median OS was significantly increased in the cabazitaxel-
treated group independent of the duration of androgen-deprivation therapy, suggesting that 
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cabazitaxel has effect in both aggressive and non-aggressive prostate tumors.11 Furthermore, 
progression-free survival (PFS), defined as the first occurrence of prostate-specific antigen 
(PSA), radiologic or clinical progression, or death, was 1.4 months longer in the cabazitaxel-
treated group (2.8 vs. 1.4 months; p<0.0001), and the median time to PSA progression 
(TTPP) was increased from 3.1 to 6.4 months. However, both grade ≥3 hematologic and 
non-hematologic adverse events had an increased incidence in cabazitaxel-treated patients. 
The most frequent grade ≥3 hematologic adverse events were neutropenia and leukopenia, 
which occurred in 303 (82%) and 253 (68%) cabazitaxel-treated patients, respectively, vs. 
215 (58%) and 157 (42%) mitoxantrone-treated patients. Febrile neutropenia occurred in 28 
(8%) cabazitaxel-treated patients and in five (1%) mitoxantrone-treated patients. The most 
frequent grade ≥3 non-hematologic adverse event was diarrhea, which occurred in 23 (6%) 
cabazitaxel-treated patients and in one (<1%) mitoxantrone-treated patient. In the TROPIC-
study, nine (2.4%) mitoxantrone-treated patients died within 30 days of the last dose of 
the study drug (six of disease progression), whereas in the cabazitaxel-treated group, 18 
(4.9%) patients died within 30 days of the last dose (none of disease progression). The most 
frequent causes of mortality within 30 days of the last dose of the study drug were related 
to neutropenia and its complications, cardiac events, and renal failure. 
The clinical benefit for patients with mCRPC in the TROPIC study led to the approval of 
cabazitaxel for treatment of mCRPC in the US in June 2010.12 The European Medicines 
Agency approved cabazitaxel for mCRPC treatment in March 2011; later in 2011, the taxane 
was reimbursed by insurance companies in the Netherlands. Pending final registration of 
cabazitaxel, a compassionate use program (CUP) was established in the Netherlands and 
25 other countries in 2010 to allow access to cabazitaxel for patients with mCRPC and to 
record overall safety. These programs have been introduced to facilitate the availability of 
new treatments that are not yet reimbursed for patients with a severe disease when no 
satisfactory alternative is available and when it is expected that the new medicine will be 
approved by official authorities in the near future. Recruitment for this CUP was terminated 
in the Netherlands in June 2011 as cabazitaxel would be reimbursed. In this study we report 
the safety and efficacy of cabazitaxel in patients with mCRPC as recorded in the Dutch CUP 
to give an indication of the experience with cabazitaxel in a routine clinical setting.
Patients and Methods
Patients
Patients in five Dutch medical centers were included. Patients were eligible for cabazitaxel 
treatment if they had mCRPC and documented disease progression during or after treatment 
with a docetaxel-containing regimen. Patients needed to be surgically or medically castrated; 
be ≥ 18 years; have an Eastern Cooperative Oncology Group (ECOG) performance status of 
0, 1, or 2; have a life expectancy of ≥3 months; and have adequate bone marrow, liver, and 
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renal functions. Patients were excluded from participation if they had received previous 
radiotherapy to ≥40% of the bone marrow, previous radionuclide therapy, or if they had 
received anticancer therapy within four weeks of enrollment. Patients were also excluded 
when they presented with grade ≥2 peripheral neuropathy, grade ≥2 stomatitis, an infection 
treated with systemic antibiotic or antifungal medication, or known brain or leptomeningeal 
involvement. Other criteria that excluded patients from participation were a history of a 
grade ≥3 hypersensitivity reaction to docetaxel, polysorbate 80-containing medications 
or predniso(lo)ne, an active cancer other than mCRPC, an uncontrolled severe illness or 
medical condition, concurrent or planned treatment with potent inhibitors or inducers of 
cytochrome P450 3A4/5, participation in a clinical trial with any investigational drug, and 
reproductive potential without implementation of an accepted and effective method of 
contraception. 
Study design
This study is an analysis of the treatment of patients with mCRPC with cabazitaxel through 
the CUP. While patients are treated within the CUP, they are closely monitored to assess 
the safety of the new medicine. Because of the nature of the study, it was an ambispective 
multicenter observational study. Safety data were collected prospectively; efficacy data were 
collected retrospectively. The study was approved by the institutional ethics committees, 
and written informed consent was obtained from all participants.
Treatment
All patients initially received 25 mg/m2 cabazitaxel for 1 h intravenously on day 1 of a 21-
day cycle, as well as 10 mg oral prednisone or prednisolone daily. Primary prophylaxis with 
granulocyte colony-stimulating factor (G-CSF) was considered in patients with high-risk clinical 
features for febrile neutropenia as described by European Organisation for Research and 
Treatment of Cancer (EORTC) guidelines, such as previous episodes of (febrile) neutropenia, 
age > 65 years, poor performance and/or nutritional status, extensive previous radiation, 
and/or serious comorbidities.13 G-CSF was administered when the physician estimated the 
chance for febrile neutropenia to be ≥ 20%. Patients were pretreated intravenously with an 
antihistamine (clemastine 1 mg), a corticosteroid (dexamethasone 8 mg or equivalent), and 
an H2 antagonist (ranitidine or equivalent) at least 30 minutes before cabazitaxel treatment. 
Additional oral or intravenous anti-emetic prophylaxis was administered at the physician’s 
discretion. The recommended additional anti-emetic prophylaxis was metoclopramide. 
Patients who experienced grade ≥3 nausea and/or vomiting received more aggressive anti-
emetic prophylaxis, namely, ondansetron. However, physicians were allowed to diverge 
from this protocol. Therefore, four patients received granisetron as anti-emetic prophylaxis. 
Furthermore, ondansetron was administered immediately if limited effect was expected 
from metoclopramide in an individual patient or if (severe) nausea and/or vomiting was 
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expected based on previous toxicities from other chemotherapy (docetaxel).
The protocol required a treatment delay when patients had an absolute neutrophil count 
of ≤1500/mm3, a thrombocyte count of ≤75000/mm3, grade ≥3 non-hematologic toxicities 
(except alopecia and nail changes) that had not recovered to the baseline, an aspartate 
aminotransferase or alanine aminotransferase concentration >1.5 times the upper limit of 
normal, and/or a bilirubin concentration higher than the upper limit of normal. If patients 
had not recovered from these toxic effects after two weeks of treatment delay, treatment was 
terminated. The protocol required a dose reduction to 20 mg/m2 after an episode of grade 
≥3 neutropenia and/or febrile neutropenia, grade 4 thrombocytopenia, grade ≥3 vomiting 
despite appropriate anti-emetic prophylaxis, grade ≥3 diarrhea or persisting diarrhea despite 
appropriate medication, grade ≥3 stomatitis, grade 2 peripheral neuropathy (patients with 
grade ≥3 peripheral neuropathy were withdrawn from treatment), liver abnormalities 
as described earlier, a creatinine clearance between 40 and 60 ml/min (patients with a 
creatinine clearance <40 ml/min were withdrawn from treatment), and any other grade ≥3 
toxicity (except for alopecia and nail changes) that had improved to grade 2 or better. Dose 
re-escalation or further dose reductions were not allowed.  
Although cabazitaxel treatment was discontinued after a maximum of ten cycles in the 
TROPIC study, physicians and patients were allowed to decide to continue treatment 
beyond ten cycles in the CUP if patients responded well to cabazitaxel treatment. Treatment 
was discontinued based on the patient’s or physician’s decision, adverse events, disease 
progression, and/or death. Patients were allowed to discontinue treatment at any time for 
any reason.
Outcome measures
Every patient underwent an extensive medical assessment before initiation of cabazitaxel 
treatment. This assessment included the collection of data regarding demographics (date 
of birth), vital signs, height, weight, ECOG performance status, history of prostate cancer, 
findings during physical examination, and hematologic (neutrophil and thrombocyte count, 
hemoglobin) and biochemical laboratory diagnostics (liver function, kidney function, and 
serum PSA concentration, among others). Furthermore, CT and bone scans were obtained 
if no recent test results were available. Before each cabazitaxel administration, new and 
existing symptoms were assessed and graded, physical examinations were performed, 
liver and renal functions were checked, a hematologic assessment was done, the serum 
PSA level was determined, and when clinically indicated, other diagnostic tests (e.g., CT, 
MRI, radiography, bone scans, and electrocardiograms) were performed. When cabazitaxel 
treatment was terminated, vital signs (weight, ECOG performance status) were registered 
and blood tests were performed. Prostate cancer progression, subsequent treatments, and 
OS were followed up until death or until the last date the patient was known to be alive 
before February 21, 2013.
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OS was calculated as the number of days between the first day of cabazitaxel treatment 
and death or censoring. Other efficacy parameters were TTPP, PFS, best clinical response, 
and PSA response. TTPP and PSA response were considered the most reliable efficacy 
parameters, because serum PSA levels had been determined in patients every three weeks, 
whereas other diagnostic tests, such as radiologic assessments, were performed at the 
physician’s discretion at random time points.
TTPP was calculated from the first day of cabazitaxel treatment according to Prostate Cancer 
Clinical Trials Working Group 2 (PCWG2) recommendations.14 In patients who had an initial 
PSA decrease, PSA progression was defined as an increase of at least 25% over the nadir 
PSA concentration. In patients with no decline from the baseline PSA level, PSA progression 
was defined as an increase of at least 25% over the nadir PSA concentration for a duration 
of ≥12 weeks of treatment. Furthermore, a patient’s TTPP was not determined if a different 
treatment was started before PSA progression was measured or if >3 months elapsed 
between two subsequent PSA measurements. 
To report PSA-based outcomes, waterfall plots were used as recommended by the PCWG2.14 
First, the maximum PSA decrease during cabazitaxel treatment was assessed; if the PSA 
did not decrease at all, the maximum PSA level during cabazitaxel treatment was assessed 
instead. Second, the PSA change after 4 cycles was assessed.
PFS was defined as the number of months between initiation of cabazitaxel treatment 
and the first date of progression as measured by PSA progression (using the same 
criteria as for TTPP), tumor progression (either from increased measurable lesions or 
from increased lesions on CT/MRI/X-ray/bone scans), symptomatic progression, and/or 
death. Because tumor measurements were performed at the physician’s discretion, in no 
patient was PFS based solely on tumor progression, i.e., patients with radiologic disease 
progression always had clinical progression or PSA progression as well. Furthermore, 
some patients discontinued cabazitaxel treatment because of symptoms and PSA 
progression, whereas, according to the definition of PCWG2, this progression may have 
been caused by a flare.14 Therefore, the PFS could not be determined in these patients. 
The best clinical response was considered progressive disease when both serum PSA levels 
were continuously increased compared with the baseline serum PSA level, PSA levels had 
a rising trend, and overall, patients did not have an improved condition. A partial response 
was defined as a PSA decrease of ≥50% compared with the baseline in at least two separate 
PSA measurements three weeks apart and an improvement in the patient’s symptoms. 
Furthermore, if measurable lesions had decreased in size, it was considered a partial 
response as well, regardless of serum PSA levels or a change in symptoms.
Patients were intensively monitored for adverse events throughout the study by physician 
visits and diagnostic tests such as blood tests and electrocardiograms. Adverse events 
were graded according to the National Cancer Institute Common Terminology Criteria for 
Adverse Events version 3.0.15 Adverse events could result in the addition of medication to 
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treat or prevent the adverse events, dose reduction, dose delay, or withdrawal from the 
study. All adverse events from the onset of treatment until 30 days after the last cabazitaxel 
administration were recorded.
Statistical analyses
All analyses were performed with the study population that received at least one dose 
of cabazitaxel. Microsoft Excel was used to calculate the median, interquartile range 
(IQR), range, mean and standard deviation (SD) for patient characteristics, treatment 
characteristics and G-CSF use. IBM SPSS Statistics (version 20) was used for the statistical 
analyses of efficacy parameters. OS, TTPP, and PFS were analyzed using the Kaplan-Meier 
method. OS data were censored at the last date the patient was known to be alive; PFS data 
were censored at the last date the disease state of the patient was assessed if no disease 
progression had occurred. Log-rank tests were used to calculate differences in TTPP and 
OS between groups that had been stratified based on age, body mass index (BMI), time 
between prostate cancer and mCRPC diagnosis, initial Gleason score, ECOG performance 
score at the start of cabazitaxel treatment, PSA levels at the start of cabazitaxel treatment, 
previous docetaxel therapy, and pretreatment with abiraterone/enzalutamide, as well for 
calculating the significance of the difference between median received cabazitaxel cycles. 
Role of outside organizations
Sanofi-Aventis provided a database with all treatment-emergent adverse events (TEAEs) 
registered. The authors had full access to safety data collected in the CUP by Sanofi-Aventis; 
analyses were performed independently from Sanofi-Aventis. The decision to submit the 
report for publication was made by the chief investigators (MDW and HG), who wrote the 




Between July 28, 2010 and April 27, 2011, cabazitaxel treatment was initiated in 49 of 51 
patients selected in five hospitals to participate in the CUP. Two patients withdrew from 
the CUP between selection and treatment initiation, as the result of being unable to visit 
the hospital because of a deteriorating condition. Data from these two patients were not 
included in the analyses, because the aim of our study was not to perform an intention-to-
treat analysis but to determine the safety and efficacy of cabazitaxel in Dutch clinics. Median 
age of the 49 patients who received at least one administration of cabazitaxel was 64.6 years 
(IQR 58.6-70.0); three patients were older than 75 years (Table 1). Most patients (71.4%) 
had an ECOG performance status of 1 during selection; 12 patients (24.5%) had an ECOG 
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performance status of 2. A majority of patients (85.7%) had at least 2 sites of metastases; 
the two most frequent metastatic sites were bone and lymph nodes. Lung and liver 
metastases had been diagnosed in 6 (12.2%) and 7 (14.3%) patients, respectively. Twenty-
four patients (49.0%) had received 2 or more chemotherapy regimens, and 10 patients 
(20.4%) had received abiraterone (10.2%), enzalutamide (8.2%), and/or immunotherapy 
(ipilimumab/CNTO95) (4.1%) before cabazitaxel. Patients had received a median dose of 
750 mg/m2 (IQR 450-900 mg/m2) docetaxel during the last docetaxel regimen. For patients 
whose disease progressed after the last docetaxel dose, median time from last docetaxel 
administration to disease progression was 3.22 months (IQR 1.36-6.87 months); 9 patients 
(18.4%) had disease progression during docetaxel treatment, whereas 11 patients (22.4%) 
had progressive mCRPC >6 months after the last dose of docetaxel. Before treatment 
initiation, the median serum PSA level was 355.5 ng/ml (IQR 123.0-1515.4 ng/ml) (Table 1). 
All but 1 patient (98.0%) had an initial PSA concentration ≥20 ng/ml.
Patients completed a median of 6 cycles (range 1-21 cycles) of cabazitaxel treatment in 
126 days (range 21-469 days) (Fig. 1, Table 2). Nine patients (18.4%) completed 10 cycles 
of cabazitaxel treatment. Twelve patients (24.5%) required a dose reduction during the 
first 10 cycles; 1 additional patient required a dose reduction at the 20th cycle (Table 2). 
Seven patients needed dose reduction only at cycle 8 or higher; furthermore, the majority 
of patients (n=9) who needed a dose reduction had a dose reduction during their last or 
second to the last cycle (data not shown). Twenty patients (40.8%) required a dose delay 
(Table 2).
G-CSF was administered for prophylactic use to 8 patients (16.3%) for a total of 49 cycles. 
These eight patients completed a median number of 9.0 cabazitaxel cycles (IQR 7.5-10.0); 
the median number of cabazitaxel cycles in patients not treated with G-CSF was 5.0 (IQR 
4.0-8.0).
After discontinuation of cabazitaxel treatment, 26 patients started other second-line 
systemic therapies. Twenty-three patients were treated with abiraterone acetate, two 
patients with docetaxel, and three patients with mitoxantrone. Three patients were 
treated with ipilimumab or placebo in a study setting, and four patients were treated with 
enzalutamide. Finally, three patients received a second cabazitaxel regimen after treatment 
with abiraterone acetate. 
Safety
All patients reported TEAEs during treatment; 46 (93.9%) patients had adverse events 
possibly related to cabazitaxel treatment, as assessed at the start of each cabazitaxel 
cycle (Table 3). Although a serious adverse event (SAE) occurred in 16 (32.7%) patients, 
none of these adverse events resulted in patient death. Grade ≥3 events occurred in 25 
(51.0%) patients; grade 4 events occurred in five (10.2%) patients. Sixteen (32.7%) patients 




Mean [years (SD)] 63.6 (8.1)
Median [years (IQR)] 64.6 (58.6-70.0)
Patients <65 years 26 (53.1%)
Patients ≥75 years 3 (6.1%)
Performance status at the start of therapy
ECOG 0 2 (4.1%)
ECOG 1 35 (71.4%)
ECOG 2 12 (24.5%)
Extent of metastatic disease





Local recurrence 23 (46.9%)
Regional lymph node 17 (34.7%)










Number of chemotherapy regimens
1 25 (51.0%)
≥2 24 (49.0%)
Other mCRPC therapy (abiraterone acetate, enzalutamide and/or 10 (20.4%)
immunotherapy)
Docetaxel use
Number of previous docetaxel regimens
Mean (SD) 1.1 (0.3)
Median (range) 1.0 (1-3)
Cumulative dose of last docetaxel administration (mg/m²)
Mean (SD) 742.50 (358.58)
Median (IQR) 750 (450-900)
Disease progression relative to docetaxel administration
<0 (during treatment) 9 (18.4%)
<3 months since last dose 17 (34.7%)
≥3-<6 months since last dose 12 (24.5%)
≥6 months since last dose 11 (22.4%)
Median time from last docetaxel dose to disease 3.22 (1.36-6.87)
progression [months (IQR)]
Serum PSA concentration (ng/ml)
Median (IQR) 355.5 (123.0-1515.4)
≥20 ng/ml 48 (98.0%)
Data are number of patients (%) if not specified otherwise. ECOG, Eastern Cooperative Oncology Group; IQR, interquartile range; 
PSA, prostate-specific antigen; SD, standard deviation
Table 1. Baseline characteristics of patients treated with cabazitaxel via the Dutch CUP (n=49)
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Figure 1. Cabazitaxel treatment in the Dutch CUP population. The graph displays the number of patients treated 
at cycle n.
Figure 2. Kaplan-Meier estimates of (A) overall survival (OS) and (B) time to PSA progression (TTPP) in the Dutch 
cabazitaxel treated CUP population. 
Vertical bars on the curves display censored observations. 
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All grade ≥3 TEAEs and SAEs, as well as grade 1 or 2 events that occurred in ≥2 patients, 
are listed in Table 3. The most frequent TEAE was fatigue, which occurred in 30 (61.2%) 
patients; grade ≥3 fatigue occurred in five (10.2%) patients. Other non-hematologic grade 
≥3 TEAEs that were reported in at least two patients, were urosepsis (6.1%), bone pain 
(6.1%), paraplegia (4.1%), pulmonary embolism (4.1%), urinary tract infections (4.1%) and 
a decreased appetite (4.1%). The most frequent reported non-hematologic SAEs were 
hematuria and urosepsis, which occurred in 4 (8.2%) and 3 (6.1%) patients, respectively. 
One patient experienced grade 3 hematuria; this patient had received multiple fractions 
of radiation (3 × 8Gy and, 4 × 5Gy) to the pelvic region before cabazitaxel therapy. Two 
of four patients with grade 2 hematuria had received radiation therapy at an earlier stage 
as well. A grade ≥3 cardiac disorder (myocardial infarction) and diarrhea each occurred in 
one patient. Other frequently reported non-hematologic adverse events (all grades) were 
nausea (44.9%), diarrhea (40.8%), vomiting (26.5%) and malaise (20.4%) (Table 3). Grade 1 
or 2 peripheral neuropathy was reported in nine patients (18.4%). Eleven patients (22.4%) 
had a weight loss of ≥5% of their total body weight. 
Hematologic adverse events occurred in 17 (34.7%) patients. Of all cabazitaxel-treated 
patients with mCRPC, six patients (12.2%) experienced grade ≥3 hematologic adverse events, 
of which grade ≥3 (febrile) neutropenia and anemia occurred most frequently (4.1%). Seven 
hematologic SAEs were reported: anemia (twice), febrile neutropenia (twice), neutropenic 
infection, neutropenic sepsis, and hemorrhagic anemia.
Efficacy
Median follow-up was 24.1 months (IQR 22.4-26.9 months). At the cutoff date for the final 
analysis, 40 patients had died. Kaplan-Meier analysis of OS is displayed in Figure 2A. Median 
OS was 8.7 months (IQR 6.0-15.9 months); mean OS was 12.9 months (95% Confidence 
Interval (CI) 10.3-15.5 months) (Fig. 2A, Table 4). Fourteen patients (28.6%) had continuous 
progressive disease despite cabazitaxel treatment; nine patients (18.4%) had a partial 
response. Hence, disease control (partial response plus stable disease) was established in 
35 patients (71.4%). In these 35 patients, median OS was 13.3 months (IQR 7.9 months-
undetermined); mean OS was 15.6 months (95% CI 12.5-18.8 months).
TTPP was determined in 36 patients (Fig. 2B, Table 4). Mean TTPP was 3.8 months (95% 
CI 2.8-4.7 months); median TTPP was 2.8 months (IQR 1.7-5.9 months). Strikingly, the two 
patients with the longest TTPP (13.3 and 10.5 months) had received the most cabazitaxel 
cycles (21 and 14, respectively). The two patients, in whom cabazitaxel treatment was 
discontinued after ten cycles solely because of completion of ten cycles, had a TTPP of 9.0 
and 7.5 months. This suggests that it might be clinically beneficial to continue treatment 
beyond ten cycles when there are no other indicators to stop cabazitaxel treatment; this 
needs to be investigated in more detail.
Predictive and prognostic factors for response to cabazitaxel treatment were determined. 




Number of treatment cycles
Mean (SD) 6.39 (3.96)
Median (range) 6 (1-21)
Number of patients that completed ≥10 cycles 9 (18.4%)
Treatment time (days)
Mean (SD) 144 (88)
Median (range) 126 (21-469)
Number of patients with a treatment delay 20 (40.8%)
Number of patients with a dose reduction 13 (26.5%)
dose reduction ≤cycle 10 12 (24.5%)
Table 2. Treatment characteristics in cabazitaxel-treated patients (n=49)
Data are number of patients (%) unless specified otherwise. SD, standard deviation
Patients with possibly related TEAE 46 (93.9%)     
Patients who discontinued treatment due to TEAE 16 (32.7%)     
Patients with hematological grade ≥3 adverse event 6 (12.2%)     
Patients with ≥5% weight loss 11 (22.4%)     
Patients with any grade 4 adverse event 5 (10.2%)     
Patients with any grade 5 adverse event 0      
       
grade 3 or 4 SAE     all grades
Any adverse event 25 (51.0%) 16 (32.7%) 49 (100%)
HEMATOLOGICAL ADVERSE EVENT       
Anemia 2 (4.1%) 2 (4.1%) 14 (28.6%)
Hemorrhagic anemia 1 (2.0%) 1 (2.0%) 1 (2.0%)
Neutropenia 2 (4.1%) 2 (4.1%) 3 (6.1%)
Febrile neutropenia 2 (4.1%) 2 (4.1%) 2 (4.1%)
Leukopenia 1 (2.0%) 0 3 (6.1%)
Thrombocytopenia 1 (2.0%) 0 2 (4.1%)
NON-HEMATOLOGICAL ADVERSE EVENT       
Fatigue 5 (10.2%) 0 30 (61.2%)
Bone pain 3 (6.1%) 1 (2.0%) 12 (24.5%)
Urosepsis 3 (6.1%) 3 (6.1%) 3 (6.1%)
Decreased appetite 2 (4.1%) 0 7 (14.3%)
Urinary tract infection 2 (4.1%) 0 5 (10.2%)
Paraplegia 2 (4.1%) 2 (4.1%) 2 (4.1%)
Pulmonary embolism 2 (4.1%) 2 (4.1%) 2 (4.1%)
Nausea 1 (2.0%) 0 22 (44.9%)
Diarrhea 1 (2.0%) 0 20 (40.8%)
Vomiting 1 (2.0%) 0 13 (26.5%)
Back pain 1 (2.0%) 0 6 (12.2%)
Hematuria 1 (2.0%) 4 (8.2%) 5 (10.2%)
Spinal cord compression 1 (2.0%) 2 (4.1%) 2 (4.1%)
Myocardial infarction 1 (2.0%) 1 (2.0%) 1 (2.0%)
Hypocalcemia 1 (2.0%) 0 1 (2.0%)
Duodenal ulcer hemorrhage 1 (2.0%) 1 (2.0%) 1 (2.0%)
Colitis 1 (2.0%) 0 1 (2.0%)
Hydronephrosis 1 (2.0%) 0 1 (2.0%)
Malaise 0 0 10 (20.4%)
Table 3. Adverse events reported during cabazitaxel treatment
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Pyrexia 0 1 (2.0%) 8 (16.3%)
Dehydration 0 1 (2.0%) 1 (2.0%)
Diplopia 0 1 (2.0%) 1 (2.0%)
Peripheral neuropathy 0 0 9 (18.4%)
Pain in extremity 0 0 7 (14.3%)
Arthralgia 0 0 6 (12.2%)
Constipation 0 0 5 (10.2%)
Headache 0 0 5 (10.2%)
Muscle spasms 0 0 4 (8.2%)
Cough 0 0 4 (8.2%)
Rectal hemorrhage 0 0 3 (6.1%)
Dysgeusia 0 0 3 (6.1%)
Peripheral sensory neuropathy 0 0 3 (6.1%)
Peripheral oedema 0 0 3 (6.1%)
Abnormal hepatic function 0 0 2 (4.1%)
Nasopharyngitis 0 0 2 (4.1%)
Dyspnoea 0 0 2 (4.1%)
Epistaxis 0 0 2 (4.1%)
Oropharyngeal pain 0 0 2 (4.1%)
Groin pain 0 0 2 (4.1%)
Muscular weakness 0 0 2 (4.1%)
Musculoskeletal chest pain 0 0 2 (4.1%)
Musculoskeletal pain 0 0 2 (4.1%)
Musculoskeletal stiffness 0 0 2 (4.1%)
Urinary retention 0 0 2 (4.1%)
Influenza-like illness 0 0 2 (4.1%)
Data are number of patients (%). Toxic effects were graded according to the National Cancer Institute Common Terminology Criteria 
for Adverse Events (v 3.0). All adverse events that occurred in at least two patients are listed, as well as all grade 3 or 4 adverse 
events and SAEs. TEAE, treatment-emerging adverse event; SAE, serious adverse event
Figure 3. Waterfall plots showing (A) the maximal change in serum PSA levels from baseline during/after cabazitaxel 
therapy before initiation of another mCRPC treatment; (B) the change in serum PSA levels from baseline after four 
cabazitaxel cycles. 
If patients had been treated for less than 4 cycles, the serum PSA level during/after the last cabazitaxel cycle was used.
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Age, BMI, time between prostate cancer and mCRPC diagnosis, initial Gleason score, and 
ECOG performance score did not significantly influence the clinical outcome for cabazitaxel-
treated patients (Table 4). However, patients with a PSA <500 ng/ml at the start of treatment 
had a longer OS than patients with an initial PSA level of ≥500 ng/ml (10.1 months vs. 
7.9 months; p=0.016). Patients who had received <10 cycles of docetaxel treatment had 
a significantly decreased median TTPP (2.8 vs. 3.5 months) and OS (7.8 vs. 10.0 months) 
compared with patients who had received ≥10 docetaxel cycles (p=0.049 and p=0.015, 
respectively) (Table 4). Furthermore, ten of the twelve patients (83.3%) who had a TTPP >4 
months had received ≥10 cycles of docetaxel before cabazitaxel treatment, whereas four 
of the nine patients (44.4%) who had a TTPP <2 months, had received ≥10 docetaxel cycles 
before cabazitaxel treatment (data not shown). The number of cabazitaxel cycles received 
was not significantly different between patients who had received <10 cycles and those 
who had received ≥10 docetaxel cycles, because the median number of cabazitaxel cycles 
was 5 and 6, respectively (p=0.163). Similarly, the percentage of patients who discontinued 
treatment because of adverse events did not differ between the two groups (30.0% and 
27.6%, respectively; p=0.858). Patients pretreated with abiraterone and/or enzalutamide 
had a decreased OS (5.9 vs. 10.0 months; p=0.027) (Table 4). The median TTPP tended to 
differ significantly as well (2.1 vs. 3.2 months; p=0.052). Between these groups of patients, 
the median number of cabazitaxel cycles was not significantly different (4 vs. 6; p=0.065).
PFS was similar to TTPP, because disease progression was first indicated by a rising PSA level 
in most patients. PFS was determined in 46 patients. Median PFS was 2.8 months (IQR 1.7-
4.9 months), and mean PFS was 3.8 months (95% CI 2.8-4.7 months) (Table 4). 
Figure 3 displays waterfall plots of the two analyses of PSA progression as recommended 
by the PCWG2.14 Fifteen patients had a continuous increase in PSA levels. One patient had 
a PSA measurement at the start of the cabazitaxel treatment only because this patient had 
SAEs during the first cycle and did not have his PSA measured afterwards. Six patients had 
an initial PSA decrease, but had their serum PSA levels increase to the baseline PSA level or 
higher during the first four cycles. The remaining 27 patients had a decrease in PSA levels 
that was sustained during the first four cycles of cabazitaxel treatment. Of these patients, 
19 had a PSA decrease of ≥25% for at least four cycles. The maximum decrease in PSA 
was 92.9%; this patient’s PSA level decreased from 3669 ng/ml to 172.4 ng/ml during six 
cabazitaxel cycles. Despite the PSA decrease, the patient discontinued treatment because 
of a deteriorating condition. Seven months after discontinuation of cabazitaxel, his PSA level 
had increased to 5000 ng/ml. 
Finally, we studied whether patients who had a decrease in PSA levels by at least 25% and 
50% compared with the baseline PSA serum concentration, had an increased OS and TTPP 
compared with patients who did not have such a PSA response. Patients who had at least 
a 25% decrease in PSA after four cycles of cabazitaxel had a median TTPP and OS of 6.2 
(IQR 4.4-7.5) and 16.6 (9.4-undetermined) months, respectively, compared with 2.1 (0.8-
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2.8) and 7.9 (IQR 5.9-10.0) months in the rest of the patients (p<0.001). Patients who had 
at least a 50% decrease in PSA had a median TTPP and OS of 6.9 (IQR 5.9-9.0) and 16.6 
(15.0-undetermined) months, respectively, compared with 2.3 (1.4-3.5) and 8.3 (IQR 5.9-
Overall survival (OS) (n=49)
Mean [months (95% CI)] 12.9 (10.3-15.5)
Median [months (IQR)] 8.7 (6.0-15.9)
Time to PSA progression (TTPP) 
(n=36)
Mean [months (95% CI)] 3.8 (2.8-4.7)
Median [months (IQR)] 2.8 (1.7-5.9)
Progression-free survival (PFS) (n=46)
Mean [months (95% CI)] 3.8 (2.8-4.7)
Median [months (IQR)] 2.8 (1.7-4.9)
Best response (n=49)
Progressive disease (%) 14 (28.6%)
Partial response (%) 9 (18.4%)
OS in patients who responded to 
cabazitaxel (n=35)
Mean [months (95% CI)] 15.6 (12.5-18.8)
Median [months (IQR)] 13.3 (7.9-N/A)
           
Patient characteristic TTPP OS
 # Median (IQR) # Median (IQR)
age <65 years 20 3.2 (1.4-4.9) p=0.458 26 8.3 (5.9-17.8) p=0.731age ≥65 years 16 2.6 (2.1-5.9) 23 9.9 (7.6-15.9)
 
BMI <25 10 2.8 (2.1-5.9)
p=0.972
15 9.9 (6.9-N/A)
p=0.616BMI 25-30 20 2.6 (1.4-4.9) 24 8.2 (5.7-14.9)
BMI >30 5 3.5 (2.1-4.4) 9 13.3 (8.7-15.9)
 
time to mCRPC <12 months 8 2.1 (0.7-3.1) p=0.282 11 7.6 (5.9-10.1) p=0.121time to mCRPC ≥12 months 28 2.8 (2.1-6.0) 38 9.9 (6.0-17.8)
 
Gleason score <8 10 2.8 (2.2-3.5) p=0.407 12 12.5 (6.0-15.6) p=0.750Gleason score 8-10 16 2.5 (2.1-6.7) 22 9.4 (8.2-17.9)
 
ECOG <2 28 2.8 (2.1-6.0) p=0.118 37 10.0 (7.6-16.6) p=0.347ECOG ≥2 8 1.7 (0.7-3.1) 12 7.0 (4.8-9.4)
 
PSA <500 ng/ml 23 3.1 (0.8-5.9) p=0.655 26 10.1 (7.9-N/A) p=0.016PSA ≥500 ng/ml 13 2.6 (2.1-6.0) 23 7.9 (5.7-14.1)
 
Docetaxel <10 cycles 15 2.8 (1.4-3.5) p=0.049 19 7.8 (5.9-10.3) p=0.015Docetaxel ≥10 cycles 21 3.5 (2.1-6.9) 30 10.0 (7.9-N/A)
 





p=0.027no prior treatment with abiraterone/
enzalutamide
29 3.2 (2.1-6.2) 41 10.0 (7.6-17.8)
Table 4. Efficacy parameters of cabazitaxel treatment
The IQR could not be determined if >25% of patients were alive at the cutoff date (N/A). #, number of patients; IQR, interquartile 
range; BMI, body mass index; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; PSA, prostate-specific antigen.
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13.3) months in the rest of the patients (p=0.017 and p=0.024, respectively). However, 
between patients who had a 25% to 50% decrease and those who had a >50% decrease in 
PSA, the TTPP and OS did not differ significantly (p=0.854 and p=0.644, respectively).
Discussion
In the TROPIC study, patients with mCRPC treated with cabazitaxel had an increased PFS and 
OS compared with mitoxantrone-treated patients irrespective of the aggressiveness of the 
tumor.10, 11 However, both grade ≥3 hematologic and non-hematologic adverse events had 
an increased incidence in cabazitaxel-treated patients. Since the completion of this phase 
III study, several studies with cabazitaxel reported fewer high-grade adverse events.16-18 In 
the TROPIC study, grade ≥3 adverse events occurred in 82% of all patients; adverse events 
were assessed on a weekly basis.10 Of all patients included in the German CUP, grade ≥3 
TEAEs occurred in 30.6% of patients.19 In our study, grade ≥3 adverse events occurred in 
51.0% of patients. Similarly, grade ≥3 neutropenia, leukopenia, and diarrhea were reported 
in 82%, 68%, and 6% of patients in the TROPIC study, respectively.10 Grade ≥3 neutropenia, 
leukopenia, and diarrhea were reported in 7.2%, 9.0%, and 0.9% of patients of the German 
CUP, respectively.19 Preliminary data of cabazitaxel-use in patients with mCRPC through a 
CUP in Italy reported grade ≥3 neutropenia, leukopenia, and diarrhea in 48.9%, 25.6%, and 
1.1% of patients, respectively.16 In an expanded access program (EAP) in Spain grade ≥3 
neutropenia and diarrhea occurred in 24% and 1.5% of cabazitaxel-treated patients with 
mCRPC, respectively.17 All three studies assessed adverse events once every three weeks. 
In line with these results, grade ≥3 neutropenia, leukopenia and diarrhea occurred in 4.1%, 
2.0%, and 2.0% of patients who participated in the Dutch CUP, respectively. The decreased 
number of hematologic adverse events may be partially result from the use of prophylactic 
G-CSF in high-risk patients according to EORTC guidelines13, whereas in the TROPIC study 
no prophylactic G-CSF was allowed. Furthermore, in the TROPIC study TEAEs were assessed 
weekly, whereas in the CUPs and docetaxel phase III study, TEAEs were assessed once every 
three weeks, simulating the clinical practice setting.3 Most of the TEAEs that were missed 
by doing an assessment every three weeks instead of weekly, were asymptomatic TEAEs 
that disappeared within three weeks (such as neutropenia without fever), and thus were 
not clinically relevant. Finally, patients and/or doctors could have decided to discontinue 
cabazitaxel treatment at an earlier stage because of the availability of abiraterone acetate 
as an alternative drug for patients with mCRPC, preventing the onset of grade ≥3 adverse 
events. This latter is confirmed by the lower percentage of patients completing ten cycles 
compared with the TROPIC study (18% vs. 28%). Nevertheless, these data indicate that 
SAEs such as febrile neutropenia are relatively well controlled in a clinical setting in which 
physicians administer prophylactic G-CSF and other preventive medicine to patients who 
are at high risk for the development of SAEs. 
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In the cabazitaxel-treated arm of the TROPIC study five patients died of cardiac problems 
within 30 days of cabazitaxel treatment.10 According to the investigators, none of these 
cardiac events were related to cabazitaxel. A subsequent study, which directly investigated 
the relationship between cabazitaxel use and cardiac disorders, concluded that cabazitaxel 
had no significant effect on the QTc interval in patients with advanced solid tumors.18 It is 
generally thought that the increased number of mortal cardiac events in the cabazitaxel-
treated group of the TROPIC study was not related to cabazitaxel. In the Dutch CUP, one 
patient had a myocardial infarction between cabazitaxel courses; grade 5 TEAEs did not 
occur in participating patients.
Collected efficacy parameters in our study were OS, TTPP, and PFS. Time to radiologic or 
clinical progression was not determined, because clinical progression was not reported 
in a standardized format, and radiologic assessments had been performed based on the 
physician’s decision. In general, most physicians performed radiologic tests only when other 
tools to measure disease progression, such as PSA measurements and clinical assessments, 
were inconclusive.
Median OS was considerably lower in the Dutch CUP population compared with OS in the 
cabazitaxel-treated population of the TROPIC study (8.7 vs. 15.1 months). The median TTPP 
was lower as well: 2.8 vs. 6.4 months. In the German CUP, the mean biochemical PFS and 
OS were 3.8 and 13.9 months, respectively. This was comparable to our results, in which the 
mean TTPP and OS were 3.8 and 12.9 months, respectively. Our results were also similar to 
preliminary results from the Spanish EAP; the median PFS in this study was 4.4 months.17 
The Italian CUP did not report efficacy data. The most likely explanation for this discrepancy 
between the TROPIC study and our study is a difference in the patient population: in general, 
patients in the Dutch CUP had more advanced prostate cancer than patients in the TROPIC 
study. Only 31% of cabazitaxel-treated patients in the TROPIC study had received two or 
more chemotherapy regimens; in the Dutch CUP 49.0% of patients had received two or 
more chemotherapy regimens. Furthermore, ten patients (20.4%) had received abiraterone 
(five patients), enzalutamide (four patients) and/or immunotherapy (ipilimumab/CNTO95) 
(two patients) before cabazitaxel, whereas patients enrolled in the TROPIC study had no 
previous treatment with these agents. Recent research concludes that treating patients 
with abiraterone or enzalutamide before taxane therapy may reduce the efficacy of 
taxanes.20, 21 In a retrospective study of 35 chemonaive patients treated with abiraterone 
who subsequently received docetaxel at progression, a median OS of 12.5 months and a PSA 
response in 9 patients (25.7%) were reported with docetaxel, which is significantly lower 
than figures reported in the TAX-327 trial (19.8 months and 45%, respectively).3, 20 Another 
evident difference in the patient population is the number of metastatic sites in patients: 
85.7% of patients in the Dutch CUP had ≥2 metastatic sites, whereas only 61% of patients in 
the TROPIC study had ≥2 metastatic sites.10 Furthermore, patients in our study had a median 
PSA of 355.5 ng/ml at the start of cabazitaxel treatment, whereas the median PSA was 143.9 
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ng/ml in patients who would be treated with cabazitaxel at the start of the TROPIC study. 
These observations strengthen the need for observational studies as presented in this 
chapter: the current clinical situation does not necessarily comply with the study population 
of the phase III registration study. 
Recently, hormonal therapy with abiraterone acetate has been approved by the US Food 
and Drug Administration (FDA) and in the Netherlands as a second-line therapy for patients 
with mCRPC, based on the results of the COU-AA-301 study.22 Thus, both cabazitaxel and 
abiraterone acetate are therapeutic options for patients with symptomatic mCRPC who 
progressed during or after docetaxel treatment. Enzalutamide has just been approved by 
the US FDA as well but is awaiting approval in the European Union; a phase III study has 
indicated prolonged OS when administered as second-line therapy in patients with mCRPC.23 
CUPs with enzalutamide are ongoing. Finally, docetaxel could be re-introduced after an 
initial response and a substantial docetaxel-free interval. There is no scientific evidence for 
the most preferred treatment strategy in patients with symptomatic mCRPC after docetaxel-
based therapy. Therefore, a wide variety of clinical studies is being performed to create a 
scientific basis for the optimal treatment strategy for this group of patients.
To further improve the tolerability of cabazitaxel in patients with mCRPC without 
compromising efficacy, three phase II studies are assessing different dosing schedules, such 
as weekly cabazitaxel at 10 mg/m2 or biweekly cabazitaxel at 16 mg/m2.24-26 Furthermore, 
a phase III study (PROSELICA) is comparing the efficacy of 20 mg/m2 cabazitaxel to 25 mg/
m2 cabazitaxel, both administered once every three weeks.27, 28 The CABARESC study is a 
phase II study in which budesonide is added to cabazitaxel to prevent cabazitaxel-induced 
diarrhea, the most frequent grade ≥3 non-hematologic adverse event in the TROPIC study.29 
In another clinical study, octreotide is added to cabazitaxel to prevent diarrhea as well.30 
However, considering the low percentage of grade ≥3 diarrhea reported in this CUP and 
other CUPs, one can question whether these studies are still needed, because it seems that 
diarrhea is already well controlled in a regular clinical setting.
Therapy efficacy and/or tolerability may be further improved by combining cabazitaxel 
with other treatments, such as the combination of cabazitaxel with custirsen (OGX-011)31, 
abiraterone acetate32, tasquinimod33, carboplatin34, or bavituximab35. Other studies are 
investigating the use of cabazitaxel in patients with less advanced prostate cancer, such 
as the FIRSTANA study, which compares the efficacy of cabazitaxel (25 or 20 mg/m2) to 
docetaxel as first-line therapy in patients with mCRPC.36, 37 Further clinical benefit could be 
achieved by selecting a subgroup of patients with mCRPC that is most likely to respond to 
cabazitaxel. Since fourteen patients (28.6%) in the Dutch CUP did not respond to cabazitaxel 
treatment at all, and patients who initially responded exhibited a wide variation in the 
duration of response, a marker predicting cabazitaxel response would prevent unnecessary 
treatment of patients, thereby cutting costs, reducing adverse events, and preventing delays 
in initiating other therapies that are targeting the tumor. No such marker has been identified 
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yet. The initial Gleason score has been identified as a predictive factor in abiraterone-treated 
patients, an initial Gleason score of 8 to 10 resulting in a lesser response to the agents.38 A 
short time (<12 months) between the time of prostate cancer and mCRPC diagnosis was a 
prognostic factor for a lower PFS in patients treated with abiraterone and other endocrine-
manupilating agents.39 Since PFS in docetaxel-treated patients was not associated with the 
time to castration resistance, this may be a predictive factor in abiraterone-treated patients 
as well. The time to castration-resistance and the initial Gleason score were not significantly 
predictive or prognostic for the cabazitaxel response (TTPP/OS) in the Dutch CUP. 
Our study and other studies suggest that pretreatment with abiraterone or enzalutamide 
may compromise the efficacy of cabazitaxel.20, 21 However, patients who received this 
pretreatment may have had more aggressive or more advanced prostate cancer. The ECOG 
performance status at the start of cabazitaxel treatment did not differ significantly though 
(p=0.294, data not shown). Abiraterone and enzalutamide are currently being assessed as 
first-line therapy in patients with mCRPC.40, 41 Considering the results from our study and 
other studies,20, 21 we think potential cross-resistance needs to be assessed more thoroughly 
in prospective randomized drug sequence studies.
The results of the Dutch CUP further suggest that if patients had received <10 docetaxel 
cycles, indicating they had disease progression or SAEs during docetaxel treatment, they 
are likely to have a lesser response to cabazitaxel treatment compared with patients who 
received ≥10 docetaxel cycles. This observation was not confounded by the number of 
cabazitaxel cycles received, because these numbers were similar between the two groups. 
Therefore, cabazitaxel may have a higher efficacy in patients who received at least 10 
docetaxel treatments, suggesting that some patients are particularly sensitive to taxanes and 
reach a significant survival benefit with this therapy. In summary, the relationship between 
previous docetaxel, abiraterone, or enzalutamide treatment and cabazitaxel response needs 
further study, and more specific predictive markers need to be identified. 
With the introduction of cabazitaxel as a second-line therapy in patients with mCRPC, 
treatment options for this group of patients have expanded. Results from the Dutch CUP 
study indicate that cabazitaxel has effect in patients with advanced mCRPC in a clinical 
setting, delaying disease progression and/or improving symptoms, while resulting in 
moderate toxicity. However, we are still at the beginning stage of the expansive research 
that is needed to optimize the treatment algorithm for patients with mCRPC.
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Background: Cabazitaxel and abiraterone have both received approval for treating metastatic 
castrate-resistant prostate cancer (mCRPC) patients after first-line docetaxel therapy. In the 
CAST-study, the clinical outcome of docetaxel-treated mCRPC patients treated sequentially 
with both cabazitaxel and abiraterone was evaluated, to study whether treatment sequence 
could influence clinical outcome. 
Methods: Data were collected retrospectively from mCRPC patients at twelve hospitals 
across the Netherlands who initiated cabazitaxel and/or abiraterone before December 
2012. Primary outcome measure was overall survival (OS); secondary measures were 
progression-free survival (PFS), biochemical PFS, and best clinical and PSA response. Hospital 
admission data during treatment were collected, as well as toxicities resulting in treatment 
discontinuation or patient death. 
Results: Sixty-three and 69 patients received Cab→Abi (cabazitaxel prior to abiraterone) and 
Abi→Cab (abiraterone prior to cabazitaxel) before July 10th, 2013, respectively. Median OS 
was 19.1 months and 17.0 months in Cab→Abi and Abi→Cab treated patients, respectively 
(p=0.369). Median PFS and biochemical PFS were significantly extended in Cab→Abi treated 
patients: 8.1 versus 6.5 (p=0.050) and 9.5 versus 7.7 months (p=0.024), respectively. 
Although partial responses to cabazitaxel occurred in both groups, Abi→Cab treated patients 
had a significantly decreased antitumor response from cabazitaxel than Cab→Abi treated 
patients (median PFS 5.0 versus 2.6 months, p<0.001). Minor differences in toxicities were 
observed based on therapy sequence; generally, toxicity from cabazitaxel could be severe, 
while abiraterone toxicity was milder. 
Conclusions: This retrospective analysis indicates that primary progression on cabazitaxel 
or abiraterone did not preclude a response to the other agent in mCRPC patients. However, 
tumor response of both agents, particularly cabazitaxel, was lower when administered as 





Metastatic castrate-resistant prostate cancer (mCRPC) is the second deadliest cancer in 
men in the Western world.1, 2 Recently, novel therapeutic agents have emerged for the 
systemic treatment of these patients. Two such therapies are cabazitaxel and abiraterone 
acetate, which received United States Food and Drug Administration (US FDA) and European 
Medicines Agency (EMA) approval between 2010 and 2011 for use in mCRPC patients 
following disease progression during or after docetaxel. Although abiraterone also received 
FDA and EMA approval for use in docetaxel-naive mCRPC patients, it has not been registered 
for this indication in the Netherlands.
Abiraterone acetate (Zytiga®, Johnson&Johnson) selectively inhibits the enzyme cytochrome 
P450 c17 (CYP17), thereby blocking testosterone biosynthesis.3 In a double-blind phase III 
registration study (COU-AA-301), patients treated with abiraterone plus prednisone had 
an increased median overall survival (OS) (15.8 versus 11.2 months), median radiologic 
progression-free survival (PFS) (5.6 versus 3.6 months), and median biochemical PFS (8.5 
versus 6.6 months) as compared to patients treated with placebo plus prednisone.4, 5 
Mineralocorticoid-related adverse events (fluid retention, hypokalemia, hypertension) and 
urinary tract infections were more frequently reported in the abiraterone-treated group 
than in patients receiving placebo.
Cabazitaxel (Jevtana®, Sanofi-Aventis) is a second generation taxane which exerts its 
antitumor activity by targeting microtubule dynamics.6 In preclinical studies, cabazitaxel 
was capable of inhibiting cancer cell lines with acquired resistance against docetaxel.7, 8 In a 
phase III registration study (TROPIC), patients treated with cabazitaxel plus prednisone had 
an increased median OS (15.1 versus 12.7 months), median PFS (2.8 versus 1.4 months) 
and median biochemical (6.4 versus 3.1 months) as compared to patients treated with 
mitoxantrone plus prednisone.9 Grade ≥3 hematological adverse events such as (febrile) 
neutropenia occurred more frequently in cabazitaxel-treated patients. Frequently reported 
grade ≥3 non-hematological adverse events included diarrhea, fatigue and asthenia. 
Aforementioned registration studies were conducted parallel to each other; both agents 
resulted in a significant survival benefit. Direct comparison of cabazitaxel with abiraterone 
based on these studies is not possible. Therefore, both agents are approved in the post-
docetaxel setting, but regulatory agencies such as the EMA and US FDA have made no 
mention of treatment sequence. 10-12 However, therapy sequence may influence clinical 
outcome13-17: resistance to one therapy may result in resistance to another therapy by 
similar mechanisms of action, or progression of mCRPC may result in decreased sensitivity 
to therapy. No clinical study has studied cabazitaxel and abiraterone treatment sequence. 
For this reason the CAST-study was conducted. In this retrospective study, the clinical 
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outcome is reported of (subgroups of) Dutch mCRPC patients treated with both cabazitaxel 
and abiraterone after receiving docetaxel as first-line therapy, evaluating antitumor activity 
and safety of both agents.
Patients and Methods
Patients
Twelve Dutch hospitals participated in this study, comprising the Netherlands Cancer 
Institute, five university hospitals and six regional hospitals across the nation. Eligible patients 
had confirmed mCRPC, for which they had received docetaxel at least once; all patients were 
medically or surgically castrated. Patients who had received abiraterone and/or cabazitaxel 
prior to docetaxel were excluded. All other mCRPC patients receiving cabazitaxel and/or 
abiraterone, as registered in electronic patient files, were included, including patients who 
received other treatments for their mCRPC before cabazitaxel and/or abiraterone therapy.
Study design and ethics
This study was a retrospective, multicenter, observational study. All patients had been 
informed before initiation of mCRPC treatment that data could be used anonymously 
for research purposes and were able to object at any time without consequences. Oral 
informed consent was acquired from patients who were still under treatment; data from 
other patients were collected if patients had not objected to data collection for research 
purposes. This is in accordance with the Dutch code of conduct for medical research and 
is in compliance with all Dutch and international laws regarding research with human data. 
Medical ethics committee approval was obtained before data collection.
Treatment
Standard treatment consisted of 1000 mg oral abiraterone acetate daily plus 10 mg oral 
prednisone daily or intravenous cabazitaxel 20 or 25 mg/m2 every 21 days plus 10 mg oral 
prednisone daily. However, physicians were allowed to deviate from this protocol, for dose 
reductions, to initiate treatment at a lower dose, or to delay treatment. Discontinuation 
of treatment was based on disease progression, adverse events, patient’s or physician’s 
decision, and/or death. This decision was made entirely by the physician and patient; 
participation in the CAST-study did not influence this decision. 
Medication to reduce or prevent side effects was allowed during cabazitaxel or abiraterone 
therapy, as well as additional symptomatic treatment against mCRPC, such as radiotherapy 
or denosumab. Although cabazitaxel and abiraterone are mentioned as second- and third-
line therapies in this study, patients were allowed to receive alternative mCRPC therapies 
in between docetaxel, cabazitaxel and abiraterone. All such treatment decisions were made 




average clinical setting in the Netherlands.
Outcome measures
The primary outcome measure for patients who received both cabazitaxel and abiraterone 
was OS, defined as the number of days between start of second-line therapy (cabazitaxel or 
abiraterone) and death or censoring, regardless of therapies afterwards. Secondary outcome 
measures were PFS, biochemical PFS, and best clinical and prostate-specific antigen (PSA) 
response. 
To determine PSA progression and response, guidelines from the Prostate Cancer Clinical 
Trials Working Group (PCWG) 2 were followed.18 Hence, PSA progression was defined as 
an increase of ≥25% and ≥2 ng/ml over nadir PSA concentration. In general, PSA serum 
levels were measured in patients every three to four weeks. For determining the nadir PSA 
level, potential PSA flares were taken into account (patients with a continuous PSA rise from 
baseline within 12 weeks, not confirmed with imaging). Biochemical PFS was calculated from 
therapy start until PSA progression. Patients whose tumors responded to another systemic 
treatment before PSA progression, patients with PSA progression after more than three 
months between the last PSA assessment, and patients who died before PSA progression, 
were considered lost-to-follow-up.
PFS was calculated from therapy start until progression or censoring. Progression was 
established when PSA progression, radiological progression (CT/MRI/X-ray/bone scans), 
symptomatic progression (pain or other clinical symptoms) and/or death had occurred, 
following PCWG2 criteria. One form of progression sufficed to consider the patient’s disease 
to be progressive, except for symptomatic progression. Symptomatic progression without 
radiological or PSA progression was not considered disease progression as this could be the 
subjective opinion of a patient unrelated to mCRPC progression, unless symptoms resulted 
in therapy adjustments (e.g. increased analgesic use or discontinuation of treatment). 
Radiological imaging was performed at the physician’s discretion, and reviewed locally. 
‘Total (biochemical) PFS’ is the sum of the separate (biochemical) PFS for cabazitaxel and 
abiraterone.
A patient’s best response was defined as progressive disease (PD) when serum PSA levels 
were continuously increased compared to baseline for at least 12 weeks since treatment 
initiation (to exclude patients with PSA flares), and/or an increase in lesion size in radiologic 
imaging methods within three months of initiation of therapy. A partial response (PR) was 
defined as a PSA decrease of ≥50% compared to baseline in at least two separate PSA 
measurements three weeks apart or a decrease in lesion size (when no new lesions had 
occurred and no other lesions had increased in size). All patients who did not fit the criteria 
for PR or PD were considered to have stable disease as the best response. If results were in 
contrast with each other, it was considered stable disease, except when physicians reported 
an increased tumor lesion size: in that case the disease was always considered progressive. 
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Adherence to this protocol was similar to PCWG2 recommendations.18
For safety data, adverse events had been collected inconsistently between physicians 
and hospitals. Therefore, collection of adverse event data according to the National 
Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) was 
not possible. Instead, all hospital admissions between treatment initiation and 30 days 
after the last administration of cabazitaxel or abiraterone were registered. These were 
registered consistently in all hospitals. Adverse events, regardless of severity, resulting in 
discontinuation of treatment or patient death were recorded separately.
Statistical analyses
Microsoft Excel was used to calculate the mean, median, interquartile range (IQR), range 
and standard deviation (SD) for patient characteristics, treatment characteristics, best 
response and adverse events. SPSS (version 20) was used for the Kaplan-Meier analyses of 
treatment duration, follow-up, OS and (biochemical) PFS. If patient death had not occurred 
or its date was unknown, OS data were censored at the last date the patient was known to 
be alive. If no disease and/or PSA progression had occurred, (biochemical) PFS data were 
censored at the last date the disease state of the mCRPC patient was assessed. Log-rank 
tests were used to compare durations (OS etc.) between patient groups. For comparison of 
other parameters between patient groups, student’s t-tests were conducted. Cox regression 
analyses were performed to calculate hazard ratios (HRs).
Results
Patients
Between January 15th, 2009 and November 30th, 2012, 326 patients initiated abiraterone 
and/or cabazitaxel treatment at one of the twelve participating Dutch centers. The database 
was closed on July 10th, 2013. At this time, 44.5% and 15.0% of patients had only received 
abiraterone or cabazitaxel treatment, respectively. Sixty-three patients (19.3%) had received 
cabazitaxel followed by abiraterone (Cab→Abi), and 69 patients (21.2%) had received 
abiraterone followed by cabazitaxel (Abi→Cab). These percentages were similar when 
evaluating patients who had passed away before database cutoff (data not shown).
Baseline characteristics of Cab→Abi and Abi→Cab treated patients
Baseline patient and tumor characteristics of Cab→Abi and Abi→Cab treated patients at 
the start of second-line therapy are listed in Table 1. Patients treated with Cab→Abi were 
younger (65.6 vs. 69.8 years; p<0.001) and had a higher median PSA level at baseline 
(291 vs 130 ng/ml; p=0.022). Prior treatment between groups was similar, except for the 




(Abi→Cab); p=0.020). While patients had received a similar median number of docetaxel 
cycles (10 vs. 9; p=0.552), patients receiving Abi→Cab had discontinued docetaxel more 
frequently due to toxicity (36.2% vs. 12.7%; p=0.002), whereas a higher percentage of 
Cab→Abi treated patients had completed all planned cycles (usually ten) (52.4% vs. 33.3%; 
p=0.027). Although not reaching statistically significance, patients in the Cab→Abi group 
had in general a shorter duration from diagnosis to second-line mCRPC therapy, but a longer 
duration between mCRPC diagnosis and second-line mCRPC therapy, and docetaxel and 
second-line mCRPC therapy. Other baseline characteristics were similar between groups.
Treatment characteristics of Cab→Abi and Abi→Cab treated patients
Treatment characteristics from second-line mCRPC therapy onwards are listed in Table 2. 
Of note, second-line therapy was considered cabazitaxel or abiraterone, third-line therapy 
the other agent, regardless of therapies between docetaxel, cabazitaxel and abiraterone. 
While there was no difference in second-line therapy duration (mean 159.9 versus 152.9 
days; p=0.955), patients treated with Cab→Abi received significantly longer third-line 
therapy (mean 138.8 versus 100.8 days; p=0.021). Indeed, patients receiving cabazitaxel 
in the third-line (Abi→Cab) received significantly less cabazitaxel cycles (median 4 versus 
7 cycles; p<0.001). Abiraterone was primarily discontinued due to disease progression; 
toxicity played a role in about one-third of patients discontinuing cabazitaxel, both in the 
second- and third-line. 
Efficacy of Cab→Abi and Abi→Cab therapy
Median time to follow-up was 23.7 months and 21.8 months in Cab→Abi and Abi→Cab 
treated patients, respectively (p=0.068). Median OS was slightly greater in Cab→Abi treated 
patients: 19.1 months versus 17.0 months; however, this difference did not reach statistical 
significance (p=0.369) (Fig. 1A). When stratifying all patients based on second-line therapy, 
including patients that received cabazitaxel (n=112) or abiraterone (n=214) only, mCRPC 
patients that received abiraterone after docetaxel had a slightly greater median OS (13.2 
versus 12.5 months); this difference was not statistically significant either (p=0.386). 
Median total PFS and total biochemical PFS were 8.1 versus 6.5 months (p=0.050) and 9.5 
versus 7.7 months (p=0.024) in Cab→Abi versus Abi→Cab treated patients, respectively (Fig. 
1B-C). Assessing (biochemical) PFS during second and third-line therapy separately, it was 
observed that (biochemical) PFS differed between Cab→Abi and Abi→Cab treated patients 
during second-line therapy, but were similar in the third-line (Table 3). When assessing best 
clinical and PSA responses, it was noted that during third-line therapy fewer patients had 
PRs, while an increased percentage of patients had PD. This was particularly evident when 
comparing cabazitaxel responses between second- and third-line therapy. Patients receiving 
cabazitaxel in the third-line also had a significantly shorter treatment duration than in the 
second-line (data not shown). Waterfall plots depicting maximum change in PSA from 
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Table 1. Baseline patient and tumor characteristics of patients treated with both cabazitaxel and abiraterone
Cab→Abi (n=63) Abi→Cab (n=69) p-value
Age
Median [years (range)] 65.6 (44-79) 69.8 (52-88) <0.001
Gleason score
Unknown 7 (11.1%) 8 (11.6%)
Median (range) 8 (6-10) 8 (6-10) 0.080
Gleason ≥8 37 (66.1%) 34 (55.7%)
Metastatic disease
Number of metastatic lesions
1 11 (17.5%) 8 (11.6%) 0.928
2 35 (55.6%) 43 (62.3%)
≥3 17 (27.0%) 18 (26.1%)
Prior treatment
Radical prostatectomy 11 (17.5%) 5 (7.2%) 0.073
TUR-P 12 (19.0%) 11 (15.9%) 0.642
Surgical castration 7 (11.1%) 1 (1.4%) 0.020
Androgen-deprivation therapy 62 (98.4%) 69 (100%) 0.297
Lymph node dissection 13 (20.6%) 14 (20.3%) 0.961
Radiotherapy:
- prostate 26 (41.3%) 27 (39.1%) 0.804
- metastases 32 (50.8%) 24 (34.8%) 0.064
Samarium-153/strontium-89 3 (4.8%) 3 (4.3%) 0.910
Ipilimumab/placebo 4 (6.3%) 6 (8.7%) 0.614
Enzalutamide/placebo 1 (1.6%) 1 (1.4%) 0.949
Docetaxel:
 # cycles [median (range)] 10 (3-20) 9 (2-33) 0.552
Reason to stop:
- End of treatment 33 (52.4%) 23 (33.3%) 0.027
- Progressive disease 22 (34.9%) 23 (33.3%) 0.849
- Patient’s decision 2 (3.2%) 1 (1.4%) 0.510
- Physician’s decision 5 (7.9%) 7 (10.1%) 0.662
- Toxicity 8 (12.7%) 25 (36.2%) 0.002
- Unknown 0 (0.0%) 1 (1.4%) 0.341
- Other 0 (0.0%) 2 (2.9%) 0.176
Docetaxel rechallenge 9 (14.3%) 12 (17.4%) 0.413
Other 9 (14.3%) 15 (21.7%) 0.401
Time in months [median (IQR)] between:
PCa diagnosis and 2nd line therapy 49.7 (27.6-73.1) 61.1 (29.3-89.1) 0.195
mCRPC diagnosis and 2nd line therapy 17.8 (12.0-24.2) 16.5 (10.1-29.0) 0.427
last docetaxel and 2nd line therapy 5.6 (3.0-9.3) 3.7 (1.8-6.9) 0.051
Serum PSA concentration (ng/ml) at start second-
line therapy
Median (IQR) 291 (98-635) 130 (50-293) 0.022
<20 ng/ml 2 (3.2%) 9 (13.0%)
ECOG performance status at start second-line 
therapy
0-1 53 (84.1%) 58 (84.1%) 0.302
2 9 (14.3%) 11 (15.9%)
3 1 (1.6%) 0 (0.0%)
Data are number of patients (%) if not specified otherwise.  Abi, abiraterone; Cab, cabazitaxel; CNS, central nervous system; ECOG, 
Eastern Cooperative Oncology Group; IQR, interquartile range; mCRPC, metastatic castrate-resistant prostate cancer; PCa, prostate 




Cab→Abi (n=63) Abi→Cab (n=69) p-value
Second-line treatment
Mean treatment duration (days) (SD) 159.9 (70.9) 152.9 (89.1) 0.955
Patients with dose reduction (%) 23 (36.5%) 0 (0.0%)
Median cumulative dose (range) 150 (60-515) 129 (25-392)
Patients with additional therapy during treatment:
- Radiotherapy 7 (11.1%) 8 (11.6%)
- TUR-P/surgery 1 (1.6%) 1 (1.4%)
Reason to discontinue:
- End of treatment 13 (20.6%) 0 (0.0%)
- Progressive disease 37 (58.7%) 67 (97.1%)
- Toxicity 20 (31.7%) 4 (5.8%)
- Other 15 (23.8%) 7 (10.1%)
Patients without other therapy between Cab and Abi (%) 48 (76.2%) 51 (73.9%) 0.765
Patients with systemic therapy between Cab and Abi (%) 1 (1.6%) 10 (14.5%) 0.007
Enzalutamide/placebo (AFFIRM participants) 0 (0.0%) 5 (7.2%) 0.029
Docetaxel rechallenge 1 (1.6%) 6 (8.7%) 0.069
Ipilimumab 0 (0.0%) 1 (1.4%) 0.341
Mitoxantrone 0 (0.0%) 1 (1.4%) 0.341
Third-line treatment
Mean treatment duration (days) (SD) 138.8 (97.3) 100.8 (59.8) 0.021
Patients with dose reduction 3 (4.8%) 11 (15.9%)
Median cumulative dose (range) 109 (69-187) 100 (19-250)
Patients with additional therapy during treatment:
- Radiotherapy 19 (30.2%) 4 (5.8%)
- TUR-P/surgery 0 (0.0%) 0 (0.0%)
Reason to discontinue:
- 3rd line therapy still ongoing 3 (4.8%) 8 (11.6%)
- End of treatment 0 (0.0%) 5 (7.2%)
- Progressive disease 52 (82.5%) 42 (60.9%)
- Toxicity 5 (7.9%) 23 (33.3%)
- Death 3 (4.8%) 3 (4.3%)
- Other 10 (15.9%) 8 (11.6%)
Number of Cab cycles
Mean (SD) 7.3 (3.2) 4.6 (2.7) <0.001
Median (range) 7 (3-21) 4 (1-10)
Patients who initiated therapy at 20 mg/m 2 6 (9.5%) 9 (13.0%) 0.528
Patients who completed ≥10 cycles 18 (28.6%) 6 (8.7%)
Treatment duration of Cab and Abi combined (days)
Mean (SD) 298.7 (133.8) 253.8 (114.1) 0.172
Median (IQR) 275 (215-344) 238 (160-322)
Treatment after Cab and Abi
Patients who had discontinued third-line therapy 60 61
Patients with treatment after Cab and Abi 29 (48.3%) 34 (55.7%) 0.712
Enzalutamide/placebo 8 (13.3%) 13 (21.3%) 0.340
Radiotherapy 15 (25.0%) 20 (32.8%) 0.505
Samarium-153 3 (5.0%) 2 (3.3%) 0.579
Mitoxantrone 5 (8.3%) 6 (9.8%) 0.876
Cabozantinib/placebo 8 (13.3%) 4 (6.6%) 0.171
Cab rechallenge 3 (5.0%) 4 (6.6%) 0.793
Abi rechallenge 1 (1.7%) 4 (6.6%) 0.209
Other 9 (15.0%) 6 (9.8%) 0.405
Table 2. Treatment characteristics of patients treated with both cabazitaxel and abiraterone
Cumulative dose: Cab, mg/m²; Abi, g. Abi, abiraterone; Cab, cabazitaxel; IQR, interquartile range; SD, standard deviation; TUR-P, 
transurethral resection of the prostate
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Figure 1. Overall survival (OS) (A), progression-free survival (PFS) (B) and biochemical PFS (C) in metastatic castrate-
resistant prostate cancer (mCRPC) patients treated with both cabazitaxel and abiraterone. 
CI, confidence interval; HR, hazard ratio.
Table 3. Efficacy of Cab->Abi and Abi->Cab treatment
Cab→Abi (n=63) Abi→Cab (n=69) p-value
Second-line treatment
PFS
Mean [months (95% CI)] 5.3 (4.5-6.1) 3.2 (2.7-3.8) <0.001
Median [months (IQR)] 5.0 (2.1-7.8) 2.7 (1.4-4.6)
Biochemical PFS 
Mean [months (95% CI)] 6.0 (5.1-6.9) 3.4 (2.9-4.0) <0.001
Median [months (IQR)] 6.2 (3.0-8.4) 2.8 (1.5-5.0)
Best clinical response 
Progressive disease (%) 8 (12.7%) 19 (27.5%)
Partial response (%) 29 (46.0%) 18 (26.1%)
Best PSA response 
Progressive (%) 5 (7.9%) 21 (30.4%)






Mean [months (95% CI)] 2.9 (2.2-3.6) 3.2 (2.5-3.8) 0.451
Median [months (IQR)] 2.4 (0.9-3.5) 2.6 (1.3-4.5)
Biochemical PFS 
Mean [months (95% CI)] 3.6 (2.7-4.5) 4.0 (3.3-4.7) 0.389
Median [months (IQR)] 2.7 (1.4-4.7) 4.1 (1.4-5.1)
Best clinical response (n=62) (n=68)
Progressive disease (%) 24 (38.7%) 21 (30.9%)
Partial response (%) 10 (16.1%) 18 (26.5%)
Best PSA response (n=61) (n=66)
Progressive (%) 17 (27.9%) 14 (21.2%)
Partial response (%) 11 (18.0%) 21 (31.8%)
Patients with stable disease as the best response, are not reported in the table. CI, confidence interval; IQR, interquartile range; OS, 
overall survival; PFS, progression-free survival; PSA, prostate-specific antigen
Figure 2. Waterfall plots depicting maximum prostate-specific antigen (PSA) changes from baseline (A) and change 
in PSA from baseline at 12 weeks (B) in mCRPC patients treated with cabazitaxel and abiraterone. 
Abi, abiraterone; Cab, cabazitaxel.
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baseline and change in PSA from baseline at 12 weeks are displayed in Figure. 2. Cab→Abi 
treated patients had more frequently continuously rising PSA levels during cabazitaxel than 
Abi→Cab treated patients (Fig. 2A). This difference did not occur in abiraterone-treated 
patients; however, when assessing change in PSA from baseline at 12 weeks, patients 
receiving abiraterone after docetaxel had a slightly worse PSA outcome (Fig. 2B).
Subsequent performed subgroup analyses did not indicate that a subpopulation had a 
significantly improved OS when treated with one of the treatment sequences (Fig. 3A). 
However, a trend towards favorable median OS in Cab→Abi treated patients was observed 
in all subpopulations (HR>1; p>0.05 though), except for patients treated with less than 10 
cycles and patients who discontinued docetaxel due to PD (HR 0.90 and 0.76, respectively). 
Similar results were found when performing subgroup analyses for PFS (Fig. 3B). Patients 
aged below 65, patients with a Gleason 8-10, patients who received ≥10 docetaxel cycles 
and patients who had not received enzalutamide before abiraterone had a significantly 
better PFS when treated with Cab→Abi (HR 2.64, 1.64, 1.85 en 1.44, respectively, p≤0.05).
Safety of Cab→Abi and Abi→Cab therapy
In total, about 60% of patients needed hospitalizations during cabazitaxel or abiraterone 
treatment (Table 4). In the second-line, 15.9% of cabazitaxel-treated patients required ≥2 
hospitalizations, while only 7.2% of abiraterone patients required at least two hospitalizations 
(Abi→Cab group). No difference in hospitalizations was evident in the third-line. The primary 
adverse event causing hospitalization during cabazitaxel was febrile neutropenia (9.5% in 
Cab→Abi treated patients; 14.5% in Abi→Cab treated patients). Intriguingly, patients in 
the Abi→Cab group required more hospitalizations due to pain during both treatments 
(31.9% vs. 17.5% of Cab→Abi patients), while patients treated with Cab→Abi required more 
hospitalizations due to urinary tract infections (15.9% vs. 8.7%) and urinary obstruction 
during both treatments (7.9% vs. 1.4%).
Discontinuation of treatment due to toxicity occurred primarily during cabazitaxel therapy, 
with 21 patients (16.9%) having discontinued entirely because of toxicities (Table 4). For 
both therapies, main reasons to discontinue treatment were fatigue, malaise, nausea and 
vomiting. In cabazitaxel-treated patients, polyneuropathy was another frequently occurring 
toxicity resulting in treatment discontinuation. 
Fifteen patients (11.4%) died within 30 days of the last administration of abiraterone or 
cabazitaxel (Table 5). Two-thirds of these patients were treated with Cab→Abi. The greater 
number of deaths in this patient group most likely reflects the general trend of physicians to 
continue abiraterone treatment longer as compared to cabazitaxel, e.g. when patients have 
a lower ECOG performance status. Three patients (60.0%) in the Abi→Cab group died due to 





In recent years, cabazitaxel, abiraterone, enzalutamide, sipuleucel-T and radium-223 have 
been introduced to the clinic for mCRPC treatment. This rapidly expanding variety of available 
therapies has significantly improved survival of mCRPC patients.19 However, many questions 
remain how these therapies should be deployed in clinic to maximize clinical benefit. 
Treatment with one agent may influence the efficacy of another therapy. Recent studies 
have suggested decreased antitumor effects of mCRPC therapies when administered later 
in the disease. In a retrospective analysis of a small group of abiraterone pretreated mCRPC 
patients, docetaxel seemed to have lower antitumor efficacy than normally observed.13 No 
responses to docetaxel were evident in abiraterone-refractory patients. In other retrospective 
analyses, abiraterone had limited antitumor activity in patients treated with docetaxel and 
enzalutamide, although some patients still benefited from abiraterone therapy.16, 17 Similar 
modest antitumor activity was reported when enzalutamide was administered to mCRPC 
patients after docetaxel and abiraterone.14, 15, 20 A recent preclinical study has suggested that 
cross-resistance may occur between taxanes and abiraterone.21
Despite suggestions of cross-resistance, multiple recent retrospective studies reported 
antitumor activity from cabazitaxel in mCRPC patients after docetaxel and abiraterone or 
enzalutamide, with partial responses occurring in 14% to 30% of patients.22-24 In line with 
these study results, we observed a similar percentage of mCRPC patients who responded 
to cabazitaxel therapy after docetaxel and abiraterone, confirming that progression on 
these agents does not prelude a response to cabazitaxel. Similarly, we observed partial 
responses with abiraterone in mCRPC patients who had received docetaxel and cabazitaxel 
prior to abiraterone. Hence, these results suggest that additional clinical benefit may be 
accomplished by treating patients sequentially with all three agents.
However, when comparing PFS and biochemical PFS of cabazitaxel in Cab→Abi and Abi→Cab 
treated patients, a significantly decreased PFS and biochemical PFS was observed in patients 
who had received cabazitaxel after abiraterone. Of note, when only selecting patients who 
discontinued second-line therapy due to PD, a similar decreased antitumor efficacy of 
particularly cabazitaxel as third-line therapy was observed (data not shown). Although PFS 
and biochemical PFS did not differ significantly in abiraterone treated patients based on prior 
therapy with or without cabazitaxel, the PSA response after twelve weeks of abiraterone 
treatment was slightly better in Abi→Cab treated patients as judged by the waterfall plots. 
Further research is needed to assess whether this observed decreased antitumor efficacy 
in higher-line therapy is due to cross-resistance or other factors, such as tumor mutations, 
differences in the patient populations, or a decreased tolerability of advanced mCRPC 































































































































































































Table 4. Severe adverse events during cabazitaxel and abiraterone treatment
Cab→Abi (n=63) Abi→Cab (n=69)
During cab During abi Total During abi During cab Total
Patients with ≥1 hospitalization 21 (33.3%) 28 (44.4%) 37 (58.7%) 19 (27.5%) 35 (50.7%) 42 (60.9%)
Patients with ≥2 hospitalizations 10 (15.9%) 11 (17.5%) 20 (31.7%) 5 (7.2%) 10 (14.5%) 21 (30.4%)
Duration of hospitalizations (days) 
[median (IQR)] 5 (2-8) 5 (2-9) 5 (2-8) 5 (2-7) 5 (4-9) 5 (3-9)
Adverse events causing 
hospitalization
Anemia 1 (1.6%) 3 (4.8%) 4 (6.3%) 0 (0.0%) 3 (4.3%) 3 (4.3%)
Thrombocytopenia 1 (1.6%) 2 (3.2%) 3 (4.8%) 0 (0.0%) 1 (1.4%) 1 (1.4%)
Neutropenia 2 (3.2%) 0 (0.0%) 2 (3.2%) 0 (0.0%) 1 (1.4%) 1 (1.4%)
Febrile neutropenia 6 (9.5%) 3 (4.8%) 7 (11.1%) 0 (0.0%) 10 (14.5%) 10 (14.5%)
Pain 5 (7.9%) 6 (9.5%) 11 (17.5%) 11 (15.9%) 12 (17.4%) 22 (31.9%)
Urinary tract infection 5 (7.9%) 6 (9.5%) 10 (15.9%) 2 (2.9%) 5 (7.2%) 6 (8.7%)
Urinary obstruction 2 (3.2%) 3 (4.8%) 5 (7.9%) 0 (0.0%) 1 (1.4%) 1 (1.4%)
Hematuria 3 (4.8%) 1 (1.6%) 4 (6.3%) 1 (1.4%) 5 (7.2%) 6 (8.7%)
Renal function abnormalities 4 (6.3%) 2 (3.2%) 5 (7.9%) 2 (2.9%) 2 (2.9%) 4 (5.8%)
Pyrexia (not neutropenic) 3 (4.8%) 3 (4.8%) 6 (9.5%) 2 (2.9%) 5 (7.2%) 6 (8.7%)
Diarrhea 3 (4.8%) 1 (1.6%) 4 (6.3%) 0 (0.0%) 4 (5.8%) 4 (5.8%)
Nausea 3 (4.8%) 3 (4.8%) 4 (6.3%) 4 (5.8%) 4 (5.8%) 8 (11.6%)
Vomiting 4 (6.3%) 2 (3.2%) 6 (9.5%) 4 (5.8%) 4 (5.8%) 8 (11.6%)
Constipation 1 (1.6%) 2 (3.2%) 3 (4.8%) 1 (1.4%) 1 (1.4%) 2 (2.9%)
Dyspnoe 1 (1.6%) 2 (3.2%) 3 (4.8%) 3 (4.3%) 3 (4.3%) 5 (7.2%)
Pneumonia 2 (3.2%) 4 (6.3%) 6 (9.5%) 2 (2.9%) 2 (2.9%) 4 (5.8%)
Infection of the GI tract 0 (0.0%) 1 (1.6%) 1 (1.6%) 1 (1.4%) 2 (2.9%) 3 (4.3%)
Sepsis e.c.i. 1 (1.6%) 1 (1.6%) 2 (3.2%) 1 (1.4%) 3 (4.3%) 4 (5.8%)
Liver function test 
abnormalities 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (4.3%) 3 (4.3%)
Hypokalemia 0 (0.0%) 1 (1.6%) 1 (1.6%) 0 (0.0%) 2 (2.9%) 2 (2.9%)
Edema 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (1.4%) 1 (1.4%)
Allergic response 1 (1.6%) 0 (0.0%) 1 (1.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Spinal cord compression 4 (6.3%) 4 (6.3%) 7 (11.1%) 1 (1.4%) 4 (5.8%) 5 (7.2%)
Pathological fracture 0 (0.0%) 2 (3.2%) 2 (3.2%) 0 (0.0%) 1 (1.4%) 1 (1.4%)
Hypotension 1 (1.6%) 0 (0.0%) 1 (1.6%) 0 (0.0%) 2 (2.9%) 2 (2.9%)
Vertigo 0 (0.0%) 1 (1.6%) 1 (1.6%) 3 (4.3%) 1 (1.4%) 4 (5.8%)
Other 4 (6.3%) 12 (19.0%) 16 (25.4%) 11 (15.9%) 12 (17.4%) 20 (29.0%)
Discontinuation due to toxicity
# patients that discontinued 
therapy 63 60 69 61
- toxicity sole reason to 
discontinue 9 (14.3%) 2 (3.3%) 1 (1.5%) 12 (19.7%)
- toxicity important factor for 
discontinuation 11 (17.5%) 3 (5.0%) 3 (4.3%) 10 (16.4%)
- adverse events resulting in 
discontinuation:
- febrile neutropenia 1 (1.6%) 0 (0.0%) 0 (0.0%) 2 (3.3%)
- other hematological 
toxicity 1 (1.6%) 1 (1.7%) 0 (0.0%) 2 (3.3%)
- fatigue 8 (12.7%) 1 (1.7%) 2 (2.9%) 9 (14.8%)
- nausea/vomiting/malaise 5 (7.9%) 1 (1.7%) 1 (1.4%) 6 (9.8%)
- diarrhea 2 (3.2%) 0 (0.0%) 0 (0.0%) 3 (4.9%)
- polyneuropathy 5 (7.9%) 0 (0.0%) 0 (0.0%) 4 (6.6%)
- liver function abnormality 2 (3.2%) 1 (1.7%) 0 (0.0%) 2 (3.3%)
- other non-hematological 
toxicity 6 (9.5%) 3 (5.0%) 1 (1.4%) 11 (18.0%)
#, number; Abi, abiraterone; Cab, cabazitaxel; IQR, interquartile range
CAST-study
67
4(mutations that occur, pathways that are circumvented). Some evidence exists that taxanes play a role in the transnuclear localization of the androgen receptor, suggesting that taxanes 
target tumor cells in the androgen receptor pathway too.25 Such overlapping mechanisms of 
action may form a basis for cross-resistance.
In the CAST-study, we did not observe a statistically significant difference in median OS 
between Cab→Abi and Abi→Cab treated patients. However, a trend towards improved OS 
in Cab→Abi treated patients was noted, except for the subgroup of patients with rapid PD 
during docetaxel therapy. In a similar retrospective study, a better survival was reported in a 
cohort of patients treated with Cab→Abi compared to Abi→Cab treated patients.26 However, 
analysis of all patients that received cabazitaxel and/or abiraterone after docetaxel, including 
patients who received only one therapy, indicated that patients receiving abiraterone as 
second-line therapy tended to have a survival advantage, particularly due to a subgroup of 
patients with an extensive response duration (>1 year) to abiraterone. Therefore, no clear 
benefit of one therapy sequence over the other was observed in terms of OS. Larger patient 
groups may be needed to observe significant differences between therapy sequence, but 
currently this is the largest retrospective study comparing such treatment sequence in 
mCRPC patients.
When evaluating the safety data of Cab→Abi and Abi→Cab treated patients, we observed 
more severe toxicity during cabazitaxel treatment than during abiraterone treatment, similar 
to toxicity reports in their respective phase III studies.4, 9 Although results from cabazitaxel 
compassionate use programs reported fewer adverse events as compared to the TROPIC 
study,9, 27, 28 our results indicate that particularly febrile neutropenia can be serious and even 
life-threatening, contributing to patient death in 2-3% of cabazitaxel-treated patients. The 
potentially severe toxicity from cabazitaxel needs to be taken into account by physicians and 
patients when deciding treatment for their mCRPC. 
This study has various limitations due to its retrospective nature. Patients’ and treatments’ 
characteristics were inevitably not completely equal between treatment groups and not all 
Cab→Abi (n=63) Abi→Cab (n=69)
# patients 10 (15.9%) 5 (7.2%)
reason for patient death
- disease progression 8 (80.0%) 2 (40.0%)
- febrile neutropenia 0 (0.0%) 2 (40.0%)
- Non-neutropenic infection 0 (0.0%) 1 (20.0%)
- ileus 1 (10.0%) 0 (0.0%)
- unknown 1 (10.0%) 0 (0.0%)
#, number; Abi, abiraterone; Cab, cabazitaxel
Table 5. Patient deaths within 30 days of last treatment
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potentially variable characteristics were collected in the clinical setting (such as baseline 
lactate dehydrogenase or circulating tumor cell counts). Treatment choices were not 
standardized but based on factors such as the physician’s and patient’s preference. E.g., 
patients who responded well to docetaxel, were most likely more interested in cabazitaxel 
as second-line therapy than patients who discontinued docetaxel early due to heavy toxicity. 
Differences in the use of tumor imaging methods were evident: while some patients received 
bone and/or CT scans multiple times during treatment, others had not received a CT scan 
at all. Serum PSA levels were consistently measured every 3 to 4 weeks, but this marker has 
its limitations too.29 All such limitations occur with every retrospective study. Nevertheless, 
when several retrospective studies have a similar conclusion, this may be the best evidence 
we can get as a prospective randomized study may never be performed. Such a prospective 
study would need an extensive study duration and will be costly, whereas its clinical value 
will be limited due to the rapidly changing treatment landscape. E.g., patients had more 
advanced disease and had received extensive (experimental) chemotherapies in early 
cabazitaxel and abiraterone studies compared to mCRPC patients currently receiving these 
therapies. To a lesser extent the study population in our retrospective study is presumably 
not completely equal to the current mCRPC population, e.g. as some of these patients would 
receive enzalutamide these days. In the Netherlands, abiraterone is still only administered 
after docetaxel, while in other countries abiraterone is also administered before docetaxel.
In conclusion, this retrospective analysis of mCRPC patients treated with both cabazitaxel and 
abiraterone post-docetaxel found that progression on one agent did not prelude a response 
to the other agent, although antitumor efficacy of the agents, particularly cabazitaxel, was 
decreased when administered as higher-line therapy. Abi→Cab treated patients had more 
hospital admissions during cabazitaxel than Cab→Abi treated patients and discontinued 
cabazitaxel more frequently due to toxicity, while, as expected, abiraterone resulted 
generally in less severe toxicity as compared to cabazitaxel. These results should be used in 
the shared decision-making between patients and physicians, balancing the pros and cons 
of cabazitaxel or abiraterone after docetaxel. Further research is needed to provide more 
data regarding optimal treatment sequencing.
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Introduction: Metastatic castrate-resistant prostate cancer (mCRPC) is the second deadliest 
cancer in men. The group of taxanes, which target microtubules of mitotic cells, is currently 
the only chemotherapy which has proven to increase overall survival in mCRPC patients. 
Other mitotic inhibitors are being explored for their clinical potential in mCRPC treatment.
Areas covered: In this review, we summarize recent developments in the application of 
mitotic inhibitors for mCRPC from a clinical perspective. The four main groups of mitotic 
inhibitors currently being tested in clinical trials are microtubule inhibitors, polo-like kinase 
1 inhibitors, aurora kinase inhibitors and kinesin-spindle protein inhibitors. Compounds of 
these groups of inhibitors that are in clinical development for mCRPC are discussed. For this 
extensive overview, relevant literature was searched in PubMed and clinicaltrials.gov, and in 
presentations at ASCO/AACR meetings.
Expert opinion: In general, mitotic inhibitors are clinically well tolerated but exert limited 
antitumor activity compared to preclinical study results. However, efficacy of mitotic 
inhibitors is improving, either by personalizing treatment, by introducing more active 
compounds, by decreasing resistance of cancer cells against mitotic inhibitors, or by using 
mitotic inhibitors in combination therapies.




Metastatic castrate-resistant prostate cancer (mCRPC) is the second deadliest cancer in 
men, being only surpassed by lung cancer.1 The five-year survival rate of mCRPC patients is 
only 30%.1 Due to this high mortality, a major area of prostate cancer research focuses on 
the development of new therapies that are effective in mCRPC patients. 
Despite clinical testing of a wide variety of compounds, only two groups of compounds have 
been implemented to treat patients with advanced prostate cancer: hormonal therapy, which 
targets androgen receptors and/or androgen synthesis, and antimitotic chemotherapeutic 
agents. This chapter focuses on the latter one. 
The development of antimitotic drugs for prostate cancer treatment started in 1974, when 
patients with advanced prostate cancer were treated with estramustine.2 In the 1980s, it 
became known that estramustine interferes with microtubules, thereby targeting cancer 
cells in mitosis. In 1981, another antimitotic chemotherapeutic agent was tested in mCRPC 
patients: vincristine.3 In this study, 15% of patients treated with vincristine monotherapy had 
an objective response (partial response (PR) or stable disease (SD)), the median response 
duration being 22 weeks. In the same study, an objective response was established in 26% 
of estramustine-treated patients for a median duration of 20 weeks. Addition of vincristine 
to estramustine monotherapy did not improve its efficacy. 
Following this study, many other antimitotic agents have been tested in prostate cancer 
patients, with varying success. In this chapter, we will discuss the recent clinical development 
of different groups of mitotic inhibitors. We will focus on studies with mCRPC patients, but 
will also discuss results from clinical studies that tested antimitotic compounds in other 
advanced solid tumors with a potential impact on the treatment of mCRPC patients. Finally, 
we will briefly discuss results from recent studies, mostly preclinical, that are paving the way 
for future directions of clinical trials involving mitotic inhibitors in mCRPC patients.
Taxanes
Four Food and Drug Administration (FDA)-approved drugs have shown to increase 
progression-free survival (PFS) and overall survival (OS) in mCRPC patients: the hormonal 
therapies abiraterone acetate (Zytiga) and enzalutamide (Xtandi), and the taxanes docetaxel 
(Taxotere) and cabazitaxel (Jevtana). Generally, it is considered that taxanes act on cancer 
cells by targeting and stabilizing microtubules. Taxanes are thought to target cells in mitosis, 
as the incorrect formation of microtubules leads to mitotic arrest, and ultimately, apoptosis 
(Fig. 1). Although docetaxel was initially selected as an antitumor agent for its ability to cause 
mitotic arrest in cancer cells, it is now known that taxanes have other antitumor effects 
too, such as anti-angiogenic effects and p53 nuclear accumulation, the latter resulting in 
enhanced p53-induced apoptosis.4, 5 Furthermore, as reviewed by Thadani-Mulero et 
al.6, taxanes inhibit nuclear accumulation of the androgen receptor, as its trafficking is 
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microtubule-dependent. These intracellular effects may also contribute to mCRPC inhibition.
Docetaxel
In the early 2000s, mCRPC patients were treated with mitoxantrone (Novantrone), an 
anthracenedione which exerts its antitumor effect by inhibition of type II topoisomerase 
and by DNA/RNA intercalation.7 This therapy was approved based on the results of a 
phase III study in which 160 mCRPC patients were treated with prednisone with or without 
mitoxantrone.8 The study concluded that mitoxantrone increased quality of life, but did 
not increase OS in the (relatively small) group of patients treated with mitoxantrone. The 
treatment scope for mCRPC patients radically changed with the introduction of docetaxel in 
2004. Docetaxel binds to β-tubulin, stabilizing microtubules by polymerization.9 Therefore, 
mitosis is disrupted and cells arrest in G2/M phase, resulting in apoptosis, independent 
from p53. Docetaxel also counters the effect of expression of the anti-apoptotic oncogenes 
bcl-2 and bcl-xL.9 In 2004, the TAX-327 phase III study concluded that 335 mCRPC patients 
treated once every three weeks with docetaxel plus prednisone had an increased median 
OS compared to 337 mCRPC patients treated with mitoxantrone plus prednisone (18.9 vs. 
16.5 months, respectively).10 Adverse events resulting in discontinuation of treatment were 
fatigue, musculoskeletal or nail changes, sensory neuropathy, and infections. Similarly, a 
phase III study from the Southwest Oncology Group found an increased OS of 1.9 months 
in mCRPC patients treated with docetaxel plus estramustine (median OS 17.5 months) 
compared to treatment with mitoxantrone plus prednisone (median OS 15.6 months).11 
These studies resulted in FDA approval of docetaxel as first-line therapy in mCRPC patients. 
About 50% of docetaxel-treated mCRPC patients had a PR. To improve its efficacy, studies 
combining docetaxel with other antitumor agents have been performed in mCRPC patients. 
A recent meta-analysis of twelve phase II studies indicated that docetaxel-based combination 
Figure 1. Overview of a cell in metaphase (left) and telophase (right), detailing the main localizations of mitotic 
targets during mitosis. Eg5 and tubulin are localized at microtubules throughout mitosis. Plk1 and aurora kinases 
mainly localize to the spindle poles during metaphase and to the midbody at the end of mitosis. While aurora B 
localizes to the midbody at the end of mitosis as well, during metaphase it mainly localizes to centromeres. It needs 
to be taken into account that these enzymes localize to a lesser extent to other mitotic structure too.
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therapy may be more effective in mCRPC patients, increasing survival with similar adverse 
events compared to docetaxel monotherapy.12 However, treatment efficacy was not improved 
in any published phase III study in which high-dose calcitriol (vitamin D), bevacizumab 
(Avastin), risedronate, atrasentan (Xinlay), zibotentan, or GVAX immunotherapy was added 
to docetaxel treatment (Table 1).13-20 Furthermore, combining docetaxel with aflibercept 
(Zaltrap) did not significantly increase median OS in mCRPC patients; the combination of 
lenalidomide (Revlimid) with docetaxel did not have a statistically significant treatment 
effect either.21, 22 Currently, phase III studies are being performed in which docetaxel is 
combined with dasatinib (Sprycel) or OGX-011 (Custirsen) in mCRPC patients (Table 1).23-26 
Furthermore, multiple combination therapies have been tested with success in phase I/II 
clinical trials, such as the combination of docetaxel and temozolomide (Temodal) and the 
combination of docetaxel with zoledronic acid (Zometa).27, 28 Nevertheless, docetaxel plus 
prednisone remains standard first-line therapy.
Cabazitaxel
Recently, a second generation taxane, cabazitaxel (Jevtana), has received FDA approval as 
second-line therapy for mCRPC patients. Cabazitaxel is potentially superior to docetaxel, 
having low affinity with P-glycoprotein (P-gp), an ATP-dependent drug efflux pump.29 For 
registration, a randomised phase III clinical trial was performed in 755 patients with mCRPC 
who had progression after docetaxel treatment (TROPIC).30 In this study, patients received 
either 12 mg/m2 mitoxantrone or 25 mg/m2 cabazitaxel in combination with daily oral 
prednisone. Men treated with cabazitaxel had both increased OS and PFS, the median of 
the parameters being increased by 2.4 months (15.1 vs. 12.7 months) and 1.4 months (2.8 
vs. 1.4 months), respectively. Time to tumor progression (TTP) and time to prostate-specific 
antigen (PSA) progression were increased after cabazitaxel treatment as well, and 39.2% of 
cabazitaxel-treated patients had a reduction in serum PSA concentration of ≥50%. Grade ≥3 
neutropenia (82% vs. 58%), leukopenia (68% vs. 42%), anemia (11% vs. 5%) and diarrhea 
(6% vs. <1%) were increased in cabazitaxel-treated patients. Results of compassionate use 
programs have been published by Heck et al. and others.31-33 These post-marketing studies 
report similar responses, but less adverse events in mCRPC patients. Other clinical studies, 
summarized in Table 2, are being conducted to further optimize cabazitaxel use in mCRPC 
patients. 
Other taxanes
Besides aforementioned FDA-approved taxanes, other taxanes have been or are tested in 
prostate cancer as well, the most noteworthy being (nab-)paclitaxel and tesetaxel. 
Paclitaxel (Taxol) is a taxane that has been approved by the FDA for its use in ovarian cancer, 
breast cancer, non-small-cell lung cancer (NSCLC), and AIDS-related Kaposi sarcoma. A phase 
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a PR was established in only 4.3% of patients, while grade 4 toxicities such as leukopenia 
occurred in 61% of patients.34 Since then, multiple phase II studies have been conducted 
in mCRPC patients combining paclitaxel with radiotherapy or other chemotherapeutic 
agents.35-47 Most phase II studies concluded that the results did not warrant a phase III study, 
as either toxicity was too high, or efficacy was insufficient.36, 39, 42-46 No phase III study has 
been initiated in mCRPC patients.
Recently, the FDA approved nanoparticle albumin-bound (nab)-paclitaxel (Abraxane) in 
combination with carboplatin for the initial treatment of advanced NSCLC patients. The in 
vivo antitumor activity of nab-paclitaxel was lower in prostate cancer models than in mice 
with lung cancer and for this reason less thoroughly explored.48 However, nab-paclitaxel was 
evaluated in a phase II study as neoadjuvant therapy in high-risk prostate cancer patients 
before radical prostatectomy, with disappointing results.49 In another phase II study, nab-
paclitaxel was evaluated as a first-line therapy in 38 mCRPC patients.50 SD for >8 weeks 
was established in 43% of evaluable patients, the drug being well tolerated, leading to the 
conclusion that nab-paclitaxel may be useful in patients who are not suitable for docetaxel-
based therapy. No phase III studies have been initiated in mCRPC patients. Currently, a phase 
I study combining nab-paclitaxel with vandetanib, an inhibitor of tyrosine kinases, vascular 
endothelial growth factor receptor (VEGFR) and other kinases, is being conducted.51
Tesetaxel (DJ-927) is the first identified taxane which is administered orally.52 This taxane 
has a half maximal inhibitory concentration (IC50) of 0.395 ng/ml in DU-145 prostate cancer 
cells, and exerts antitumor effects in P-gp-mediated multidrug resistant cell lines in vitro 
and in vivo.52 Phase I studies with tesetaxel have been conducted; no mCRPC patients were 
Table 2. Ongoing clinical trials that aim to improve the efficacy of cabazitaxel in mCRPC patients. 
Study name Phase Aim Reference
PROSELICA III to compare cabazitaxel administered at 20 mg/m² to standard 
cabazitaxel treatment
208
- II to evaluate the use of cabazitaxel administered weekly at 10 mg/m² 209
ConCab II to compare cabazitaxel administered on day 1, 8, 15 and 22 at 10 mg/
m² in a 5-week cycle to standard cabazitaxel treatment
210
ProstyII II to evaluate the use of cabazitaxel administered biweekly at 16 mg/m² 211
- II to evaluate the reduction in diarrhea after addition of octreotide to 
standard cabazitaxel treatment
212
CABARESC II to evaluate the reduction in diarrhea after addition of budosenide to 
standard cabazitaxel treatment
213
FIRSTANA III to compare cabazitaxel to docetaxel as first-line therapy 214
AFFINITY III to compare standard cabazitaxel treatment with or without the 
addition of custirsen (OGX-011)
215
CATCH I to determine the recommended treatment dose of tasquinimod 
when added to standard cabazitaxel treatment
216
- I to evaluate the use of combination therapy with cabazitaxel and 
abiraterone acetate
217
- I/II to evaluate the use of combination therapy with cabazitaxel and 
bavituximab
218





included in these clinical trials. Patients with advanced solid tumor responded well to 
tesetaxel treatment (with or without capecitabine), 3.6% of patients having a PR or complete 
response, and 62.5% having SD.53, 54 The compound was well absorbed and had acceptable 
toxicities, the most frequent dose-limiting toxicity (DLT) being (febrile) neutropenia and 
gastrointestinal disorders. A phase II study with tesetaxel in patients with progressive 
mCRPC is ongoing.55
Other microtubule inhibitors
Besides taxanes, other microtubule inhibitors have been developed for mCRPC patients. The 
development of most of these inhibitors, such as vincristine, has been discontinued, except 
for the epothilones.56 
Epothilones stabilize microtubules by binding to tubulin as well.57 Despite their similar 
mechanism of action, the structure of epothilones is quite different from taxanes, and 
interestingly, epothilones have antitumor effects in taxane-resistant cancer cell lines.57-59 
Furthermore, epothilones are effective in tumors that overexpress multidrug resistance 
proteins such as multidrug resistance protein 1 (MDR1) and multidrug resistance-associated 
protein 1 (MRP1).59, 60
Ixabepilone (BMS-247550), an epothilone B analogue, is the only epothilone that has received 
FDA approval, namely for the treatment of advanced breast cancers. Its use is controversial, 
as OS was only extended in subset analyses of two phase III studies with patients with breast 
cancer.61-65 Five phase I/II studies have been conducted with ixabepilone in mCRPC patients 
(Table 3).66-70 Because a phase II study comparing mitoxantrone to ixabepilone reported that 
the two compounds have similar efficacies and toxicities, it is unlikely that ixabepilone will 
have a future role in mCRPC treatment.69 However, ixabepilone is currently being tested in a 
phase II study as neoadjuvant therapy in patients with high risk, clinically localized prostate 
cancer. Preliminary results indicate that ixabepilone effectively reduced the PSA levels in a 
majority (87.5%) of patients.71 However, as the clinical significance of changes in serum PSA 
levels after therapy is disputed, the prostate cancer working group (PCWG) recommends to 
focus on PSA progression instead of PSA response.72 Therefore, long-term follow up of these 
patients needs to be done to assess the clinical benefit for patients, especially as ixabepilone 
also had significant toxic effects, with only 31.3% of patients being able to finish treatment.
Patupilone (EPO906), epothilone B, has been studied in mCRPC patients in two phase II 
clinical trials (Table 3).73, 74 In the phase II study by Hussain et al., patupilone hardly showed 
Table 3 (right page). Clinical studies testing epothilones in metastatic castrate-resistant prostate cancer patients.
Only studies have been included in which all patients had been diagnosed with mCRPC. # pts, number of patients; SD, stable 
disease; PR, partial response; PFS, progression-free survival; TTPP, time to PSA progression; TTP, time to progression; OS, overall 
survival; PSA, prostate-specific antigen; mCRPC, metastatic castrate-resistant prostate cancer; MTD, maximum tolerated dose; 
RP2D, recommended phase II dose; DLT, dose-limiting toxicity; AE, adverse event; IV, intravenous; Ref, reference.




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































any efficacy, as 15 out of 16 patients with measurable disease had continuous progressive 
disease (PD), and only 13% of all patients had a decrease in PSA of ≥50%. The second phase 
II study, performed by the Canadian Urologic Oncology Group, reported that 47% of patients 
had a PSA decline of ≥50%, and 24% of patients with measurable disease had a measurable 
PR. This improved response was most likely caused by the different patient population, as 
patients in the second study had more advanced prostate cancer. Intriguingly, patients in 
both studies did not have significant hematological toxicities, diarrhea and fatigue being the 
most frequent grade ≥3 adverse events.
KOS-862, epothilone D, was tested in 38 mCRPC patients who had progressed following 
docetaxel therapy.75 This epothilone lacked antitumor activity, while toxicity was severe.
Finally, sagopilone (ZK-EPO), a fully synthetic epothilone, plus prednisone have recently been 
tested in chemonaive mCRPC patients in a phase II study.76 Similar to patupilone, very few 
patients treated with this compound had hematological adverse events. Although 37.0% of 
patients had a PSA decrease of ≥50%, the measured efficacy did not warrant a comparison 
between sagopilone and docetaxel in a phase III study. 
Kinesin spindle protein inhibitors
While taxanes were the first group of chemotherapeutic agents that successfully extended 
survival in mCRPC patients, a major disadvantage of these tubulin-targeting agents is that 
they target microtubules in healthy non-dividing cells too, where microtubules have both 
mechanical (structural) and transportational functions.77 Due to this lack of specificity for 
cancer cells, administration of taxanes may result in serious side effects in patients, such 
as neurotoxicity.10 Therefore, mitotic inhibitors with improved specificity for tumor cells 
would provide benefit for patients. Kinesin spindle protein (KSP) inhibitors specifically target 
mitotic cells by inhibiting the mitotic kinesin Eg5, an enzyme of the kinesin-5 subfamily.78, 79 
Eg5 is active during mitosis only, separating spindle poles during metaphase, as it crosslinks 
two antiparallel microtubules and moves to the plus-ends of both microtubules (Fig. 1).79 
Inhibition of Eg5 leads to mitotic arrest, ultimately resulting in apoptosis.80 The exact 
mechanism by which apoptosis is induced is still disputed.80-84 Healthy cells that rapidly divide 
are inhibited by KSP inhibitors too. Therefore, the major side effects in patients treated 
with KSP inhibitors are of hematological origin, such as neutropenia and thrombocytopenia. 
Stimulating the bone marrow by addition of granulocyte colony-stimulating factor (G-CSF) 
can decrease the severity of some hematological adverse events. 
Multiple KSP inhibitors have been identified, but only one KSP inhibitor has been tested 
specifically in prostate cancer patients, namely ispinesib. 
Ispinesib (SB-715992, NSC-727990)
Ispinesib is a highly specific and potent inhibitor of the KSP ATPase.85 This quinazolinone 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































derivative has been successfully tested in phase I clinical trials in patients with advanced 
solid tumors (Table 4).86-89 In one phase I study combining docetaxel and ispinesib, the 
majority (58.3%) of patients had been diagnosed with mCRPC.86 Of the 14 patients with 
mCRPC included in this trial, six patients had SD for ≥18 weeks, and one patient had a 
PSA decrease of ≥50%. Toxicity was acceptable. A phase II clinical trial was started by the 
Southwest Oncology Group in which ispinesib was administered to mCRPC patients who 
had progressed during/after docetaxel.90 Patients were i.v. treated once every three weeks 
with 18 mg/m2 ispinesib 1h. No response was seen in the first 21 patients included in this 
trial. Immunohistochemistry analysis on archival tumor tissue from 16 of the 21 patients 
indicated that 15 out of 16 patients did not have significant expression of KSP inside the 
tumor. Therefore, it was concluded that ispinesib is most likely not effective in primary 
prostate tumors due to the low mitotic index of these tumors, resulting in low KSP expression. 
However, a more recent study found that 50% of prostate tumor samples stained positive 
for KSP.91 
Other KSP inhibitors
Four other potent and selective KSP inhibitors have been tested in patients with solid tumors 
in phase I studies: SB-743921, MK-0731, AZD-4877 and ARRY-520 (Table 4).92-97 Although 
none of these phase I studies focused on prostate cancer patients in particular, mCRPC 
patients were included in studies for MK-0731 and AZD-4877. 
MK-0731, a compound that is thought to have an allosteric regulation of KSP, was 
administered to seven mCRPC patients.93 Four mCRPC patients received MK-0731 at the 
maximum tolerated dose (MTD) of 17 mg/m2. Although PSA reductions of >50% were 
observed, no mCRPC patient had SD for more than 5 months.
AZD-4877 has been tested in patients with advanced solid malignancies in three phase 
I studies (Table 4). In the study by Infante et al., two mCRPC patients were included.95 
Individual observations of these patients were not reported. In a Japanese phase I study 
with AZD-4877, one included patient had prostate cancer and one prostate/renal cancer. 
Both patients received 15 mg AZD4877 via a 1h i.v. infusion on days 1, 8 and 15 of a 28-day 
cycle.94 The patient with prostate/renal cancer had SD for more than two cycles. 
ARRY-520 is currently being tested in phase I/II studies in patients with multiple myeloma. 
The clinical development of ispinesib, SB-743921, MK-0731, or AZD-4877 have all been 
discontinued, as these KSP inhibitors had limited antitumor effects at the MTD in patients 
with advanced solid tumors and/or mCRPC in particular. New KSP inhibitors such as K858 
and S-trityl-L-cysteine are in preclinical development and could potentially decrease adverse 
events and/or increase the efficacy of KSP inhibitors.91, 98, 99




Aurora kinases are a group of serine/threonine kinases characterized by an activation loop, a 
destruction box, and three conserved aurora boxes at the amino terminal domain.100, 101 The 
aurora family consists of three enzymes: aurora A, B and C. Aurora A localizes to the spindle 
poles during mitosis and to the midbody during cytokinesis (Fig. 1).100 Its activity peaks 
during pro-metaphase, but it plays a role in regulation of the cell cycle from late S-phase 
to mitotic exit, including regulation of centrosome maturation, mitotic entry, centrosome 
separation, bipolar spindle assembly, chromosome alignment and cytokinesis.101-105 Aurora 
B has a nuclear localization during mitosis, but during cytokinesis it localizes to the midbody 
as well (Fig. 1).100 Aurora B is active during G2/M phase; its activity peaks from the end of 
metaphase until the end of cytokinesis.101, 106 It is necessary for mitotic entry, the correct 
regulation of spindle microtubule-kinetochore attachments, chromosome condensation, 
the mitotic spindle assembly checkpoint, chromosome segregation, and cytokinesis.101 
Aurora C is hardly expressed in normal cells except germ line cells, and is involved in meiosis. 
Although it was thought that aurora C does not play a role in tumorigenesis, some recent 
preclinical studies indicate that aurora C may have oncogenic activity as well.107, 108
Aurora A and B are overexpressed in various cancers, including prostate cancer.109 
Overexpression of aurora A is associated with the transformation of prostate 
adenocarcinoma to treatment-related androgen-independent neuroendocrine prostate 
cancer.110-112 Furthermore, preclinical studies have indicated that aurora A may aid in 
androgen-independent prostate cancer cell growth by phosphorylating and activating the 
androgen receptor.113 Inhibition of aurora kinases results in polyploidy and apoptosis.114, 115 
Therefore, multiple aurora kinase inhibitors have been introduced in clinic. In the following 
sub-sections, aurora kinase inhibitors that have recently been studied in clinical trials with 
(amongst others) mCRPC patients will be discussed (Table 5).
Danusertib (PHA-739358)
Danusertib is a pan-aurora kinase inhibitor that binds to the ATP pocket. This pyrrolopyrazole 
targets other tyrosine kinases, most notably Abl, as well.116, 117 The IC50s were 220 and 120 
nM in DU-145 and PC3 prostate cancer cells, respectively, as determined by cell proliferation 
assays.117 In the in vivo transgenic adenocarcinoma of the mouse prostate model, danusertib 
inhibited tumor growth in 81.3% of mice.117 Results from two phase I studies with danusertib 
in patients with advanced solid tumors, amongst others mCRPC, have been published (Table 
5).118, 119 None of the included mCRPC patients had a PR or prolonged (≥6 months) SD. In the 
phase II study conducted in mCRPC patients, 2 out of 81 evaluable patients (2.5%) had a 
PSA reduction of ≥50% after three months.120 Median PFS was 2.8 months; 13.6% (11/81) of 
patients had a PFS ≥6 months. The main grade ≥3 adverse event was neutropenia, the most 
frequent side effect of aurora kinase inhibitors in general. Due to the limited PSA response, 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Alisertib is a second-generation aurora kinase A inhibitor. It is thought to be more potent 
than its predecessor, MLN8054, and has reduced benzodiazepine-like adverse events 
compared to MLN8054 (Table 5).121 It effectively inhibits a wide variety of tumor cell lines 
in vitro; in PC3 cells the IC50 was 54 nM.
122, 123 In vivo administration of alisertib resulted in 
tumor growth inhibition, amongst others in CWR22 prostate cancer xenografts.122 
Multiple phase I/II studies have been conducted with alisertib in solid tumors. Only one 
study by Dees et al. included mCRPC patients; none of the four mCRPC patients had a PR.124 
In addition, one phase I study is currently ongoing to evaluate the safety and tolerability of 
MLN8237 in combination with docetaxel, which has a focus on mCRPC.125
Barasertib (AZD1152)
Barasertib is the first identified highly selective aurora B inhibitor.126 This 5-acetanilide-
substituted 3-aminopyrazole effectively inhibited tumor growth of colorectal, leukemic 
and lung cancers in vivo.126, 127 A preclinical study in prostate cancer cells concluded that 
pretreatment of these cells with barasertib, administered at 60 nM for 48 h, increased DNA 
damage inflicted by radiotherapy, and impaired DNA repair mechanisms.128 
Two phase I studies with barasertib in patients with advanced solid tumors have been 
published.129, 130 In the study by Boss et al., two mCRPC patients were included and received 
weekly barasertib via a 2h i.v. infusion.129 Of all patients in this treatment schedule, 36.8% of 
patients had SD after six weeks of treatment.
ENMD-2076
ENMD-2076, a tartrate salt, is a tyrosine kinase inhibitor with activity not only against aurora 
A (IC50 14 nM) and B (IC50 350 nM), but also against other enzymes, such as enzymes involved 
in angiogenesis (VEGFR, fibroblast growth factor receptor (FGFR), etc.) or the FMS-like 
tyrosine kinase-receptor 3 (Flt3) (IC50 1.86 nM), a potential target for leukemic tumors.
131, 
132 The antiproliferative IC50 value for PC3 cells was established at 600 nM, for other tumor 
cell lines IC50s were in the nanomolar range (25-700 nM) as well. Treating mice with doses 
ranging between 50 and 225 mg/kg resulted in effective tumor growth inhibition of a wide 
variety of tumors.132
In clinical studies, the most frequent DLT/grade ≥3 treatment-emergent adverse event was 
hypertension instead of neutropenia.133, 134 No patient included in clinical trials had been 
diagnosed with mCRPC. Phase II studies with ENMD-2076 are ongoing in patients with 
metastatic sarcomas and advanced/metastatic triple-negative breast cancer.135, 136
Tozasertib (MK-0457, VX-680)
Tozasertib is a pan-aurora kinase inhibitor, targeting the ATP-binding site of aurora 
kinases, and is most effective in inhibiting aurora A.137 Its IC50 is in the lower nanomolar 
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range (<100nM) in a variety of cell lines, amongst others PC3 cells. As tozasertib has cross-
reactivity with Flt-3, it has most extensively been studied in leukemia, but some phase I/
II studies have been conducted with tozasertib in patients with solid tumors as well. In the 
published phase I study with tozasertib in patients with advanced solid tumors, two mCRPC 
patients were included, of which one had SD for six cycles.138 This patient had been treated 
with a combination of tozasertib orally and i.v. at the MTD. 
Other aurora kinase inhibitors
Various other aurora kinase inhibitors have been tested recently in patients with advanced 
solid tumors: (1) AT9283, an inhibitor of aurora A and B, as well as other serine/threonine 
kinases, such as Jak2, Jak3 and Abl; (2) PF-03814735, an orally bioavailable inhibitor of 
aurora A and B; (3) BI 811283, an aurora kinase B inhibitor; (4) MK-5108, an aurora kinase 
A inhibitor; and (5) SNS-314, a pan-aurora kinase inhibitor.138-143 SD was reported as the 
best response in phase I studies with these compounds in patients with advanced solid 
tumors.144-149 Due to the limited response, no further studies are conducted with these 
agents in adults with solid tumors.
New aurora kinase inhibitors are emerging from preclinical research, which potentially 
optimize the effect of aurora kinase inhibition, while minimizing adverse events. Examples 
of such inhibitors are HOI-07, AMG-900 and GSK1070916A, of which the latter two are 
currently studied in clinical trials.150-152
AMG-900 is a recently discovered, highly selective and potent orally bioavailable pan-
aurora kinase inhibitor. It inhibits cell lines resistant against paclitaxel and the aurora kinase 
inhibitors AZD1152, MK-0457 and danusertib in low nanomolar ranges (<5 nM).151 Oral 
administration of AMG-900 at a concentration of 15 mg/kg (days 1 and 2 weekly) or 3 mg/
kg/day in vivo inhibited tumor growth by 50-97% in nine different xenograft models, of 
which three were multidrug-resistant tumor models. A phase I study is ongoing in patients 
with advanced solid tumors, in which the MTD has been determined at 24 mg without G-CSF 
support when administered for four consecutive days every two weeks.153 
GSK1070916A is a selective ATP-competitive inhibitor of aurora B and C, with a high enzyme-
inhibitor dissociation half-life of >8h for the aurora B-INCENP (inner centromere protein) 
enzyme.152, 154 In PC3, LNCaP and DU-145 prostate cancer cell lines, the IC50 was ≤15 nM.
155 
In in vivo studies, administration of GSK1070916A resulted in delayed tumor growth, and 
in tumor reductions in lung, colorectal and hematological cancer models.155 A phase I study 
has been initiated in patients with advanced solid tumors.156 
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Polo-like kinase 1 inhibitors
Polo-like kinase 1 (Plk1) is a serine/threonine kinase, which is a part of the family of five 
polo-like kinases.157 The enzyme plays essential roles during mitosis: major functions 
include activation of Cdc2, bipolar spindle assembly, centrosome maturation, chromosome 
condensation and separation, regulation of the anaphase-promoting complex and initiation 
of cytokinesis (Fig. 1).158, 159 More recently, extra-mitotic roles of Plk1 have been discovered, 
such as downregulation of p53.160, 161 Plk1 is overexpressed in various tumors, amongst others 
in prostate cancer.158, 162 Its expression is increased in androgen-insensitive prostate cancer 
cells, suggesting that it plays a role in androgen-independent growth, similar to aurora 
kinases.163 As Plk1 is overexpressed and contains two highly specific polo-box domains 
(PBDs) in the C terminus, agents that bind to these PBDs can highly selectively target cancer 
cells.158 Multiple Plk1 inhibitors have been developed, of which volasertib, TAK-960, TKM-
080301, NMS-1286937 and rigosertib are currently being studied in patients with solid 
tumors. Similar to aurora kinase inhibitors, neutropenia is the most frequent adverse event 
in patients treated with Plk1 inhibitors.
HMN-214
HMN-214, an oral prodrug of HMN-176, was the first Plk1 inhibitor tested in clinic.164 
HMN-176 is a stilbazole derivative cytotoxic to PC3 and DU-145 cells as well as cisplatin-, 
adriamycin-, vincristine-, etoposide- and taxol-resistant cancer cell lines.164 HMN-214 had 
equal or superior antitumor activity in mice with established PC3 tumors compared to 
cisplatin, adriamycin, vincristine and tegafur-uracil (UFT).164 In a phase I study, HMN-214 
had limited antitumor effects.165 No patient had been diagnosed with prostate cancer. From 
another phase I study, final results have not been reported.166 No phase II trial has been 
initiated.
Volasertib (BI 6727)
BI 2536 and its successor volasertib are dihydropteridine derivatives, inhibiting Plk1 by 
competitively binding to its ATP-binding pocket.167, 168 The compounds have IC50s in the 
low nanomolar range in amongst others prostate cancer cells, and exert in vivo antitumor 
activity as well.167-169 A summary of clinical trials with BI 2536 and volasertib in patients with 
solid tumors can be found in Table 6.
In one phase II and two phase I studies mCRPC patients were treated with BI 2536. None 
of the two mCRPC patients included in the phase I study by Mross et al. had SD for >3 
months.170 In the other phase I study, one of three mCRPC patients had SD for >3 months.171 
In the phase II study, twenty mCRPC patients were treated with 200 mg BI 2536 via a 1h 
i.v. infusion.172 One-third of evaluable patients had SD after four courses. Grade 3 or 4 
neutropenia was observed in 20% (4 out of 20) of patients. Due to the limited antitumor 
activity, it was decided not to assess BI 2536 any further as a single agent. Although BI 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2536 was well tolerated by patients, combination therapy was not pursued due to the 
introduction of volasertib.
Volasertib is thought to have superior efficacy and/or to be less toxic compared to BI 
2536.169 One phase I study in which patients with advanced solid tumors were treated with 
BI 6727 has been published.173 In this study, four patients had been diagnosed with mCRPC. 
Three of 65 patients had a PR (4.6%), none of whom were mCRPC patients. SD for more 
than 3 months was established in 26.2% of patients. As volasertib was well tolerated, (pre)
clinical research with this small molecule as a monotherapy and in combination with other 
therapies is ongoing.169, 174-179
GSK-461364
GSK-461364, a thiophene amide, is an ATP-competitive Plk1 inhibitor, which has over a 
100-fold greater potency for Plk1 than 50 other kinases, including Plk2 and Plk3.180 In a 
panel of >120 cancer cell lines, GSK-461364 had IC50s below 100 nM in 91% of cell lines, the 
inhibitor thus causing a prometaphase arrest.181 In a phase I study performed in patients 
with advanced solid malignancies (Table 6), one mCRPC patient was included.182 This patient 
did not respond to GSK-461364 treatment. No phase II studies have been initiated with this 
compound.
Other Plk1 inhibitors
Apart from aforementioned Plk1 inhibitors, three Plk1 inhibitors with different delivery 
methods have been developed: TAK-960, NMS-1286937 and TKM-080301. These compounds 
had promising results in preclinical studies and are currently being studied in patients with 
advanced solid tumors in phase I clinical trials (Table 6).183-185
NMS-1286937 (NMS-P937) is an orally bioavailable 4,5-dihydro-1H-pyrazolo[4,3-h]
quinazoline derivative.186 It targets highly selectively Plk1 (IC50 2 nM), and inhibits cell 
proliferation in a wide variety of cancer cell lines, both solid and hematological, at 
low nanomolar concentrations.187 NMS-1286937 effectively inhibited tumor growth in 
established human colorectal and leukemic xenografts with minimal and reversible weight 
loss.186, 187
TAK-960 is another orally bioavailable Plk1 inhibitor. It exhibited antitumor activity in vitro 
at low nanomolar concentrations, arresting tumor cells, including cells that express MDR1, 
in G2/M phase.188 TAK-960 inhibited tumor growth amongst others in mice with established 
PC3 human prostate tumors.
TKM-080301 is a lipid nanoparticle (LNP) containing small interfering RNA against human 
Plk1 mRNA.189, 190 Due to its selective distribution, myelosuppression and other common 
side effects of Plk1 inhibitors may be reduced. Indeed, in vivo studies reported that tumor 
growth was inhibited and toxicity largely restricted to the liver and spleen.190




Rigosertib (Estybon) is a benzyl styryl sulfone analog, which inhibits both Plk1, by 
competitively binding to the substrate binding site, and the PI3K pathway.191, 192 IC50 values 
of rigosertib in DU-145 and PC3 cells were 200 and 150 nM, respectively.191 The in vivo 
antitumor activity of rigosertib was increased when combined with other chemotherapeutic 
agents (oxaliplatin, doxorubicin or gemcitabine).191 Therefore, clinical studies have not been 
initiated in mCRPC patients, but mostly focus on tumors in which these chemotherapies are 
used, such as pancreatic cancer (Table 6).193 
Conclusions
Docetaxel and cabazitaxel are mitotic inhibitors and are currently used in clinic as first- and 
second-line therapies for mCRPC patients. Due to this success, and with new mitotic targets 
for cancer therapy being discovered, multiple mitotic inhibitors are being studied for their 
use in mCRPC treatment. These inhibitors can be divided into four groups: microtubule 
inhibitors, KSP inhibitors, Plk1 inhibitors and aurora kinase inhibitors. Of these last three 
groups, Plk1 inhibitors and aurora kinase inhibitors are currently most extensively studied 
in mCRPC patients. Currently, these inhibitors seem to have most clinical potential in 
hematological tumors. However, combination therapies and new compounds with increased 
potency and selectivity are being studied in patients with prostate cancer and other solid 
tumors as well. 
Expert opinion
Recently, the treatment scope for mCRPC patients has expanded. Besides docetaxel, other 
life-extending therapies, such as the second-generation taxane cabazitaxel, have entered 
the market. Therefore, the need for a good biomarker to assess the response to therapy 
has become stringent. Although changes in serum PSA levels are now mostly used as an 
indicator for the response to mCRPC treatment, its clinical significance remains controversial. 
Increasing serum PSA levels during the first 12 weeks of treatment are considered unreliable; 
therefore, physicians are encouraged to continue treatment beyond 12 weeks despite rising 
PSA levels, unless PD is determined via other objective assessments.72 This recommendation 
would cause overtreatment and a treatment delay in patients who do have continuous PD. 
Overtreatment and treatment delays could be further reduced by introducing markers 
that predict the response to therapy. Such markers form the basis for targeted therapy 
in other cancers: e.g., breast cancer patients whose tumors express estrogen receptor or 
human epidermal growth factor receptor 2 will be treated with tamoxifen or trastuzumab, 
respectively.194, 195 Although mitotic inhibitors are targeted therapies against a single or 
group of enzyme(s), such as Plk1, it is intriguing that none of aforementioned clinical trials 
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determined a priori the expression of the targeted enzyme(s) in the tumor, while tissue is 
available from all mCRPC patients as biopsies have been taken. Not all tumors overexpress 
these enzymes: e.g., only about 50% of prostate tumors overexpress KSP or Plk1.91, 162 Future 
clinical studies need to determine whether the a priori expression of the targeted mitotic 
enzyme inside mCRPC cells is of influence of the antitumor efficacy of the mitotic inhibitor in 
humans. KSP inhibitors or Plk1 inhibitors may have no effect in 50% of mCRPC patients whose 
tumors do not overexpress the targeted enzyme. Aurora kinase inhibitors may exert most 
antitumor effect in aggressive tumors with a treatment-related neuroendocrine phenotype, 
as aurora A is more regularly overexpressed in these tumors.111 If this is confirmed, treatment 
of mCRPC patients may be personalized based on this expression profile. Alternatively, if 
these inhibitors do exert an antitumor effect in tumors that do not express the targeted 
enzyme, off-target antitumor effects of these inhibitors need to be assessed. 
With an increasing number of therapies to which only part of mCRPC patients respond, it is 
expected that personalized medicine, in which treatment is based on the expression profiles 
of tumors, will play an increasingly important role in mCRPC treatment.
The antitumor effect of mitotic inhibitors could be further improved by improving the 
specificity of the compound for cancer cells. This can be achieved by optimizing the 
compound itself and/or by improving its method of delivery, e.g. by delivery in LNPs which 
specifically bind to tumor cells. Furthermore, compounds could potentially be used in 
combination therapy to accomplish synergistic antitumor effects.  
Preclinical studies suggest that mitotic inhibitors may be combined with docetaxel.112, 196, 197 
In a recently performed phase I study in patients with advanced solid tumors, combination 
of MK-5108 with docetaxel resulted in a PR in 2 out of 17 patients (no patient with MK-5108 
mono-therapy had a PR), but also in more serious adverse events.148 Other clinical trials 
combining aurora kinase inhibitors with docetaxel are being performed, such as a phase 
I study with MLN8237.125 An important limitation of these clinical studies is that aurora 
kinase inhibitors are administered after docetaxel treatment, while a preclinical report 
suggests that this combination therapy is most effective when aurora kinase inhibitors are 
administered before docetaxel.143 
Recently, Feng et al. discovered that miR-100 (microRNA) resensitized docetaxel-resistant 
lung adenocarcinoma SPC-A1 cells to docetaxel.198 Plk1 was identified as a direct target 
of miR-100, and knock-down of Plk1 or (over)expression of miR-100 resulted in increased 
sensitivity to docetaxel in vitro and in vivo, respectively. 
These data indicate that the combination of mitotic inhibitors with docetaxel could 
potentially result in an enhanced antitumor effect in mCRPC patients.
Other combinations involving mitotic inhibitors should be tested as well. Multiple clinical 
trials are currently being performed in which mitotic inhibitors are combined with other 
compounds, such as the combination of volasertib with the triple angiokinase inhibitor 
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BIBF1120 (an inhibitor of the VEGF receptor, and PDGFR (platelet-derived growth factor 
receptor) and FGFR kinase activity in cancer cells).176 With the increasing interest in 
combination therapies for cancer treatment, it is important to select combination therapies 
based on a rationale. Recently, a preclinical study from our group indicated that the 
combination of mitotic inhibitors with histone deacetylase (HDAC-)inhibitors may have 
clinical benefit in prostate cancer patients.169, 199, 200 This combination therapy targets the 
mitotic pathway from both a genetic and epigenetic perspective, while other cancer-related 
pathways are targeted as well. More (pre)clinical studies need to be performed to create 
and test such rational combination therapies.
Resistance of tumor cells to taxanes and other chemotherapies limits their use. Only 50% of 
mCRPC patients respond to docetaxel therapy, and eventually all tumors become docetaxel 
refractory.10 The response rate is similar or even lower after treatment with other mitotic 
inhibitors. A wide variety of intracellular alterations have occurred in docetaxel-resistant 
mCRPC cells, such as increased expression of the Notch and Hedgehog signaling pathways 
and increased expression of TGF-β, MDR1 and MRP1.201, 202 As summarized by Madan et al., 
these alterations result in increased drug efflux by transmembranic pumps such as P-gp, 
changes in the site to which taxanes bind to microtubules, increased dynamic activity of 
microtubules, and changed expression of subunits of microtubules such as βIII.203 Research 
is ongoing in which intracellular changes leading to chemotherapy resistance are being 
utilized as markers for therapy response. Furthermore, other studies are assessing how 
these intracellular changes can be prevented, reverted or targeted, which would have 
significant clinical consequences.
As aforementioned therapy improvements – overcoming therapy resistance, and introducing 
personalized medicine, compounds with improved specificity, improved methods of 
delivery and combination therapy – are currently extensively studied, it is expected that 





 1.  Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62(1):10-29.
 2.  Muntzing J, Shukla SK, Chu TM, Mittelman A, Murphy GP. Pharmacoclinical study of oral 
estramustine phosphate (Estracyt) in advanced carcinoma of the prostate. Invest Urol 
1974;12(1):65-68.
 3.  Soloway MS, de Kernion JB, Gibbons RP et al. Comparison of estramustine phosphate 
and vincristine alone or in combination for patients with advanced, hormone refractory, 
previously irradiated carcinoma of the prostate. J Urol 1981;125(5):664-667.
 4.  Belotti D, Vergani V, Drudis T et al. The microtubule-affecting drug paclitaxel has 
antiangiogenic activity. Clin Cancer Res 1996;2(11):1843-1849.
 5.  Giannakakou P, Nakano M, Nicolaou KC et al. Enhanced microtubule-dependent trafficking 
and p53 nuclear accumulation by suppression of microtubule dynamics. Proc Natl Acad Sci 
U S A 2002;99(16):10855-10860.
 6.  Thadani-Mulero M, Nanus DM, Giannakakou P. Androgen receptor on the move: boarding 
the microtubule expressway to the nucleus. Cancer Res 2012;72(18):4611-4615.
 7.  Poirier TI. Mitoxantrone. Drug Intell Clin Pharm 1986;20(2):97-105.
 8.  Tannock IF, Osoba D, Stockler MR et al. Chemotherapy with mitoxantrone plus prednisone 
or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian 
randomized trial with palliative end points. J Clin Oncol 1996;14(6):1756-1764.
 9.  Khan MA, Carducci MA, Partin AW. The evolving role of docetaxel in the management of 
androgen independent prostate cancer. J Urol 2003;170(5):1709-1716.
 10.  Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus 
prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-1512.
 11.  Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with 
mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 
2004;351(15):1513-1520.
 12.  Serpa NA, Tobias-Machado M, Kaliks R, Wroclawski ML, Pompeo AC, Del GA. Ten years 
of docetaxel-based therapies in prostate adenocarcinoma: a systematic review and 
meta-analysis of 2244 patients in 12 randomized clinical trials. Clin Genitourin Cancer 
2011;9(2):115-123.
 13.  Scher HI, Jia X, Chi K et al. Randomized, open-label phase III trial of docetaxel plus high-dose 
calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate 
cancer. J Clin Oncol 2011;29(16):2191-2198.
 14.  Kelly WK, Halabi S, Carducci M et al. Randomized, double-blind, placebo-controlled phase 
III trial comparing docetaxel and prednisone with or without bevacizumab in men with 
metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 2012;30(13):1534-
1540.
 15.  Meulenbeld HJ, van Werkhoven ED, Coenen JL et al. Randomised phase II/III study of docetaxel 
with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer 
(CRPC), the Netherlands Prostate Study (NePro). Eur J Cancer 2012;48(16):2993-3000.
 16.  Armstrong AJ, Creel P, Turnbull J et al. A phase I-II study of docetaxel and atrasentan in 
men with castration-resistant metastatic prostate cancer. Clin Cancer Res 2008;14(19):6270-
6276.
 17.  Quinn DI, Tangen CM, Hussain M et al. SWOG S0421: Phase III study of docetaxel (D) and 
Antimitotic agents for prostate cancer treatment
99
5
atrasentan (A) versus docetaxel and placebo (P) for men with advanced castrate resistant 
prostate cancer (CRPC). [abstract]. J Clin Oncol 30, 2012 (suppl; abstr 4511).
 18.  Higano C, Saad F, Somer B et al. A phase III trial of GVAX immunotherapy for prostate cancer 
versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer 
(CRPC). [abstract]. In: Genitourinary Cancers Symposium, 2009 Feb 26-28, Orlando, FL (Abstr 
LBA150).
 19.  Small E, Demkow T, Gerritsen R et al. A phase III trial of GVAX immunotherapy for prostate 
cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, 
castration-resistant prostate cancer (CRPC). [abstract]. In: Genitourinary Cancers Symposium, 
2009 Feb 26-28, Orlando, FL (Abstr 7).
 20.  Nelson JB, Fizazi K, Miller K et al. Phase 3, randomized, placebo-controlled study of zibotentan 
(ZD4054) in patients with castration-resistant prostate cancer metastatic to bone. Cancer 
2012;118(22):5709-5718.
 21.  Sanofi and Regeneron Announce Regulatory and Clinical Update for Zaltrap® (aflibercept). 
Tarrytown, NY; Sanofi, 2012. Available at: http://en.sanofi.com/Images/30138_20120405_
ZALTRAP_BLA_VENICE_en.pdf [Last accessed 11 December 2012].
 22.  Lenalidomide Plus Docetaxel: Phase III Results Fall Short. Plainsboro, NJ: OncLive, 2012. 
Available at: http://www.onclive.com/publications/oncology-live/2012/january-2012/
Lenalidomide-Plus-Docetaxel-Phase-III-Results-Fall-Short [Last accessed 11 December 
2012].
 23.  Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in 
Castration-Resistant Prostate Cancer (READY). Bethesda, MD: US National Institute of 
Health, 2012. Available at: http://clinicaltrial.gov/ct2/show/NCT00744497 [Last accessed 12 
December 2012].
 24.  Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-
011 in Men With Prostate Cancer (SYNERGY). Bethesda, MD: US National Institute of 
Health, 2012. Available at: http://clinicaltrial.gov/ct2/show/NCT01188187 [Last accessed 12 
December 2012].
 25.  Araujo JC, Mathew P, Armstrong AJ et al. Dasatinib combined with docetaxel for castration-
resistant prostate cancer: results from a phase 1-2 study. Cancer 2012;118(1):63-71.
 26.  Chi KN, Hotte SJ, Yu EY et al. Randomized phase II study of docetaxel and prednisone with 
or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin 
Oncol 2010;28(27):4247-4254.
 27.  Tamaskar I, Mekhail T, Dreicer R et al. Phase I trial of weekly docetaxel and daily temozolomide 
in patients with metastatic disease. Invest New Drugs 2008;26(6):553-559.
 28.  Facchini G, Caraglia M, Morabito A et al. Metronomic administration of zoledronic acid and 
taxotere combination in castration resistant prostate cancer patients: phase I ZANTE trial. 
Cancer Biol Ther 2010;10(6):543-548.
 29.  Bradshaw DM, Arceci RJ. Clinical relevance of transmembrane drug efflux as a mechanism of 
multidrug resistance. J Clin Oncol 1998;16(11):3674-3690.
 30.  de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for 
metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a 
randomised open-label trial. Lancet 2010;376(9747):1147-1154.
 31.  Heck MM, Hoppner M, Horn T, Thalgott M, Gschwend JE, Retz M. Compassionate use of 
abiraterone and cabazitaxel: First experiences in docetaxel-pretreated castration-resistant 
prostate cancer patients. Urologe A 2012.
Chapter 5
100
 32.  De Velasco G, Aparicio LA, Esteban E et al. Cabazitaxel in patients with advanced CRPC after 
docetaxel failure: Results of expanded access program (EAP) in Spain: Safety and efficacy. 
[abstract]. J Clin Oncol 30, 2012 (suppl; abstr e15149).
 33.  Bracarda S, Di Lorenzo G, Gasparro D et al. Updated safety result of a large Italian early 
access program (EAP) with cabazitaxel plus prednisone (CbzP) in metastatic castration-
resistant prostate cancer (mCRPC) patients who progressed during or after docetaxel (D) 
therapy. [abstract]. J Clin Oncol 30, 2012 (suppl; abstr e15185).
 34.  Roth BJ, Yeap BY, Wilding G, Kasimis B, McLeod D, Loehrer PJ. Taxol in advanced, hormone-
refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology 
Group. Cancer 1993;72(8):2457-2460.
 35.  Hudes GR, Nathan F, Khater C et al. Phase II trial of 96-hour paclitaxel plus oral estramustine 
phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 1997;15(9):3156-
3163.
 36.  Smith DC, Esper P, Strawderman M, Redman B, Pienta KJ. Phase II trial of oral estramustine, 
oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin 
Oncol 1999;17(6):1664-1671.
 37.  Smith DC, Chay CH, Dunn RL et al. Phase II trial of paclitaxel, estramustine, etoposide, and 
carboplatin in the treatment of patients with hormone-refractory prostate carcinoma. 
Cancer 2003;98(2):269-276.
 38.  Berry W, Friedland D, Fleagle J et al. A phase II study of weekly paclitaxel/estramustine/
carboplatin in hormone-refractory prostate cancer. Clin Genitourin Cancer 2006;5(2):131-
137.
 39.  Mackler NJ, Pienta KJ, Dunn RL et al. Phase II evaluation of oral estramustine, oral etoposide, 
and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma. 
Clin Genitourin Cancer 2007;5(5):318-322.
 40.  Kelly WK, Halabi S, Elfiky A et al. Multicenter phase 2 study of neoadjuvant paclitaxel, 
estramustine phosphate, and carboplatin plus androgen deprivation before radiation 
therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and 
Leukemia Group B 99811. Cancer 2008;113(11):3137-3145.
 41.  Sanfilippo NJ, Taneja SS, Chachoua A, Lepor H, Formenti SC. Phase I/II study of biweekly 
paclitaxel and radiation in androgen-ablated locally advanced prostate cancer. J Clin Oncol 
2008;26(18):2973-2978.
 42.  Sella A, Yarom N, Zisman A, Kovel S. Paclitaxel, estramustine and carboplatin combination 
chemotherapy after initial docetaxel-based chemotherapy in castration-resistant prostate 
cancer. Oncology 2009;76(6):442-446.
 43.  Sewak S, Kosmider S, Ganju V et al. Phase II study of paclitaxel and vinorelbine (Pacl-Vin) 
in hormone-refractory metastatic prostate cancer: double tubulin targeting. Intern Med J 
2010;40(3):201-208.
 44.  DiPaola RS, Chen YH, Stein M et al. A randomized phase II trial of mitoxantrone, estramustine 
and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in 
patients with metastatic castrate-resistant prostate cancer: ECOG 3899. J Transl Med 
2010;8:20.
 45.  Beer TM, Ryan C, Alumkal J, Ryan CW, Sun J, Eilers KM. A phase II study of paclitaxel poliglumex 
in combination with transdermal estradiol for the treatment of metastatic castration-
resistant prostate cancer after docetaxel chemotherapy. Anticancer Drugs 2010;21(4):433-
438.
Antimitotic agents for prostate cancer treatment
101
5
 46.  Smith DC, Tangen CM, van Veldhuizen PJJ et al. Phase II evaluation of early oral estramustine, 
oral etoposide, and intravenous paclitaxel combined with hormonal therapy in patients with 
high-risk metastatic prostate adenocarcinoma: Southwest Oncology Group S0032. Urology 
2011;77(5):1172-1176.
 47.  Jeske S, Tagawa ST, Olowokure O, Selzer J, Giannakakou P, Nanus DM. Carboplatin plus 
paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer. 
Urol Oncol 2011;29(6):676-681.
 48.  Desai N, Trieu V, Yao Z et al. Increased antitumor activity, intratumor paclitaxel concentrations, 
and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, 
compared with cremophor-based paclitaxel. Clin Cancer Res 2006;12(4):1317-1324.
 49.  Shepard DR, Dreicer R, Garcia J et al. Phase II trial of neoadjuvant nab-paclitaxel in high risk 
patients with prostate cancer undergoing radical prostatectomy. J Urol 2009;181(4):1672-
1677.
 50.  Kolevska T, Ryan CJ, Huey V et al. Phase II trial of nab-paclitaxel as first-line therapy of 
hormone refractory metastatic prostate cancer (HRPC). [abstract]. J Clin Oncol 27:15s, 2009 
(suppl; abstr 5152).
 51.  Phase I Abraxane Weekly and Three Weekly Schedule With Vandetanib. Bethesda, MD: 
US National Institute of Health, 2013. Available at: http://clinicaltrial.gov/ct2/show/
NCT00667147 [Last accessed 21 January 2013].
 52.  Shionoya M, Jimbo T, Kitagawa M, Soga T, Tohgo A. DJ-927, a novel oral taxane, overcomes 
P-glycoprotein-mediated multidrug resistance in vitro and in vivo. Cancer Sci 2003;94(5):459-
466.
 53.  Baas P, Szczesna A, Albert I et al. Phase I/II study of a 3 weekly oral taxane (DJ-927) in patients 
with recurrent, advanced non-small cell lung cancer. J Thorac Oncol 2008;3(7):745-750.
 54.  Saif MW, Sarantopoulos J, Patnaik A, Tolcher AW, Takimoto C, Beeram M. Tesetaxel, a new 
oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients 
with advanced solid tumors. Cancer Chemother Pharmacol 2011;68(6):1565-1573.
 55.  Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate 
Cancer. Bethesda, MD: US National Institute of Health, 2012. Available at: http://clinicaltrial.
gov/ct2/show/NCT01296243 [Last accessed 12 December 2012].
 56.  Daliani DD, Assikis V, Tu SM et al. Phase II trial of cyclophosphamide, vincristine, and 
dexamethasone in the treatment of androgen-independent prostate carcinoma. Cancer 
2003;97(3):561-567.
 57.  Sepp-Lorenzino L, Balog A, Su DS et al. The microtubule-stabilizing agents epothilones A and 
B and their desoxy-derivatives induce mitotic arrest and apoptosis in human prostate cancer 
cells. Prostate Cancer Prostatic Dis 1999;2(1):41-52.
 58.  Lee FY, Borzilleri R, Fairchild CR et al. BMS-247550: a novel epothilone analog with a mode 
of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 
2001;7(5):1429-1437.
 59.  Chou TC, O’Connor OA, Tong WP et al. The synthesis, discovery, and development of a highly 
promising class of microtubule stabilization agents: curative effects of desoxyepothilones 
B and F against human tumor xenografts in nude mice. Proc Natl Acad Sci U S A 
2001;98(14):8113-8118.
 60.  Dorff TB, Gross ME. The epothilones: new therapeutic agents for castration-resistant 
prostate cancer. Oncologist 2011;16(10):1349-1358.
 61.  Hortobagyi GN, Gomez HL, Li RK et al. Analysis of overall survival from a phase III study 
Chapter 5
102
of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to 
anthracyclines and taxanes. Breast Cancer Res Treat 2010;122(2):409-418.
 62.  Sparano JA, Vrdoljak E, Rixe O et al. Randomized phase III trial of ixabepilone plus capecitabine 
versus capecitabine in patients with metastatic breast cancer previously treated with an 
anthracycline and a taxane. J Clin Oncol 2010;28(20):3256-3263.
 63.  Roche H, Conte P, Perez EA et al. Ixabepilone plus capecitabine in metastatic breast cancer 
patients with reduced performance status previously treated with anthracyclines and 
taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III 
studies. Breast Cancer Res Treat 2011;125(3):755-765.
 64.  Jassem J, Fein L, Karwal M et al. Ixabepilone plus capecitabine in advanced breast cancer 
patients with early relapse after adjuvant anthracyclines and taxanes: a pooled subset 
analysis of two phase III studies. Breast 2012;21(1):89-94.
 65.  Withdrawal of IXEMPRA, (ixabepilone) EMEA/H/C/000930. London, UK: European Medicines 
Agency, 2009. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/
Other/2010/01/WC500062430.pdf [Last accessed 12 December 2012].
 66.  Smaletz O, Galsky M, Scher HI et al. Pilot study of epothilone B analog (BMS-247550) and 
estramustine phosphate in patients with progressive metastatic prostate cancer following 
castration. Ann Oncol 2003;14(10):1518-1524.
 67.  Rosenberg JE, Ryan CJ, Weinberg VK et al. Phase I study of ixabepilone, mitoxantrone, 
and prednisone in patients with metastatic castration-resistant prostate cancer previously 
treated with docetaxel-based therapy: a study of the department of defense prostate cancer 
clinical trials consortium. J Clin Oncol 2009;27(17):2772-2778.
 68.  Galsky MD, Small EJ, Oh WK et al. Multi-institutional randomized phase II trial of the 
epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in 
patients with progressive castrate metastatic prostate cancer. J Clin Oncol 2005;23(7):1439-
1446.
 69.  Rosenberg JE, Weinberg VK, Kelly WK et al. Activity of second-line chemotherapy in 
docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 
study of ixabepilone or mitoxantrone and prednisone. Cancer 2007;110(3):556-563.
 70.  Liu G, Chen YH, Dipaola R, Carducci M, Wilding G. Phase II trial of weekly ixabepilone in men 
with metastatic castrate-resistant prostate cancer (E3803): a trial of the Eastern Cooperative 
Oncology Group. Clin Genitourin Cancer 2012;10(2):99-105.
 71.  Layton JL, Plette AM, Renzulli JF et al. The impact of neoadjuvant weekly ixabepilone for 
high-risk prostate cancer: A phase I/II clinical trial. [abstract]. J Clin Oncol 30, 2012 (suppl 5; 
abstr 158).
 72.  Scher HI, Halabi S, Tannock I et al. Design and end points of clinical trials for patients with 
progressive prostate cancer and castrate levels of testosterone: recommendations of the 
Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26(7):1148-1159.
 73.  Hussain A, DiPaola RS, Baron AD, Higano CS, Tchekmedyian NS, Johri AR. Phase II trial 
of weekly patupilone in patients with castration-resistant prostate cancer. Ann Oncol 
2009;20(3):492-497.
 74.  Chi KN, Beardsley E, Eigl BJ et al. A phase 2 study of patupilone in patients with metastatic 
castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic 
Oncology Group study P07a. Ann Oncol 2012;23(1):53-58.
 75.  Beer TM, Higano CS, Saleh M et al. Phase II study of KOS-862 in patients with metastatic 
androgen independent prostate cancer previously treated with docetaxel. Invest New Drugs 




 76.  Beer TM, Smith DC, Hussain A et al. Phase II study of first-line sagopilone plus prednisone 
in patients with castration-resistant prostate cancer: a phase II study of the Department of 
Defense Prostate Cancer Clinical Trials Consortium. Br J Cancer 2012;107(5):808-813.
 77.  Roberts K. Cytoplasmic microtubules and their functions. Prog Biophys Mol Biol 1974;28:371-
420.
 78.  Mayer TU, Kapoor TM, Haggarty SJ, King RW, Schreiber SL, Mitchison TJ. Small molecule 
inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science 
1999;286(5441):971-974.
 79.  Kapitein LC, Peterman EJ, Kwok BH, Kim JH, Kapoor TM, Schmidt CF. The bipolar mitotic 
kinesin Eg5 moves on both microtubules that it crosslinks. Nature 2005;435(7038):114-118.
 80.  Sarli V, Giannis A. Targeting the kinesin spindle protein: basic principles and clinical 
implications. Clin Cancer Res 2008;14(23):7583-7587.
 81.  Vijapurkar U, Wang W, Herbst R. Potentiation of kinesin spindle protein inhibitor-induced 
cell death by modulation of mitochondrial and death receptor apoptotic pathways. Cancer 
Res 2007;67(1):237-245.
 82.  Tao W, South VJ, Diehl RE et al. An inhibitor of the kinesin spindle protein activates the 
intrinsic apoptotic pathway independently of p53 and de novo protein synthesis. Mol Cell 
Biol 2007;27(2):689-698.
 83.  Liu M, Aneja R, Liu C et al. Inhibition of the mitotic kinesin Eg5 up-regulates Hsp70 through 
the phosphatidylinositol 3-kinase/Akt pathway in multiple myeloma cells. J Biol Chem 
2006;281(26):18090-18097.
 84.  Chin GM, Herbst R. Induction of apoptosis by monastrol, an inhibitor of the mitotic kinesin 
Eg5, is independent of the spindle checkpoint. Mol Cancer Ther 2006;5(10):2580-2591.
 85.  Lad L, Luo L, Carson JD et al. Mechanism of inhibition of human KSP by ispinesib. Biochemistry 
2008;47(11):3576-3585.
 86.  Blagden SP, Molife LR, Seebaran A et al. A phase I trial of ispinesib, a kinesin spindle protein 
inhibitor, with docetaxel in patients with advanced solid tumours. Br J Cancer 2008;98(5):894-
899.
 87.  Burris III HA, Jones SF, Williams DD et al. A phase I study of ispinesib, a kinesin spindle protein 
inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with 
solid tumors. Invest New Drugs 2011;29(3):467-472.
 88.  Chu QS, Holen KD, Rowinsky EK et al. Phase I trial of novel kinesin spindle protein (KSP) 
inhibitor SB-715992 IV Q 21 days. [abstract]. J Clin Oncol 22:14S, 2004 (July 15 Suppl; abstr 
2078).
 89.  Heath EI, Alousi A, Eder JP et al. A phase I dose escalation trial of ispinesib (SB-715992) 
administered days 1-3 of a 21-day cycle in patients with advanced solid tumors. [abstract]. J 
Clin Oncol 24:18S, 2006 (June 20 suppl; abstr 2026).
 90.  Beer TM, Goldman B, Synold TW et al. Southwest Oncology Group phase II study of ispinesib 
in androgen-independent prostate cancer previously treated with taxanes. Clin Genitourin 
Cancer 2008;6(2):103-109.
 91.  Xing ND, Ding ST, Saito R et al. A potent chemotherapeutic strategy in prostate cancer: 
S-(methoxytrityl)-L-cysteine, a novel Eg5 inhibitor. Asian J Androl 2011;13(2):236-241.
 92.  Holen KD, Belani CP, Wilding G et al. A first in human study of SB-743921, a kinesin 
spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a 
recommended phase II dose. Cancer Chemother Pharmacol 2011;67(2):447-454.
Chapter 5
104
 93.  Holen K, DiPaola R, Liu G et al. A phase I trial of MK-0731, a Kinesin Spindle Protein (KSP) 
inhibitor, in patients with solid tumors. Invest New Drugs 2011.
 94.  Esaki T, Seto T, Ariyama H et al. Phase I Study to Assess the Safety, Tolerability and 
Pharmacokinetics of AZD4877 in Japanese Patients with Solid Tumors. Arch Drug Inf 
2011;4(2):23-31.
 95.  Infante JR, Kurzrock R, Spratlin J et al. A Phase I study to assess the safety, tolerability, and 
pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid 
tumors. Cancer Chemother Pharmacol 2012;69(1):165-172.
 96.  Stephenson JJ, Lewis N, Martin JC et al. Phase I multicenter study to assess the safety, 
tolerability, and pharmacokinetics of AZD4877 administered twice weekly in adult patients 
with advanced solid malignancies. [abstract]. J Clin Oncol 26, 2008 (May 20 suppl; abstr 
2516).
 97.  Goncalves PH, Sausville EA, Edelman MJ et al. A phase I study of ARRY-520 in solid tumors. 
[abstract]. J Clin Oncol 28:15s, 2010 (suppl; abstr 2570).
 98.  Nakai R, Iida S, Takahashi T et al. K858, a novel inhibitor of mitotic kinesin Eg5 and antitumor 
agent, induces cell death in cancer cells. Cancer Res 2009;69(9):3901-3909.
 99.  Wiltshire C, Singh BL, Stockley J et al. Docetaxel-resistant prostate cancer cells remain 
sensitive to S-trityl-L-cysteine-mediated Eg5 inhibition. Mol Cancer Ther 2010;9(6):1730-
1739.
 100.  Carmena M, Earnshaw WC. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 
2003;4(11):842-854.
 101.  Dar AA, Goff LW, Majid S, Berlin J, El-Rifai W. Aurora kinase inhibitors--rising stars in cancer 
therapeutics? Mol Cancer Ther 2010;9(2):268-278.
 102.  Hirota T, Kunitoku N, Sasayama T et al. Aurora-A and an interacting activator, the LIM protein 
Ajuba, are required for mitotic commitment in human cells. Cell 2003;114(5):585-598.
 103.  Marumoto T, Hirota T, Morisaki T et al. Roles of aurora-A kinase in mitotic entry and G2 
checkpoint in mammalian cells. Genes Cells 2002;7(11):1173-1182.
 104.  Marumoto T, Honda S, Hara T et al. Aurora-A kinase maintains the fidelity of early and late 
mitotic events in HeLa cells. J Biol Chem 2003;278(51):51786-51795.
 105.  Berdnik D, Knoblich JA. Drosophila Aurora-A is required for centrosome maturation and 
actin-dependent asymmetric protein localization during mitosis. Curr Biol 2002;12(8):640-
647.
 106.  Terada Y, Tatsuka M, Suzuki F, Yasuda Y, Fujita S, Otsu M. AIM-1: a mammalian midbody-
associated protein required for cytokinesis. EMBO J 1998;17(3):667-676.
 107.  Slattery SD, Mancini MA, Brinkley BR, Hall RM. Aurora-C kinase supports mitotic progression 
in the absence of Aurora-B. Cell Cycle 2009;8(18):2984-2994.
 108.  Khan J, Ezan F, Cremet JY et al. Overexpression of active Aurora-C kinase results in cell 
transformation and tumour formation. PLoS One 2011;6(10):e26512.
 109.  Chieffi P, Cozzolino L, Kisslinger A et al. Aurora B expression directly correlates with prostate 
cancer malignancy and influence prostate cell proliferation. Prostate 2006;66(3):326-333.
 110.  Beltran H, Rickman DS, Park K et al. Molecular characterization of neuroendocrine prostate 
cancer and identification of new drug targets. Cancer Discov 2011;1(6):487-495.
 111.  Mosquera JM, Beltran H, Park K et al. Concurrent AURKA and MYCN gene amplifications 
are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia 
2013;15(1):1-10.
 112.  Jeet V, Russell PJ, Verma ND, Khatri A. Targeting Aurora Kinases: A Novel Approach to Curb 
Antimitotic agents for prostate cancer treatment
105
5
the Growth & Chemoresistance of Androgen Refractory Prostate Cancer. Curr Cancer Drug 
Targets 2011.
 113.  Shu SK, Liu Q, Coppola D, Cheng JQ. Phosphorylation and activation of androgen receptor by 
Aurora-A. J Biol Chem 2010;285(43):33045-33053.
 114.  Jeong NY, Yoon YG, Rho JH et al. The novel resveratrol analog HS-1793-induced polyploid 
LNCaP prostate cancer cells are vulnerable to downregulation of Bcl-xL. Int J Oncol 
2011;38(6):1597-1604.
 115.  Moretti L, Niermann K, Schleicher S et al. MLN8054, a small molecule inhibitor of aurora 
kinase a, sensitizes androgen-resistant prostate cancer to radiation. Int J Radiat Oncol Biol 
Phys 2011;80(4):1189-1197.
 116.  Fancelli D, Moll J, Varasi M et al. 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of 
a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile. J Med 
Chem 2006;49(24):7247-7251.
 117.  Carpinelli P, Ceruti R, Giorgini ML et al. PHA-739358, a potent inhibitor of Aurora kinases 
with a selective target inhibition profile relevant to cancer. Mol Cancer Ther 2007;6(12 Pt 
1):3158-3168.
 118.  Steeghs N, Eskens FA, Gelderblom H et al. Phase I pharmacokinetic and pharmacodynamic 
study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid 
tumors. J Clin Oncol 2009;27(30):5094-5101.
 119.  Cohen RB, Jones SF, Aggarwal C et al. A phase I dose-escalation study of danusertib 
(PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-
stimulating factor in a 14-day cycle in patients with advanced solid tumors. Clin Cancer Res 
2009;15(21):6694-6701.
 120.  Meulenbeld HJ, Bleuse JP, Vinci EM et al. Randomized phase II study of danusertib in patients 
with metastatic castration-resistant prostate cancer after docetaxel failure. BJU Int 2012.
 121.  Sells T, Ecsedy JA, Stroud S et al. MLN8237: an orally active small molecule inhibitor of aurora 
A kinase in phase I clinical trials. [abstract]. Proc Am Assoc Cancer Res (AACR) 49, 2008 (abstr 
2997).
 122.  Manfredi MG, Ecsedy JA, Chakravarty A et al. Characterization of Alisertib (MLN8237), 
an investigational small-molecule inhibitor of aurora A kinase using novel in vivo 
pharmacodynamic assays. Clin Cancer Res 2011;17(24):7614-7624.
 123.  Maris JM, Morton CL, Gorlick R et al. Initial testing of the aurora kinase A inhibitor MLN8237 
by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer 2010;55(1):26-34.
 124.  Dees EC, Cohen RB, von Mehren M et al. Phase I study of aurora A kinase inhibitor MLN8237 
in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability 
of two oral formulations. Clin Cancer Res 2012;18(17):4775-4784.
 125.  A Phase 1 Study of MLN8237 in Patients With Advanced Solid Tumors Including Castration-
Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen. Bethesda, MD: 
US National Institute of Health, 2012. Available at: http://clinicaltrial.gov/ct2/show/
NCT01094288 [Last accessed 12 December 2012].
 126.  Mortlock AA, Foote KM, Heron NM et al. Discovery, synthesis, and in vivo activity of a 
new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase. J Med Chem 
2007;50(9):2213-2224.
 127.  Wilkinson RW, Odedra R, Heaton SP et al. AZD1152, a selective inhibitor of Aurora B 




 128.  Niermann KJ, Moretti L, Giacalone NJ et al. Enhanced radiosensitivity of androgen-resistant 
prostate cancer: AZD1152-mediated Aurora kinase B inhibition. Radiat Res 2011;175(4):444-
451.
 129.  Boss DS, Witteveen PO, van der Sar J et al. Clinical evaluation of AZD1152, an i.v. inhibitor of 
Aurora B kinase, in patients with solid malignant tumors. Ann Oncol 2011;22(2):431-437.
 130.  Schwartz GK, Carvajal RD, Midgley R et al. Phase I study of barasertib (AZD1152), a selective 
inhibitor of Aurora B kinase, in patients with advanced solid tumors. Invest New Drugs 2012.
 131.  Sawyers CL. Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute 
myeloid leukemia. Cancer Cell 2002;1(5):413-415.
 132.  Fletcher GC, Brokx RD, Denny TA et al. ENMD-2076 is an orally active kinase inhibitor with 
antiangiogenic and antiproliferative mechanisms of action. Mol Cancer Ther 2011;10(1):126-
137.
 133.  Diamond JR, Bastos BR, Hansen RJ et al. Phase I safety, pharmacokinetic, and 
pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in 
patients with advanced solid tumors. Clin Cancer Res 2011;17(4):849-860.
 134.  Matulonis UA, Lee J, Lasonde B et al. ENMD-2076, an oral inhibitor of angiogenic and 
proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer. Eur J 
Cancer 2012.
 135.  Study of ENMD-2076 in Patients With Advanced/Metastatic Soft Tissue Sarcoma. Bethesda, 
MD: US National Institute of Health, 2012. Available at: http://clinicaltrials.gov/ct2/show/
NCT01719744 [Last accessed 12 December 2012].
 136.  A Phase II Study of the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Previously 
Treated Locally Advanced and Metastatic Triple-Negative Breast Cancer. Bethesda, MD: 
US National Institute of Health, 2012. Available at: http://clinicaltrials.gov/ct2/show/
NCT01639248 [Last accessed 12 December 2012].
 137.  Harrington EA, Bebbington D, Moore J et al. VX-680, a potent and selective small-molecule 
inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004;10(3):262-
267.
 138.  Traynor AM, Hewitt M, Liu G et al. Phase I dose escalation study of MK-0457, a novel Aurora 
kinase inhibitor, in adult patients with advanced solid tumors. Cancer Chemother Pharmacol 
2011;67(2):305-314.
 139.  Howard S, Berdini V, Boulstridge JA et al. Fragment-based discovery of the pyrazol-4-yl urea 
(AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. J Med Chem 
2009;52(2):379-388.
 140.  Dawson MA, Curry JE, Barber K et al. AT9283, a potent inhibitor of the Aurora kinases and Jak2, 
has therapeutic potential in myeloproliferative disorders. Br J Haematol 2010;150(1):46-57.
 141.  Jani JP, Arcari J, Bernardo V et al. PF-03814735, an orally bioavailable small molecule aurora 
kinase inhibitor for cancer therapy. Mol Cancer Ther 2010;9(4):883-894.
 142.  Gürtler U, Tontsch-Grunt U, Jarvis M, et al. Effect of BI 811283, a novel inhibitor of Aurora B 
kinase, on tumor senescence and apoptosis. [abstract]. J Clin Oncol 28, 2010 (suppl; abstr 
e13632).
 143.  van der Porten EC, Taverna P, Hogan JN, Ballinger MD, Flanagan WM, Fucini RV. The Aurora 
kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and 
synergy with microtubule-targeted agents in a colon carcinoma model. Mol Cancer Ther 
2009;8(4):930-939.
 144.  Arkenau HT, Plummer R, Molife LR et al. A phase I dose escalation study of AT9283, a small 
Antimitotic agents for prostate cancer treatment
107
5
molecule inhibitor of aurora kinases, in patients with advanced solid malignancies. Ann 
Oncol 2011.
 145.  Mross KB, Scheulen ME, Frost A et al. A phase I dose-escalation study of BI 811283, an 
Aurora B inhibitor, administered every three weeks in patients with advanced solid tumors. 
[abstract]. J Clin Oncol 28:15s, 2010 (suppl; abstr 3011).
 146.  Scheulen ME, Mross KB, Richly H et al. A phase I dose-escalation study of BI 811283, an 
Aurora B inhibitor, administered days 1 and 15, every four weeks in patients with advanced 
solid tumors. [abstract]. J Clin Oncol 28, 2010 (suppl; abstr e13065).
 147.  Schoffski P, Jones SF, Dumez H et al. Phase I, open-label, multicentre, dose-escalation, 
pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 
in advanced solid tumours. Eur J Cancer 2011;47(15):2256-2264.
 148.  Minton SE, LoRusso P, Lockhart AC, et al. A phase I study of MK-5108, an oral aurora A kinase 
inhibitor, in both monotherapy and in combination with docetaxel in patients with advanced 
solid tumors. [abstract]. J Clin Oncol 28, 2010 (suppl; abstr e13026).
 149.  Robert F, Verschraegen C, Hurwitz H et al. A phase I trial of sns-314, a novel and selective 
pan-aurora kinase inhibitor, in advanced solid tumor patients. [abstract]. J Clin Oncol 27:15s, 
2009 (suppl; abstr 2536).
 150.  Xie H, Lee MH, Zhu F et al. Identification of an Aurora kinase inhibitor specific for the Aurora 
B isoform. Cancer Res 2012.
 151.  Payton M, Bush TL, Chung G et al. Preclinical evaluation of AMG 900, a novel potent and 
highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. 
Cancer Res 2010;70(23):9846-9854.
 152.  Anderson K, Lai Z, McDonald OB et al. Biochemical characterization of GSK1070916, a potent 
and selective inhibitor of Aurora B and Aurora C kinases with an extremely long residence 
time1. Biochem J 2009;420(2):259-265.
 153.  Carducci MA, Shaheen MF, Paller CJ et al. First-in-human study of AMG 900, an oral pan-
Aurora kinase inhibitor, in adult patients (pts) with advanced solid tumors. [abstract]. J Clin 
Oncol 30, 2012 (suppl; abstr 3009).
 154.  Adams ND, Adams JL, Burgess JL et al. Discovery of GSK1070916, a potent and selective 
inhibitor of Aurora B/C kinase. J Med Chem 2010;53(10):3973-4001.
 155.  Hardwicke MA, Oleykowski CA, Plant R et al. GSK1070916, a potent Aurora B/C kinase 
inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft 
models. Mol Cancer Ther 2009;8(7):1808-1817.
 156.  Aurora B/C Kinase Inhibitor GSK1070916A in Treating Patients With Advanced Solid Tumors. 
Bethesda, MD: US National Institute of Health, 2012. Available at: http://clinicaltrials.gov/
ct2/show/NCT01118611 [Last accessed 12 December 2012].
 157.  de Cárcer G, Manning G, Malumbres M. From Plk1 to Plk5: functional evolution of polo-like 
kinases. Cell Cycle 2011;10(14):2255-2262.
 158.  Chopra P, Sethi G, Dastidar SG, Ray A. Polo-like kinase inhibitors: an emerging opportunity 
for cancer therapeutics. Expert Opin Investig Drugs 2010;19(1):27-43.
 159.  Strebhardt K. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. 
Nat Rev Drug Discov 2010;9(8):643-660.
 160.  Takaki T, Trenz K, Costanzo V, Petronczki M. Polo-like kinase 1 reaches beyond mitosis--
cytokinesis, DNA damage response, and development. Curr Opin Cell Biol 2008;20(6):650-
660.




 162.  Weichert W, Schmidt M, Gekeler V et al. Polo-like kinase 1 is overexpressed in prostate 
cancer and linked to higher tumor grades. Prostate 2004;60(3):240-245.
 163.  Deeraksa A, Pan J, Sha Y et al. Plk1 is upregulated in androgen-insensitive prostate cancer 
cells and its inhibition leads to necroptosis. Oncogene 2012.
 164.  Takagi M, Honmura T, Watanabe S et al. In vivo antitumor activity of a novel sulfonamide, 
HMN-214, against human tumor xenografts in mice and the spectrum of cytotoxicity of its 
active metabolite, HMN-176. Invest New Drugs 2003;21(4):387-399.
 165.  Garland LL, Taylor C, Pilkington DL, Cohen JL, Von Hoff DD. A phase I pharmacokinetic study 
of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, 
in patients with advanced solid tumors. Clin Cancer Res 2006;12(17):5182-5189.
 166.  Patnaik A, Forero L, Goetz A et al. HMN-214, a novel oral antimicrotubular agent and 
inhibitor of pololike- and cyclin-dependent kinases: Clinical, pharmacokinetic (PK) and 
pharmacodynamic (PD) relationships observed in a phase I trial of a daily x 5 schedule every 
28 days. [abstract]. J Clin Oncol 22, 2003 (suppl; abstr 514).
 167.  Steegmaier M, Hoffmann M, Baum A et al. BI 2536, a potent and selective inhibitor of polo-
like kinase 1, inhibits tumor growth in vivo. Curr Biol 2007;17(4):316-322.
 168.  Rudolph D, Steegmaier M, Hoffmann M et al. BI 6727, a Polo-like kinase inhibitor 
with improved pharmacokinetic profile and broad antitumor activity. Clin Cancer Res 
2009;15(9):3094-3102.
 169.  Wissing MD, Rosmus N, Gonzalez M et al. Targeting prostate cancer through a combination 
of Polo-like kinase inhibitors and histone deacetylase inhibitors. [abstract]. Proc Am Assoc 
Cancer Res (AACR), 2010 (abstr 5414).
 170.  Mross K, Frost A, Steinbild S et al. Phase I dose escalation and pharmacokinetic study of BI 
2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors. J Clin Oncol 
2008;26(34):5511-5517.
 171.  Hofheinz RD, Al-Batran SE, Hochhaus A et al. An open-label, phase I study of the polo-
like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors. Clin Cancer Res 
2010;16(18):4666-4674.
 172.  Pandha HS, Protheroe A, Wylie J et al. An open label phase II trial of BI 2536, a novel Plk1 
inhibitor, in patients with metastatic hormone refractory prostate cancer (HRPC). [abstract]. 
J Clin Oncol 26, 2008 (May 20 suppl; abstr 14547).
 173.  Schoffski P, Awada A, Dumez H et al. A phase I, dose-escalation study of the novel Polo-like 
kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours. Eur J Cancer 
2012;48(2):179-186.
 174.  Dumez H, Gombos A, Schöffski P et al. Phase I trial of the polo-like kinase (Plk) inhibitor 
volasertib (BI 6727) combined with cisplatin or carboplatin in patients with advanced solid 
tumors. [abstract]. J Clin Oncol 30, 2012 (suppl; abstr 3018^).
 175.  Stadler WM, Vaughn DJ, Sonpavde G et al. Phase II study of single-agent volasertib (BI 6727) 
for second-line treatment of urothelial cancer (UC). [abstract]. J Clin Oncol 29, 2011 (suppl 
7; abstr 253).
 176.  Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors. Bethesda, MD: US National 
Institute of Health, 2012. Available at: http://clinicaltrial.gov/ct2/show/NCT01022853 [Last 
accessed 12 December 2012].
 177.  BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer. Bethesda, MD: US National Institute 
of Health, 2012. Available at: http://clinicaltrial.gov/ct2/show/NCT01121406 [Last accessed 




 178.  An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 (Volasertib)in 
Combination With Oral BIBW 2992 (Afatinib) in Patients With Advanced Solid Tumours. 
Bethesda, MD: US National Institute of Health, 2012. Available at: http://clinicaltrial.gov/
ct2/show/NCT01206816 [Last accessed 12 December 2012].
 179.  BI 6727 (Volasertib) Monotherapy Phase I Trial in Japanese Patients With Advanced 
Solid Tumours. Bethesda, MD: US National Institute of Health, 2012. Available at: http://
clinicaltrial.gov/ct2/show/NCT01348347 [Last accessed 12 December 2012].
 180.  Gilmartin AG, Bleam MR, Richter MC et al. Distinct concentration-dependent effects of the 
polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis. 
Cancer Res 2009;69(17):6969-6977.
 181.  Laquerre S, Sung C, Gilmartin A et al. A potent and selective Polo-like kinase 1 (Plk1) Inhibitor 
(GSK461364) induces cell cycle arrest and growth inhibition of cancer cell. [abstract]. Proc 
Am Assoc Cancer Res (AACR), 2007 (abstr 5389).
 182.  Olmos D, Barker D, Sharma R et al. Phase I study of GSK461364, a specific and competitive 
Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies. Clin Cancer Res 
2011;17(10):3420-3430.
 183.  Study of NMS-1286937 in Adult Patients With Advanced/Metastatic Solid Tumors. Bethesda, 
MD: US National Institute of Health, 2012. Available at: http://clinicaltrial.gov/ct2/show/
NCT01014429 [Last accessed 12 December 2012].
 184.  Dose Escalation Study to Determine Safety, Pharmacokinetics, and Pharmacodynamics of 
Intravenous TKM-080301. Bethesda, MD: US National Institute of Health, 2012. Available at: 
http://clinicaltrial.gov/ct2/show/NCT01262235 [Last accessed 12 December 2012].
 185.  Study of Orally Administered TAK-960 in Patients With Advanced Nonhematologic 
Malignancies. Bethesda, MD: US National Institute of Health, 2012. Available at: http://
clinicaltrial.gov/ct2/show/NCT01179399 [Last accessed 12 December 2012].
 186.  Beria I, Bossi RT, Brasca MG et al. NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline 
derivative as potent and selective Polo-like kinase 1 inhibitor. Bioorg Med Chem Lett 
2011;21(10):2969-2974.
 187.  Valsasina B, Beria I, Alli C et al. NMS-P937, an orally available, specific, small molecule Polo-
Like Kinase 1 inhibitor with antitumor activity in solid and haematological malignancies. Mol 
Cancer Ther 2012.
 188.  Hikichi Y, Honda K, Hikami K et al. TAK-960, a novel, orally available, selective inhibitor of 
Polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing 
regimens. Mol Cancer Ther 2011.
 189.  Judge AD, Robbins M, Tavakoli I et al. Confirming the RNAi-mediated mechanism of action of 
siRNA-based cancer therapeutics in mice. J Clin Invest 2009;119(3):661-673.
 190.  Semple SC, Judge AD, Robbins M et al. Preclinical characterization of TKM-080301, a lipid 
nanoparticle formulation of a small interfering RNA directed against polo-like kinase 1. 
[abstract]. Proc Am Assoc Cancer Res (AACR); Cancer Res 71, 2011 (suppl 8; abstr 2829).
 191.  Gumireddy K, Reddy MV, Cosenza SC et al. ON01910, a non-ATP-competitive small molecule 
inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 2005;7(3):275-286.
 192.  Chapman CM, Sun X, Roschewski M et al. ON 01910.Na is selectively cytotoxic for chronic 
lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition 
and induction of oxidative stress. Clin Cancer Res 2012;18(7):1979-1991.
 193.  Ma WW, Messersmith WA, Dy GK et al. Phase I study of Rigosertib, an inhibitor of the 
Chapter 5
110
phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine 
in patients with solid tumors and pancreatic cancer. Clin Cancer Res 2012;18(7):2048-2055.
 194.  Riggs BL, Hartmann LC. Selective estrogen-receptor modulators -- mechanisms of action and 
application to clinical practice. N Engl J Med 2003;348(7):618-629.
 195.  Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and 
future perspectives in HER2-overexpressing breast cancer. Ann Oncol 2007;18(6):977-984.
 196.  Qi W, Liu X, Cooke LS et al. AT9283, a novel aurora kinase inhibitor, suppresses tumor growth 
in aggressive B-cell lymphomas. Int J Cancer 2011.
 197.  Qi W, Cooke LS, Liu X et al. Aurora inhibitor MLN8237 in combination with docetaxel 
enhances apoptosis and anti-tumor activity in mantle cell lymphoma. Biochem Pharmacol 
2011;81(7):881-890.
 198.  Feng B, Wang R, Chen LB. MiR-100 resensitizes docetaxel-resistant human lung 
adenocarcinoma cells (SPC-A1) to docetaxel by targeting Plk1. Cancer Lett 2012;317(2):184-
191.
 199.  Kachhap SK, Rosmus N, Collis SJ et al. Downregulation of homologous recombination DNA 
repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription 
factor. PLoS One 2010;5(6):e11208.
 200.  Paller C, Wissing M, Kim E, et al. Preclinical profile of AMG900 in combination with HDACIs 
in prostate cancer. [abstract]. Proc Am Assoc Cancer Res (AACR), 2012 (abstr 2049).
 201.  Marin-Aguilera M, Codony-Servat J, Kalko SG et al. Identification of docetaxel resistance 
genes in castration-resistant prostate cancer. Mol Cancer Ther 2012;11(2):329-339.
 202.  Domingo-Domenech J, Vidal SJ, Rodriguez-Bravo V et al. Suppression of acquired docetaxel 
resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-
initiating cells. Cancer Cell 2012;22(3):373-388.
 203.  Madan RA, Pal SK, Sartor O, Dahut WL. Overcoming chemotherapy resistance in prostate 
cancer. Clin Cancer Res 2011;17(12):3892-3902.
 204.  Beer TM, Javle MM, Ryan CW et al. Phase I study of weekly DN-101, a new formulation of 
calcitriol, in patients with cancer. Cancer Chemother Pharmacol 2007;59(5):581-587.
 205.  Coleman RL, Duska LR, Ramirez PT et al. Phase 1-2 study of docetaxel plus aflibercept in 
patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol 
2011;12(12):1109-1117.
 206.  Isambert N, Freyer G, Zanetta S et al. Phase I dose-escalation study of intravenous 
aflibercept in combination with docetaxel in patients with advanced solid tumors. Clin 
Cancer Res 2012;18(6):1743-1750.
 207.  Demetri GD, Lo RP, MacPherson IR et al. Phase I dose-escalation and pharmacokinetic 
study of dasatinib in patients with advanced solid tumors. Clin Cancer Res 
2009;15(19):6232-6240.
 208.  Eisenberger MA, Hardy-Bessard A, Mourey L, et al. Comparison of two doses of cabazitaxel 
plus prednisone in patients (pts) with metastatic castration-resistant prostate cancer 
(mCRPC) previously treated with a docetaxel (D)-containing regimen. [abstract]. J Clin 
Oncol 30, 2012 (suppl; abstr TPS4692^).
 209.  Study of Weekly Cabazitaxel for Advanced Prostate Cancer. Bethesda, MD: US National 
Institute of Health, 2012. Available at: http://clinicaltrial.gov/ct2/show/NCT01518283 [Last 
accessed 21 December 2012].
 210.  A Study Looking at Novel Scheduling of Cabazitaxel for Patients With Metastatic Prostate 
Cancer (ConCab). Bethesda, MD: US National Institute of Health, 2012. Available at: http://
Antimitotic agents for prostate cancer treatment
111
5
clinicaltrial.gov/ct2/show/NCT01541007 [Last accessed 21 December 2012].
 211.  Second-line Chemotherapy in Castration Resistant Prostate Cancer (ProstyII). Bethesda, 
MD: US National Institute of Health, 2012. Available at: http://clinicaltrial.gov/ct2/show/
NCT01558219 [Last accessed 21 December 2012].
 212.  Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer 
(CRPC) Previously Treated With Docetaxel. Bethesda, MD: US National Institute of Health, 
2012. Available at: http://clinicaltrial.gov/ct2/show/NCT01469338 [Last accessed 21 
December 2012].
 213.  Cabaresc NL. Rotterdam, NL: Stichting DUOS, 2012. Available at: http://www.stichtingduos.
nl/studies/cabaresc-nl/ [Last accessed 21 December 2012].
 214.  Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration 
Resistant Prostate Cancer (FIRSTANA). Bethesda, MD: US National Institute of Health, 2012. 
Available at: http://clinicaltrial.gov/ct2/show/NCT01308567 [Last accessed 21 December 
2012].
 215.  Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd 
Line Chemotherapy in Prostate Cancer (AFFINITY). Bethesda, MD: US National Institute of 
Health, 2012. Available at: http://clinicaltrial.gov/ct2/show/NCT01578655 [Last accessed 
21 December 2012].
 216.  The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate 
Cancer. Bethesda, MD: US National Institute of Health, 2012. Available at: http://
clinicaltrial.gov/ct2/show/NCT01513733 [Last accessed 21 December 2012].
 217.  Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant 
Prostate Cancer. Bethesda, MD: US National Institute of Health, 2012. Available at: http://
clinicaltrial.gov/ct2/show/NCT01511536 [Last accessed 21 December 2012].
 218.  Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer. 
Bethesda, MD: US National Institute of Health, 2012. Available at: http://clinicaltrial.gov/
ct2/show/NCT01335204 [Last accessed 21 December 2012].
 219.  Cabazitaxel With or Without Carboplatin in Patients With Metastatic Castration-Resistant 
Prostate Cancer Previously Treated With Docetaxel-Based Therapy. Bethesda, MD: 
US National Institute of Health, 2012. Available at: http://clinicaltrial.gov/ct2/show/
NCT01505868 [Last accessed 21 December 2012].
 220.  De Souza PL, Mellado B, Pfister C, et al. Randomized phase II trial of patupilone plus 
prednisone versus docetaxel plus prednisone in patients with chemotherapy-naïve, 
metastatic, castrate-resistant prostate cancer (CRPC). [abstract]. J Clin Oncol 28:15s, 2010 
(suppl; abstr 4553).
 221.  Gerecitano JF, Stephenson JJ, Lewis NL et al. A Phase I trial of the kinesin spindle protein 
(Eg5) inhibitor AZD4877 in patients with solid and lymphoid malignancies. Invest New 
Drugs 2012.
 222.  Macarulla T, Cervantes A, Elez E et al. Phase I study of the selective Aurora A kinase 
inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and 
pharmacodynamics. Mol Cancer Ther 2010;9(10):2844-2852.
 223.  Dees EC, Infante JR, Cohen RB et al. Phase 1 study of MLN8054, a selective inhibitor of 
Aurora A kinase in patients with advanced solid tumors. Cancer Chemother Pharmacol 
2011;67(4):945-954.
 224.  Cervantes A, Elez E, Roda D et al. Phase I pharmacokinetic/pharmacodynamic study of 
MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with 
Chapter 5
112
advanced solid tumors. Clin Cancer Res 2012;18(17):4764-4774.
 225.  Mosse YP, Lipsitz E, Fox E et al. Pediatric Phase I Trial and Pharmacokinetic Study of 
MLN8237, an Investigational Oral Selective Small-Molecule Inhibitor of Aurora Kinase A: A 
Children’s Oncology Group Phase I Consortium Study. Clin Cancer Res 2012;18(21):6058-
6064.
 226.  Matulonis UA, Sharma S, Ghamande S et al. Phase II study of MLN8237 (alisertib), an 
investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory 
epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Gynecol Oncol 
2012;127(1):63-69.
 227.  Lee P, Alvarez RH, Melichar B, et al. Phase I/II study of the investigational aurora A kinase 
(AAK) inhibitor MLN8237 (alisertib) in patients (pts) with non-small cell lung cancer 
(NSCLC), small cell lung cancer (SCLC), breast cancer (BrC), head/neck cancer (H&N), and 
gastroesophageal (GE) adenocarcinoma: Preliminary phase II results.. [abstract]. J Clin 
Oncol 30, 2012 (suppl; abstr 3010).
 228.  Falchook GS, Goff BA, Kurzrock R, et al. Phase I/II study of weekly paclitaxel with or without 
MLN8237 (alisertib), an investigational aurora A kinase inhibitor, in patients with recurrent 
epithelial ovarian, fallopian tube, or primary peritoneal cancer (OC), or breast cancer (BrC): 
Phase I results. [abstract]. J Clin Oncol 30, 2012 (suppl; abstr 5021).
 229.  Frost A, Mross K, Steinbild S et al. Phase i study of the Plk1 inhibitor BI 2536 administered 
intravenously on three consecutive days in advanced solid tumours. Curr Oncol 
2012;19(1):e28-e35.
 230.  Ellis PM, Chu QS, Leighl N et al. A Phase I Open-Label Dose-Escalation Study of Intravenous 
BI 2536 Together With Pemetrexed in Previously Treated Patients With Non-Small-Cell Lung 
Cancer. Clin Lung Cancer 2012.
 231.  Schoffski P, Blay JY, De Greve J et al. Multicentric parallel phase II trial of the polo-like 
kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, 
ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European 
Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes 
(NOCI). Eur J Cancer 2010;46(12):2206-2215.
 232.  Sebastian M, Reck M, Waller CF et al. The efficacy and safety of BI 2536, a novel Plk-1 
inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, 
or failed, chemotherapy: results from an open-label, randomized phase II clinical trial. J 
Thorac Oncol 2010;5(7):1060-1067.
 233.  Mross K, Dittrich C, Aulitzky WE et al. A randomised phase II trial of the Polo-like kinase 
inhibitor BI 2536 in chemo-naive patients with unresectable exocrine adenocarcinoma 
of the pancreas - a study within the Central European Society Anticancer Drug Research 
(CESAR) collaborative network. Br J Cancer 2012;107(2):280-286.
 234.  BI 6727 (Volasertib) Human ADME Trial in Various Solid Tumours. Bethesda, MD: US 
National Institute of Health, 2012. Available at: http://clinicaltrials.gov/ct2/show/
NCT01145885 [Last accessed 21 December 2012].
 235.  Dose Finding Study of BI 6727 (Volasertib) in Patients With Various Solid Cancers. 
Bethesda, MD: US National Institute of Health, 2012. Available at: http://clinicaltrial.gov/
ct2/show/NCT00969553 [Last accessed 21 December 2012].
 236.  Trial of BI 6727 (Volasertib) Monotherapy and BI 6727 in Combination With Pemetrexed 
Compared to Pemetrexed Monotherapy in Advanced NSCLC. Bethesda, MD: US National 
Institute of Health, 2012. Available at: http://clinicaltrial.gov/ct2/show/NCT00824408 [Last 
Antimitotic agents for prostate cancer treatment
113
5
accessed 21 December 2012].
 237.  Jimeno A, Li J, Messersmith WA et al. Phase I study of ON 01910.Na, a novel modulator 
of the Polo-like kinase 1 pathway, in adult patients with solid tumors. J Clin Oncol 
2008;26(34):5504-5510.
 238.  Ohnuma T, Holland JF, Goel S, et al. Final results of a phase I dose-escalation study of 
ON 01910.Na in combination with oxaliplatin in patients with advanced solid tumors. 
[abstract]. J Clin Oncol 29, 2011 (suppl; abstr e13584).
 239.  Bowles DW, Diamond JR, Lam ET, et al. Phase I study of oral rigosertib in patients with 
advanced solid tumors. [abstract]. J Clin Oncol 30, 2012 (suppl; abstr 3017).
 240.  Vainshtein JM, Ghalib MH, Kumar M, et al. Phase I study of ON 01910.Na, a novel polo-like 
kinase 1 pathway modulator, administered as a weekly 24-hour continuous infusion in 
patients with advanced cancer. [abstract]. J Clin Oncol 26, 2008 (May 20 suppl; abstr 2515).
 241.  Ohnuma T, Cho SY, ROboz J, et al. Phase I study of ON 01910.Na by 3-day continuous 
infusion (CI) in patients (pts) with advanced cancer. [abstract]. J Clin Oncol 24:18S, 2006 
(June 20 suppl; abstr 13137).
 242.  Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors. Bethesda, 
MD: US National Institute of Health, 2012. Available at: http://clinicaltrial.gov/ct2/show/
NCT01168011 [Last accessed 21 December 2012].
 243.  Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients. Bethesda, MD: US 
National Institute of Health, 2012. Available at: http://clinicaltrial.gov/ct2/show/
NCT00856791 [Last accessed 21 December 2012].
 244.  Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer 
(ONTRAC). Bethesda, MD: US National Institute of Health, 2012. Available at: http://
clinicaltrial.gov/ct2/show/NCT01360853 [Last accessed 21 December 2012].

Chapter 5b
Tales of how great drugs were brought down by a 
flawed rationale -- Letter
Michel D. Wissing, Michael A. Carducci, Hans Gelderblom, Paul J. van Diest




In January 2012, Komlodi-Pasztor and colleagues published a paper in which they explained 
why, in their opinion, the rationale used for these inhibitors was flawed.1 They concluded 
there is a low likelihood that any inhibitor of mitotic enzymes would play a role in the 
management of solid tumors. In the letter to the editor presented below, we explain why 
their reasoning is incorrect, leading to a conclusion we consider preliminary.
Letter
In a recent article, Komlodi-Pasztor and colleagues argued that cancer researchers used a 
flawed rationale to develop inhibitors of mitotic enzymes, such as polo-like kinase 1 (PLK1) 
and aurora kinases.1 Scientists had been misled by the success of microtubule-targeting 
agents (MTA) by assuming that MTAs act on cancer cells solely by mitotic inhibition, whereas 
their primary targets are microtubules in interphase. Inhibitors of enzymes solely expressed 
during mitosis would not have a significant antitumor effect on solid tumors in clinical 
studies, as most solid tumors have a mean mitotic index of less than 1%. 
However, despite the low mitotic index, mitotic enzymes are frequently overexpressed in 
cancer; for example, Weichert and colleagues reported that 52.6% of all human prostate 
carcinomas have strong expression of PLK1.2 This suggests that mitotic enzymes also play 
a role beyond mitosis. Indeed, PLK1 has been found to regulate among others p53 and 
microtubule dynamics in interphase as well.3
The authors describe that cancer cells have mitotic slippage after 1 to 2 days of treatment 
with antimitotic agents.1 They fail to mention that such cells either become aneuploid or 
polyploid, or are arrested in interphase.4 Although cells may initially be viable, all these 
states eventually result in cell death.
The authors explain the discrepancy between in vivo results and clinical efficacy of 
antimitotic agents further by the (twice) daily administration in mice, whereas in humans 
intravenous administration is done at a weekly or longer interval.1 With the discovery of 
orally bioavailable compounds, such as the aurora kinase-inhibitors alisertib (MLN-8237), 
ENMD-2076, PF-03814735, MK-5108, and AMG-900 and the PLK1-inhibitors HMN-214, TAK-
960, and NMS-1286937, similar dosing frequencies can be achieved in humans as in mice.
The major advantage of inhibitors of mitotic enzymes compared with MTAs is the lack of 
irreversible neuropathy after treatment; adverse events are fewer and rarely irreversible. 
Research is ongoing to increase the efficacy of aurora kinase- and PLK1-inhibitors, which 
could be accomplished by increased bioavailability to the tumor, that is, oral bioavailability, 
an improved pharmacokinetic profile, or activation by tumor-specific markers. Furthermore, 
addition of granulocyte colony-stimulating factor suppresses the adverse effect of mitotic 
inhibitors on the bone marrow, thereby allowing higher dosing. Aurora kinase- and PLK1-
inhibitors could also have clinical potential in combination therapy, as combination therapy 
Antimitotic agents for prostate cancer treatment
117
5
could result in equal/improved efficacy and decreased toxicity compared with current 
treatment protocols. Therefore, we think that these promising agents should be further 
developed and deserve thorough testing in clinical trials.
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Histone deacetylases (HDACs) have emerged as important targets for cancer treatment. 
HDAC-inhibitors (HDACis) are well tolerated in patients and have been approved for the 
treatment of patients with cutaneous T-cell lymphoma (CTCL). To improve the clinical benefit 
of HDACis in solid tumors, combination strategies with HDACis could be employed. In this 
study, we applied Analysis of Functional Annotation (AFA) to provide a comprehensive list of 
genes and pathways affected upon HDACi-treatment in prostate cancer cells. This approach 
provides an unbiased and objective approach to high-throughput data mining. By performing 
AFA on gene expression data from prostate cancer cell lines DU-145 (an HDACi-sensitive 
cell line) and PC3 (a relatively HDACi-resistant cell line) treated with HDACis valproic acid 
or vorinostat, we identified biological processes that are affected by HDACis and are for 
this reason potential treatment targets for combination therapy. Our analysis revealed that 
HDAC-inhibition resulted among others in upregulation of major histocompatibility complex 
(MHC) genes and deregulation of the mitotic spindle checkpoint by downregulation of 
genes involved in mitosis. These findings were confirmed by AFA on publicly available data 
sets from HDACi-treated prostate cancer cells. In total, we analyzed 375 microarrays with 
HDACi treated and non-treated (control) prostate cancer cells. All results from this extensive 
analysis are provided as an online research source (available at http://luigimarchionni.org/
HDACIs.html). By publishing these data, we aim to enhance our understanding of the cellular 
changes after HDAC-inhibition, and to identify novel potential combination strategies with 
HDACis for the treatment of prostate cancer patients.




An important mechanism of cells to epigenetically regulate gene expression is by acetylating 
and deacetylating histones.1 Histone deacetylases (HDACs) are a class of enzymes that 
deacetylate lysine residues in the N-terminal tails of histones, thereby blocking gene 
transcription.1 HDACs are frequently overexpressed in cancer; their overexpression leads 
among others to epigenetic silencing of tumor suppressor genes.1 Therefore, various HDAC-
inhibitors (HDACis) have been developed for cancer therapy, of which vorinostat (SAHA) 
and Romidepsin are approved by the United States Food and Drug Administration (US FDA) 
for the treatment of cutaneous T-cell lymphomas (CTCL). HDACis arrest cells in G0/G1 or 
G2/M phase dependent on the dose of HDACi and/or cell type used.2 Despite preclinical 
data showing great promise and their success in liquid tumors, the potential of HDACis as 
single agents against solid tumors, specifically prostate cancer (PCa), seems to be limited in 
clinical studies.2
It seems that improving DNA accessibility with HDACis is merely the first step in cancer 
treatment. Therefore, recent studies have focused on combination strategies involving 
HDACis, with success. Valproic acid (VPA) in combination with epirubicin/FEC (5-fluorouracil, 
epirubicin, cyclophosphamide) resulted in an objective response in 64% of patients with solid 
advanced malignancies.3 Combination therapy with the HDACi magnesium valproate and 
DNA demethylating agent hydralazine resensitized 80% of cancer patients to chemotherapy 
on which they had previously progressed.4 This combination was successfully added to 
doxorubicin and cyclophosphamide therapy in breast cancer patients as well.5 The addition 
of vorinostat to the mammalian target of rapamycin (mTOR) inhibitor temsirolimus improved 
anticancer activity against renal cell carcinoma in vitro and in vivo.6 Other recent preclinical 
studies indicated that HDACis such as VPA may sensitize cancer cells, among others PCa 
cells, to radiotherapy.7, 8 In non-small cell lung cancer studies it was found that cells may 
be sensitized for radiotherapy through acetyl p53-mediated downregulation of c-myc.9 The 
rationale for such combination studies with HDACis was that HDACis may reverse epigenetic 
changes made by the tumor, downregulate gene expression involved in DNA damage repair 
and/or upregulate apoptosis in cancer cells.
In this study, we apply analysis of functional annotation (AFA) to HDACi-treated PCa cells, 
thereby providing a rationale for novel combination strategies with HDACis. AFA is a high-
throughput bioinformatics approach to identify sets of genes that are differentially expressed 
between conditions, such as cancer cells pre- and post-treatment. It is conceptually 
similar to gene set enrichment analysis (GSEA).10-14 This unbiased method enables the 
interpretation of large amounts of gene expression data generated by microarray analysis 
through superimposition, selection, analysis and visualization of information encompassing 
distinct biological concepts, such as cellular signaling pathways, protein-protein interaction 
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(PPI) networks, gene ontology (GO), gene expression regulation by transcription factors and 
microRNA (miRNA) targets. In our study, AFA was used to detect cellular processes that 
are affected by HDACis in PCa cell lines. We analyzed data from an elaborate microarray 
experiment with an HDACi-sensitive (DU-145) and a (relatively) HDACi-insensitive PCa cell 
line (PC3) treated with the HDACis VPA and vorinostat (SAHA).15 We further complemented 
this analysis with gene expression profiles from HDACi-treated LNCaP and PC3 cells using 
all available data from the public domain.16, 17 Overall, we analyzed 375 distinct microarray 
experiments involving HDACi-treated PCa cells, which to our best knowledge is the largest 
analysis of this kind to date. By creating an encyclopedia of expression changes induced by 
HDACis in PCa cell lines, we have implemented a resource publicly available to the research 
community for use in future research, both for improving our understanding of the cellular 
effects of HDACis on PCa cells, and for developing hypotheses to test drug combinations with 
HDACis in preclinical studies. Finally, based on the AFA results, we present a rationale for 
the combination of HDACis with mitotic spindle checkpoint inhibitors and immunotherapy. 
Further (pre)clinical evaluation is necessary to validate these rationales.
Materials and Methods
Ethics statement
Anonymized human PCa specimens were obtained from the University Medical Center 
Utrecht (UMCU), after it was ensured that enough material remained to serve the patient’s 
and family’s needs, and in accordance to the Dutch code of conduct for the use of leftover 
body material.18 All investigations involving human samples were performed in strict 
adherence to the Declaration of Helsinki.
Cell lines and chemicals
PCa cells were obtained from the American Type Culture Collection (ATCC) and maintained 
as described previously by our group.15 Stock solutions of 10 mM vorinostat (AtonPharma/
Merck) dissolved in DMSO were used for all experiments; vorinostat was further diluted 
in complete RPMI-1640 media (Invitrogen). VPA (Sigma-Aldrich) was stored as a salt, and 
freshly dissolved in complete RPMI-1640 media (RPMI-1640 media supplemented with 10% 
fetal bovine serum (FBS)) before each experiment. Colcemid (Sigma-Aldrich) was acquired 
as a 10 µg/ml solution in Hank’s balanced salt solution (HBSS) and stored at 4°C.
Microarray experiment
Microarray data were obtained from time course experiments in which PC3 and DU-145 
cells were treated with VPA or vorinostat for 48 h, and are available from the National 
Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) database 
(series GSE34452). Expression data were processed using the R-Bioconductor library 
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limma.19-24 Differential gene expression data were acquired using a generalized linear model 
approach (“multiple-loop, double-cube” design) as described by Kortenhorst et al.15 A 
detailed explanation of all procedures and methods used for microarray data preprocessing, 
and differential gene expression analysis and detection has been described in detail 
previously.15, 25 Briefly, we applied a complex design based on a “multiple-loop, double-
cube” cDNA microarray experiment in this previous study, to enhance our understanding of 
the molecular underpinnings of HDACi resistance in PCa cells. To this end, we analyzed gene 
expression data from a total of 22 dual-color microarray hybridizations comparing DU-145 
and PC3 cells treated with vorinostat and VPA after an incubation of 48 and 96 h. Data were 
normalized using within-array “loess” normalization, and an ANOVA coupled with empirical 
Bayes standard errors shrinkage was used to identify differentially expressed genes between 
treated cells and controls. HDAC inhibition resulted in differential expression of 2.8% to 
10% of genes (adjusted p-value < 0.001) across all conditions. Between 51% to 72% of such 
genes were upregulated, while 28% to 49% were downregulated. Larger differential gene 
expression was observed in DU-145 cells compared with PC3 cells, with VPA treatment 
compared with vorinostat, and with longer drug exposures.
Other public domain data were obtained from GEO and the Connectivity Map, publicly 
available from the NCBI GEO database, along with MIAME (minimum information 
about a microarray experiment) compliant information. Details regarding the source of 
gene expression data sets used, the platforms and annotation packages employed, the 
preprocessing procedures adopted for each data set, as well as the statistical details of the 
analysis performed, are described extensively at http://luigimarchionni.org/HDACIs.html.
Analysis of Functional Annotation (AFA)
We applied Analysis of Functional Annotation (AFA), a gene set analysis approach, on 
differential gene expression data obtained from distinct comparisons and across different 
studies to identify biological processes and signaling pathways modulated by HDACis in 
PCa cells.10, 11, 26-28 Overall, this methodology extends gene set analysis procedures, such as 
gene set enrichment analysis (GSEA) or parametric analysis of gene set enrichment (PAGE), 
by investigating biological processes enrichment over multiple experimental conditions as 
briefly summarized below.12-14
Functional gene sets (FGS), recapitulating distinct and complementary biological concepts 
such as cellular signaling pathways, PPI networks, downstream transcriptional responses, 
gene expression regulatory networks orchestrated by transcription factors and microRNA 
targets, were retrieved in the form of gene lists from various publicly available databases 
(see http://luigimarchionni.org/HDACIs.html). These collections included the Reactome, 
the Human Protein Reference Database (HPRD), GO, the Kyoto Encyclopedia of Genes 




A one-sided Wilcoxon rank sum test was separately applied across all investigated 
comparisons to test whether any given FGS was differentially expressed, upregulated or 
downregulated, using the absolute and signed t-statistics to order genes (for details on 
the linear model analysis see http://luigimarchionni.org/HDACIs.html and Kortenhorst et 
al.15). The enrichment analysis was performed on all non-redundant genes present on the 
microarray, according to the NCBI Entrez Gene database annotation.38 Filtering of redundant 
microarray features (i.e., probes mapping to the same NCBI Entrez Gene identifier) was 
achieved by retaining only the probes with the largest absolute t-statistics for further 
analysis. Correction for multiple hypotheses testing was applied separately for each FGS 
collection by applying the Benjamini and Hochberg method.39 Differentially expressed FGS 
were visualized using heatmaps; an adjusted p-value < 0.05 was considered significant.
To validate the results from the AFA on our microarray data, we further performed differential 
gene expression analysis and AFA on publicly available datasets of HDACI-treated PCa cells. 
Three datasets were available (GSE8645, GSE31620, and Connectivity Map). In one dataset 
(GSE8645), LNCaP cells had been treated with either 7.5µM CG-1521 or 5µM Trichostatin 
A (both HDACIs) for 24h, after which a microarray was performed.40 In dataset GSE31620, 
LNCaP cells were treated for 36h with TSA and/or the DNA-methylating agent 5-Azacytidine 
after which miRNA microarrays were performed.16 In the Connectivity Map, PC3 cells had 
been treated with various HDACIs at various dosages for 6 hours.17 A detailed description of 
these datasets is available at http://luigimarchionni.org/HDACIs.html.
Flow cytometry
DU-145 and PC3 cells were synchronized in S-phase by a double thymidine block (Fig. 1). 
Cells were plated in 100 mm dishes; at 30–50% confluency, cells were incubated in DMEM-
10/thymidine media (DMEM (Invitrogen) supplemented with 10% FBS and 2 mM thymidine 
(Sigma-Aldrich)) for 12h. Subsequently, cells were washed twice in PBS and incubated in 
DMEM-10 media. After 16h, the media was replaced with DMEM-10/thymidine and cells 
were incubated for 12–14h. Cells were released from S-phase by removing the thymidine-
containing media; three hours later DMEM-10 media containing an HDACi and/or colcemid 
was added. Cells were harvested immediately after the S-phase release, at the start of 
treatment, and 3, 6, 9, 11, 14 or 17h after treatment initiation.
Cells were prepared for flow cytometry analysis using the method of Vindelov.41 Flow 
cytometry was performed on a BD-LSR II flow cytometer (BD Biosciences); data were 
interpreted using CellQuest (BD Biosciences).
Tissue Microarrays (TMAs) and immunohistochemistry (IHC)
For TMAs, human PCa samples were obtained from archives of the Pathology Department 
of the UMCU. Samples from 71 patients who had undergone radical prostatectomy were 
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collected; information concerning survival and PSA recurrence of these patients was 
collected. Tumors had been formalin-fixed and paraffin-embedded after resection.
From paraffin blocks four 1 mm cores were taken per specimen. These cores were transferred 
to a recipient composite paraffin block using a Beecher MT1 manual arrayer (Beecher 
Instruments). Four micron slides were prepared from each TMA. Spots that contained 
necrotic/dead tissue or fibrin instead of cancer cells were excluded.
IHC was performed with 4 µm paraffin sections on the BOND-MAX (Leica) using the Bond 
Polymer Refine Detection™ (Leica) kit. With the exception of beta-2 microglobulin (B2M), 
antigen retrieval was performed in citrate buffer (pH 6.0) for 20 min at 100 °C. Sections 
were then incubated with anti-HLA-A antibody HCA2 (HCE kweek, UMCU) 1:200, anti-HLA-B 
antibody HC10 (HCE kweek) 1:400, anti-B2M (Dako) 1:600, anti-HLA-DR-α (Dako) 1:60 or 
anti-HLA-DR-β (Dako) 1:800, consecutively followed by incubation with Bond Polymer Refine 
Detection kit items (Leica) and incubation with DAB solution (Bond Polymer Refine Detection, 
Leica). Slides were counterstained with hematoxylin (Bond Polymer Refine Detection, Leica), 
and blindly examined and scored for protein expression by two investigators (MSQK, PJD). 
Appropriate negative and positive controls were used.
Results
AFA after treatment with HDACIs
We previously used a “multiple-loop, double-cube” design to identify genes differentially 
expressed in PCa cell lines upon HDAC-inhibition with VPA or SAHA.15 In the current study 
we applied AFA, as previously described, to enable the interpretation of these results in 
the context of relevant cancer biology.10, 11, 26, 27, 42 To this end, we selected FGS from distinct 
databases, recapitulating different and complementary biological concepts: a) cellular 
Figure 1. Summary of the flow cytometry protocol. 
†, timepoints at which cells were harvested
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signaling pathways from Pathway Commons, b) PPI networks from the NCBI Entrez Gene 
database, c) downstream transcriptional responses, and d) gene expression regulatory 
networks orchestrated by transcription factors and microRNA targets. These collections 
included, among others, the HPRD, GO, KEGG, MSigDB, Pathway Commons and NCBI 
Entrez Gene databases.14, 29-37, 43 FGS whose expression altered most significantly upon 
HDAC-inhibition in DU-145 and PC3 cells across all conditions after correction for multiple 
testing (adjusted p-value < 0.05, top five FGS or more in case of ties), were retrieved and are 
displayed in Figure 2. This approach enabled the identification of biological themes that are 
differentially expressed upon HDAC-inhibition across all conditions irrespective of the gene 
expression direction change (Fig. 2A), as well as biological processes that are selectively 
up- or downregulated across all conditions (Figs. 2B and C, respectively). The complete lists 
with all AFA results, including FGS that were differentially expressed between cell lines, 
treatments and/or time-points, with all relevant statistics (e.g., fold-change, p-values, false 
discovery rates (FDR), log-odds), are available online at http://luigimarchionni.org/HDACIs.
html.
We further explored the AFA results by analyzing the relationship among identified FGS 
in terms of gene overlap, identifying common and distinct sets of genes driving the 
enrichment. To this end, we assembled “gene to FGS” membership matrices for enriched 
FGS presented in Figure 2, and performed hierarchical clustering and social network analysis 
to group them based on gene overlap (for details see Figs S1-S6 at http://luigimarchionni.
org/HDACIs.html).44 This revealed both FGS groups whose enrichment was driven by similar, 
if not identical, genes, as well as FGS groups with minimal gene overlap, whose enrichment 
was hence due to separate and distinctive genes. Even more interesting, such divergent FGS 
groups pointed to complementary, yet distinct, biological concepts. For instance, a number 
of different FGS corresponding to specific signaling pathways and to their downstream 
targets were enriched, with minimal overlap of the underlying genes, providing a stronger 
rationale for pathway modulation upon HDACi-treatment. An example of such findings is the 
epidermal growth factor signaling, for which the FGS corresponding to both the pathway 
machinery (e.g., “ErbB1 receptor signaling network” from National Cancer Institute (NCI)-
Pathway Commons) and the downstream targets (e.g., “EGFR Signaling Pathway” targets 
from HPRD) proved to be enriched (Fig. 2B and Figs. S2 and S5 at http://luigimarchionni.
org/HDACIs.html). 
Overall, treatment with HDACis altered gene expression programs related to biological 
processes that are well known to be involved in tumor development and progression, such as 
cell adhesion and cell cycle related FGS. In addition, well-established potential drug targets 
were modulated, such as the c-myc, the androgen receptor signaling, and the Epidermal 
Growth Factor Receptor 1 (EGFR1) signaling pathways. Furthermore, the interpretation of 






































































































































































































































































































































































































































































































































the AFA results attracted attention to two groups of functionally connected FGS that were 
up- or downregulated after HDAC-inhibition: major histocompatibility complexes (MHC) 
genes and mitotic spindle checkpoint genes, respectively (Fig. 2). These FGS will be further 
discussed below.
Treatment of PCa cells with HDACIs results in upregulation of MHC genes
Interpretation of the AFA results indicated that HDACis may play a role in immuno-editing, 
as it transcriptionally modulated genes involved in this biological process. In fact, the 
“Signaling in Immune system” Reactome FGS proved to be most significantly upregulated 
across all studied conditions along with FGS related to IL-4 and Interferon signaling pathways 
(Fig. 2B). B2M, Human Leukocyte Antigen (HLA) class I molecules, and Interferon induced 
proteins were among the most upregulated genes driving this upregulation (see http://
luigimarchionni.org/HDACIs.html). Upregulation of FGS related to the immune system was 
observed in other collections as well: for example PPI networks with LILRB1 (Leukocyte 
immunoglobulin-like receptor B1) and LILRB2 were also upregulated upon HDAC-inhibition 
(Fig. 2B). Furthermore, the cAMP Response Element Binding protein (CREB) and the 
interferon-stimulated response element (ISRE) site gene sets were differentially expressed 
upon HDACi-treatment (see http://luigimarchionni.org/HDACIs.html). Interestingly, CREB is 
part of an enhanceosome that increases transcription of MHC-I, B2M and MHC-II genes, and 
interferon is a major regulator of MHC-I transcription.45, 46
We validated our data by performing differential gene expression analysis and AFA on an 
additional 353 microarray experiments from three publicly available data sets (GSE8645 
and GSE31620, and Connectivity Map) involving PCa cells treated with HDACis.16, 17 We 
assessed the overall agreement of differential gene expression across all analyzed data 
sets using Correspondence At the Top (CAT) curves as described previously, which overall 
proved to be greater than expected by chance (Figs. S7-S16 at http://luigimarchionni.org/
HDACIs.html).10, 26, 47 We also compared and validated AFA results identifying the biological 
themes and processes which were consistently differentially expressed across the data sets, 
treatment conditions, and data points analyzed (Figs. S17-S19 at http://luigimarchionni.org/
HDACIs.html). Overall, FGS related to the immune system were significantly upregulated 
across most of the analyzed conditions, spanning distinct HDACis, cell lines and treatment 
time points (Fig. S18 at http://luigimarchionni.org/HDACIs.html).
Based on the finding that FGS related to the immune system are differentially expressed 
upon HDACi-treatment, we hypothesized that PCa cells may alter the expression of genes 
related to the immune system, a change that is reverted by HDACis. To further explore this 
hypothesis, we assessed whether the expression of MHC proteins in human PCa tissue 
is deregulated compared with normal prostate tissue. For this purpose, a PCa Tissue 
Analysis of the genomic response of PCa cells to HDACIs
129
6Microarray (TMA) was performed using specimens from 71 patients who had undergone a 
radical prostatectomy. Protein expression of HLA-A, HLA-B, HLA-DRA and B2M was scored 
in PCa tissue and normal surrounding tissue (Fig. 3). Repeated measurement analysis 
using the panel of all four proteins revealed a significant combined change in MHC protein 
expression in human PCa tissue compared with normal surrounding tissue (p < 0.001). B2M 
and HLA-B were primarily responsible for this deregulation. B2M protein expression was 
downregulated compared with normal surrounding tissue (p=2.5·10-7), while HLA-B was 
upregulated (p=0.009), as determined by student’s t-tests (Fig. 3). There was no eminent 
change in HLA-A and HLA-DRA protein expression. As a final note, B2M expression of non-
cancerous tissue tended to be decreased in patients with PSA recurrence (p=0.06), possibly 
indicating that deregulation of B2M is correlated with PCa progression (data not shown).
Treatment of PCa cells with HDACIs results in downregulation of mitotic spindle checkpoint 
genes
Our AFA results indicated that HDACIs changed the expression of genes relevant to 
mitosis as well (Fig. 2, Figs. S17 and S19 at http://luigimarchionni.org/HDACIs.html). In the 
supplementary data (http://luigimarchionni.org/HDACIs.html) a summary can be found of 
genes contributing to altered expression of the “Cell cycle, mitotic” Reactome FGS in DU-145 
and PC3 cells treated with VPA or vorinostat. Treatment of DU-145 cells with 1 mM VPA or 1 
μM vorinostat resulted in a transcriptional downregulation of genes coding for kinetochore 
and other mitotic proteins (adjusted p-value <10-9). In contrast, the more resistant PC3 cells 
showed less downregulation (adjusted p-value <10-9 only after 96h treatment with VPA) (Fig. 
2 and http://luigimarchionni.org/HDACIs.html). 
Figure 3. IHC staining of human prostate tissue in a TMA. A) Representative images of human PCa and normal 
prostate tissue stained for B2M (top) and HLA-B (bottom) show decreased expression of B2M and increased 
expression of HLA-B in PCa tissue compared with normal surrounding tissue in a PCa patient. B) Bar graph displaying 




Without proper kinetochore formation, chromosomes will not divide equally across the 
two daughter cells. To prevent aneuploidy, cells activate the spindle assembly checkpoint, 
which prevents progression through mitosis if metaphase is not completed properly.48 We 
hypothesized that treatment with HDACis VPA or vorinostat could result in a functional spindle 
checkpoint defect by downregulation of kinetochore proteins and other proteins involved in 
this checkpoint. In PC3 cells we expected the spindle checkpoint to be intact, as there is less 
transcriptional downregulation of mitotic spindle checkpoint and kinetochore genes. To test 
this hypothesis, DU-145 and PC3 cells were synchronized in S-phase by a double thymidine 
block (Fig. 1), released and subsequently treated with colcemid—a spindle poison that 
depolymerizes microtubules and limits microtubule formation in mitosis. Cells with an intact 
spindle checkpoint will recognize a defect in microtubule attachment through kinetochore 
signaling and be arrested in mitosis. In the absence of a functioning kinetochore, the 
spindle checkpoint is not intact and cells progress through mitosis in the absence of proper 
chromosome segregation by microtubules. Both PC3 and DU-145 cells accumulated in G2/
M-phase after 18h of treatment with colcemid; a small sub-G0 population was measured 
as well. Therefore, it can be assumed that these cells have an intact spindle assembly 
checkpoint (Fig. 4A). Separate doses of colcemid were chosen for DU-145 and PC3 cells since 
the standard dose of 0.1 µg/ml led to toxicity in DU-145 cells (Fig. 4A). Next, we treated 
synchronized PC3 and DU-145 cells after release from S-phase with SAHA or simultaneously 
with HDACis and colcemid. During the 20 h after administration of 9 µM SAHA, most PC3 cells 
were initially in the G2/M phase, but later in G1-phase as well. Treatment of DU-145 cells 
with SAHA resulted in an increased G1- and (later) sub-G0 population. After combination 
treatment, PC3 cells mainly accumulated in G2/M-phase after ≥9 h of treatment, most likely 
these cells are mitotically arrested by activation of the spindle checkpoint (Fig. 4B; Fig. S20 
at http://luigimarchionni.org/HDACIs.html). On the other hand, treatment of DU-145 cells 
for ≥ 9 h resulted in a time-dependent increase in a large sub-G0 population apart from a 
population in G2/M phase, the latter population getting smaller after 20 h of treatment (Fig. 
4C; Fig. S21 at http://luigimarchionni.org/HDACIs.html). This may indicate that part of the 
HDACi-sensitive cells (DU-145 cells) override the spindle checkpoint, leading to a G0/G1 
arrest and eventually apoptosis, while cells that are relatively resistant to HDACis (PC3 cells) 
are arrested in mitosis by activation of the spindle assembly checkpoint.
Discussion
In the past decade, a growing number of scientists have concluded that single agents, often 
targeting a single pathway, are insufficiently effective for cancer treatment, as many complex 
signaling pathways are involved in cancer development and progression. Therefore, clinical 
trials have shifted focus to combination therapy to either target different pathways or target 
the same major pathway from different angles. However, many recent phase III studies have 
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Figure 4. HDACis and spindle checkpoint activation in PCa cells. Simultaneous inhibition of PCa cells with HDACis 
and colcemid leads to accumulation of cells in mitosis in PC3 cells, but to a time-dependent increase of a sub-G0 
population in DU-145 cells. A) DU-145 and PC3 cells were treated with 0.1 μg/ml colcemid. This resulted in mitotic 
accumulation of PC3 cells (M2), but DU-145 cells exhibited an increased sub-G0 population (M4), indicating 
cytotoxicity. DU-145 cells were successfully arrested in mitosis with low toxicity at a final concentration of 0.04 μg/
ml colcemid. Combining HDACis with colcemid resulted in mitotic accumulation of PC3 cells (B), while it resulted in 
a time-dependent increase of a sub-G0 population in DU-145 cells (C).
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concluded that clinical benefit of these combination therapies is limited, while toxicity is 
increased.49-51 To speed up the implementation of combination therapies in clinic and to 
reduce costs of failing expensive clinical trials, there is a strong need to develop preclinical 
tools to identify successful combination strategies. 
In this study, we show that AFA allows unbiased hypothesis generation for combination 
therapies. This systems biology approach successfully unraveled the mechanisms of action 
of HDACis, without the bias of assumptions based on previous literature or the preference 
of the researcher. We show major FGS expression changes after HDACi-treatment, induced 
either directly through regulation of histones or indirectly by regulating (multiple) genes 
in pathways. A major advantage of AFA is that it is able to identify and visualize modest 
gene expression changes when occurring across a predefined category, without prior 
arbitrary cut-offs for fold change, p-value, and/or false discovery rates (FDR). This is 
particularly relevant since previous studies have indicated that fluctuations in such basal 
gene expression patterns at levels less than what is considered significant (i.e., FDR < 0.05) 
do have a functional relationship.52 Furthermore, AFA combines biological information from 
different knowledge domains and different conditions and is thus equal to GSEA done over 
multiple contrasts. FGS representing similar biological concepts proved to be in agreement 
with each other, supporting the strength of AFA. In summary, AFA enables us to identify 
specific biological and molecular processes affected by chemotherapeutic agents in greater 
detail, as subtle but consistent changes can be identified, providing a framework for further 
investigation. 
Hence, we performed differential gene expression analysis and applied AFA to four distinct 
data sets, ultimately analyzing over 42,475 distinct FGS over a total of 375 different 
samples. This analysis, which we made publically available online, is the largest performed 
on PCa cells treated with HDACis. Therefore, it constitutes an invaluable resource for the 
identification of FGS that are targeted by HDACis. Finally, we have investigated two of the 
identified molecular concepts for which multiple FGS proved affected upon HDAC-inhibition 
more into detail, namely, MHC genes and mitotic spindle checkpoint genes.
The immune system plays a prominent role in the development, progression and treatment 
of cancers, among others PCa.53 Recognition of cancer cells by the immune system leads 
to eradication of these cells. Therefore, cancer cells need to escape this immune response 
(immune escape). This is accomplished by both genetic mutations and epigenetic 
modifications resulting in the loss of MHC class I and II molecules in some cancer cells 
(immuno-editing); these cells then get selected for further proliferation.53 Indeed, we show 
in this study that in human primary PCa tissue samples MHC-related gene expression is 
deregulated. This is in line with earlier reports: for instance Sharpe et al. concluded that 
expression of MHC class I and II determinants (such as B2M) was downregulated in tissue 
samples from PCa patients.54 While B2M expression is downregulated, HLA-A expression 
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does not differ significantly in our results. Tamura et al. concluded that expression of HLA-A 
is downregulated when PCa cells progress from hormone therapy sensitive to hormone 
resistant PCa.55 Downregulation of HLA-A may not have occurred in our patients’ samples 
yet, as most cancers are in an early stage when a radical prostatectomy is performed.
Immunotherapy has become a common approach to treat cancer. It can be used to target 
specific pathways, such as the use of trastuzumab to target HER2 positive breast cancer 
cells,43 or to modulate the immune system against cancer cells. The role of immunotherapy 
in PCa treatment is less well established. Although it is generally accepted that the immune 
system plays a role in PCa, the exact mechanism by which the immune system is involved 
in PCa initiation, progression and treatment remains unclear.54, 56 Sipuleucel-T has been 
approved by the US FDA as a cellular immunotherapy that improves overall survival in 
asymptomatic or minimally symptomatic metastatic castrate-resistant PCa patients, and 
other immunotherapies such as ipilimumab are in advanced stages of clinical development.57, 
58 However, some have doubted its efficacy.59, 60 Therefore, immunotherapy is not yet widely 
used in PCa treatment.
As VPA and vorinostat upregulate FGS involved in the immune system in DU-145 and PC3 
cells, treatment by HDACis may prompt a natural or induced immune response against 
tumor cells by the immune system or immunotherapy, respectively. Studies in other cancer 
types have also found that HDACis enhance the expression of immunologically important 
molecules and induce immune responses, strengthening our findings.61 As there currently 
is no tissue available from patients after treatment with HDACis, it is not possible to assess 
whether such immune responses occur in PCa patients. However, our results indicate 
that HDACis may revert the acquired B2M deficiency found in cancer cells resistant to 
immunotherapy.62 Considering the increasing importance of immunotherapy in PCa, it 
is imperative that future studies test the hypothesis that pretreatment with HDACis may 
sensitize PCa cells for immunotherapy. The clinical response to sipuleucel-T, ipilimumab and/
or other immunotherapies may be increased through reversal of (epi)genetic modifications 
that lead to immune escape of the cancer cell.
Results from our study further indicate that posttranslational changes may not be 
solely responsible for the regulatory effects of HDACis during mitosis, but translational 
downregulation of genes involved in mitotic regulation may also play a role in creating 
mitotic defects. Treatment with high doses of SAHA seems to result in progression through 
mitosis in the absence of a mitotic spindle in HDACi-sensitive cells. This may lead to 
aneuploidy, a G0/G1 phase arrest and eventually to cell death.63 Similar results have been 
reported by Noh et al.,64 in which treatment of HeLa cells with Trichostatin A resulted in a 
transcription-dependent defective mitosis with loss of checkpoint control. This effect may 
be increased when treating PCa cells with agents that deregulate the spindle assembly 
checkpoint. Combination therapy of HDACis with one such spindle checkpoint deregulator, 
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aurora kinase inhibitors, has recently been tested in lymphoma cells in vitro and in vivo, with 
success.65 Both results from this study and our results encourage testing combinations of 
HDACis with aurora kinase inhibitors or other agents that deregulate the spindle checkpoint, 
such as polo-like kinase 1 (Plk1-)inhibitors, in PCa and other solid tumors. Preliminary results 
of preclinical studies by our group involving combination therapies with HDACis (VPA/
vorinostat) and an aurora kinase inhibitor (AMG 900) or Plk1-inhibitors (BI 2536/volasertib 
[BI 6727]) in PCa indicate that these combinations result in increased antitumor activity with 
acceptable toxicities.66, 67
Our AFA results identified other FGS differentially expressed upon HDACi-treatment that 
may be of clinical importance too, such as upregulation of the androgen receptor signaling 
pathway. Increased sensitivity to androgen therapy after VPA treatment has been reported 
with other PCa cell lines.68 Our data suggest that DU-145 and PC3 cells may have increased 
sensitivity to androgen therapy after HDACi-treatment as well, potentially by upregulation 
of androgen receptor expression.8 Further studies need to be performed to assess increased 
androgen sensitivity after HDACI-treatment in PCa.
In summary, in this study we successfully applied AFA. This created an expansive and 
complete library of biological processes modulated by HDACis in PCa cell lines, and hence is 
a valuable resource for researchers involved in research with HDACis. We further explored 
two pathways that were differentially expressed upon HDACi-treatment that may be of 
interest for future combination therapy. Novel studies combining HDACis with inhibitors 
of identified pathways are needed to assess clinical benefit for PCa patients. Furthermore, 
this study indicates that AFA can be used as an unbiased rational approach to identify novel 
combination strategies against cancer. Performing such analyses generates a comprehensive 
list of FGS differentially expressed upon cancer cell treatment.
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Combinations of anticancer therapies with high efficacy and low toxicities are highly sought 
after. Therefore, we studied the effect of polo-like kinase 1 (Plk1) inhibitors on prostate 
cancer cells as a single agent and in combination with histone deacetylase (HDAC) inhibitors 
valproic acid and vorinostat. IC50s of Plk1 inhibitors BI 2536 and BI 6727 were determined in 
prostate cancer cells by MTS assays. Morphological and molecular changes were assessed 
by immunoblotting, immunofluorescence, flow cytometry, real-time RT-PCR, and pulldown 
assays. Efficacy of combination therapy was assessed by MTS and clonogenic assays. IC50 
values in DU145, LNCaP, and PC3 cells were 50, 75, and 175 nM, respectively, for BI 2536 
and 2.5, 5, and 600 nM, respectively, for BI 6727. Human prostate fibroblasts and normal 
prostate epithelial cells were unaffected at these concentrations. While DU145 and LNCaP 
cells were solely arrested in mitosis upon treatment, PC3 cells accumulated in G2 phase 
and mitosis, suggesting a weak spindle assembly checkpoint. Combining Plk1 inhibitors with 
HDAC inhibitors had synergistic antitumor effects in vitro. DMSO-treated prostate cancer 
cells were used as controls to study the effect of Plk1 and HDAC inhibition. Plk1 inhibitors 
decreased proliferation and clonogenic potential of prostate cancer cells. Hence, Plk1 may 
serve as an important molecular target for inhibiting prostate cancer. Combining HDAC 
inhibitors with BI 2536 or BI 6727 may be an effective treatment strategy against prostate 
cancer.




Of the five known polo-like kinases (Plks), Plk1 has been studied most extensively. Plk1 is a 
serine-threonine kinase characterized by a N-terminal protein kinase domain and two highly 
specific C-terminal polo-box domains (PBDs).1 It is crucial during cell division, playing an 
important role from G2/M transition through cytokinesis;2 it may have functions beyond 
mitosis as well.3, 4 Elevated levels of Plk1 have been found in multiple cancers, including 
prostate cancer (PCa), colorectal cancer, breast cancer and non-small cell lung cancer.5 Plk1 
overexpression is associated with a poor prognosis in various cancer types, making Plk1 a 
potential marker for cancer progression.2, 5, 6 Because of its highly specific PBD domains and 
overexpression in multiple cancers, several Plk1 inhibitors have been developed and are 
being tested in phase I and/or II clinical trials for treating both solid and non-solid tumors.2 
Two dihydropteridinone derivatives, BI 2536 and BI 6727 (Volasertib), act as Plk1 inhibitors 
by inhibiting the enzyme activity of Plk1 in an ATP-competitive way, resulting in significant 
antitumor activity in vitro and in vivo in a wide variety of cancer cell lines.2, 7, 8 In in vitro 
kinase assays, BI 2536 inhibits Plk1, as well as the two closely related kinases, Plk2 and 
Plk3, at lower nanomolar concentrations (half maximal inhibitory concentration (IC50) values 
0.83, 3.5, and 9 nM, respectively); similarly, BI 6727 potently inhibits Plk1, as well as Plk2 
and Plk3 (IC50 values 0.87, 5, and 56 nM, respectively), but it is ineffective against a panel of 
50 known kinases, even at 10 µM concentrations.7 Phase I and II studies conducted with BI 
2536 as a single agent against various cancers, including metastatic castrate-resistant PCa, 
reported some antitumor effects in patients, while the compound was well tolerated.9-12 BI 
6727 is expected to be more potent against tumors due to its favorable pharmacokinetic 
properties, demonstrating sustained tumor exposure, a high volume of distribution, a long 
terminal half-life, and good oral bioavailability.8 A phase I study with BI 6727 in patients with 
advanced solid tumors confirmed these preclinical observations, the compound having a 
favorable pharmacokinetic profile, promising antitumor activity and manageable toxicities.13 
Combining Plk1 inhibitors, which arrest cells in mitosis, with agents that arrest cells in other 
phases of the cell cycle could potentially further enhance cancer cell death.
In this study, we tested BI 2536 and BI 6727 in PCa cell lines both as a single agent and in 
combination with histone deacetylase (HDAC) inhibitors valproic acid (VPA) and vorinostat 
(suberoylanilide hydroxamic acid (SAHA)). HDACs deacetylate lysine residues in the 
N-terminal tails of histones, thereby blocking gene transcription; therefore, inhibition of 
HDACs changes the expression of a wide variety of genes in cancer cells, leading to growth 
arrest and/or apopotosis.14, 15 Although HDAC inhibitors were initially hypothesized to 
upregulate silenced genes only, we and others have found a significant number of genes 
silenced upon HDAC inhibition in PCa cell lines.16 Using analysis of functional annotation 
(AFA) we found multiple pathways downregulated by HDAC inhibitors, several of these being 
involved in mitosis and the cell cycle, such as Plk1.17 We speculated that combining Plk1 
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with HDAC inhibitors would have an additive and potentially synergistic effect in inhibiting 
PCa cells. Our rationale for combining the two inhibitors for treatment of PCa was 2-fold. 
First, building on our AFA data, we hypothesized that combining HDAC  and Plk1 inhibitors 
might target Plk1 function through two different approaches. HDAC inhibition would lead 
to downregulation of Plk1 transcript and, hence, less Plk1 protein molecule per cell, which 
could be effectively inhibited at enzymatic level with the Plk1 inhibitor. Second, HDAC and 
Plk1 inhibitors inhibit cells in different stages of cell cycle. In an asynchronous culture, an 
HDAC inhibitor would effectively target cells in the G1/G2 phase of the cell cycle, while Plk1 
inhibitors could target cells that are in the mitotic phase of the cell cycle. This could lead 
to an effective/enhanced inhibition in cell proliferation. Further, cells that are resistant to 
HDAC inhibition and progress through the interphase could be halted at mitosis by Plk1 
inhibition and vice versa. To the best of our knowledge, this is the first report that combines 
HDAC inhibitors with Plk1 inhibitors for PCa treatment. 
Materials and methods
Cell lines and treatment
PCa cell lines were obtained from the American Type Culture Collection (ATCC; Manassas, 
VA, USA). Human prostate fibroblasts, kindly provided by dr. J. Isaacs (Johns Hopkins Medical 
Institutions, Baltimore, MD, US), were obtained from a prostate biopsy on a 62-year old 
patient with PCa having a Gleason score of 4. 957 E/human telomerase reverse transcriptase 
(hTERT) cells (hTERT-immortalized normal prostate epithelial cells),18 also kindly provided by 
dr. J. Isaacs, were grown in keratinocyte serum-free medium (K-SFM) supplemented with 
epithelial growth factor (EGF) and bovine pituitary extract (BPE) (Invitrogen, Carlsbad, CA, 
USA). All other cells were grown in Roswell Park Memorial Institute (RPMI-)1640 (Invitrogen) 
media supplemented with 10% fetal bovine serum (FBS). Cells were grown in a humidified 
incubator at 37°C in a 5% CO2 atmosphere. 
Stock solutions of 10 mM of SAHA (AtonPharma, Lawrenceville, NJ, USA), BI 2536 and BI 
6727 (Boehringer Ingelheim, Ingelheim am Rhein, Germany), made in dimethyl sulfoxide 
(DMSO), and stock solutions of 1M of sodium salt of VPA (Sigma-Aldrich, St. Louis, MO, 
USA), dissolved in complete RPMI media, were used for all experiments. For experiments, 
compounds were further diluted in complete RPMI media.
Proliferation assay
Cells were plated in 96-well plates containing 100 μl complete RPMI media and allowed 
to adhere overnight before treatment. Forty-eight hours after treatment, cell viability was 
measured using the CellTiter 96™ AQueous Non-Radioactive Cell Proliferation Assay (Promega, 
Madison, WI, USA) according to the manufacturer’s instructions. Absorption at 490nm was 
determined using a microplate reader (Molecular Devices, Sunnyvale, CA, USA). 




PCa cells were plated in 60 mm dishes and drugged at 50-60% confluency. Dishes were 
incubated for 48 h, after which 1x103 (DU145/PC3) or 2x103 cells (LNCaP) from each treated 
or control dish were plated in triplicate in 60 mm dishes and incubated for 12 days. Colonies 
were stained with a crystalviolet solution (Sigma-Aldrich) and counted manually.
Fluorescence microscopy
Cells were treated with BI 2536 or BI 6727 at 50-70% confluency. All cells, both floating and 
attached, were collected after 24 h of treatment, washed in phosphate-buffered saline (PBS) 
and fixed with 10% neutral buffered formalin (NBF). For visualization and quantification of 
polo-arrested cells, fixed cells were washed in PBS and their nuclei were counterstained 
with Hoechst 33258 (Sigma-Aldrich). Samples (25 μl) of the cell solution were mounted on 
slides. Cells were visualized with a Nikon Eclipse Ti inverted research microscope (Nikon 
Instruments, Linthicum, MD, USA). Multiple fields per slide were photographed, and the 
numbers of polo-arrested and non polo-arrested cells were counted manually. 
For immunofluorescence, cells fixed in formalin were permeabilized with 0.125% Triton 
X-100 for 5 min. The permeabilized cells were incubated with primary antibodies for Plk1 
(Antibody sc-5585, Santa Cruz Biotechnology, Santa Cruz, CA, USA) or phosphorylated 
aurora kinases (Antibody #2914, Cell Signaling Technology). Cells were washed in PBS and 
probed with Alexa Fluor conjugated secondary antibodies (Molecular Probes, Invitrogen). 
Nuclei were counterstained with DAPI (4’,6-diamidino-2-phenylindole) (Sigma-Aldrich)  and 
cells were mounted on slides. Confocal images were taken using the Zeiss LSM 510 meta-
confocal microscope (Carl Zeiss, Thornwood, NY, USA).
Plk1 activity assay
To assess Plk1 activity, glutathione S-transferase (GST)-PBD pulldown assays were performed 
according to Park et al.,19 with some modifications. The assay is based on the principle that 
active Plk1 phosphorylates the centromeric protein polo box interacting domain 1 (PBIP1) 
at T78 which creates a docking site resulting in a strong interaction between PBIP1 and a 
PBD domain of Plk1. Using tandemly linked PBIP1 motifs (6 repeats in our experiments) 
harboring the T78 phosphorylation site, expressed in bacteria as a GST fusion protein, active 
Plk1 can be pulled out from cells and tissue lysates, which can then be analyzed by Western 
blotting. 
In brief, GST-PBIPtides were expressed and purified from Escherichia coli BL21 by using 
glutathione sepharose (GE Healthcare, Waukesha, WI, USA). Proteins bound to the beads 
were quantified by bicinchoninic acid (BCA) reagent (Pierce Biotechnology, Rockford, IL, 
USA). For GST-PBIPtide pulldown assays, PCa cells were lysed in lysis buffer (20 mM Tris-Cl 
(pH8.0), 150 mM NaCl, 0.5% Nonidet P-40, 1.5 mM EDTA, 1 X phosphoSTOP (Roche, Palo 
Alto, CA, USA), and 1X protease inhibitor (Roche)). The resulting 500 mg of protein lysates 
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were clarified by centrifugation at 15,000 g for 20 minutes at 4 °C and incubated with bead-
bound GST-PBIPtide (100 mg) to precipitate PBIPtide-bound Plk1. Bead-bound Plk1 was 
detected by Western blotting using a Plk1 antibody (Santa Cruz Biotechnology).
Flow cytometry
Cells were plated in 100 mm dishes and drugged at 50-70% confluency. After 24 h of 
treatment, both floating and attached cells were collected, washed in PBS and fixed in a 
solution containing 10% NBF. Cells were permeabilized in 90% methanol, probed with a 
primary antibody against phosphorylated H3, followed by an Alexa Fluor-488 conjugated 
secondary antibody. Nuclei were stained with Hoechst 33258 in PBS containing 10% FBS. 
Flow cytometry was performed on the LSRII 4-laser, 18-color benchtop flow cytometer (BD 
Biosciences, San Jose, CA, USA). Data were analysed using BD FACSDivaTM software and 
FlowJo. 
Immunoblotting and densitometry
Immunoblotting was performed as described previously.17 Total protein (10 µg) was used 
for electrophoresis and blotted on polyvinylidene difluoride (PVDF) membrane. Primary 
antibodies were diluted in blocking buffer (5% milk) to a 1:1000 dilution, except for vinculin 
and actin, which were diluted 1:4000. Secondary antibodies were used at a 1:4000 dilution. 
Blots were developed using enhanced chemoluminescence (ECL) (GE Healthcare) or Femto 
(Pierce Biotechnology) and density of bands was quantified by ImageJ software.
Real-time quantitative reverse transcription polymerase chain reaction (RT-PCR) analysis
PCa cells were treated at 50-70% confluency with BI 2536 or BI 6727 for 6 or 24 h. Cells were 
lysed using TRIzol (Invitrogen) and total RNA was extracted. Total RNA (1 µg) was used for 
complentary DNA (cDNA) synthesis using the iScript cDNA synthesis kit (Bio-Rad, Hercules, 
CA, USA). One tenth of the first strand cDNA reaction was used for RT-PCR amplification and 
analyzed further as described by Kachhap et al.17
Statistical methods
Studies to assess synergy in cell proliferation (i.e. in MTS assays) and clonogenic survival 
assays were performed utilizing Calcusyn (Biosoft, Cambridge, UK) similar to previous 
preclinical studies testing combination therapies.20, 21 This software compares the antitumor 
effect of combination therapy at the provided doses to the (often extrapolated) doses of 
single agents required to produce an equal antitumor effect. To quantify levels of synergy, 
Calcusyn calculates a combination index (CI) using the Chou-Talalay method.22 The calculated 
CI values were grouped in different levels of synergy (no synergy (CI>0.9), moderate synergy 
(0.7<CI≤0.9), synergy (0.3<CI≤0.7, +), strong synergy (0.1<CI≤0.3, ++), very strong synergy 
(CI≤0.1, +++)) according to the manufacturer’s instructions. 




BI 2536 and BI 6727 cause defects in mitotic progression and inhibit proliferation of PCa 
cells. 
Proliferation of PCa cells, as judged by MTS assays, was considerably reduced by both BI 
2536 and BI 6727 (Fig. 1A). For BI 2536, the IC50 in DU145 cells was about 60nM, in LNCaP 
cells approximately 75 nM, and in PC3 cells about 175 nM (left graph, Fig. 1A). These IC50 
values were below serum plasma levels as determined in patients treated with BI 2536, who 
had a Cmax (maximum measured concentration in plasma) of 921 ng/ml (1.765 µM).
23 It was 
noted that with increasing concentrations, proliferation of LNCaP cells was stably 50% lower 
compared to control cells, while in DU145 and PC3 cells proliferation activity decreased to 
25% relative to controls. We inferred that this was most likely due to the slower proliferative 
nature of untreated LNCaP cells (doubling time 48 h) compared to DU145 (doubling time 
35 h) and PC3 (doubling time 30 h) cells. BI 6727 effectively inhibited DU-145 and LNCaP 
cells: the IC50 in DU145 and LNCaP cells was in the low nanomolar range (<10 nM), but in 
PC3 cells, the IC50 was approximately 600 nM. Despite the relatively high IC50 in PC3 cells, 
this concentration was still comparable to serum plasma levels (Cmax 2.346 µM) established 
in patients treated with BI 6727.13 
Figure 1. Plk1 inhibitors BI 2536 and BI 6727 reduce cell viability in PCa cells by inducing polo-arrest. A) MTS 
assays after treatment of PCa and normal human prostate cells with BI 2536 (left) or BI 6727 (right) for 48 h. B) 
Visualization of nuclei of PCa cells upon treatment for 24 h with BI 2536 or BI 6727 by staining with Hoechst 33258. 
Arrows point to polo-arrested cells, arrows with asterisk to enlarged polo-arrested cells.
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To explore whether the BI compounds have inhibitory effects on the proliferation of normal 
prostate cells, we treated 957 E/hTERT (doubling time 60 h), an immortalized normal 
prostate cell line, and human prostate fibroblast cells (doubling time 55 h) with the Plk1 
inhibitors. As depicted in Fig. 1A, both cell lines were relatively unaffected by the inhibitors 
at concentrations that severely reduced the viability of cancer cells, a feature that may 
be attributed to the rapid proliferative nature of cancer cells compared to their normal 
counterparts, suggesting that at concentrations at which Plk1 inhibitors exhibit their effect 
in PCa cells, the inhibitors are not very toxic to healthy cells. 
To investigate whether the reduction in cell proliferation was a result of Plk1 inhibition, 
we assessed the morphology of BI treated cells. Typical polo-arrested cells undergo mitotic 
dysregulation, exhibiting condensed chromosomes that fail to congress in the metaphase 
plate and appear randomly distributed through the cell, a feature attributed to monopolar 
spindles caused by Plk1 inhibition.2 We visualized Hoechst 33258 stained nuclei of cells 
treated with Plk1 inhibitors for 24 h under a fluorescent microscope. Dysregulated mitosis 
was evident in DU145 and LNCaP cells after treatment with either BI compound at low 
nanomolar concentrations (≤50 nM), indicating that these cells were polo-arrested, while 
PC3 cells displayed mitotic dysregulation only at higher concentrations of the compounds 
(Fig. 1B, arrows). With an increase in concentration of the Plk1 inhibitors an increased 
number of enlarged cells, suggestive of polyploid cells or cells in G2/M phase, were also 
visible (Fig. 1B, arrows with asterisk and enlarged image). We next quantified these polo-
arrested cells. Our data indicate that irrespective of the compound, DU145 cells exhibit 
most polo-arrested cells as compared to other PCa cell lines. This response cannot be solely 
attributed to a shorter doubling time of DU145 cells (±24 h), as PC3 cells, which have a 
comparable doubling time, exhibited only 40-50% of polo-arrested cells when treated with 
BI 2536. This further suggested a differential response of PCa cells to both inhibitors.
BI 2536 and BI 6727 affect Plk1 enzyme activity in PCa cells differently.
Cancer cells are known to overexpress Plk1, which may provide a selective growth advantage.2 
As expected, both normal prostate cell lines had lower level of total Plk1 than their cancer 
counterparts. The differential response of PCa cells to Plk1 inhibitors could result from 
differences in dependence on Plk1 among the cell lines. Therefore, we first studied protein 
expression levels of total Plk1 after Plk1 inhibition by Western blot analysis (Fig. 2A). In 
general, cells treated with low nanomolar concentrations of the BI compounds did not exhibit 
a significant change in total Plk1 protein levels compared to untreated cells. However, with 
increasing concentrations of the BI compounds, an increase in total Plk1 was evident (Fig. 
2A). BI 6727 treated DU145 cells were an exception: low nanomolar concentrations of the 
inhibitor increased the amount of Plk1 to its saturation level, as increasing concentrations 
did not demonstrate any further increase in Plk1 expression. This result may reflect the 
difference in response to BI 6727 as the compound is highly effective against DU145 cells 
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even at lower nanomolar concentrations (as evident in Fig. 1A). To investigate whether the 
increase in Plk1 protein after treatment with the inhibitors was a direct effect of increased 
transcription, we quantified Plk1 transcripts by real-time RT-PCR. Messenger RNA (mRNA) 
levels of total Plk1 were measured after 6 h (early response) and 24 h (delayed response) 
of BI treatment. Plk1 expression was found to be induced in DU145 and LNCaP cells at 
different time points. Although LNCaP cells demonstrated an earlier response with both 
of the inhibitors, DU-145 cells exhibited a delayed response when treated with BI6727. 
Further, induction of Plk1 transcript in DU-145 cells was restricted to a higher concentration 
Figure 2. Plk1 inhibition leads to differential responses in Plk1 expression and activity among PCa cell lines. A) 
Western blot analyses for total Plk1 after treatment of PCa cells with Plk1 inhibitors for 24 h. B) Real time RT-PCRs 
performed after 6 and 24 h of BI treatment show mRNA levels of Plk1 in PCa cells after BI treatment. *, p<0.01; 
concentrations in nM. C) Western blots indicating the levels of PBIPtide precipitated active Plk1 after GST-PBD pull 
down assays performed with BI treated PCa cell lysates. 
Numbers above Western blots indicate densitometric quantification of protein expression levels relative to untreated controls, 
normalized to the housekeeper vinculin. 
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of BI 6727. On the other hand, Plk1 expression in PC3 cells was modestly induced only 
when treated with a high concentration (750 nM) of BI 6727 (>1.5-fold increase; Fig. 2B). 
These results led us to infer that induction of Plk1 in DU145 and LNCaP cells could be a 
consequence of the cells being arrested in mitosis wherein Plk1 protein levels peak. We 
speculated that the increase in Plk1 protein after Plk1 inhibition seen in our Western blots 
may not reflect an increase in Plk1 activity. To ascertain this, Plk1 activity was determined by 
pulling down active Plk1 using the T78 PBIP1-GST peptide (see materials and methods). GST 
fusion PBIPtide proteins were expressed in Bl21 cells and purified for the assay.19 Lysates of 
Plk1 inhibitor treated and control PCa cells were used to pull down active Plk1. Active Plk1 
levels were assessed by Western blotting. As depicted in Fig. 2C, a marked reduction in Plk1 
Figure 3. Plk1 inhibition results in a differential response in the cellular distribution of Plk1 (yellow) among PCa cell 
lines DU145 (top) and PC3 (bottom) as depicted by immunofluorescence. 
Nuclei were stained with DAPI (blue). BI treatment led to an increase in cytoplasmic staining of Plk1 in DU145 cells (arrowheads). A 
representative cell in the composite image (arrow) is magnified below.
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activity was evident in both DU145 and LNCaP cells after treatment with Plk1 inhibitors. 
Although Plk1 activity decreased after BI treatment compared to untreated cells in all PCa 
cells, Plk1 activity was markedly higher in BI treated PC3 cells compared to BI treated DU145 
and LNCaP cells (Fig. 2C). 
BI 2536 and BI 6727 affect the subcellular localization of Plk1 in PCa cells. 
Because the subcellular localization of Plk1 changes relative to its function in different stages 
of mitosis and cytokinesis, we visualized Plk1 distribution by immunofluorescence after 
treating the cells with different concentrations of the BI compounds (Fig. 3). In untreated 
cells, Plk1 staining was most evident in mitosis where it seemed to localize to kinetochores 
as punctate dots, in the central spindle, in the centrosomal regions, and in the midbody 
during cytokinesis. This corroborates other reports in which Plk1 localized to the mitotic 
spindle poles and kinetochores during mitosis.24, 25 Consistent with earlier reports, we also 
observed centrosomal and faintly diffused cytoplasmic staining for Plk1 during interphase in 
untreated cells.24 When BI 2536 and BI 6727 were administered, Plk1 localized to condensed 
chromosomes. Furthermore, an increase in cytoplasmic Plk1 staining was observed in 
DU145 cells, which seemed to be dose-dependent. However, PC3 cells exhibited this effect 
to a much lesser extent after similar treatment. Overall, PC3 cells demonstrated a distinct 
reduction in Plk1 staining and mitotic figures after BI treatment compared to DU145 cells. 
This observation is in accordance with our Western blot data, which indicated a larger 
increase in total Plk1 expression in DU145 cells compared to PC3 cells (Fig. 2A). Although 
there is an increase in Plk1 expression after treatment with the inhibitors, Plk1 activity is 
markedly reduced in DU145 cells, as demonstrated by the pulldown activity assay (Fig. 2C). 
Therefore, it is unlikely that the increased cytoplasmic localization of Plk1 seen through 
immunofluorescence is enzymatically active. The differences in subcellular localization of 
Plk1 further indicate a differential response of PCa cells to the inhibitors.
Expression and localization of active aurora kinases differ in PCa cells after BI 2536 and BI 
6727 treatment
During mitosis, there is extensive crosstalk between Plk1 and aurora A and B kinases, two 
other key regulators of mitosis.26 Aurora-A phosphorylates Plk1 during G2/M transition, 
while Plk1 controls aurora-A localization to the spindle poles through hBora.27, 28 Previous 
reports have indicated that Plk1 inhibition leads to mislocalization of aurora A.27 Therefore, 
we assessed changes in aurora expression and localization after Plk1 inhibition. Because 
phosphorylation of aurora is necessary for the enzyme to exert its kinase activity, we 
determined active aurora A-C using an antibody that recognizes phosphorylated aurora 
A-C.29 As indicated by Western blots, protein expression levels of phosphorylated aurora A-C 
in LNCaP cells were increased after treatment with high nanomolar concentrations of the BI 
compounds (Fig. 4A). Phosphorylated aurora A protein levels were elevated in DU145 cells 
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Figure 4. Expression and localization of active aurora kinases differ between PCa cells after treatment with BI 2536 
and BI 6727. A) Western blot analyses for phosphorylated aurora A-C (from high to low molecular weight: aurora 
A, B, C) after 24 h of Plk1 inhibition with BI 2536 and BI 6727 in PCa cell lines. B) Immunofluorescence for aurora 
(yellow) and DAPI (blue) in DU145 (top) and PC3 (bottom) cells treated for 24 h with BI 2536 (left) or BI 6727 (right). 
A representative cell (arrowhead) is magnified below.
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when treated with BI 2536; in BI 6727 treated cells an increase in phosphorylated aurora A-C 
levels was observed with increasing dosage. Intriguingly, PC3 cells did not exhibit an increase 
in phosphorylated aurora proteins. To investigate whether this was not due to an aurora-null 
phenotype in PC3 cells, we performed a Western blot analysis in PC3 cells for total aurora 
kinase A and B (data not shown). Aurora A was the predominant isoform present in PC3 
cells, which showed a slight increase on treatment with BI compounds. These data indicated 
that PC3 cells were not null for aurora protein kinase. To test whether PC3 cells lacked the 
ability to phosphorylate aurora kinase, protein expression levels of phosphorylated aurora 
A-C proteins were tested after nocodazole treatment. Phosphorylation of aurora kinases 
increased after nocodazole treatment in DU145, LNCaP, and PC3 cells, suggesting that the 
lack of phosphorylated aurora kinases in PC3 cells after treatment with the BI compounds 
was not due to their inability to phosphorylate aurora kinases. Thus, expression of 
phosphorylated aurora in response to treatment with the BI compounds differed among 
PCa cells.
As with Plk1, the localization of aurora kinases changes during progression through the 
cell cycle.29 We visualized phosphorylated aurora A-C in untreated and BI treated PCa 
cells (Fig. 4B). Similar to previous reports, phosphorylated aurora A-C seemed to localize 
to kinetochores, poles, and spindles of mitotic cells in untreated controls.29, 30 PC3 cells 
arrested in mitosis after treatment with the compounds exhibited aurora localization similar 
to mitotically arrested BI treated DU145 cells. However, the total number of mitotic figures 
in PC3 cells was lower compared to DU145 cells, which may explain the lack of signal in 
the Western blot. Although we did not observe any marked increase in cytoplasmic aurora 
staining as observed in Plk1 after treatment, we did find a total lack of polar and spindle 
staining for aurora while kinetochore staining was retained. In this respect, our results 
differ from a previous report which found an increase in cytoplasmic aurora A after Plk1 
knockdown.27 One explanation could be the differences in antibodies used: while our 
observations are solely based on active/phosphorylated forms of aurora kinases, previous 
localization experiments were based on antibodies that recognized total aurora A. However, 
our results are in agreement with other reports that have observed impaired recruitment of 
aurora A to the centrosome and mitotic spindle.28, 30
PCa cell lines exhibit variable degrees of mitotic arrest upon treatment with BI 2536 and BI 
6727.
Next, we determined the effect of BI 2536 and BI 6727 on known markers of mitosis. Cells 
were treated for 24 h with the BI compounds at varying concentrations and protein expression 
levels were assessed by Western blots (Fig. 5A). At a final treatment concentration of 250nM 
with either compound, DU145 and LNCaP cells had a marked increase in phosphorylated 
histone H3, suggesting an increase in mitotic population. However, PC3 cells demonstrated 
only a slight increase in phosphorylated histone H3 when treated with higher nanomolar 
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concentrations of BI 6727, while there was an absence of any detectable protein when 
treated with BI 2536. Cyclin B1, another mitotic marker, increases late in G2-phase, and is 
degraded by cell-division cycle protein 20 (CDC20) when cells progress through the spindle 
assembly checkpoint (SAC), marking the progression from metaphase to anaphase.25, 31 
DU145 and LNCaP cells had increased levels of cyclin B1 after BI treatment, suggesting cells 
are arrested early in mitosis. On the other hand, cyclin B1 protein levels remained unchanged 
compared to untreated controls in PC3 cells after treatment with BI 2536. Treatment of 
PC3 cells with high nanomolar concentrations of BI 6727 yielded an increase in cyclin B1 
expression. This suggested that upon treatment with BI compounds, PC3 cells do undergo 
mitotic arrest, albeit at higher doses of BI compounds than DU145 and LNCaP cells. We next 
assessed the levels of CDC20, a protein that plays a key role in the anaphase promoting 
complex.31 Activation of the SAC leads to proteolysis of CDC20, causing a (pro)metaphase 
arrest. Treatment of DU145 and LNCaP cells with BI compounds led to a decrease in CDC20 
protein levels, demonstrating activation of the SAC. However, PC3 cells did not show an 
appreciable change in CDC20 protein levels. This further adds to the notion that PC3 cells 
lack a strong SAC, which results in cells progressing through mitosis despite Plk1 inhibition, 
as was evident in the MTS assay results (Fig. 1A). 
Prolonged mitotic arrest may trigger apoptosis.32, 33 To assess whether BI treatment leads 
to induction of apoptosis, we assessed poly (ADP-ribose) polymerase (PARP) cleavage as a 
surrogate marker for apoptosis (Fig. 5B). Cleaved PARP was increased in all three PCa cell 
Figure 5. Mitotic markers (A), but not apoptotic markers (B) are differentially expressed in PCa cell lines after 
treatment with BI 2536 and BI 6727. 
Numbers above Western blots indicate densitometric quantification of protein expression levels relative to untreated controls, 
normalized to the housekeeper vinculin.
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lines with increasing dosage of both BI compounds. After treatment with BI 6727, DU145, 
and LNCaP cells demonstrated an increase in cleaved PARP at 10 nM, while cleaved PARP was 
increased in PC3 cells at concentrations of 50 nM and higher only. Thus, both BI 2536 and 
BI 6727 have the ability to trigger apoptosis in all PCa cell lines, albeit to variable degrees. 
Since PC3 cells do undergo apoptosis, we wondered whether these cells are arrested in 
a cell cycle phase other than mitosis. We used p21 as a marker for G1 arrest and were 
surprised to find a significant dose-dependent induction of p21 in PC3 cells on treatment 
with both compounds (Fig. 6A). Analysis of mRNA levels of p21 revealed that PC3 cells 
demonstrated a marked increase in p21 transcripts after treatment with both compounds, 
while p21 was induced in DU145 cells only at higher nanomolar concentrations of BI 6727 
(Fig. 6B). Since both PC3 and DU145 cells are deficient in p53, induction of p21 on Plk1 
inhibition is through a p53-independent mechanism. Induction of p21 in PC3 cells suggests 
a G1 arrest; however, p21 is also known to cause G2 arrest in p53-deficient cells.34, 35 To 
distinguish between these possibilities, we conducted a fluorescence-activated cell sorting 
(FACS) analysis of PCa cells after treatment with BI 2536 and BI 6727 (Fig. 6C). Cells were 
stained for phosphorylated histone H3 to differentiate between cells in G2 phase and in 
mitosis. Our data indicated that all PCa cell lines exhibited mitotic arrest after BI treatment as 
indicated by the phosphorylated H3-positive fraction. However, the degree of arrest differed 
among cell lines. DU145 cells were most sensitive to BI 6727, followed by LNCaP and PC3 
cells. LNCaP cells were slightly more sensitive to BI 2536, with 98% of the cells accumulated 
in mitosis at the highest concentration, while in DU145 and PC3 cells, only 67 and 45% of the 
cells were in mitosis, respectively. Although the baseline percentage of PC3 cells in G2 phase 
was low compared to other PCa cell lines, an increase in cells in G2 phase was observed 
on treatment with either BI compound. Thus, at higher concentrations, the BI compounds 
caused DU145 and LNCaP cells to accumulate in mitosis and PC3 cells to accumulate both in 
the G2 and mitotic phase of the cell cycle arrest, eventually triggering apoptosis. Moreover, 
LNCaP cells exhibited an increase in polyploid cells after Plk1 inhibition.
Combinations of Plk1 inhibitors BI 6727 or BI 2536 with HDAC inhibitors VPA or SAHA have 
synergistic effects in vitro.
On the basis of previous findings that HDAC inhibitors downregulate Plk1 expression, we 
argued that combining HDAC inhibitors with Plk1 inhibitors would increase cell death, as 
the combination would maximize inhibition of the Plk1 pathway. Besides, we and others 
have shown that HDAC inhibitors can inhibit growth and proliferation of cancer cells 
through multiple pathways, such as cell cycle arrest, apoptosis, angiogenesis inhibition, 
and senescence.15, 36, 37 To ascertain whether downregulation of Plk1 by HDAC inhibitors 
at the transcript level was translated to protein expression levels, we determined protein 
expression levels of Plk1 by Western blots after treatment of DU145 and PC3 cells with HDAC 
inhibitors VPA and SAHA. As expected, Plk1 expression was decreased after treatment with 
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Figure 6. DU145 and LNCaP cells are arrested exclusively in mitosis after BI 2536 and BI 6727 treatment, while PC3 
cells accumulate both in G2- and M-phase. A) Western blot analysis of p21 after treatment of PCa cells with BI 2536 
or BI 6727 for 24 h. B) Real time RT-PCRs performed after 6 and 24 h of BI treatment of DU145 and PC3 cells to 
measure p21 mRNA levels.*, p<0.01; concentrations in nM. C) Flow cytometry performed after treatment of PCa 
cells with BI 2536 and BI 6727 for 24 h to measure the percentage of cells at a respective cell cycle stage. 
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Figure 7. Combination treatment of Plk1 inhibitors BI 2536 (left) and BI 6727 (right) with HDAC-inhibitors VPA and 
SAHA (vorinostat) in PCa cell lines results in synergy, as indicated by results from MTS (A) and clonogenic (B) assays. 
+, synergism; ++, strong synergism; +++, very strong synergism, as determined by Calcusyn (Biosoft). For DU145 cells: BI 2536 Lo, 
10 nM; BI 2536 Hi, 100 nM (MTS) or 250 nM (clonogenics); BI 6727 Lo, 10nM; BI 6727 Hi, 25nM. For LNCaP cells: BI Lo, 50 nM; BI 
Hi, 250nM. For PC3 cells: BI 2536 Lo, 50 nM; BI 2536 Hi, 250 nM; BI 6727 Lo, 300 nM; BI 6727 Hi, 500 nM. VPA in mM, SAHA in mM.
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the HDAC inhibitors at concentrations that correspond with serum plasma levels established 
in cancer patients treated with VPA (3 mM) or SAHA (6.17 µM) at the maximum tolerated 
dose (MTD) or below in phase I clinical trials (data not shown).38, 39 Next, we treated PCa 
cells with combinations of Plk1 inhibitors BI 2536 or BI 6727 and HDAC inhibitors VPA or 
SAHA. Proliferation and survival were assessed by MTS and clonogenic assays, respectively 
(Fig. 7). For the MTS assays (Fig. 7A), two concentrations were chosen per inhibitor based 
on the IC50 values for the respective cell line. Concentrations used in clonogenic assays were 
derived from results of the MTS assays (Fig. 7B). All concentrations used were at or below 
the plasma serum levels at the MTD in patients as determined in clinical studies.13, 23, 38, 
39 Clonogenic results suggested that combining the BI compounds with HDAC inhibitors 
had a synergistic effect in DU-145 and PC3 cells (Fig. 7B and Table 1). There were three 
important features evident from these studies. First, combinations of HDAC inhibitors 
with BI 2536 had a greater synergistic effect on all PCa cell lines than combinations with BI 
6727. The lower synergistic effect in combinations with BI 6727 was most likely due to this 
compound being highly effective as a single agent at very low concentrations: i.e., BI 6727 
at a concentration of 10 nM resulted in 5% clonogenic survival in DU145 cells compared to 
untreated DU145 cells (Fig. 7B). Second, combining BI compounds with SAHA led to more 
synergy than combinations with VPA. This is well illustrated in MTS assays performed after 
treatment of PCa cells with BI 6727: while combinations of BI 6727 with SAHA did exhibit 
a synergistic effect, in general, combinations of BI 6727 with VPA failed to exhibit clear 
synergy, as synergism was limited to DU145 cells. Third, and most important, increasing 
treatment concentrations overall diminished synergistic effects; at times, it even seemed 
to result in antagonistic effects. A clear example is evident in clonogenic assays performed 
with DU145 cells treated with BI 2536 and/or VPA: at low concentrations of the single 
agents, survival of DU145 cells was inhibited by 40–50%, while the combination of the two 
compounds inhibited survival of DU145 cells highly effectively (>90%); on the other hand, 
at higher nanomolar concentrations, cells were effectively inhibited by BI 2536 alone (<10% 
clonogenic survival), while the combination of BI 2536 with VPA led to 15–30% clonogenic 
survival (Fig. 7B). To further validate that combination of low-dose HDAC inhibitor and Plk1 
inhibitors does lead to an enhanced decrease in clonogenic potential, we performed the 
clonogenic experiments with a range of Plk1 inhibitor concentrations with low doses of 
HDAC inhibitors (data not shown). We did find a significant increase in cell death in both 
DU145 and PC3 cells at lower concentrations of Plk1 inhibitors when combined with HDAC 
inhibitors.
In summary, both BI 2536 and BI 6727 were successful in inhibiting PCa growth and survival 
in vitro. Combining these Plk1 inhibitors with HDAC inhibitors VPA or SAHA resulted in a 
synergistic effect depending on the type of inhibitor, the concentration of the inhibitor and 
the PCa cell line.




Insights gained from various studies indicate that cancer is fueled by multiple pathways, 
which are either mutated or amplified, to gain growth and invasive potential. The oncogene 
addiction hypothesis, put forward by Weinstein, states that cancer cells are addicted to such 
molecular pathways, which, if targeted, could reverse or inhibit the cancer phenotype.40 
This has been the rationale for several successful targeted therapies such as tamoxifen and 
trastuzumab for breast cancer, and imatinib for gastrointestinal cancers and leukemia.41-43 A 
protein upregulated in several cancers that could serve as a target in PCa is Plk1. Multiple 
small molecules have been generated to inhibit Plk1 and are currently in clinical trials.2 Our 
study investigates two such compounds, BI 2536 and BI 6727. Multiple phase II clinical trials 
have been conducted with BI 2536.9-12 All trials concluded that BI 2536 was well tolerated.9 
A newer, potentially improved compound is BI 6727.2, 7, 8 Phase I dose escalation studies in 
patients with advanced solid tumors reported partial responses in patients with sarcoma, 
head and neck cancer, urothelial cancer, ovarian cancer and melanoma, the limiting side 
effect being of hematological origin, similar to BI 2536.13, 44 Currently, a phase II clinical 
trial for this compound is being performed in patients with metastatic urothelial cancer.45 
Preliminary results of this study are promising, the drug being well tolerated in patients, 
14% of the patients having a partial response and 24% of the patients having stable disease.
In the current study, we assessed the effect of BI 2536 and BI 6727 in PCa cells at the molecular 
level. We further assessed the in vitro potency of both compounds as chemotherapeutics 
in the treatment of PCa, both as a single agent and in combination with HDAC inhibitors. 
Our results reveal that both BI 2536 and BI 6727 are potent inhibitors of PCa cell growth, BI 
6727 being the more effective of the two. However, we did observe a difference in response 
to the BI compounds across PCa cell lines. We argued that this differential response could 
be on account of inherent molecular differences between cell lines. Our data indicate that 
changes in Plk1 activity as a result of treatment with the BI compounds differ among the 
cell lines: while Plk1 activity was effectively decreased in DU145 and LNCaP cells upon 
treatment, the activity in PC3 cells was relatively refractory to BI treatment. As our study 
does not include mutation analysis of Plk1 in PCa cell lines, the possibility of PC3 cells 
harboring a Plk1 mutant which render the cells less sensitive to the BI compounds cannot 
be ruled out. Alternatively, differences in response may arise from differential reliance on 
Plk1 among PCa cells, which may reflect the heterogeneity in molecular pathways that drive 
PCa. Another difference may be the presence of a strong SAC in DU145 and LNCaP cells 
compared to PC3 cells, which may account why PC3 cells are not effectively arrested in 
mitosis after drug treatment. Nonetheless, we found that the BI compounds can arrest PC3 
cells in G2 and M phase, decrease their clonogenic potential, and induce apoptosis, albeit at 
higher nanomolar concentrations. Arrest of PC3 cells in G2-phase by the Plk1 inhibitors may 
suggest that Plk1 has functions beyond mitosis.4
Plk1 inhibitors, such as BI 6727, have a relatively low toxicity profile in humans, but more than 
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half of the patients with metastatic urothelial cancer treated with BI 6727 had progressive 
disease after six weeks of treatment.45 Better treatment outcomes for PCa patients could be 
accomplished by combining BI compounds with other chemotherapeutics, to accomplish an 
additive or synergistic effect while keeping toxicities manageable. To our knowledge, only 
one phase II clinical trial assessing combinational therapy with a BI compound is currently 
being performed, in which BI 6727 is combined with cisplatin and carboplatin in patients 
with advanced solid tumors.44 In this study, preliminary data show a partial response in 
8% and stable disease in 50% of the patients. In our study we combined BI 2536 and BI 
6727 with HDAC inhibitors. Taking lead from our previous AFA study and those of others 
which indicated that HDAC inhibitors downregulate mitotic checkpoint genes, Plk1 being 
one of them,17, 46 we reasoned that Plk1 would be inhibited from a transcriptional angle 
by the HDAC inhibitors and by direct enzyme inhibition by the Plk1 inhibitors, leading to 
enhanced cell death. As hypothesized, combining BI compounds with HDAC inhibitors had 
synergistic effects both in MTS and clonogenic assays. Synergism was more pronounced in 
the combination of BI 2536 with HDAC inhibitors and when both types of inhibitors were 
added in lower concentrations. Intriguingly, higher concentrations of BI compounds and 
HDAC inhibitors had the same effect as a single agent or were even found to be seemingly 
Table 1. Combination indices of different combinations of Plk1 inhibitors with HDAC-inhibitors in DU145, LNCaP 
and PC3 prostate cancer cell lines. 
For DU145 cells: BI 2536 Lo, 10 nM; BI 2536 Hi, 100 nM (MTS) or 250 nM (clonogenics); BI 6727 Lo, 10nM; BI 6727 Hi, 25nM. For 
LNCaP cells: BI Lo, 50 nM; BI Hi, 250nM. For PC3 cells: BI 2536 Lo, 50 nM; BI 2536 Hi, 250 nM; BI 6727 Lo, 300 nM; BI 6727 Hi, 500 
nM. VPA in mM, SAHA in mM
Combination index
MTS assays   Clonogenic assays
  
Inhibitor combination DU145 LNCaP PC3   DU145 PC3
BI2536
   BI lo + VPA1 0.447 0.000 0.554   0.152 0.294
   BI hi + VPA1 53.814 0.019 1.164   4.963 0.299
   BI lo + VPA1.5 0.670 0.012 0.426   0.290 0.170
   BI hi + VPA1.5 1.103 318.620 0.714   3.381 0.189
   BI lo + SAHA0.5 0.232 0.031 0.079   0.090 0.013
   BI hi + SAHA0.5 25.581 6.777 0.042   5.939 0.021
   BI lo + SAHA1 0.488 0.451 0.078   0.279 0.029
   BI hi + SAHA1 1855.938 0.494 0.032   3.115 0.048
  
BI 6727   
   BI lo + VPA1 0.444 0.813 0.737   0.690 0.246
   BI hi + VPA1 0.686 1.034 0.847   10.378 0.327
   BI lo + VPA1.5 0.538 0.981 0.951   0.835 0.215
   BI hi + VPA1.5 0.656 1.399 0.901   96.972 0.346
   BI lo + SAHA0.5 0.062 0.395 0.684   0.079 0.432
   BI hi + SAHA0.5 0.132 0.835 0.731   0.451 0.398
   BI lo + SAHA1 0.216 0.253 1.055   0.129 0.218
   BI hi + SAHA1 0.616 0.681 0.894   0.398 0.400
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antagonistic. Therefore, our data underscores the importance of correct dosing of both 
compounds to achieve the desired effect. 
In summary, this study tested the Plk1 inhibitors BI 2536 and BI 6727 in PCa cells, and 
elucidated the molecular mechanism by which the BI compounds effectively inhibit PCa 
cells. Furthermore, this study clearly indicates that the combination of two cell-cycle 
arresting chemotherapeutical agents, Plk1 inhibitors with HDAC inhibitors, has a synergistic 
effect in inhibiting PCa cells. However, to fully validate this claim, we feel in vivo studies are 
warranted before further evaluation in clinical trials for PCa.
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Histone deacetylase inhibitors (HDACIs) are being tested in clinical trials for the treatment 
of solid tumors. While most studies have focused on the re-expression of silenced tumor 
suppressor genes, a number of genes/pathways are downregulated by HDACIs. This provides 
opportunities for combination therapy: agents that further disable these pathways through 
inhibition of residual gene function are speculated to enhance cell death in combination 
with HDACIs. A previous study from our group indicated that mitotic checkpoint kinases such 
as PLK1 and Aurora A are downregulated by HDACIs. We used in vitro and in vivo xenograft 
models of prostate cancer (PCa) to test whether combination of HDACIs with the pan-aurora 
kinase inhibitor AMG 900 can synergistically or additively kill PCa cells. AMG 900 and HDACIs 
synergistically decreased cell proliferation activity and clonogenic survival in DU-145, LNCaP, 
and PC3 PCa cell lines compared to single agent treatment. Cellular senescence, polyploidy 
and apoptosis was significantly increased in all cell lines after combination treatment. In 
vivo xenograft studies indicated decreased tumor growth and decreased aurora B kinase 
activity in mice treated with low dose AMG 900 and vorinostat compared to either agent 
alone. Pharmacodynamics was assessed by scoring for phosphorylated histone H3 through 
immunofluorescence. Our results indicate that combination treatment with low doses of 
AMG 900 and HDACIs could be a promising therapy for future clinical trials against PCa.




In recent years, the introduction of various novel therapies for prostate cancer (PCa), such 
as taxanes, has significantly extended survival of patients.1, 2 Nevertheless, PCa remains the 
second deadliest cancer in the Western world.3 Therefore, research is needed to further 
improve clinical outcomes by identifying therapies with improved antitumor efficacy and/
or reduced toxicities.  
In the search for new molecular targets for PCa treatment, aurora kinases are a promising 
candidate.4 Three paralogous genes (aurora A, B, and C) comprise the aurora family of serine/
threonine protein kinases in mammalian cells. Aurora A and B are essential regulators of 
mitosis, while aurora C primarily plays a role in meiosis. Aurora A is an oncogene upregulated 
in several tumor types.5 Its phosphorylation is required for cell cycle progression, centrosome 
maturation, and spindle assembly.6, 7 Aurora B, also overexpressed in tumor cells, is most 
active during the G2/M-phase, and its phosphorylation is essential for the final steps of 
cytokinesis.6, 8, 9 Active aurora B phosphorylates histone H3 on serine 10, a molecular event 
vital for chromosome condensation and mitotic progression.6, 8 Inhibition of aurora A and 
B inactivates the spindle assembly checkpoint, resulting in endoreduplication, polyploidy 
and eventually, apoptosis.6, 10-12 The orally bioavailable pan-aurora kinase inhibitor AMG 900 
aborts cytokinesis by inhibition of autophosphorylation of aurora kinases.11 It is effective 
in multidrug resistant models, possibly through circumvention of the drug efflux effector 
P-glycoprotein.11
AMG 900 may yield enhanced antitumor activity in the presence of additional cancer 
therapeutics.11, 13 Previous studies by our group have demonstrated that several genes 
involved in mitotic checkpoints, including polo-like kinase 1 (Plk1) and aurora kinases, are 
downregulated by HDACIs.14, 15 Recently we have demonstrated that combination of HDACIs 
with a Plk1 inhibitor synergistically induced apoptosis, decreased cell proliferation, and 
decreased clonogenic survival of PCa cells.16 Based on our success with Plk1 inhibitors, 
we hypothesized that addition of HDACIs could potentiate apoptosis in PCa cells that 
are treated with aurora kinase inhibitors. Further, HDACIs exhibit promising antitumor 
effects in PCa in vitro and in vivo,17, 18 and have successfully been used in concert with 
other chemotherapeutics.19, 20 Therefore, HDACIs could serve as a rational choice for 
complementing the apoptotic effects of AMG 900. Hence, we combined AMG 900 with the 
HDACIs VPA and vorinostat in PCa cells in our current study. We found that combination of 
HDACIs with AMG 900 has a synergistic antitumor effect, the HDACIs activating an apoptotic 





Cell culture and treatment
PCa cell lines (DU-145, LNCaP, PC3) were obtained from ATCC. Cells were grown in RPMI-
1640 (Invitrogen) with 10% fetal bovine serum (FBS) (Gemini) and maintained in a 37°C 
humidified incubator supplemented with 5% CO2. VPA (Sigma-Aldrich) was prepared in 
RPMI at a 1M stock on the day of treatment of the cells. Vorinostat (AtonPharma) and AMG 
900 (Amgen) were maintained in 10 mM DMSO stock solutions at -20°C and diluted in RPMI 
upon use. Compounds were administered concomitantly in combination studies.
Cell viability and synergy
MTS assays were performed with CellTiter 96™ Aqueous Non-Radioactive Cell Proliferation 
Assay reagent (Promega) according to the manufacturer’s instructions. In brief, PCa cells 
were plated in 96-well plates, allowed to adhere overnight and treated with the selected 
compounds for 72 h. Subsequently, MTS reagent was added. Absorption at 490 nm was 
measured after approximately 2 h using a colorimetric plate reader (Molecular Devices). 
To compare the antitumor effect of single agent treatments with combination treatment, 
synergy was determined using CalcuSyn software (Biosoft). CalcuSyn calculates a 
combination index (CI) at different levels of growth, using the formula for mutually non-
exclusive mechanisms: (D1/Dx1) + (D2/Dx2) + (D1*D2/(Dx1*Dx2)), where D1 and D2 are 
the doses of drug 1 and drug 2 in combination required to produce x percentage effect, and 
Dx1 and Dx2 are the doses of drug 1 and drug 2 alone required to produce the same effect. 
Synergy levels (no synergy (CI>0.9), moderate synergy (0.7<CI≤0.9, +), synergy (0.3<CI≤0.7, 
++), strong synergy (0.1<CI≤0.3, +++), very strong synergy (CI≤0.1, ++++)) were determined 
from CI ranges, using the Chou-Talalay method following the manufacturer’s instructions.21, 
22
Cell survival  
Clonogenic assays were performed to assess long-term cell survival. PCa cells were plated 
in complete RPMI media. Upon reaching 50-60% confluency, drugs were added at the 
appropriate concentration and dishes were incubated for 48 h. Then, cells (1.25x103 for 
DU-145 and PC3 cells, 2x103 for LNCaP cells) were replated and grown in triplicate in 60 mm 
dishes containing fresh, complete RPMI media. After 10-14 days (depending on the doubling 
time of cell line), crystal violet stain (Sigma) was used to stain colonies and colonies were 
counted. All dishes from one cell line were stained at the same time point. The average 
number of colonies in DMSO-treated controls was considered 100% clonogenic survival in 
each separate cell line and in each separate experiment. Student’s t-tests were performed 
to assess whether clonogenic survival of a cell line differed significantly between doses 
of a single agent; synergy was determined with CalcuSyn when comparing single agent 
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treatment with combination treatment.21, 22
Cellular senescence
PCa cells were plated in 6-well plates (25-50x103 cells per well) and allowed to adhere 
overnight. Compounds were added to the complete RPMI media for 48 h, after which 
senescent cells were stained using the senescence β-galactosidase staining kit (Cell Signaling 
Technology) according to the manufacturer’s instructions. In brief, cells were washed in 
phosphate buffered saline (PBS) and fixed in Fixative Solution (2% formaldehyde and 0.2% 
glutaraldehyde in 1X PBS). After fixing, cells were washed in PBS and incubated with Staining 
Solution (containing 40 mM citric acid/sodium phosphate (pH 6.0), 150 mM NaCl, 2 mM 
MgCl2, 5 nM potassium ferrocyanide, and 1 mg/ml X-gal in 5% dimethylformamide) in a 37°C 
incubator for 24 h. Cells were washed in PBS and visualized under an Olympus IX70 inverted 
microscope using an Uplan FL 10x phase contrast lens. Multiple images (>5) were taken 
from each well. Senescent (blue) and total cells were counted in five fields of approximately 
30 cells/field for each treatment. Student’s t-tests were performed to determine whether 
cellular senescence significantly differed between combination treatment and single agent 
treatment.
Fluorescence microscopy
Cells were drugged at 50-70% confluency for 48 h and fixed with neutral buffered formalin 
for 10 minutes, followed by permeabilization with 0.125% Triton X-100 for 5 minutes. 
Cells were blocked with 10% bovine serum albumin (BSA) overnight. Cells were probed 
with a primary antibody against phosphorylated aurora kinase A/B/C (antibody #2914, 
Cell Signaling Technology) at a 1:100 dilution followed by an Alexa Fluor-555 (Invitrogen) 
conjugated secondary antibody at a 1:400 dilution in blocking buffer. Cells were washed 
in PBS and further incubated with Alexa Fluor-488 conjugated phosphorylated histone 
H3 antibody (antibody #9713 at a 1:100 dilution, Cell Signaling Technology). Cells were 
counterstained with Hoechst 33258 and mounted on slides. Confocal images were taken 
with the Zeiss LSM 510 meta-confocal microscope (Carl Zeiss) using a 63x objective.
Flow cytometry
Cells were plated in 100 mm dishes and drugged at 50-70% confluency. Both floating 
and attached cells were collected 48 h after treatment, washed in PBS and fixed with 4% 
freshly-made paraformaldehyde. Cells were then permeabilized with 90% cold methanol. 
Permeabilized cells were stained with Alexa Fluor-488 conjugated phosphorylated histone 
H3 antibody (1: 100 dilution, Cell Signaling Technology). Nuclei were stained with propidium 
iodide (Sigma) in PBS containing 1% BSA. Flow cytometry was performed on a FACSCalibur 





Western blotting was performed as described previously.14 Loading volumes equal to 20 µg 
of total protein were used. Primary antibodies were diluted 1:1000 in blocking solution with 
the exceptions of vinculin (Millipore) and phosphorylated aurora A/B/C (antibody #2914, 
Cell Signaling Technology), which were diluted 1:4000 and 1:500, respectively. Conjugated 
secondary antibodies were diluted 1:4000 in blocking solution. Blocking solution (5% milk 
in TBST (100 mM Tris-HCl pH 7.4, 0.1% Tween 20, 150 mM NaCl in H2O)) was used to dilute 
antibodies against p21 (BD Biosciences), cyclin B1 (Cell Signaling Technology), vinculin, 
and cleaved PARP (Cell Signaling Technology), as well as all secondary antibodies. 5% BSA 
was used for phosphorylated aurora A/B/C and phosphorylated and total histone H3 (Cell 
Signaling Technology). Blots were developed with ECL (GE) or Femto (Pierce Biotechnology) 
and scanned into a computer at a resolution of 300 dots per inch (dpi). Densitometric 
analyses were performed using ImageJ (Research Services Branch, National Institute of 
Mental Health); density of bands of the protein of interest was normalized to the density 
of bands of the housekeeper (actin, vinculin or total aurora A), and protein expression of 
treated cells was compared to the control.
In vivo
Animals
The animal protocol was approved by the Institutional Animal Care and Use Committee 
(IACUC) of Johns Hopkins University (JHU). All IACUC guidelines and United States Department 
of Agriculture regulations were followed. The mice used in this study were 8-week old JHU 
Oncology NOD/SCIDs (JHU bred colony) and were housed under aseptic conditions on a 12 
h light-dark cycle with food and water provided ad lib. Each cage contained ≤ 5 mice, which 
were differentiated by treatment groups. 
Two million DU-145 PCa cells, suspended in complete RPMI media, were embedded in a 
1:2 solution of Matrigel (BD Biosciences) and injected subcutaneously into the right flank 
of the mice. The tumor inoculation success rate was approximately 90%. Following a 3 
week growth incubation period, tumor volume was estimated with digital calipers, using 
the standard formula: π/6*length*width*height. Before treatment initiation, mice were 
stratified by tumor size and assigned into homogenous groups (8-9 per group). Once 
average tumor volume was above 200 mm3, treatment was initiated in all mice. Treatments 
were administered 4 consecutive days per week for a total duration of 4 weeks. Vorinostat 
(50 mg/kg) was administered once daily via intraperitoneal injections on mornings of days 
1-4 of the dosing cycle. AMG 900 was administered through gavage on days 1 and 2 of each 
dosing cycle. Mice were treated with vehicle (2% hydroxylpropyl methyl cellulose (HPMC) 
and 1% Tween 80 in deionized water (pH 2.2) with methane sulfonic acid (MSA)), or AMG 
900 at a concentration of 3.75 mg/kg or 7.5 mg/kg (provided weekly by AMGEN in glycerin). 
Tumor size and mice bodyweights were measured on the day preceding each dosing cycle 
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(day 0/7) and the final day of dosing (day 4) each week. Tumors were harvested when the 
volume reached 1000 mm3, which occurred 26 to 35 days after start of the treatment. For 
histological assessment of the tumors, mice were perfused with 2% paraformaldehyde 
through a cardiac catheter, and then tumors were excised, infiltrated in sucrose, embedded 
in O.C.T. compound (Sakura Finetek) and stored at -80°C. Tissue sections were prepared for 
hematoxylin-eosin staining by fixing the tissue in formalin and embedding in paraffin after 
tumor excision.
Tumor growth analysis
In vivo data from the DU-145 xenograft model were analyzed with a random intercept 
hierarchical linear model. The primary statistical outcome was tumor volume. To adjust for 
the initial volume, tumor volumes on days 3 through 26 for each mouse were divided by the 
volume on day 0 and then the log of these values was taken for analysis. The intercept in 
this longitudinal model was specified such that it represented the log ratio of the final tumor 
volume to the initial volume (time was coded using negative numbers and 0 for the final 
day). The model had the formula: git = β0 + ζ0i + β1 time it + β2 group i + β3 (group i * time it) + εit
where git denotes the log ratio tumor volume for mouse i at time t, β0 is the intercept 
representing the log ratio of the tumor volume on day 26 to the initial volume for the control 
group, β1 is the linear effect of time for the control group, β2 is the group effect on day 26, 
and β3 is the group effect in terms of the linear effect of time. The mouse specific effect 
ζ0i represented the deviation of each mouse from the group intercept. This corrected for 
the correlation between measurements taken on the same mouse. Since the mice in this 
experiment were considered a representative sample from a larger population, the effect 
was considered random and it was assumed that the population distribution from which 
they were sampled had a normal distribution. 
Tissue Immunostaining
Sections (20 µm) were cut from frozen tissues and mounted on microscope slides (Fisher 
Scientific). Sections were blocked in blocking buffer (5% goat serum, 0.5% BSA, 0.1% Triton 
X-100 and 0.01% sodium azide in PBS) and probed overnight with the primary antibody 
phosphorylated histone H3 in a 1:100 dilution (antibody #9713, Cell Signaling Technology). 
Sections were washed in PBS containing 0.1% Triton X-100 and probed overnight with Alexa 
Fluor-546 conjugated anti-rabbit antibody in a 1:500 dilution (Invitrogen). Subsequently, 
sections were washed in PBS and fixed with 10% formalin, and nuclei were stained with 
DAPI present in the mountant (Invitrogen). Coverslips were mounted on the slides and 
sections were imaged with a Nikon Eclipse Ti microscope at 20x (Nikon). The percentage 
of fluorescent cells was assessed in at least three fields of view per treatment group by 
dividing the density of red (phosphorylated histone H3 positive cells) by the density of 
blue (DAPI staining all nuclei) color with ImageJ. Student’s t-tests were performed to assess 
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for statistically significant differences in the percentage of cells that stained positively for 
phosphorylated histone H3 and phosphorylated aurora A/B/C.
Results 
AMG 900 and HDACIs inhibit aurora kinase expression and clonogenic survival of PCa cells.
After treatment of DU-145, PC3 and LNCaP PCa cells with AMG 900 for 12 h, the relative 
decrease in protein expression of phosphorylated aurora A/B/C was compared to protein 
levels of total aurora A. In all three cell lines, protein expression of phosphorylated aurora 
decreased in a dose-dependent manner at concentrations above 1 nM (Fig. 1A). Next, long-
term clonogenic assays were performed to determine cell survival of PCa cells after AMG 
900 treatment at 1 and 5 nM. At 5 nM, AMG 900 effectively inhibited clonogenic survival in 
all PCa cell lines (>70%) (Fig. 1B). These results mirrored those of Payton et al., who reported 
that the IC50 of AMG 900 in proliferation assays was around 5 nM for DU-145 and PC3 cells.
11 
Based on aforementioned results, we selected AMG 900 at 1nM (low dose, less effective) 
and 5 nM (high dose, effective) for drug combination studies. VPA and vorinostat were 
administered at concentrations of 1 mM and 1.5 mM, and 0.5 µM and 1 µM, respectively, 
as at these concentrations the compounds downregulated phosphorylated aurora A/B/C 
protein expression levels in DU-145 and PC3 cells (data not shown), while previous studies 
Figure 1. AMG 900 effectively targets PCa cells at concentrations above 1 nM. A) Western blot quantifying the 
protein levels of phosphorylated aurora A (48 kDa), B (40 kDa) and C (35 kDa) after treatment of PCa cells with AMG 
900 (concentrations indicated above each lane) for 48 h. Bands were normalized to total levels of aurora A. B) Bar 
graph representing relative clonogenic survival after AMG 900 treatment of PCa cell lines. 
Colonies were counted in triplicate.
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suggested acceptable toxicities at these concentrations.16, 18, 23
Combinations of low dose AMG 900 with HDACIs decrease proliferation activity and 
clonogenic survival of PCa cells. 
We employed MTS and clonogenic assays to assess the effect of combinations of AMG 900 
with VPA and vorinostat on the proliferation activity and long-term survival of PCa cells 
compared to a single agent. In both assays, treatment of PCa cells with 1 nM AMG 900 did 
not result in antitumor activity, similar to previous results (compare Fig. 1 to Fig. 2). In MTS 
assays, low dose VPA combined with low dose AMG 900 showed enhanced inhibition of cell 
proliferation compared to high dose AMG 900 used as a single agent in both DU-145 and 
LNCaP cells (Fig. 2A). Moderate synergistic effects were observed in DU-145 cells treated 
with combinations of AMG 900 (1 nM) and VPA (1 mM and 1.5 mM) (CI=0.796 and CI=0.777, 
respectively), and in LNCaP cells treated with combinations of AMG 900 (1 nM) and VPA (1 
mM) (CI=0.848). In PC3 cells the proliferation, as evaluated by MTS assays, was decreased 
by 10% at the most after treatment with AMG 900 and/or VPA. Combinations of vorinostat 
and AMG 900 enhanced the inhibition of cell proliferation in all three cell lines compared to 
treatment with single agents, except when combining a low dose of vorinostat (0.5 µM) with 
Figure 2. Combinations of AMG 900 with HDACIs VPA and vorinostat decrease the proliferation activity and long-
term clonogenic survival of PCa cells compared to single agent use. A-B) Proliferation activity of PCa cells after 
treatment with AMG 900 and VPA (A) or vorinostat (B), as measured by MTS assays. C-D) Quantification of colonies 
to assess clonogenic survival of PCa cells after treatment with AMG 900 and VPA (C) or vorinostat (D). 




a low dose of AMG 900 (1 nM) (Fig. 2B). Synergistic effects, as defined by CalcuSyn, were 
observed in PC3 cells treated with combinations of 1 µM vorinostat and AMG 900 (1 nM and 
5 nM) (CI=0.375 and CI=0.558, respectively).21, 22 
Cell death through aurora kinase inhibition may involve aborted cytokinesis progressing 
to apoptosis, which may not be registered as a change in a short-term proliferation assay. 
Therefore, we assessed the long-term effect of combination treatment on clonogenic 
survival in PCa cell lines. Treatment of PCa cells with 1 nM AMG 900 did not result in 
decreased clonogenic survival; however, combinations of low dose AMG 900 with either 
VPA or vorinostat resulted in a remarkably decreased clonogenic survival compared to single 
agent treatment (Fig. 2C-D). Subsequent analyses performed with CalcuSyn demonstrated 
that administration of AMG 900 (1 nM) combined with VPA (1 mM and 1.5 mM) resulted in 
a strongly synergistic decrease in survival compared to the single compounds in DU-145 and 
PC3 cells (0.171<CI<0.260) (Fig. 2C).21, 22 In LNCaP cells a moderately synergistic decrease in 
clonogenic survival was seen in combination treatments of low dose AMG 900 and low dose 
VPA (CI=0.765). Treatment of cells with combinations of AMG 900 (1 nM) and vorinostat 
(0.5 µM and 1 µM) resulted in a decrease in clonogenic survival that was synergistic or 
moderately synergistic in all three PCa cell lines (0.340<CI<0.809) (Fig. 2D). The higher dose 
of AMG 900 as a single agent severely inhibited clonogenic survival in all three cell lines. As 
a result, virtually no synergy could be measured in combination treatments involving high 
dose AMG 900. 
Combinations of AMG 900 with VPA or vorinostat increase cellular senescence of PCa cells.
During MTS and clonogenic assays, we observed PCa cell phenotypes resembling a senescent 
morphology after treatment with AMG 900 with or without HDACIs. Treated cells displayed 
a flattened morphology compared to untreated controls, and some treated DU-145 and PC3 
cells showed cytoplasmic vacuoles and granularity. We performed a Western blot analysis for 
p21 as a surrogate marker of cellular senescence in PCa cells treated with (combinations of) 
AMG 900 and HDACIs.24 Protein levels of p21 were not assessed in combinations with high 
dose AMG 900, as during the course of the treatment, cells treated with this combination 
constituted mainly apoptotic cells confounding analysis. In line with previous studies,18, 25 
protein expression of p21 was significantly increased after HDACI treatment compared to 
untreated controls; to a lesser extent AMG 900 treatment also resulted in an increase in 
p21 protein levels (Fig. 3A). Combination treatment further increased p21 levels, suggesting 
increased cellular senescence. To ascertain whether cellular senescence is indeed increased 
after combination treatment compared to single agent use in PCa cells, we stained DU-
145, PC3 and LNCaP cells for senescence associated (SA) β-galactosidase enzyme activity 
(Fig. 3B). Consistent with our previously observed morphological transformations, DU-
145 and PC3 cells treated with combinations of AMG 900 and HDACIs had increased SA 
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Figure 3. AMG 900 combined with HDACIs VPA or vorinostat increases cellular senescence in PCa cell lines 
compared to single agent use. A) Western blot for p21, a marker of cellular senescence or a G1/G2 phase cell cycle 
arrest, after treating DU-145, LNCaP and PC3 cells as indicated above each lane. Bands were normalized to the 
housekeeper vinculin. B) Representative images of PC3 cells after performing an SA β-galactosidase assay. Blue cells 
are SA β-galactosidase positive cells, indicating cellular senescence. C) Quantification of SA β-galactosidase positive 
staining after treatment of PCa cells with AMG 900 and/or HDACIs. 
Ai, AMG 900; VPA, valproic acid; SAHA, suberanilohydroxamic acid (vorinostat); *, combination treatments with a significantly 
increased percentage of senescent cells (p≤0.05).
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β-galactosidase staining. LNCaP cells had a baseline level of blue SA β-galactosidase staining 
in untreated controls; combination treatment of LNCaP cells with AMG 900 and HDACIs 
resulted in increased SA β-galactosidase staining. Quantification of β-galactosidase positive 
cells confirmed that the percentage of senescent cells was significantly increased in PCa cells 
treated with combinations of AMG 900 and HDACIs (35-60% SA β-galactosidase positive 
cells) compared to cells treated with single agents alone (≤25% SA β-galactosidase positive 
cells) (p≤0.05), except for combination treatment of LNCaP cells with AMG 900 (1 nM) and 
vorinostat (0.5 µM) compared to cells treated with vorinostat alone (p=0.116) (Fig. 3C). 
Combination treatment with AMG 900 and HDACIs increases PCa cells with multipolar 
spindles and polyploidy as compared to single agent treatment.
Since aurora kinases localize to distinct subcellular structures in mitotic cells, we probed 
DU-145 and PC3 cells with an antibody against phosphorylated aurora kinase A/B/C to 
investigate whether treatment results in differences in localization of these enzymes (Fig. 
4). We co-stained the cells for phosphorylated histone H3 as histone H3 is phosphorylated at 
serine 10 by aurora B during mitosis and can thus be used as a marker for aurora B activity.26 
After treatment with AMG 900, alone or in combination with HDACIs, localization of aurora 
was limited to the spindle poles. It was further observed that PC3 cells treated with low dose 
AMG 900 and HDACIs exhibited multipolar spindles, similar to 5 nM of AMG 900, suggesting 
endoreduplication and polyploidy. Both cell lines showed a near complete loss in aurora 
staining after a combination treatment with 5 nM of AMG 900 and HDACIs. Of note, addition 
of AMG 900 also caused a decrease in histone H3 phosphorylation in a dose-dependent 
manner in both PCa cell lines, with DU-145 demonstrating a greater decrease compared 
to PC3 cells. These results demonstrate that AMG 900 inhibits aurora kinases in PCa cells, 
potentially causing an increase in multipolar polyploid cells. 
To further quantify the effects of combining HDACIs and AMG 900 in PCa cells, we performed 
cell cycle analysis after treatment (Figs. 5A-B). Cells were stained with phosphorylated H3 
as a marker of aurora kinase activity. It is also a marker for cells in mitosis. DU-145 cells 
exhibited the greatest dose-dependent decrease in phosphorylated histone H3 positive cells 
upon AMG 900 treatment (Fig. 5A). In both cell lines combination treatment resulted in 
an additional decrease in phosphorylated histone H3 positive cells, most evidently after 
combination therapy with the HDACI vorinostat. As expected, flow cytometry showed AMG 
900 alone induced polyploidy in a dose-dependent manner with DU-145 cells exhibiting 
increased polyploidy as compared to LNCaP and PC3 (Fig. 5B). Combinations of vorinostat 
and low dose AMG 900, again to a greater extent than VPA and low dose AMG 900, led to 
a much greater increase in polyploidy as compared to single agents across PCa cell lines 
investigated. 
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All above data pointed to enhanced antitumor effects after treatment with a combination 
of low concentration of AMG 900 with HDACIs. To investigate whether combinations led 
to increased apoptosis, we probed PCa cells for cleaved PARP, a marker for apoptosis. As 
expected, combination treatments with low dose AMG 900 resulted in an increase in PARP 
cleavage (Fig. 5C). DU-145 cells exhibited a greater increase in PARP cleavage as compared 
to PC3 cells. These data demonstrate that AMG 900 can effectively inhibit aurora kinase 
activity in PCa cells, although the degree of inhibition may differ between cell types. Addition 
of an HDACI further potentiates apoptosis.
Low dose AMG 900 in combination with vorinostat inhibits histone H3 phosphorylation and 
suppresses growth of DU-145 xenografts.
The effect of combination treatment with AMG 900 and HDACIs on in vivo tumor growth 
inhibition was evaluated in mice bearing DU-145 xenografts. Vorinostat was selected as 
HDACI in these experiments, as it is already approved for the treatment of cancers in humans 
and the treatment administration does not require continuous administration as does VPA 
in mice.18 Mice were treated with vehicle alone, with AMG 900 at 3.75 (low dose) or 7.5 
Figure 4. Confocal analysis of DU-145 and PC3 PCa cells treated with AMG 900 and HDACIs VPA and vorinostat 
stained for phosphorylated histone H3 (green) and phosphorylated aurora kinase A/B/C (red). 
Ai, AMG 900; VPA, valproic acid; SAHA, suberanilohydroxamic acid (vorinostat).
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mg/kg (high dose), and/or with vorinostat at 50 mg/kg, corresponding to doses that had 
been used previously with limited toxicity.11, 27 The mean tumor growth during treatment 
is depicted in Figure 6A. We used the random intercept model to assess the overall effects 
for time, group, and the time by group interaction, which were all significant (interaction 
p-value <0.0001). Specifically, the tumor growth rate in mice after single agent treatment 
with high dose AMG 900 and combination treatment with either low- or high dose AMG 900 
and vorinostat was significantly reduced compared to the tumor growth rate in control mice 
(p-values 0.020, 0.014 and 0.036, respectively). In the group treated with a combination 
of low dose AMG 900 and vorinostat the average tumor growth rate was also lower than 
the tumor growth rate in groups treated with low dose AMG 900 alone or vorinostat alone 
(p=0.003 and p=0.008, respectively). Tumor growth rates in mice treated with low dose 
Figure 5. AMG 900 combined with HDACIs VPA or vorinostat (SAHA) decreases phosphorylated histone H3, and 
increases polyploidy and apoptosis in PCa cells. A-B) Flow cytometry analysis of PCa cell lines treated with AMG 
900 and/or HDACIs. Cells were sorted by phosphorylated histone H3 expression (A) and by the number of sets of 
chromosomes (B). C) Western blot analysis for cleaved PARP in PCa cells treated with AMG 900 and/or HDACIs. 
Bands were normalized to the housekeeper actin. Ai, AMG 900; VPA, valproic acid; SAHA, suberanilohydroxamic acid (vorinostat).
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AMG 900 and vorinostat combination treatment were similar to tumor growth rates in mice 
treated with high dose AMG 900 (p=0.833) and in mice treated with high dose AMG 900 and 
vorinostat (p=0.721).
These data are in concordance with our in vitro findings that the combination of low dose 
AMG 900 and HDACIs enhances inhibition of tumor cell growth. As the groups receiving 
combination treatment did not exhibit a significant difference in overall bodyweight 
compared to vehicle-treated controls and did not show signs of severe toxicity (no diarrhea 
or lethargy), our data suggest that combination treatment resulted in few toxicities in mice 
with stable weight.
Tumors from sacrificed mice were stained for phosphorylated histone H3 to assess 
aurora B inhibition (Fig. 6B). Vehicle and vorinostat treated tumors displayed about 4% 
phosphorylated histone H3 positive staining (p=0.713), while treatment with low dose AMG 
900 decreased the percentage of phosphorylated histone H3 positive cells to about 2% 
(p=0.004) (Fig. 6C). Both combination treatment with low dose AMG 900 and vorinostat, 
and treatment with high dose AMG 900 alone or in combination with vorinostat resulted in 
0.5% of the DU-145 cells being stained positively for phosphorylated histone H3, indicating 
significantly inhibited aurora B kinase activity in these tumors compared to vehicle treated 
tumors (p<0.001 and p=0.001, respectively). Inhibition of aurora B kinase activity did not 
differ between the combination treatment with low dose AMG 900 and vorinostat and high 
dose AMG 900 alone (p=0.806). 
Discussion
Tumor cell resistance and dose-limiting toxicities frequently result in administration of 
molecularly targeted agents below the efficacy threshold in patients. The efficacy of 
treatment could be increased by rationally combining antitumor therapies. Previously, 
we applied Analysis of Functional Annotation (AFA) to analyze data from a microarray 
experiment with VPA- or vorinostat-treated PCa cells that demonstrated HDACI-induced 
changes in gene expression in these cells.23 These data highlighted multiple pathways 
that were up- or downregulated by vorinostat and VPA in PCa cells.15 One can envisage 
pathways downregulated by HDACIs as opportunities for combining treatment modalities 
that are ineffective in the pathways’ presence. Several genes involved in the mitotic spindle 
checkpoint were downregulated by HDACI treatment, such as aurora kinase inhibitors, 
pointing to combinations of HDACIs with mitotic spindle checkpoint inhibitors as a promising 
anticancer strategy.14 Combination therapy of aurora kinase inhibitors with HDACIs had 
promising results in preclinical experiments with blood cancers;28, 29 such combinations have 
not been assessed in solid tumors. For this purpose, we successfully combined AMG 900, a 
pan-aurora kinase inhibitor, with HDACIs VPA and vorinostat in PCa cells in this study. AMG 
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900 is currently being tested in phase I clinical trials in patients with advanced solid tumors 
and in patients with acute leukemias;30 vorinostat is FDA-approved with a primary indication 
for cutaneous T-cell lymphoma. 
Our data indicate that combining aurora kinase inhibitors with HDACIs yields additive and 
even synergistic effects in inhibiting growth of both androgen-dependent (LNCaP) and 
androgen-independent (DU-145, PC3) PCa cell lines. We propose that multiple factors 
contribute to the observed synergy: (1) HDACIs target cells in different stages of the cell cycle 
(interphase) than AMG 900 (mitosis).11, 31 It is conceivable that cells which escape targeting 
by AMG 900 and progress through mitosis would be inhibited by HDACIs. (2) HDACIs may 
complement the action of the aurora kinase inhibitor by directly upregulating expression 
of genes that trigger the apoptotic/senescence pathway, such as p21, p27, and Bcl-2.28, 32 
(3) HDACIs also target aurora kinases but from a transcriptional angle instead of by direct 
catalytic inhibition; therefore, the aurora kinase pathway is targeted more effectively with 
Figure 6. Low dose AMG 900 combined with vorinostat enhances growth suppression of DU-145 xenografts and 
inhibits histone H3 phosphorylation in vivo, similar to treatment with high dose AMG 900. A) Tumor growth curves 
of NOD/SCID mice bearing established DU-145 tumors treated with vehicle, AMG 900 and/or SAHA for a maximum 
of four weeks. B) Representative images of tumor sections stained for phosphorylated histone H3 (red) and DAPI 
(blue). C) Bar graph displaying the percentage of phosphorylated histone H3 positive cells per treatment group. 
Tumor volumes are represented as mean ± SEM (n=9). *, groups with a significantly decreased tumor growth rate (A) or less 
phosphorylated histone H3 (C) compared to the control group (p≤0.05). pH3, phosphorylated histone H3; Ai, AMG 900; SAHA, 
suberanilohydroxamic acid (vorinostat).
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combination therapy.33-35 Furthermore (4), our data indicate that combinations of HDACIs 
and AMG 900 could trigger senescense. Senescence is known to be induced by activation 
of p21/Cip1 via p53.24 However, AMG 900 induces p21/Cip1 proteins in LNCaP, which has a 
wild type p53, and PC3 and DU-145 cells, which are p53 null and mutant, respectively. This 
indicates that p21 is induced independently of p53. In line with this observation, HDACIs 
are known to induce p21 and senescence independently of the p53-p21 pathway.32, 36, 37 
Intriguingly, the antitumor effect of AMG 900, enhanced with HDACIs, was more pronounced 
in clonogenic assays than in MTS assays. In line with previous studies with aurora kinase 
inhibitors, we hypothesized endoreduplication to be the mechanism of action.10, 11, 38 Though 
this process inexorably leads to cell death, it may, prior to that point, leave mitochondrial 
activity unaffected. Our cell cycle and microscopic imaging analysis results demonstrated 
an increase in polyploidy and senescence after AMG 900 treatment, supporting this theory. 
Consistent with our in vitro observations, tumor growth rates were lower in mice with 
a DU-145 xenograft model that were treated with a combination of low dose AMG 900 
and vorinostat, than in comparable mice treated with each individual agent at low doses. 
Growth rates in mice given combination treatment were equivalent, however, to those 
found in mice treated with high dose AMG 900 alone. Prior research noted that AMG 900 
blocks phosphorylated histone H3 in a dose-dependent manner in multiple human tumor 
xenograft models.11 Pharmacodynamic analysis in our study demonstrated that low dose 
AMG 900 in combination with low dose vorinostat blocks phosphorylated histone H3 with 
efficacy similar to that of high dose AMG 900. 
In conclusion, combination treatment of low dose AMG 900 with HDACIs could prove to 
be a viable mode of therapy in solid tumors such as PCa. Clinically, a regimen combining 
lower concentrations of HDACIs and AMG 900 could thereby yield 1) increased efficacy 
through synergistic or additive mechanisms, and/or 2) decreased toxicity. As VPA, vorinostat 
and AMG 900 differ in dose-limiting toxicities, the combination is not expected to severely 
increase the odds of a dose-limiting toxicity.30, 39-41 Therefore, this combination of targeted 
therapies could be a candidate for clinical trials as forward-seeking translational research 
aimed at improving clinical outcomes in cancer patients. 
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Novel biomarkers predicting prostate cancer (PCa) aggressiveness and PCa docetaxel therapy 
response are needed. In this study, the correlation between nuclear Eg5-expression, PCa 
docetaxel response and PCa aggressiveness was assessed. Immunohistochemical staining 
for nuclear Eg5 was performed on 117 archival specimens from 110 PCa patients treated 
with docetaxel between 2004 and 2012. Samples were histologically categorized as positive/
negative. 
Median follow-up time from diagnosis was 11.6 years. Nuclear Eg5-expression was 
significantly related to docetaxel response (p=0.036) in tissues acquired within three years 
before docetaxel initiation. Nuclear Eg5-expression was not related to Gleason-score 
(p=0.994). Survival of patients after docetaxel initiation did not differ based on nuclear Eg5-
expression (p=0.540). Analyzing samples taken before hormonal therapy, overall survival and 
time to docetaxel use were significantly decreased in patients with nuclear Eg5-expressing 
tumors (p<0.01). Eg5-positive nuclei were found more frequently in T4-staged tumors 
(p=0.04), Gleason 8-10 tumors (p=0.08), and in metastasized tumors (p<0.01). Multivariate 
analyses indicated that nuclear Eg5-expression may be an independent parameter for tumor 
aggressiveness. Limitations of a retrospective analysis apply.
In conclusion, nuclear Eg5-expression may be a predictive biomarker for docetaxel response 
in metastatic castrate-resistant PCa patients and a prognostic biomarker for hormone-
naive PCa patients. Prospective validation studies are needed to validate nuclear Eg5 as a 
biomarker. 




Metastatic castrate-resistant prostate cancer (mCRPC) is the second deadliest cancer in men 
in the Western world.1 Primary first-line therapy for most mCRPC patients consists of the 
taxane docetaxel with prednisone,2, 3 although various other mCRPC therapies have recently 
been introduced.4-8 About 48% of patients initially respond to docetaxel therapy;2 eventually 
all patients progress during or after docetaxel therapy, usually within a few months after 
their last cycle. As docetaxel inhibits depolarization of microtubules regardless of cell type,9 
toxicities may be severe, such as polyneuropathy and bone marrow suppression.2 To prevent 
or restrict unnecessary docetaxel use, and to determine the optimal treatment sequence for 
individual mCRPC patients,10 biomarkers predicting docetaxel response need to be identified 
and implemented in clinical practice.11 
We hypothesized that nuclear Eg5 (Kindle Spindle Protein/KSP/KIF11/kinesin-5) may be 
such a marker. Eg5 separates spindle poles of a mitotic cell by crosslinking two antiparallel 
microtubules and moving to the plus-ends of both microtubules.12 Due to its essential 
function in mitosis, multiple Eg5-inhibitors have been developed for anticancer therapy, 
such as ispinesib.13 Two studies with ispinesib focused particularly on mCRPC patients, with 
ambiguous results. In a phase I study, six out of fourteen mCRPC patients had stable disease 
(SD) for ≥18 weeks and one patient had a prostate-specific antigen (PSA)-decrease of >50% 
when ispinesib was combined with docetaxel in mCRPC patients.14 In a phase II study in 
which ispinesib was administered as monotherapy, no responses were reported.15 Twenty 
out of 21 patients had been treated with docetaxel prior to ispinesib. Immunohistochemistry 
analysis on archival tumor tissue from sixteen patients indicated that only one tumor stained 
positive for Eg5. It was concluded that ispinesib is not effective in primary prostate cancer 
(PCa) due to its low mitotic index, resulting in low Eg5 expression. However, considering 
their similar mechanism of action, an alternative explanation could be that cross-resistance 
occurs between docetaxel and Eg5-inhibitors.
Recent studies indicate that Eg5 may also play a role in intracellular transport in the 
cytoplasm, suggesting that Eg5-inhibitors may target Eg5 expressing non-mitotic cells too.16, 
17. Xing et al. analyzed archival specimens from 80 patients with clinically localized PCa; half 
stained positive for Eg5, while benign prostate cells did not express Eg5.18 Considering the 
low mitotic index of PCa cells regardless of disease stage,19 these data suggest that Eg5 may 
indeed be expressed in non-mitotic PCa cells too.20 
Combining aforementioned findings, initial Eg5 expression of PCa may have been decreased 
once tumors have become docetaxel resistant.14, 15, 18 This led to our hypothesis that Eg5 may 
be a predictive marker for docetaxel response. Based on recent findings that patients with 
high Gleason-scores respond better to taxane-based therapy,21 we further hypothesized 




Collection of patient material and data
Formalin fixed and paraffin embedded (FFPE) human PCa samples (biopsies, transurethral 
resections of prostate (TUR-P), or radical prostatectomies), stored at room temperature, 
were collected from pathology archives of Leiden University Medical Center, Reinier de Graaf 
Gasthuis and Erasmus Medical Center Rotterdam. mCRPC patients who had pathological 
material available taken before docetaxel therapy were included. The study was carried out 
in accordance with the Dutch code of conduct for the secondary use of human tissues; 
informed consent was therefore not required when enough material remained to serve the 
patient’s and family’s needs.22 Additional patient information was collected anonymously in 
a database. Approval was obtained from the Medical Ethics Committee of Leiden University 
Medical Center (P12.219).
Immunohistochemistry
Samples (3µm sections) were stained for Eg5 using a polyclonal anti-Eg5 antibody (1:1500, 
HPA006916, Sigma-Aldrich) on an automated immunohistochemistry stainer (Ventana 
Benchmark Ultra) (Fig. 1). This stainer utilized the ultraView Universal DAB Detection Kit 
(760-500, Ventana) for visualization of antibodies. The kit consisted of various enzyme 
labeled secondary antibodies that bind to primary antibodies; the complex was visualized 
with hydrogen peroxidase substrate and a 3.30-diaminobenzidine (DAB) tetrahydrochloride 
(DAB) chromogen. For antigen retrieval, ULTRA CC1, an EDTA-Tris pH 8.4 solution, was 
used (950-224, Ventana). Representative images were taken at 20x10 under an Olympus 
BX41 microscope (Olympus Optical Co., Ltd.) from each slide using a colorview IIIu camera 
(Olympus), and analyzed with Cell^B imaging software (version 2.4108-181207). If an 
image was representative for the whole slide, only one picture was taken; otherwise, three 
representative views were imaged per slide.
Data analysis
Images were examined and scored blindly and independently by two researchers (MDW, 
ESdM). A clear contrast between nuclear and cytoplasmic Eg5 staining was evident (Fig. 
1). Recent studies have indicated that intracellular functions of Eg5 may differ based on its 
subcellular localization;17 not all functions may be related to docetaxel response. Therefore, 
samples were scored for positive or negative staining of nuclei, cytoplasm or any cellular 
compartment (nucleus and/or cytoplasm).
Samples were considered positive when in one high-power field of view (20x10) at least four 
cancer cells were positive, regardless of intensity. This cut-off value ensured that random 
mitotic cells, infrequently found in the negative control too, were excluded. For analysis, 
average scores from both observers were calculated. If >50% of all scores per sample were 
positive for Eg5, the sample was considered Eg5-positive; otherwise it was considered Eg5-





Clinical endpoints used in this study include survival from docetaxel initiation, overall 
survival (OS), time to symptomatic mCRPC and best therapy response.
Time to symptomatic mCRPC was defined as time between PCa diagnosis and docetaxel 
initiation. OS was calculated as time between diagnosis and patient death. If patients had 
not died or were lost to follow-up, survival was censored at the day the patient was last 
known to be alive before July 20th, 2013. Tumor aggressiveness was based on OS, time to 
symptomatic mCRPC, Gleason-score, and TNM-classification. Determination of best disease 
response (progressive disease, partial response) followed PCa working group guidelines 
as described previously, and could indicate PSA response and/or response as viewed on 
imaging such as computer tomography.23, 24
Statistical analyses
Microsoft Excel 2003 was used for basic statistical analyses; student’s t-tests were conducted 
for comparisons. SPSS (version 20) was used for the Kaplan-Meier analyses of survival 
and time to symptomatic mCRPC; log-rank tests were used to compare these parameters 
between groups. Multivariate analyses were performed using the Cox-regression model. 
P-values ≤0.050 were considered statistically significant. 
Results
Patient and tissue characteristics
In total, 117 samples were collected from 110 mCRPC patients. These patients had been 
diagnosed with PCa between 1994 and 2011 and treated with docetaxel between July 
15th, 2004 and December 24th, 2012. Median time to follow-up from date of PCa diagnosis 
was 11.6 years (interquartile range 8.7-14.2 years). Clinicopathological parameters are 
listed in Table 1. Median age of patients when diagnosed with PCa was 64 years. Median 
Gleason-score of tumors was 8. About two-thirds of patients had ≥2 measured metastatic 
localizations when docetaxel was initiated. Of note, tumor imaging methods such as CT-
scans were not performed in all patients, underestimating the number of metastatic lesions. 
All patients had been medically and/or surgically castrated. In general, patients had been 
heavily pretreated: patients had received up to five therapies before docetaxel therapy.
For immunohistochemistry, tonsil and healthy prostate tissue served as positive and negative 
controls, respectively (Figs. 1A-B). Obtained PCa tissue consisted primarily of biopsies 
(70.0%) (Table 1). In the tumor samples, a clear distinction was observed between samples 




At time of prostate cancer diagnosis [median (range)] 64 (43-84)
At time of tissue sampling [median (range)] 65 (43-86)
At time of start docetaxel [median (range)] 69 (46-87)
Disease characteristics (diagnostic imaging)
Gleason-score [median (range)]
All patients 8 (4-10)
Hormone-naive patients 8 (4-10)




Confirmed localization of metastases [number of patients (%)]






Pretreatment [number of patients (%)]
Androgen-deprivation therapy 109 (99.1%)
Radical prostatectomy 15 (13.6%)
TUR-P 25 (22.7%)
Surgical castration 4 (3.6%)
Lymph node dissection 34 (30.9%)
Radiotherapy prostate 34 (30.9%)
Radiotherapy metastases 40 (36.4%)
Other 4 (3.6%)
Docetaxel treatment
# courses [median (range)] 1 (1-3)
# cycles [median (range)] 6 (1-20)
Best response [number of patients (%)]:
       progressive disease 22 (20.0%)
       stable disease 38 (34.5%)
       partial response 49 (44.5%)
Docetaxel rechallenge [number of patients (%)] 7 (6.4%)










Type of material [number of samples (%)]
Biopsy 82 (70.0%)
TUR-P 24 (20.5%)
Radical prostatectomy 11 (9.4%)
Disease stage [number of samples (%)]
hormone-naive 87 (74.4%)
pre-docetaxel 112 (95.7%)
within three years of start docetaxel 61 (52.1%)
mCRPC post-docetaxel 5 (4.3%)
Table 1. Characteristics of mCRPC patients (n=110), their disease and treatment, and of the obtained tissue (n=117).




OS in years [median (IQR)] 4.8 (2.6-9.3)
Lost-to-follow-up [number of patients (%)] 18 (16.4%)
IQR, interquartile range; mCRPC, metastatic castrate-resistant prostate cancer; OS, overall survival; TUR-P, transurethral resection 
of the prostate
Figure 1. Immunohistochemical analysis of Eg5 expression in human clinical samples. A) Positive control: lymphatic 
tissue in a tonsil. B) Negative control: healthy prostate tissue. C) Prostate cancer (PCa) sample staining negative 
for Eg5. D) PCa sample with Eg5 expression in both the nuclei and cytoplasm. E) PCa sample with nuclear Eg5 
expression. F) PCa sample with cytoplasmic Eg5 expression. G) Percentages indicate the frequencies samples with 
this subcellular staining pattern were found in our sample set (n=117).
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positive for Eg5 in both compartments (63.2%), irrespective of the samples’ age (Figs. 1C-G). 
Samples were scored for nuclear or cytoplasm staining separately. Interobserver agreement 
of scoring was 98.1%.
Immunohistochemical Eg5 expression and docetaxel response
Eg5 expression varied in tumors from some patients who had multiple biopsies taken before 
docetaxel therapy. This variability always reflected a disappearance of Eg5 expression over 
time. It is unknown whether these changes occurred as the tumor evolved spontaneously 
or due to other therapies, such as androgen-deprivation therapy. Therefore, correlation 
between Eg5 expression and docetaxel response was evaluated for all patients (n=110) as 
well as for patients with samples taken within three years before docetaxel start (n=61). 
A clear trend was observed between nuclear Eg5 expression and a better response to 
docetaxel therapy (Fig. 2A). This correlation was significant in patients from whom tissue 
was taken within three years before docetaxel initiation: 71.9% of these patients with 
nuclear Eg5 expression had a PR versus 36.4% of patients without nuclear Eg5 expression 
(p=0.036). Conversely, cytoplasmic or any Eg5 expression did not predict docetaxel response 
(data not shown).
As a previous report identified Gleason-scores as a predictive marker for docetaxel response, 
it was tested whether a correlation existed between Gleason-score and docetaxel response 
in our set of patient samples (data not shown). Gleason-score was not related to docetaxel 
response, neither in all patients (p=0.343) nor in patients with tissue available in the three 
Figure 2. Nuclear Eg5 expression and docetaxel response in mCRPC patients. A) Best disease response to docetaxel 
therapy in mCRPC patients, grouped by nuclear Eg5 expression of their tumor. Patients with stable disease (SD) 
were excluded from this analysis. The most recent PCa tissue before docetaxel therapy was analyzed from all 
patients (left) or only from patients who had tissue available within three years before docetaxel therapy (right). 
B) Overall survival (OS) after docetaxel initiation. Patients were excluded when they only had PCa tissue available 
acquired more than three years before docetaxel therapy. Selected mCRPC patients were grouped based on nuclear 
Eg5 expression of their tumor.
PD, progressive disease; PR, partial response. 
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years before docetaxel initiation (p=0.884). Furthermore, Gleason-score and nuclear Eg5 
expression were not related in this latter subpopulation (p=0.994), suggesting that nuclear 
Eg5 expression was an independent marker of docetaxel response. 
We further explored the correlation between docetaxel response and Eg5 expression by 
investigating patients who had a PCa sample taken before and after docetaxel treatment. 
Only five patients matched these criteria. While cytoplasmic Eg5 expression did not alter in 
these patients, three out of four tumors with positive Eg5 nuclei before docetaxel therapy 
did not have nuclear Eg5 expression after docetaxel treatment. These three patients had 
progressive disease upon discontinuation of docetaxel. On the other hand, the patient whose 
tumor expressed nuclear Eg5 pre- and post-docetaxel discontinued docetaxel therapy due 
to unacceptable toxicities. Despite the small patient number, these results suggested that 
loss of nuclear Eg5 expression may be related to docetaxel resistance.
Intriguingly, although patients with nuclear Eg5 expression had a better response to 
docetaxel (Fig. 2A), no difference in OS, calculated from the start of docetaxel therapy to 
death, was evident between tumors based on nuclear Eg5 expression (p=0.540) (Fig. 2B). 
Figure 3. Tumor aggressiveness in mCRPC patients based on Eg5 expression. Patients were selected of whom PCa 
tissue acquired within three years (left) or three months (right) of diagnosis was available. Patients were divided 
in groups based on nuclear Eg5 expression. Median OS (top) and time to symptomatic mCRPC (bottom) were 
compared between patients groups.
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Immunohistochemical nuclear Eg5 expression and tumor aggressiveness
We evaluated whether tumors with nuclear Eg5 expression behaved more aggressively. 
Analyzing samples from all 110 patients, patients with tumors with nuclear Eg5 expression 
had a significantly decreased OS (median 6.6 versus 4.7 years, p=0.046) (Fig. 3A). Time from 
diagnosis to symptomatic mCRPC was also decreased (median 4.0 versus 2.8 years, p=0.037) 
(Fig. 3B). When selecting samples from hormone-naive patients (n=87), differences in OS 
and time to symptomatic mCRPC were even more pronounced (p=0.010 and p=0.006, 
respectively) (Figs. 3C-D). In this subset of patients, nuclear Eg5 expression was related to 
Gleason-score (p=0.014) and TNM-classification (tumor stage, p=0.052; any metastases, 
p=0.007; distant metastases, p=0.021); no correlation existed between nuclear Eg5 
expression and age (Fig. 4).
Multivariate analyses were performed to test whether the correlation between nuclear 
Eg5 expression and tumor aggressiveness (OS and time to symptomatic mCRPC) remained 
evident when correcting for potential confounding variables, such as Gleason-score (Table 
2). When including all patients, addition of most covariates resulted in no statistically 
significant correlation between nuclear Eg5 expression and OS or time to symptomatic 
mCRPC. This included correction for age, while this variable was neither related to nuclear 
Eg5 expression nor to prognosis, suggesting the study was underpowered for such analyses. 
However, a trend towards positive nuclear Eg5 expression and aggressive tumors was 
evident. When assessing hormone-naive patients, a clearly positive trend existed between 
nuclear Eg5 expression and tumor aggressiveness regardless of the covariate added (hazard 
Figure 4. Correlation between PCa characteristics and nuclear Eg5 expression in hormone-naive PCa patients. 
Tumors were divided in groups based on Gleason-score and TNM-classification upon diagnosis; the percentage of 
tumors with Eg5 expressing nuclei was compared. 
Gl, Gleason; T, tumor stage according to TNM-classification; N, lymph node metastases (0, no metastases; 1, metastases); M, distant 
metastases (0, no metastases; 1, metastases), N1/M1, any metastases (lymph node and/or distant metastases).
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ratio >1.75), suggesting a potential independent prognostic value for nuclear Eg5 expression. 
The correlation between nuclear Eg5 expression and time to symptomatic mCRPC was 
significant in all subgroup analyses, except when metastases (N1 and/or M1) were added as 
a covariate (p=0.063).  
Discussion
Research has been ongoing to identify prognostic biomarkers and biomarkers predictive 
for therapy response in PCa that have improved accuracy compared to established 
biomarkers such as serum PSA levels and Gleason-score, with some success.11 Urokinase 
plasminogen activator and its inhibitor PAI-1, and Ki-67 have been identified as potential 
prognostic biomarkers of PCa.25, 26 Cytoplasmic localization of the androgen-receptor and 
increased blood serum levels of Macrophage Inhibitory Cytokine 1 (MIC-1) have been 
identified as potential markers for PCa docetaxel response.27, 28 PCa tumors expressing class 
III beta-tubulin were relatively insensitive to PCa therapy: class III beta-tubulin expression 
resulted in faster recurrence after radical prostatectomies, a decreased docetaxel response 
and decreased survival.29 Unfortunately, none of these markers are available yet for use 
in clinical practice.11 Additional studies, such as the one we present here, are needed to 
identify a biomarker to be used in clinical practice.
In the current study, we found that nuclear Eg5 expression in PCa was associated with 
improved antitumor efficacy of docetaxel, independently of patient’s Gleason-score. 
Furthermore, we identified nuclear Eg5 as a prognostic marker in hormone-naive PCa 
patients: patients whose tumor expressed nuclear Eg5 had a decreased median OS and 
progressed more rapidly to mCRPC. Similar findings were reported in non-small lung cancer 
patients: patients with Eg5 expressing tumors had a better response to chemotherapy, but 
a lower OS.30 Similarly, Eg5 expression was related to worse clinical outcome in renal cell 
carcinoma patients.31
Once docetaxel was initiated, survival of mCRPC patients was similar irrespective of nuclear 
Eg5 expression. This may indicate that nuclear Eg5 expressing tumors initially respond well 
to docetaxel, resulting in decreased patient mortality. However, once these Eg5 expressing 
tumors progress, these tumors behave more aggressively, increasing patient death. This 
trend could indeed be derived from the survival curve (Fig. 2B) and might explain why 
survival of patients with nuclear Eg5 expression is not increased after docetaxel treatment 
despite responding better to docetaxel therapy. Alternatively, other factors may have 
resulted in the similar survival curve, such as unequal patient and treatment characteristics 
between groups other than Eg5 expression.
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Nuclear Eg5 expression could provide a useful tool for clinical practice. Interobserver 
agreement between researchers was very high (98.1%), as no subjective degrees of 
positive staining (mild/moderate/strong) were used. Positive/negative scoring requires 
little interpretation from the pathologist. Determination of Eg5 expression at the time of 
diagnosis would be non-invasive, as tissue material has already been acquired. Additional 
tissue sampling once the mCRPC stage has been reached, could aid the physician in deciding 
when to initiate docetaxel therapy. Patients whose tumor expresses nuclear Eg5 may benefit 
from early docetaxel treatment; patients with Eg5-negative tumors may be recommended 
to initiate other therapies first, as docetaxel response is more limited. 
In the current study, a retrospective design was chosen, resulting in several limitations. 
FFPE PCa samples were collected from pathology archives; these samples were taken for 
diagnostic purposes (biopsies) and consisted of residual materials from surgical procedures 
such as TUR-P or radical prostatectomies. Therefore, the sample set we created was 
heterogeneous in origin. However, contrary to other tumors such as breast cancer, only 
limited tissue material is available from PCa patients during their disease, as many patients 
have a prostatectomy early in their disease and primarily suffer from bone metastases, 
which are not easily accessible. Furthermore, additional tissue sampling is often not 
needed, as it currently would not influence further therapy decisions. Therefore, although 
our initial patient number was relatively large, only limited tissue material was available 
from patients shortly before docetaxel initiation. Hence, all samples taken within three 
years of docetaxel initiation were collected for analysis. This led to a heterogeneous cohort 
of samples (both biopsies and residual surgical material), representing various stages of 
PCa disease. Furthermore, patients may have received various treatments between tissue 
sampling and docetaxel initiation. E.g., antiandrogen treatment significantly changed gene 
expression profiles of prostate cancer.32 It is unknown whether such treatment specifically 
All patients Hormone-naive patients
Covariate OS [HR (95% CI)] TTD [HR (95% CI)] OS [HR (95% CI)] TTD [HR (95% CI)]
Age 1.56 (0.95-2.54) 1.56 (1.00-2.42) 2.13 (1.13-4.02) 2.29 (1.31-3.98)
Gleason 1.48 (0.91-2.40) 1.45 (0.94-2.23) 1.76 (0.92-3.36) 1.78 (1.00-3.18)
Gleason <7 and ≥7 1.58 (0.95-2.63) 1.50 (0.95-2.38) 2.61 (1.35-5.07) 2.67 (1.50-4.75)
Gleason <8 and ≥8 1.48 (0.91-2.40) 1.46 (0.95-2.26) 1.84 (0.79-3.49) 1.93 (1.09-3.41)
T stage 1.75 (1.03-2.99) 1.59 (0.99-2.53) 2.56 (1.32-4.97) 2.64 (1.47-4.75)
Any metastases 1.52 (0.81-2.85) 1.28 (0.74-2.22) 2.25 (0.99-5.13) 1.97 (0.96-4.02)
Distant metastases 1.40 (0.79-2.49) 1.25 (0.75-2.08) 1.84 (0.87-3.87) 2.33 (1.14-4.79)
Number of 
metastases 1.64 (1.01-2.65) 1.59 (1.04-2.44) 2.61 (1.35-5.07) 2.67 (1.50-4.75)
Table 2. Multivariate analysis using the Cox-regression model exploring potential confounders for the correlation 
between nuclear Eg5 expression and tumor aggressiveness.
CI, confidence interval; HR, hazard ratio; OS, overall survival; T stage, T stage according to TNM classification; TTD, time to docetaxel 
therapy.
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affects nuclear Eg5 expression. To overcome these challenges, a prospective study will be 
needed in which tissue will be collected shortly before docetaxel initiation to confirm the 
correlation between nuclear Eg5 expression and docetaxel response. However, such a study 
will need to overcome ethical and practical challenges. 
In addition, our patient population was underpowered for multivariate analyses in hormone-
naive patients. Further prospective studies are warranted to validate whether nuclear Eg5 
expression may serve as an independent prognostic biomarker. 
Previous studies found that PCa patients with aggressive tumors respond well to docetaxel, 
but also respond better to cabazitaxel, suggesting that aggressive tumors respond well to 
taxanes in general.24, 33 Therefore, additional studies are needed to assess whether Eg5 
predicts response to cabazitaxel too. Finally, our study results suggest that loss of Eg5 
expression may be related to docetaxel resistance. Although ispinesib had limited antitumor 
efficacy after docetaxel, our study and previous phase I findings suggest that ispinesib may 
be effective when administered before or concomitantly with docetaxel, when up to 70% 
of tumors express nuclear Eg5.14 However, combination therapy with docetaxel would need 
direct comparison to docetaxel monotherapy. Eg5-inhibitors may provide further clinical 
benefit when selecting mCRPC patients based on nuclear Eg5 expression (personalized 
medicine).
In conclusion, nuclear Eg5 expressing PCa is aggressive, but responds well to docetaxel. Loss 
of nuclear Eg5 expression may be associated with docetaxel resistance. Determining nuclear 
Eg5 expression in PCa samples may aid to improve timing to initiate docetaxel therapy in 
individual PCa patients. Additional prospective studies are needed to confirm the predictive 
and prognostic value of nuclear Eg5.
Acknowledgments
The authors wish to thank Natalja ter Haar and Michelle Osse for their help with the 
immunohistochemistry experiments. The authors further wish to thank Carolien Haazer and 





 1.  Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63(1):11-30.
 2.  Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus 
prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-1512.
 3.  Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with 
mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 
2004;351(15):1513-1520.
 4.  de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for 
metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a 
randomised open-label trial. Lancet 2010;376(9747):1147-1154.
 5.  de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic 
prostate cancer. N Engl J Med 2011;364(21):1995-2005.
 6.  Ryan CJ, Smith MR, de Bono JS et al. Abiraterone in metastatic prostate cancer without 
previous chemotherapy. N Engl J Med 2013;368(2):138-148.
 7.  Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after 
chemotherapy. N Engl J Med 2012;367(13):1187-1197.
 8.  Parker C, Nilsson S, Heinrich D et al. Alpha emitter radium-223 and survival in metastatic 
prostate cancer. N Engl J Med 2013;369(3):213-223.
 9.  Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 
2004;4(4):253-265.
 10.  van Soest RJ, van Royen ME, de Morree ES et al. Cross-resistance between taxanes and 
new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in 
metastatic castration-resistant prostate cancer. Eur J Cancer 2013;49(18):3821-3830.
 11.  Armstrong AJ, Eisenberger MA, Halabi S et al. Biomarkers in the management and treatment 
of men with metastatic castration-resistant prostate cancer. Eur Urol 2012;61(3):549-559.
 12.  Kapitein LC, Peterman EJ, Kwok BH, Kim JH, Kapoor TM, Schmidt CF. The bipolar mitotic 
kinesin Eg5 moves on both microtubules that it crosslinks. Nature 2005;435(7038):114-118.
 13.  Lad L, Luo L, Carson JD et al. Mechanism of inhibition of human KSP by ispinesib. Biochemistry 
2008;47(11):3576-3585.
 14.  Blagden SP, Molife LR, Seebaran A et al. A phase I trial of ispinesib, a kinesin spindle protein 
inhibitor, with docetaxel in patients with advanced solid tumours. Br J Cancer 2008;98(5):894-
899.
 15.  Beer TM, Goldman B, Synold TW et al. Southwest Oncology Group phase II study of ispinesib 
in androgen-independent prostate cancer previously treated with taxanes. Clin Genitourin 
Cancer 2008;6(2):103-109.
 16.  Wissing MD, van Diest PJ, van der Wall E, Gelderblom H. Antimitotic agents for the treatment 
of patients with metastatic castrate-resistant prostate cancer. Expert Opin Investig Drugs 
2013;22(5):635-661.
 17.  Wakana Y, Villeneuve J, van Galen J, Cruz-Garcia D, Tagaya M, Malhotra V. Kinesin-5/Eg5 is 
important for transport of CARTS from the trans-Golgi network to the cell surface. J Cell Biol 
2013;202(2):241-250.
 18.  Xing ND, Ding ST, Saito R et al. A potent chemotherapeutic strategy in prostate cancer: 
S-(methoxytrityl)-L-cysteine, a novel Eg5 inhibitor. Asian J Androl 2011;13(2):236-241.
 19.  Berges RR, Vukanovic J, Epstein JI et al. Implication of cell kinetic changes during the 
Nuclear Eg5 as a biomarker in PCa
197
9
progression of human prostatic cancer. Clin Cancer Res 1995;1(5):473-480.
 20.  Wissing MD, Carducci MA, Gelderblom H, van Diest PJ. Tales of how great drugs were brought 
down by a flawed rationale--letter. Clin Cancer Res 2013;19(5):1303.
 21.  van Soest RJ, de Morree ES, Shen L, Tannock IF, Eisenberger MA, de Wit R. Initial Biopsy 
Gleason Score as a Predictive Marker for Survival Benefit in Patients with Castration-resistant 
Prostate Cancer Treated with Docetaxel: Data from the TAX327 Study. Eur Urol 2013.
 22.  van Diest PJ. No consent should be needed for using leftover body material for scientific 
purposes. For. BMJ 2002;325(7365):648-651.
 23.  Scher HI, Halabi S, Tannock I et al. Design and end points of clinical trials for patients with 
progressive prostate cancer and castrate levels of testosterone: recommendations of the 
Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26(7):1148-1159.
 24.  Wissing MD, van Oort IM, Gerritsen WR et al. Cabazitaxel in patients with metastatic 
castration-resistant prostate cancer: results of a compassionate use program in the 
Netherlands. Clin Genitourin Cancer 2013;11(3):238-250.
 25.  Gupta A, Lotan Y, Ashfaq R et al. Predictive value of the differential expression of the urokinase 
plasminogen activation axis in radical prostatectomy patients. Eur Urol 2009;55(5):1124-
1133.
 26.  Rubio J, Ramos D, Lopez-Guerrero JA et al. Immunohistochemical expression of Ki-67 
antigen, cox-2 and Bax/Bcl-2 in prostate cancer; prognostic value in biopsies and radical 
prostatectomy specimens. Eur Urol 2005;48(5):745-751.
 27.  Darshan MS, Loftus MS, Thadani-Mulero M et al. Taxane-induced blockade to nuclear 
accumulation of the androgen receptor predicts clinical responses in metastatic prostate 
cancer. Cancer Res 2011;71(18):6019-6029.
 28.  Zhao L, Lee BY, Brown DA et al. Identification of candidate biomarkers of therapeutic 
response to docetaxel by proteomic profiling. Cancer Res 2009;69(19):7696-7703.
 29.  Ploussard G, Terry S, Maille P et al. Class III beta-tubulin expression predicts prostate 
tumor aggressiveness and patient response to docetaxel-based chemotherapy. Cancer Res 
2010;70(22):9253-9264.
 30.  Saijo T, Ishii G, Ochiai A et al. Eg5 expression is closely correlated with the response 
of advanced non-small cell lung cancer to antimitotic agents combined with platinum 
chemotherapy. Lung Cancer 2006;54(2):217-225.
 31.  Sun D, Lu J, Ding K et al. The expression of Eg5 predicts a poor outcome for patients with 
renal cell carcinoma. Med Oncol 2013;30(1):476.
 32.  Holzbeierlein J, Lal P, LaTulippe E et al. Gene expression analysis of human prostate carcinoma 
during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy 
resistance. Am J Pathol 2004;164(1):217-227.
 33.  Oudard S, de Bono JS, Özgüroglu M et al. Impact of cabazitaxel (Cbz) + prednisone (P; CbzP) 
on overall survival (OS) at 2 yrs and in patients (pts) with aggressive disease: post-hoc 
analyses of TROPIC trial. [abstract]. Ann Oncol 2012;23 (Suppl 9; abstr 1857).

Chapter 10
Radium-223 chloride: extending life in prostate 
cancer patients by treating bone metastases
Michel D. Wissing, Fijs W.B. van Leeuwen, Gabri van der Pluijm, Hans Gelderblom




The treatment scope for patients with metastatic castrate-resistant prostate cancer (mCRPC) 
is rapidly expanding. On May 15th, 2013, the US Food and Drug Administration (FDA) approved 
radium-223 chloride (223RaCl2) for the treatment of mCRPC patients whose metastases are 
limited to the bones. Radium-223 is an α-emitting alkaline earth metal ion, which, similar 
to calcium ions, accumulates in the bone. In a phase III study (ALSYMPCA), mCRPC patients 
with bone metastases received best standard-of-care treatment with placebo or 223RaCl2. 
At a prespecified interim analysis, the primary endpoint of median overall survival was 
significantly extended by 3.6 months in patients treated with radium-223 compared with 
placebo (p < 0.001). The radioisotope was well tolerated and gave limited bone marrow 
suppression. 223RaCl2 is the first bone-targeting antitumor therapy that received FDA approval 
based on a significantly extended median overall survival. Further studies are required to 
optimize its dosing and to confirm its efficacy and safety in cancer patients.




Prostate cancer is the most prevalent and second deadliest cancer in men in the United 
States and Europe.1 Most morbidity and virtually all mortality from prostate cancer occur 
once the tumor has become metastatic and castrate-resistant (mCRPC).2 Therefore, research 
aimed at the development of novel therapies for prostate cancer has primarily focused on 
this patient group. Although a decade ago no therapy existed with a proven significant 
benefit on the median overall survival of mCRPC patients, patients now have the options 
to be treated with multiple life-extending therapies. These therapies consist of agents that 
selectively target the androgen pathway (abiraterone acetate, enzalutamide) and taxanes 
(docetaxel, cabazitaxel), which target microtubules.3-8 Furthermore, the immunotherapy 
sipuleucel-T has been approved for its use in asymptomatic or minimally symptomatic 
mCRPC patients.9, 10
Prostate cancer primarily metastasizes to the bone.11 Bone metastases may lead to severe 
morbidity, such as bone marrow failure, pathological fractures, and spinal cord compression, 
reducing quality of life and potentially resulting in death.12, 13 Hence, specific treatment of 
bone metastases may significantly lower the burden of prostate cancer disease.14, 15 Multiple 
agents have been approved by the United States Food and Drug Administration (US FDA) 
for the palliative treatment of bone metastases in mCRPC patients, such as external beam 
radiotherapy and the β-emitting radiopharmaceuticals strontium-89 (1.5-2.2 MBq/kg) and 
samarium-153 (37 MBq/kg) (Table 1). Such therapies result in symptomatic relief in more 
than half of patients.16, 17 However, the duration of response is limited; the effect of these 
treatments on overall survival has not been studied. Moreover, as surrounding tissue, 
including the bone marrow, is damaged as well, significant adverse events such as bone 
marrow failure may occur in treated patients. 
Therapeutic isotope Rhenium-186 Samarium-153 Strontium-89 Radium-223
Half-life (days) 3.8 1.9 50.5 11.4
Administered agent 186Re-HEDP 153Sm-EDTMP 89SrCl2
223RaCl2
Binding inducing factor Bisphosphonate 
ligand
Lexidronam ligand Ca2+ similarity of 
Sr2+
Ca2+ similarity of 
Ra2+
Therapeutic irradiation 1 β-particle 1 β-particle 1 β-particle 4 α-particles, 2 
β-particles
Stable decay product 186Os 153Eu 89Y 207Pb
Standard dose 1295 MBq 37 MBq/kg 1.5-2.2 MBq/kg 50 kBq/kg















CRPC patients with 
symptomatic bone 
metastases and 
no known visceral 
metastatic disease




On May 15th, 2013, the FDA approved radium-223 chloride (223RaCl2; Xofigo; previously 
named alpharadin) for the treatment of bone metastases in mCRPC patients based on 
interim results from a phase III randomized clinical trial, the ALSYMPCA study (Alpharadin 
in the treatment of patients with symptomatic bone metastases in castration-resistant 
prostate cancer). This marks the first FDA-approved radionuclide that has been shown to 
extend overall survival in mCRPC patients in a phase III study. In this review, we will discuss 
the (pre)clinical development of 223RaCl2, focusing primarily on the most recent results from 
the ALSYMPCA study. Subsequently, we discuss the FDA approval and future implications 
this approval may have in clinical practice.
Radium-223 chloride
223RaCl2 is a water-soluble radium salt. In ionic form, radium accumulates in bones at 
areas with increased bone turnover because of chemical similarity to calcium ions; both 
are alkaline earth metals.18, 19 Radium-223 is an α-emitting radioisotope that decays via 
seven daughter nuclides before it stabilizes as lead-207 (Fig. 1). During the decay of each 
radium-223 isotope, four α-particles and two electrons (β-particles) are emitted (Table 1). 
Both α- and β-irradiation can induce local therapy by inducing damage in the surrounding 
tissue. Because of the size and high energy of α-particles, these particles are highly effective 
in inducing double-strand breaks in DNA within 100 µm. The half-life of radium-223 is 
11.4 days; the half-lives of its daughter nuclides range from seconds to minutes. These 
daughter nuclides do not have a chemical similarity to calcium ions. Therefore, the half-lives 
of radon-219 (4.0 s), bismuth-211 (2.1 min) and thallium-207 (4.8 min) seem to be long 
enough to allow diffusion from the primary accumulation site. 
Early preclinical and clinical studies
In a preclinical study, nude rats with MT-1 human breast cancer xenografts were treated 
with pamidronate, a bisphosphonate used against skeletal complications of cancer, with or 
without radium-223.18 Although all rats treated with pamidronate only had to be sacrificed 
within 21 days, 40% of rats treated with pamidronate and radium-223 at 10 or 30 kBq 
survived beyond 50 days. Compared with β-emitting particles such as strontium-89, rodents 
treated with radium-223 showed no signs of bone marrow suppression or other toxicities.20
In a phase I study, 223RaCl2 was administered to 15 prostate and 10 breast cancer patients 
with bone metastases.21 Patients received a single i.v. injection of radium-223 with activities 
up to 250 kBq/kg. More than 50% of patients reported pain relief, while toxicity was low. 
Grade 3 leukopenia occurred in three patients; the maximum-tolerated dose (MTD) was not 
established. Radium-223 accumulated in the skeleton, particularly in sites with metastases. 
In the blood, radioactivity levels diminished quickly: to 6% after 1 hour and to <1% 24 hours 
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after injection. Recently, similar findings were presented from another phase I study.22 In 
this study, ten mCRPC patients received radium-223 up to 200 kBq/kg, among which six 
patients received a second dose of 50 kBq/kg. The MTD was again not established, and 
radium-223 was rapidly cleared from the blood, primarily into the small bowel. 
A subsequent phase II study compared treatment of 50 kBq/kg radium-223 with placebo 
treatment in 64 CRPC patients with painful bone metastases.23, 24 Median time to skeletal-
related event (SRE) was 14 weeks in the radium-223-treated group versus 11 weeks in 
patients treated with placebo (p = 0.257).23 Low toxicity of radium-223 was confirmed in 
this phase II study. None of the 33 223RaCl2-treated patients discontinued treatment because 
of adverse events. Grades 3 and 4 hematological adverse events occurred in 3 (9.1%) and 
0 (0%) radium-223-treated patients and in 1 (3.3%) and 1 (3.3%) placebo-treated patients, 
respectively. Severe non-hematological adverse events occurred in 3 (9.1%) 223RaCl2-treated 
patients and in 5 (16.7%) placebo-treated patients. In a follow-up report 24 months after 
the first injection of study medication, no long-term treatment-related toxicity was noted.24 
Median overall survival was 65 weeks in the 223RaCl2-treated group, and 46 weeks in the 
placebo-treated group (p = 0.056).
ALSYMPCA
The ALSYMPCA phase III study was initiated in 2008, comparing the efficacy and safety of 
Figure 1. Radioactive decay of radium-223. Radium-223 decays via seven daughter nuclides to lead-207, resulting in 




223RaCl2 with that of placebo (a saline injection) in patients with symptomatic CRPC with 
bone metastases.25 Patients needed to have at least two bone metastases, diagnosed by 
bone scintigraphy. Patients were eligible if they had previously received docetaxel, if they 
were unfit for docetaxel, if they declined therapy with docetaxel, or if docetaxel was not 
available. Patients were excluded if they had visceral metastases. Patients received an i.v. 
injection (50 kBq/kg) once every 4 weeks for a maximum of 6 cycles.
In total, 921 patients were included at 135 study locations worldwide, primarily in North 
America, Australia and Europe.26 Six hundred fourteen patients received radium-223, of 
whom 352 had received docetaxel before 223RaCl2 treatment (57.3%). In the placebo group, 
a similar percentage had received prior docetaxel (56.7% (174 patients)). Other baseline 
characteristics, such as age, disease stage, and baseline opioid use, were similar between 
the two treatment groups as well.25
The primary endpoint of the ALSYMPCA study was overall survival. In general, the median 
overall survival in patients treated with radium-223 was extended by 3.6 months compared 
with placebo-treated patients (p < 0.001). For patients who had received docetaxel before 
participation in the ALSYMPCA trial, median overall survival was 14.4 months in 223RaCl2-
treated patients versus 11.3 months in placebo-treated patients (hazard ratio (HR) = 0.71; 
95% confidence interval (CI) 0.56-0.89); for patients who had not received prior docetaxel, 
the median overall survival durations were 16.1 months and 11.5 months, respectively (HR 
= 0.74; 95% CI 0.56-0.99).25
The key secondary endpoint in the ALSYMPCA trial was time to symptomatic skeletal event 
(SSE), defined as the time to first use of external-beam radiotherapy to relieve skeletal 
symptoms, new symptomatic pathologic bone fractures, spinal cord compression, or tumor-
related orthopedic surgery. Imaging to assess for skeletal events was only performed when 
clinically indicated to avoid registration of asymptomatic fractures. Time to SSE was 15.6 
months in 223RaCl2-treated patients versus 9.8 months in the placebo-treated group (p < 
0.001; HR = 0.66; 95% CI 0.52-0.83).25 Time to initial opioid use and time to external beam 
radiotherapy were both increased in patients treated with radium-223 (HR = 0.670 and HR = 
0.621, respectively).27 Sixteen and 24 weeks after initiation of radium-223 treatment, patients 
had significantly less pain compared with baseline (p < 0.001 and p = 0.001, respectively).
Further analysis revealed that an increase in the levels of total alkaline phosphatase 
was associated with an increased risk for death in the patient population studied in the 
ALSYMPCA trial (p < 0.0001).28 In patients treated with radium-223, a ≥30% reduction in 
total alkaline phosphatase levels compared with the baseline was seen in 47% of patients 
versus 3% of placebo-treated patients.25
In general, radium-223 was well tolerated by patients, with grade 3 or 4 adverse events 
occurring more frequently in the placebo-treated group (62%) than in patients treated with 
radium-223 (56%). The only reported non-hematologic grade ≥3 adverse events that occurred 
more frequently in the 223RaCl2-treated patient group were anorexia (2% versus 1%) and a 
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decreased appetite (2 patients versus 0 patients). Comparing grade ≥3 hematologic adverse 
events in the 223RaCl2-treated group with the placebo group, anemia occurred in 13% and 
13%, neutropenia in 3% and 1%, and thrombocytopenia in 6% and 2%, respectively.25 Analysis 
of these hematologic adverse events revealed that a baseline total alkaline phosphatase of 
≥220 U/L strongly predicted anemia.29 Apart from the use of radium-223 instead of placebo, 
other baseline predictors for neutropenia and thrombocytopenia were prior docetaxel use 
and more than six bone metastases. However, prior external beam radiotherapy to the bone 
was associated with a decrease in anemia and neutropenia.
FDA approval
Interim results from the ALSYMPCA phase III clinical trial led to approval of radium-223 by 
the FDA for the treatment of mCRPC patients who have symptomatic bone metastases and 
no visceral metastases. It was recommended to be administered at 50 kBq/kg every 4 weeks 
with a maximum of 6 doses, which is equal to the treatment regimen in the ALSYMPCA trial. 
This approval makes radium-223 the first agent available for CRPC patients that significantly 
increases overall survival by exclusively treating bone metastases.
Despite its decision to approve radium-223, the FDA required four additional studies, 
besides final analysis of ALSYMPCA study results.30 Non-compliance with this decision, or 
negative results could result in the FDA revoking the approval.
As mentioned previously, no MTD for radium-223 has been established.21, 22 Results from 
phase I studies suggested concentrations higher than 50 kBq/kg could be administered to 
patients with relatively few changes in the toxicity profile of the agent. Two recent phase 
II studies confirm that treatment up to 100 kBq/kg has similar toxicities compared with 
radium-223 at 50 kBq/kg, while the efficacy of radium-223 is increased.31, 32 Therefore, 
the FDA required a randomized phase II study to further assess the efficacy and safety of 
radium-223 in CRPC patients with bone metastases at concentrations higher than 50 kBq/
kg. If these results suggest a beneficial risk-benefit profile for higher doses, an additional 
phase III study will be required to confirm the optimal activity level.
The FDA required the company to perform three studies to further assess the safety of 
radium-223: an observational study in 1200 CRPC patients with bone metastases, evaluating 
the long-term safety of radium-223 administered at the recommended dose; a randomized 
clinical trial in CRPC patients with bone metastases and no visceral metastases to further 
assess the safety of radium-223, particularly for enhanced assessment of the effect of 
radium-223 on healthy bone marrow and secondary malignancies, such as acute myeloid 
lymphoma (AML) and myelodysplastic syndrome (MDS);33 finally, an assessment of the 
short- and long-term safety of a radium-223 rechallenge, for which the company was 





With the FDA approval of 223RaCl2 for CRPC patients with symptomatic bone metastases 
regardless of prior chemotherapy, the treatment scope for mCRPC patients has further 
expanded. By excluding patients with visceral metastases, the most rational step for 
oncologists would be to use radium-223 primarily as a first-line therapy in mCRPC patients. 
That said, a subpopulation may also be eligible for radium-223 treatment as second-line 
therapy or later. 
Considering the results of radium-223 treatment in the robustly designed and well-
conducted ALSYMPCA trial, it is expected that the approval and consequently clinical use of 
radium-223 will expand beyond the United States in the near future. In addition, radium-223 
may improve the quality of life and survival for patients with other tumor types who suffer 
from bone metastases. However, such expansions require additional clinical investigations. 
Finally, the FDA approval of radium-223 as the first metastasis-targeting agent based on an 
improved median overall survival confirms that selectively treating metastases may be an 
effective strategy in patients with advanced solid tumors for whom palliative treatment is 
the only option, strengthening the development of such agents.
A major limitation of the ALSYMPCA phase III study is that the group of patients selected 
for this study may not correspond to the patient population in clinical practice that will 
receive radium-223 treatment. Patients with visceral metastases were excluded from 
participation in the trial. Considering that β-emitting radionuclides, such as samarium-153, 
have been shown to induce pain relief in patients with advanced prostate cancer, further 
research is required to address whether radium-223 provides clinical benefit for patients 
with visceral metastases.16, 17 Based on the approval of radium-223, physicians may decide 
to administer this agent to this group of patients as well, although its efficacy has not been 
proven. Furthermore, patients were excluded from the ALSYMPCA study when docetaxel 
was available, patients were fit for (and willing to receive) docetaxel treatment and had not 
received docetaxel before. Nevertheless, the FDA does not exclude this group of patients for 
radium-223 treatment in its approval letter. Until the required post-marketing studies have 
been conducted that will indicate whether mCRPC patients eligible for docetaxel treatment 
will also benefit from radium-223, its clinical benefit in this patient group remains uncertain.
Currently, no long-term follow-up is known for patients in the ALSYMPCA trial, limiting the 
toxicity profile of the drug. Although the high number of therapeutic emissions in the decay 
process of radium-223 may yield a strong therapeutic effect, the daughter nuclides, which 
do not have affinity to the bone, may diffuse throughout the body and cause damage in 
healthy tissue. Although no bone marrow suppression was seen in the short term, it will be 
important to follow patients over time to ensure that there are no long-term harmful effects 
from radium-223 treatment. Most of the FDA’s post-marketing requirements therefore focus 
on drug safety, particularly on the long-term effects of radium-223 treatment and safety of 
radium-223 rechallenge at a later stage.
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NDRG1 consists of 60,085 basepairs, starting at basepair 134,318,596 and ending at 
basepair 134,378,680 from the p-terminus. It is a member of the NDRG family, consisting of 
NDRG1, NDRG2, NDRG3 and NDRG4 (of which three isoforms exist: NDRG-4B, NDRG-4Bvar 
and NDRG-4H), which are part of the alpha/beta hydrolase superfamily. The DNA of NDRG1 
contains 16 exons (Fig. 1). It encodes a 3.0 kb mRNA with a coding region of 1.185 kb.
Protein
NDRG1 is a 43 kDa protein, composed of 394 amino acids, with an iso-electric point of 5.7 
(Fig. 2). NDRG1 has an alpha/beta hydrolase-fold motif, however, the presence of hydrolytic 
catalytic activity is still questionable. NDRG1 has more than seven phosphorylation sites, 
among others a phosphopantetheine attachment site, protein kinase C, casein kinase II, 
tyrosine kinase, protein kinase A and calmodulin kinase II. NRDG1 is phosphorylated by 
protein kinase A and calmodulin kinase II, and is a physiological substrate of SGK1 and 
GSK-3β kinase, a kinase involved in cancer growth and progression. NDRG1 is relatively 
ubiquitously expressed in normal human cells, and especially highly expressed in prostate, 
brain, kidney, placenta, ovarian, testicular and intestinal cells. NDRG1 is mostly found in 
epithelial cells. In cells, NDRG1 is primarily a cytoplasmic protein. 47.8% of the NDRG1 is 
expressed in the cytosol, 26.1% in the nucleus (such as in prostate epithelial cells), and 8.7% 
in the mitochondria (such as in proximal tubule cells in the kidney). NDRG1 is also found in 
the adherens junctions. Additionally, in intestinal and lactating breast epithelia NDRG1 is 
located in the plasma membrane. NDRG1 can also be found in vacuoles, the peroxisome, 
early and recycling endosomes, and the cytoskeleton.
NDRG1 amino acid sequence is 53% homologous to NDRG2, 62% to NDRG3, 62% to NDRG4, 
and 94% homologous to the mouse analog, Ndr-1 (also known as TDD5). NDRG1 homologs 
have been found in Helianthus, Caenorhabditis, Xenopus and Drosophilia.
Figure 1. NDRG1 DNA




NDRG1 is reported to be a metastasis suppressor gene which is downregulated in prostate, 
colon and breast cancers. It has been found to be a Rab4a effector protein that recruits to the 
recycling endosomes in the trans-Golgi network by binding to the lipid phosphotidylinositol 
4-phosphate (PI4P), where it plays a role in the recycling of E-cadherin. NDRG1 also interacts 
with HSP70. NDRG1 co-localizes with APO A-I and A-II, and may be involved in lipid transport.
The function of NDRG1 may be controlled at least in part by phosphorylation. It has also 
been identified as a stress response gene, upregulated by homocysteine and hypoxia. HIF-
1-dependent and independent mechanisms have been implicated in NDRG1 induction. It is 
also controlled by AP-1 transcription factors. When exposed to stress, for example hypoxia, 
NDRG1 may play a cytoprotective role in normal healthy cells. There is evidence that NDRG1 
is involved in the induction of differentiation. NDRG1 is downregulated under conditions 
of cell growth. NDRG1 expression peaks in the G1 and G2/M phases, and is lowest in the S 
phase. NDRG1 is also a microtubule-associated protein, which may play an important role 
in maintaining spindle structure during cell division. In Schwann cells, NDRG1 is essential for 
myelin sheath maintenance. Hence, NDRG1 is a multifunctional protein with roles that may 
be tissue- and/or cell-type specific. 
Certain transcription factors such as myc, ERG1, HIF-1α bind to the NDRG1 promoter region 
and regulate its expression. 
NDRG1 is upregulated during colon epithelial cell differentiation. It is regulated by hormones 
such as androgens and estradiol. Small molecules such as Nhydroxy- N’-phenol-octane-1,8-
diotic acid diamide, calcium ionophores like BAPTA, metal ions such as Nickel and Cobalt, 
iron chelators and differentiating agents, such as retinoic acid, induce NDRG1 expression. 
Additionally, NDRG1 is induced during cellular DNA damage and endoplasmic reticulum 
stress.
Implications in solid cancers
NDRG1 has implications in prostate, breast, colon, renal, bladder, pancreatic and hepatic 
Figure 2. NDRG1 protein.
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cancer. Downregulation of NDRG1 in cancer worsens the prognosis of cancer. There is an 
inverse relationship in the levels of NDRG1 expression and the Gleason grade of the tumor 
in prostate cancer. A high PTEN (a tumor suppressor which positively regulates NDRG1) 
and NDRG1 expression improves survival rates in patients with breast and prostate cancer. 
In patients with colorectal cancer, the 2 year survival rate for patients with high NDRG1-
expression was 82.4%, while for patients with a low NDRG1-expression it was only 69.6%. 
In pancreatic cancer patients, the median survival time for patients with high NDRG1-
expression was 24.7 months, while the median survival time for patients with low NDRG1-
expression was only 10.9 months. High expression of NDRG1 in colon tumors was found to 
correlate with increased resistance to irinotecan.
An inverse relationship exists between NDRG1 and the oncogenes N-myc and c-myc, 
suggesting that members of the myc family suppress expression of NDRG1. Experimental 
evidence exist that both N-myc and c-myc downregulate NDRG1 gene expression by directly 
binding to NDRG1 promoter. 
NDRG1 is downregulated in colon, breast, prostate and pancreatic neoplasms, by c-myc 
and N-myc transcription factors. In cancer cells, NDRG1 expression is consistent through all 
phases in the cell cycle, instead of the biphasic expression in normal cells. PTEN expression 
is positively related to NDRG1 expression. NDRG1 is induced in cancer cells by histone 
deacetylase inhibitors and DNA methyl transferase inhibitors indicating that NDRG1 is 
regulated by chromatin modulation and DNA methylation.
Although NDRG1 has been reported to be downregulated in a variety of cancers, it has 
been shown to be upregulated in hepatic, pancreatic and kidney cancers. Induction of 
NDRG1 in these tumors is speculated to be in response to tumor stress or hypoxia, and 
NDRG1 is proposed as a marker for tumor hypoxia. However, in pancreatic cancer, cellular 
differentiation and not hypoxia was demonstrated to be the determining factor for NDRG1 
expression. In renal cancer, induction of NDRG1 in the tumor tissue was restricted to 
infiltrating macrophages and not cancer cells.
NDRG1 is suggested to be an early target for p53. Loss of p53 expression in cancer is 
suggested to reduce NDRG1 expression. However, p53 knockout mice show expression of 
NDRG1, suggesting that there are other mechanisms regulating NDRG1 levels. 
NDRG1 expression plays a role in vitro in primary tumor growth in prostate, breast, and 
bladder cancer: a higher expression of NDRG1 lowers the proliferation rates of these cancers. 
In pancreatic and bladder cancer cells, this reduction was proven in vivo: in pancreatic cells 
it was suggested that the reduced proliferation was caused by NDRG1 by modulating tumor 
stroma and angiogenesis. NDRG1 can recruit onto the recycling endosome in the trans-Golgi 
network by binding to phosphotidylinositol 4-phosphate. There, NDRG1 may be involved 
in the transport of various cargo back to the cells’ surface. At the molecular level, NDRG1 
may stabilize the E-cadherin molecule by recycling it back to the cells’ surface, thereby 
preventing tumor invasion.
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Implications in hereditary motor and sensory neuropathy-Lom (HMSNL) / Charcot-Marie-
Tooth disease (CMT 4D)
HMSNL/CMT 4D is caused by the Gypsy founder mutation in NDRG1, homozygote R148X, 
also called homozygote C564t. In patients with CMT disease, apart from the R148X mutation, 
another disease-causing mutation was identified, namely IVS8-1G>A (g.2290787G>A), which 
results in skipping of exon 9. The homozygote phenotype of this mutation was very closely 
related to the phenotype of HMSNL/CMT 4D patients. HMSNL/CMT 4D is a hereditary 
autosomal recessive disease, resulting in demyelination of peripheral nerves. It is the most 
common form of demyelinating CMT disease in the Roma population. The disease results 
in severe disability in adulthood. It begins consistently in the first decade of life with a gait 
disorder, followed by upper limb weakness in the second decade and, in most subjects, by 
deafness setting in in the third decade of life. Sensory loss affecting all modalities is present; 
sensory loss and motor involvement predominates distally in the limbs. Skeletal deformity, 
particularly foot deformities, are frequent.
Implications in atherosclerosis
Patients with HMSNL were found to have a high total cholesterol: HDL-C ratio. 
Atherosclerosis is an important factor for the development of cardiovascular diseases, 
like myocardial infarction and angina pectoris. NDRG1 contributes to HDL-C (high-density 
lipoproteincholesterol) levels most likely by its phosphopantetheine-binding domain 
interacting with the high-density lipoproteins apolipoprotein A-I and AII.
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The N-myc downstream regulated gene 1 (NDRG1) has been identified as a metastasis-
suppressor gene in prostate cancer (PCa). Compounds targeting PCa cells deficient in 
NDRG1 could potentially decrease invasion/metastasis of PCa. A cell based screening 
strategy was employed to identify small molecules that selectively target NDRG1 deficient 
PCa cells. DU-145 PCa cells rendered deficient in NDRG1 expression by a lentiviral shRNA-
mediated knockdown strategy were used in the primary screen. Compounds filtered from 
the primary screen were further validated through proliferation and clonogenic survival 
assays in parental and NDRG1 knockdown PCa cells. Screening of 3360 compounds revealed 
irinotecan and cetrimonium bromide (CTAB) as compounds that exhibited synthetic lethality 
against NDRG1 deficient PCa cells. A three-dimensional (3-D) invasion assay was utilized to 
test the ability of CTAB to inhibit invasion of DU-145 cells. CTAB was found to remarkably 
decrease invasion of DU-145 cells in collagen matrix. Our results suggest that CTAB and 
irinotecan could be further explored for their potential clinical benefit in patients with 
NDRG1 deficient PCa.




The majority of morbidity and mortality in prostate cancer (PCa) patients is caused by 
metastases.1 The ability of cancer cells to metastasize is a multistep process that involves 
intravasation of cells from their primary site into blood vessels and extravasation into target 
organs.2 Inhibiting any step of the metastatic process is hypothesized to negatively impact 
the spread of cancer, thereby providing clinical benefit for cancer patients. Failure of cancer 
therapies can to a large extent be attributed to a failure to halt or contain metastasis, 
particularly in PCa. To improve the clinical outcome for PCa patients, it is crucial to target 
key molecular mechanisms/pathways involved in the metastatic process of PCa cells.
In the past two decades, multiple genes have been identified that suppress the formation 
and growth of cancer metastases without affecting primary growth of the tumor, such as 
KAI1, CD44, NM23, PEBP1, RECK, MAP2K4 and the N-myc downstream regulated gene 1 
(NDRG1).3, 4 NDRG1 is downregulated in highly metastatic PCa cells.5 Our group has identified 
NDRG1 as a Rab4a GTPase effector protein involved in the vesicular recycling of the adhesion 
molecule E-Cadherin, thereby preventing its degradation and possibly preventing metastasis 
of cancer cells.6 More recently, Liu et al. reported that NDRG1 negatively modulates Wnt-
β-signaling during metastatic progression via interaction with the Wnt receptor LRP6.7 
Therefore, drugs that selectively target tumor cells deficient in NDRG1 could potentially 
decrease PCa invasion by modulating the E-Cadherin and the Wnt-β-signaling pathway. 
However, compounds that selectively target NDRG1-deficient prostate cancer cells are yet 
to be identified.
In the current study, we aimed to identify compounds that selectively target NDRG1 deficient 
PCa cells. For this purpose, we raised isogenic DU-145, LNCaP and PC3 cell lines that differed 
in their NDRG1 expression by stably knocking down (KD) NDRG1 expression using a lentiviral 
shRNA vector. By performing a drug library screen, we aimed to identify compounds that 
would be less toxic to cells by themselves, but prove to be synthetically lethal in (PCa) cells 
that had lower NDRG1 expression. Parental and NDRG1 KD DU-145 cells were utilized for 
the primary screen; all three PCa cell lines were used for validation of compounds identified 
from the primary screen. The screen was performed using the Johns Hopkins drug library 
(JHDL), a small-molecule library with 3,360 compounds consisting mostly of FDA-approved 
drugs and other bioactive molecules.8
In this study, the topoisomerase I inhibitor irinotecan and the cationic surfactant 
cetrimonium bromide (CTAB) were identified as compounds that are synthetically lethal in 
vitro in NDRG1 deficient PCa cell lines. These compounds warrant further investigation as 




Cell lines and treatment
PC3, DU-145 and LNCaP PCa cell lines were obtained from ATCC. Human prostate fibroblasts 
were obtained from a prostate biopsy on a 62-year old PCa patient with a Gleason score of 
4 and kindly provided by dr. J. Isaacs. All cell lines were grown and maintained in RPMI-1640 
media (Invitrogen) supplemented with 10% fetal bovine serum (complete RPMI media). 
Cells were maintained in a humidified incubator at 37°C in a 5% CO2 atmosphere. 
JHDL compounds were stored at -20°C in 200 μM stock solutions in DMSO; compounds were 
dissolved in H2O when they were not soluble in DMSO. Irinotecan (I1406, Sigma-Aldrich) and 
CTAB (H9151, Sigma-Aldrich) were stored as 10 mM stock solutions in DMSO at -20°C. For 
experiments the compounds were diluted in complete RPMI media to obtain the desired 
final concentration.
Knockdown experiment
Stable shRNA KD for NDRG1 in PCa cell lines were generated using MISSION lentiviral systems 
(Sigma) according to the manufacturer’s recommendations. Control cells were generated 
using non-mammalian shRNA constructs. Briefly, 1.6 x 104 cells were plated in a 96-well plate 
and incubated overnight. Cells were transduced with lentiviral particles at a Multiplicity of 
Infection (MOI) of 1, 2 and 3 with hexadimethrine bromide at a final concentration of 8 
µg/ml. Transduced clones were selected with puromycin. KDs were assessed by Western 
blotting. Clones that demonstrated maximum KD with the lowest MOI were selected. 
For topoisomerase I KD, siRNA for topoisomerase I (Santacruz Biotech) was transfected in 
DU-145 cells using Lipofectamine 2000 reagent (Invitrogen). KD was assessed 48 h after 
transfection by Western blotting.
Drug library screen
Parental DU-145 cells and DU-145 NDRG1 KD cells were seeded in 100 μl complete RPMI 
media in 96-well plates (1.5 x 103 cells/well). The cells were incubated overnight to allow 
for attachment, and subsequently treated with compounds from the JHDL at a final 
concentration of 10 μM. Cells treated with 0.05% DMSO were used as negative controls. 
Plates were incubated for 48 h, after which cell viability was measured using CellTiter 96™ 
AQueous Non-Radioactive Cell Proliferation Assay (Promega) according to the manufacturer’s 
specifications. Absorption at 490 nm was determined using a SoftMax Pro plate reader 
(Molecular Devices). Viability of treated cells was compared to viability of DMSO-treated 
control cells (relative cell viability). Then, relative cell viability of DU-145 NDRG1 KD cells 
was compared to relative cell viability of DU-145 cells (‘DU-145 NDRG1 KD/DU-145’-ratio).
IC50 assessment
To assess IC50 values of selected compounds from the library screen in various PCa cell lines, 
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MTS assays were performed in a similar way as in the aforementioned screen. In brief, cells 
were plated (DU-145 cells at 1.5 x 103 cells/well, LNCaP cells at 2 x 103 cells/well and PC3 
cells at 1 x 103 cells/well; all cells were dissolved in 100 µl complete RPMI media), allowed to 
adhere overnight and treated with the small molecules for a duration of 48 h. MTS reagent 
(Promega) was added for 2-3 h, after which a colorimetric reading was performed using 
the SoftMax Pro plate reader (Molecular Devices). Viability of treated cells was compared 
to viability of DMSO-treated control cells (relative cell viability). Independent two-sample 
t-tests were performed to compare the relative cell viability in parental cells to the relative 
cell viability in NDRG1 KD cells. Variances were assumed to be equal in parental and NDRG1 
KD cells of the same cell line. When comparing DU-145 cells to human prostate fibroblasts, 
the variance was assumed to be unequal.
Clonogenic assay
Clonogenic assays were performed to assess long-term survival after treatment with 
small molecules. Briefly, cells were plated in 60 mm dishes and treated for 48 h. Following 
treatment, 1 x 103 cells from each dish were plated in triplicate in 60 mm dishes and incubated 
for 10-12 days. Colonies were fixed and stained with a crystal violet solution (Sigma); dishes 
were scanned with a computer scanner (Microtek) and counted manually. Student’s t-tests 
were performed to assess p-values.
Immunoblotting and densitometry
Immunoblotting and densitometry were performed as described previously.9 Cleaved PARP 
primary antibody (9541, Cell Signaling Technology) and topoisomerase I primary antibody 
(TG2012-2, TopoGEN) were diluted 1:1000, NDRG1 primary antibody10 1:4000, Vinculin 
primary antibody (05-286, Millipore (Upstate)) 1:10,000; all antibodies were dissolved in 
blocking buffer (5% milk in TBST (100 mM Tris-HCl pH 7.4, 0.1% Tween 20, 150 mM NaCl in 
H2O)). Secondary antibodies were dissolved in blocking buffer (5% milk in TBST) at 1:4000 
dilution.
3-D invasion assay
Trypsinized DU-145 and DU-145 NDRG1 KD cells were suspended in complete RPMI media 
containing 0.5% methylcellulose. Ten microliters of suspended cells were placed on the 
inner side of the lid of a sterile bacterial petri plate and cultured as a hanging drop over 
a humidified plate in a CO2 incubator for 16 h. The generated spheroids were used for 3-D 
invasion assays by embedding them in collagen matrix (BD Biosciences), which was prepared 
according to the manufacturer’s instructions. CTAB was administered and the spheroids 
were imaged daily using a Nikon Eclipse Ti microscope (Nikon) under phase contrast. For 
calculation of the invasion index the total area over which the spheroid had dispersed 
(including invading and non-invading cells) and the area of non-invading cells (at the center 
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of the spheroid) were measured using ImageJ. Values were expressed as an average of at 
least 3 invasion index calculations using the formula invasion index=1–(non-invading area/
total area). Comparisons were done using the student’s t-test.
Results
Library screen for compounds targeting DU-145 cells based on NDRG1 expression
To identify novel chemotherapeutic agents that potentially decrease invasion of PCa cells, 
a synthetic lethal screen was devised based on NDRG1 expression in DU-145 cells. The goal 
was to identify PCa targeting compounds that selectively inhibit NDRG1 deficient PCa cells, 
thereby decreasing invasiveness. For this purpose, we created isogenic PCa cell lines that 
differed in NDRG1 expression. NDRG1 shRNA lentiviral constructs successfully generated 
a stable KD of NDRG1 expression in DU-145 cells (DU-145 NDRG1 KD), as judged by the 
99% decrease in NDRG1 protein levels in these cells (Fig. 1A). As high-throughput screening 
assays are prone to generating a high degree of false positives,11 our screen was robustly 
designed in a three tier fashion to weed out false positives. The primary screen involved 
treatment of isogenic parental DU-145 and DU-145 NDRG1 KD cells with compounds from 
the JHDL at a concentration of 10 µM for 48 h. Our objective was to identify compounds 
that selectively inhibit DU-145 NDRG1 KD cells and parental DU-145 cells. Therefore, hits 
were defined as compounds that selectively inhibited DU-145 NDRG1 KD cells or parental 
DU-145 cells by changing the ‘DU-145 NDRG1 KD/DU-145’-proliferation ratio to < 0.7 or > 
1.5, respectively. Furthermore, as we were only interested in PCa targeting compounds, only 
compounds that inhibited cell proliferation of PCa cells by 10% or more were selected. Of 
the 3,360 compounds in the primary screen, nineteen compounds were selected (Fig. 1B). 
Ten of these compounds selectively inhibited NDRG1 deficient DU-145 cells.
The nineteen compounds identified as hits in the primary screen were put through a 
secondary screening process wherein MTS assays were performed in triplicates (Fig. 1C). As 
a result of this approach, four compounds which inhibited NDRG1 deficient cells ≥ 30% more 
effectively in their proliferation (‘DU-145 NDRG1 KD/DU-145’-ratio < 0.7) were identified, 
namely, stearyltrimethylammonium chloride (STAC), cupric chloride (CuCl2), neocuproine 
(NCP) and cetyltrimethyl ammonium chloride (CTAC) (Fig. 1D). Furthermore, irinotecan 
hydrochloride trihydrate was included in our list of hits as well, as it was just below our 
threshold with a ‘DU-145 NDRG1 KD/DU-145’-ratio of 0.71, and as previous studies reported 
a positive correlation between NDRG1 expression and irinotecan resistance in patients with 
colorectal tumors.12,13 None of the compounds tested resulted in a ‘DU-145 NDRG1 KD/DU-
145’-proliferation ratio > 1.5.
CuCl2 and NCP were excluded from further research. CuCl2 was excluded as the difference 
in proliferation activity in cells after treatment with this inorganic salt was not significant 
and could not be repeated in additional experiments (data not shown). NCP was excluded 
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as this compound would most likely not provide any clinical benefit in metastasis-prone 
PCa patients, the small molecule acting on healthy cells, such as astrocytes, as well.14 The 
other hits from the secondary screen (STAC, CTAC and irinotecan) were selected for the 
tertiary screen, in which series of MTS and clonogenic assays were performed at varying 
concentrations in multiple PCa cell lines to conclusively rule out false positives and to 
ascertain that the inhibitory effect of the compounds was not merely restricted to one PCa 
cell line. The results of this tertiary screen will be presented next. 
Irinotecan selectively targets NDRG1 deficient PCa cells.
Irinotecan (also known as Camptothecin-11 or CPT-11) is a DNA topoisomerase I inhibitor 
that is mainly used for the treatment of colorectal carcinomas. Due to the known positive 
correlation between irinotecan resistance and NDRG1 expression in colon cancer, the 
compound could be used to validate our screening results.12, 13, 15 Furthermore, irinotecan 
was considered an interesting compound to explore for its use in PCa therapy, as the 
Figure 1. Screening of the JHDL identifies stearyltrimethylammonium chloride (STAC), cetrimonium chloride 
(CTAC), cupric chloride (CuCl2), neocuproine (NCP) and irinotecan as compounds that selectively inhibit NDRG1 
deficient DU-145 cells. A) Western blot for NDRG1 performed with DU-145 cell lysates after stable knockdown of 
NDRG1 by shRNA. Control cells had been transduced with non-mammalian shRNA constructs. B) Primary screen 
with compounds of the JHDL at 10 µM. Compounds were selected when inhibiting cell proliferation by at least 10% 
(horizontal and vertical line), and having a ‘DU-145 NDRG1 KD/DU-145’-ratio of <0.7 (area above dark diagonal line) 
or >1.5 (area under light diagonal line). C) Secondary screen with the selected compounds from the primary screen 
to discard false positives. MTS assays were performed in triplicate; compounds that changed the ‘DU-145 NDRG1 
KD/DU-145’-ratio to <0.7 and irinotecan were selected. D) Bar graphs representing proliferation activity (left) and 
the ‘DU-145 NDRG1 KD/DU-145’-ratio (right) of selected compounds from the secondary DU-145 screen. 
Ratio KD/DU, ‘DU-145 NDRG1 KD/DU-145’-ratio.
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compound is already FDA approved for treatment against other cancer types. 
We assessed the sensitivity of parental DU-145 and DU-145 NDRG1 KD cells to irinotecan 
by performing MTS assays with varying concentrations of the compound. After 48 h of 
treatment, the IC50 of parental DU-145 cells was >7.5 µM, while the IC50 of NDRG1 KD cells 
was 2.5 µM (Fig. 2A). Furthermore, at concentrations between 3 and 7.5 µM, DU-145 cells 
Figure 2. Irinotecan selectively targets NDRG1 deficient DU-145 and PC3 cells by induction of apoptosis. A) MTS 
assays performed after 48 h treatment of parental DU-145 and DU-145 NDRG1 KD cells with irinotecan. Student’s 
t-tests were performed to assess p-values. B) Images displaying clonogenic survival of parental DU-145 and DU-
145 NDRG1 KD cells after irinotecan treatment. C) Bar graph quantifying the percentage of clonogenic survival in 
DU-145 cells. D) Protein expression levels of cleaved PARP, an apoptotic marker, were assessed after treatment of 
DU-145 cells with irinotecan. Densitometry was performed with ImageJ. E) Western blots confirmed successful 
knockdown (KD) of NDRG1 protein expression in PC3 cells after transduction of the cells with shRNA that stably 
knocks down NDRG1 expression. F) Bar graph quantifying the percentage of clonogenic survival in PC3 cells after 
irinotecan treatment. G) Western blots for topoisomerase I, performed with cell lysates from untreated DU-145 
and PC3 cells. Densitometry was performed.
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demonstrated a statistically significant difference in sensitivity to irinotecan based on the 
NDRG1 status of the DU-145 cells, DU-145 NDRG1 KD cells having up to 30% decreased 
cell viability compared to parental DU-145 cells (p < 0.04). These results were in line with 
the results from the secondary screen (compare Fig. 2A to Fig. 1D). Long-term clonogenic 
survival demonstrated that DU-145 NDRG1 KD cells have about 50% less clonogenic survival 
after irinotecan treatment as compared to parental DU-145 cells (p < 0.05) (Figs. 2B-C). 
Furthermore, Western blots for cleaved PARP confirmed that apoptosis was increased after 
48 h of irinotecan treatment in NDRG1 deficient DU-145 cells (Fig. 2D). To exclude that the 
differential effect caused by irinotecan was not a cell-line dependent response, we performed 
clonogenic assays in another PCa cell line as well, namely PC3 cells. Stable KD of NDRG1 in 
PC3 cells significantly reduced NDRG1 protein expression levels (Fig. 2E). PC3 NDRG1 KD 
cells were significantly more sensitive to irinotecan at final treating concentrations between 
2 and 3 µM (p < 0.01) (Fig. 2F). Furthermore, PC3 cells were more sensitive to irinotecan 
compared to DU-145 cells in general, as irinotecan at a concentration of 4 µM effectively 
inhibited PC3 cells regardless of their NDRG1 expression, decreasing clonogenic survival to 
<5% compared to untreated controls. Since an increase in topoisomerase I expression is 
reported to be one of six general mechanisms for cellular resistance against irinotecan,16 
we analyzed topoisomerase I expression through Western blotting (Fig. 2G). We did find a 
slight increase in topoisomerase I expression in NDRG1 KD DU-145 and PC3 cells. To rule 
out that sensitivity to irinotecan in NDRG1 deficient cells is due to off target effects, we 
performed a transient knockdown of topoisomerase I in DU-145 and DU-145 NDRG1 KD cells 
and evaluated proliferation through MTS assays. In concordance with the irinotecan data, 
NDRG1 deficient cells showed a decrease in proliferation after topoisomerase I knockdown 
(data not shown).
CTAB selectively targets NDRG1 deficient PCa cells.
Two other hits in our secondary screen of the JHDL were STAC and CTAC, two cationic 
surfactants with similar characteristics. Of these two compounds, CTAC was more selective 
for NDRG1 deficient DU-145 cells than STAC (Fig. 1D). CTAC was more selective for NDRG1 
deficient LNCaP cells compared to parental LNCaP cells as well (data not shown). The two 
compounds drew our interest, as similar cationic surfactants such as cetriumonium bromide 
(CTAB) have shown to have an antitumor effect.17-19 As CTAC was more selective for NDRG1 
deficient PCa cells than STAC, and as CTAC and CTAB, which only differ in the halide groups, 
have a similar efficacy as antitumor agents, we continued our study with CTAB.17 This 
compound was also preferred as efficacy and safety in mammals have been studied more 
extensively with CTAB.
We performed MTS assays with varying concentrations of CTAB in parental DU-145 and DU-
145 NDRG1 KD cells (Fig. 3A). CTAB appeared more potent in inhibiting PCa cells than CTAC, 
which might be caused by the difference in the halide group (compare Fig. 3A with Fig. 
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1D). Although the IC50 in parental DU-145 and DU-145 NDRG1 KD cells differed by 0.5 µM 
only (4 and 3.5 µM, respectively, data not shown), multiple independently performed MTS 
assays indicated a significant decrease in cell viability of DU-145 NDRG1 KD cells compared 
to parental DU-145 cells at concentrations of 4 µM and above, DU-145 NDRG1 KD cells 
being up to 15% more effectively inhibited (p ≤ 0.004). Next we assessed differences in 
long-term survival by performing clonogenic assays. At final concentrations between 4 
and 7.5 µM, NDRG1 deficient DU-145 cells clearly exhibited less clonogenic survival than 
parental DU-145 cells (Figs. 3B-C). Due to a lack of viable cells after 48 h treatment with 
10 µM CTAB, no clonogenics could be performed at this concentration. As the difference 
between parental DU-145 and DU-145 NDRG1 KD cells was more pronounced in the long-
term clonogenic survival assay than in the short-term MTS assay, we hypothesized that 
CTAB causes a differential induction of apoptosis in the cell lines. To test this hypothesis, we 
performed a Western blot for cleaved PARP, a surrogate marker for apoptosis. Cells were 
treated with CTAB for 48 h and lysates were probed for cleaved PARP. As expected, NDRG1 
deficient DU-145 cells had increased levels of cleaved PARP compared to parental DU-145 
cells (Fig. 3D). In line with previous results, this difference in cleaved PARP expression was 
most pronounced at concentrations of 4 and 7 µM.
Figure 3. CTAB selectively targets DU-145 NDRG1 KD cells by induction of apoptosis. A) MTS assays performed after 
treatment of parental DU-145 and DU-145 NDRG1 KD cells with CTAB. Student’s t-tests were performed to assess 
p-values. B) Images displaying clonogenic survival of parental DU-145 and DU-145 NDRG1 KD cells after CTAB 
treatment. C) Bar graph quantifying the percentage of clonogenic survival in DU-145 cells after CTAB treatment. 
D) Protein expression levels of cleaved PARP, an apoptotic marker, were assessed after treatment of DU-145 cells 
with CTAB for 48 h.
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To rule out that the inhibitory effect of CTAB observed in cancer cells is caused by general 
toxicity, we treated human prostate fibroblast cells with CTAB at concentrations at which it 
is effective in inhibiting PCa cells, and performed MTS assays (Fig. 4A). In human prostate 
fibroblasts, the IC50 for CTAB was about 30 µM, while in parental DU-145 cells the IC50 was 
about 4 µM (p < 0.05 at concentrations of ≥ 3µM). This result encouraged us to determine 
the efficacy of CTAB in other PCa cell lines as well. In concordance with earlier observations, 
cell proliferation in NDRG1 deficient LNCaP cells was more effectively inhibited compared 
to parental LNCaP cells at concentrations above 5 µM, as determined by MTS assays (p < 
0.02) (Fig. 4B). Again CTAB was more potent than CTAC in the JHDL screening. Since LNCaP 
cells have weak adhesive properties compared to other PCa cell lines, technical limitations 
prevented confirming this result by clonogenic assays. Therefore, PC3 cells were used to 
confirm and validate the effect of CTAB in clonogenic assays.  This assay indicated that CTAB 
selectively inhibited NDRG1 deficient PC3 cells at final concentrations between 2.5 and 6 
µM (p ≤ 0.001) (Figs. 4C-D).
Our results indicate that NDRG1 deficient PCa cells are more sensitive to CTAB than NDRG1 
Figure 4. While non-cancerous human prostate fibroblasts are relatively unaffected by CTAB, NDRG1 KD cells are 
selectively targeted in multiple PCa cell lines. A) MTS assays were performed with human prostate fibroblasts and 
DU-145 cells after CTAB treatment. B) MTS assays performed after treatment of parental LNCaP and LNCaP NDRG1 
KD cells with CTAB. Student’s t-tests were performed to assess p-values. C) Images displaying clonogenic survival of 
parental PC3 and PC3 NDRG1 KD cells after CTAB treatment. D) Bar graph quantifying the percentage of clonogenic 
survival in PC3 cells after CTAB treatment. NDRG1 deficient PC3 cells had significantly lower survival when treated 
with CTAB at concentrations between 2.5 and 6 mM (p ≤ 0.001).
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expressing cells at concentrations which were well tolerated in xenografts.17 To test whether 
CTAB also decreases invasion of PCa at these concentrations, we conducted a 3-D invasion 
assay in collagen type I matrix (Fig. 5). A 3-D invasion assay is superior to the Boyden chamber 
invasion assay, as the cells exhibit properties and behavior which are physiologically closer 
to in vivo settings. Untreated spheroids, consisting of parental DU-145 cells, increased in size 
over the course of 48 h. However, barely any invasive structures were observed (Fig. 5A). On 
the other hand, untreated spheroids consisting of DU-145 NDRG1 KD cells exhibited highly 
invasive behavior (Fig. 5B).20 Treatment of spheroids with 5 µM CTAB resulted in a decrease 
in growth of spheroids in both cell lines, indicating that CTAB was effectively targeting both 
DU-145 cell lines. Invasion of the DU-145 NDRG1 KD spheroids into the collagen matrix 
was markedly reduced after CTAB treatment, the invasion index of untreated controls being 
0.57, while the invasion index of CTAB treated cells was 0.26 (Fig. 5C). Thus, apart from 
selectively targeting NDRG1 deficient DU-145 cells, CTAB significantly reduced invasion in 
NDRG1 deficient DU-145 cells as well (p = 0.01).
Discussion
In the constant search for improved therapy options for cancer patients, there is a growing 
need for novel chemotherapeutic agents that target metastatic tumors. Chemotherapeutics 
that target PCa invasion is limited, a major limitation for the development of such 
chemotherapeutics being the lack of a good model for invasive PCa. We reasoned that 
engineering PCa cell lines through overexpression of metastasis related oncogenes or KD/
knockout of metastasis suppressor genes could be useful in identifying compounds that 
selectively inhibit PCa invasion. For this purpose, the PCa metastasis suppressor gene 
NDRG1 was knocked down to generate a cell based screen in this study. By performing a 
synthetically lethal screen, comparing sensitivity for compounds between wildtype PCa 
cells and the engineered cells, compounds that selectively target metastasis-prone PCa cells 
were identified. This type of screens has gained prominence due to its success in identifying 
cytotoxic agents that target cells with mutations in a particular gene.21,22 The JHDL used in 
our study has previously been used to identify new antitumor agents, such as mycophenolic 
acid, nitroxoline, itraconazole and ketoconazole as potential inhibitors of angiogenesis;8, 23, 
24 ebselen oxide as an inhibitor of α-methylacyl coenzyme A racemase (AMACR) in PCa, a 
metabolic enzyme that stimulates PCa cell growth;25 glafenine as an inhibitor of the ATP-
binding cassette transporter ABCG2, an enzyme associated with multidrug resistance;26 
and digoxin and other cardiac glycosides as inhibitors of HIF-1α synthesis, thereby blocking 
tumor growth.21, 27 As most small molecules in the JHDL are FDA-approved, pharmacokinetic 
and safety profiles are already known, and the identified compounds can progress rapidly 
from preclinical development to phase II clinical trials.28 Such a repurposing strategy saves 
time between preclinical research and implementation of the drug in clinic, and reduces 




Although these chemical libraries have demonstrated their success in identifying novel 
compounds for cancer treatment,21 they do have certain limitations which have to be 
taken into account during screening. Some limitations are inherent to the nature of high-
throughput screens, while others include practical limitations related to the nature of the 
compounds present in the library. A few limitations worth mentioning include: 1) screening 
libraries often go through many freezing/thawing cycles, while the structure and activity of 
Figure 5. CTAB treatment results in decreased invasion of DU-145 NDRG1 KD cells. A-B) 3-D invasion assays 
performed with parental DU-145 (A) and DU-145 NDRG1 KD (B) cells treated with CTAB. C) Calculation of the 
invasion index. The red area contains non-invading cells and the green area contains both invading and non-




drugs may alter over time; 2) screening libraries are incomplete and often not up-to-date 
with the most recent drug developments; 3) concentrations chosen for the screen may be 
outside the effective range of the particular compound, creating false negative results; 4) 
screening results contain false positive results due to experimental limitations (i.e. to limit 
the use of resources the primary screen is performed only once); and 5) cutoff values to 
select for hits are chosen arbitrarily. However, robustness of the primary screen in this study 
was underscored by the identification of known antitumor agents such as cardiac glycosides 
and the type II topoisomerase inhibitor mitoxantrone as inhibitors of DU-145 proliferation 
(data not shown).21 The strength of our screen was further enhanced as compounds were 
validated rigorously through a three tier approach, weeding out false positives. 
Due to aforementioned limitations of high-throughput screens, it is important to interpret 
the data in the light of known information about the drugs. This is well illustrated in our 
screening results with irinotecan. Although compounds were selected in our secondary 
screen when having a ‘DU-145 NDRG1 KD/DU-145’-ratio of ≤0.70, hence we selected 
compounds that selectively target NDRG1 KD cells 30% more effectively than parental DU-
145 cells, irinotecan was taken ahead for further investigation as well, despite its ‘DU-145 
NDRG1 KD/DU-145’-ratio of 0.71. The rationale for selection of this compound is based on 
reports which indicate a negative correlation between NDRG1 expression and sensitivity of 
cells to irinotecan;12, 13, 15 our data confirm this inverse relationship. Our data further suggest 
that NDRG1 KD upregulates topoisomerase I expression, thereby increasing the sensitivity 
of NDRG1 KD PCa cells to irinotecan. Therefore, irinotecan may prove to be of clinical use 
in patients with advanced NDRG1 deficient PCa.30 Irinotecan is FDA approved for its use as 
a chemotherapeutic agent in metastatic colorectal cancer. The compound has also been 
studied in PCa: its effect in PCa was demonstrated for the first time in 1996, when it was 
being tested successfully in PC3 cells in vitro and in the Dunning R3327 AT6.3 rat model 
in vivo.31 Subsequently, a phase II clinical trial was performed in hormone-refractory PCa 
patients.32 In this study, the best response established was stable disease in eight out of 
fifteen patients (53%), which was defined as a PSA decrease of <50%, or a PSA increase of 
<25% for at least four weeks. As NDRG1 expression of the tumors was not assessed in the 
clinical trial, it is tempting to speculate that patients with stable disease might have had 
PCa with low NDRG1 protein expression.33 However, it is also possible that most patients 
selected for this study had higher NDRG1 expression levels, as the ECOG performance status 
of all PCa patients but one was 0/1, irinotecan being given as a first line therapy to patients 
with hormone-refractory PCa, while patients with NDRG1 deficient PCa generally have a 
more aggressive disease.
The other compounds we identified that selectively target NDRG1 deficient cells and 
could potentially be used in the clinic, are CTAB/CTAC and STAC. CTAB is a cationic micellar 
surfactant, part of the group of quaternary ammonium compounds. It is used as a topical 
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antiseptic and part of a group of molecules that (potentially) plays a role in cancer treatment 
in diverse ways. A cell-based phenotype-driven high-throughput screen recently identified 
CTAB as a potential compound in the treatment of head and neck cancer (HNC), inducing 
caspase activated apoptosis by inhibition of H+-ATP synthase activity and depolarization 
of the mitochondrial membrane potential, thereby decreasing ATP levels in the cell.17 In 
in vivo experiments CTAB inhibited tumor formation and delayed tumor growth. At the 
concentrations used in this study, mice had no evidence of toxicity or lethality, similar to 
our in vitro findings in human prostate fibroblasts. Furthermore, cetrimide (of which CTAB 
is one component) is used as an effective cytotoxic lavage solution for use during surgery of 
breast carcinomas,34 and other quaternary ammonium compounds, such as benzethonium 
chloride, have shown to exhibit antitumor activity as well.35
CTAB was identified in our screen as a compound that selectively inhibits proliferation of 
PCa cells in general, and NDRG1 deficient PCa cells in particular. While screenings involving 
simple endpoint proliferation assays often yield the development of highly selective and 
potent compounds, such assays provide limited information on how potential therapeutics 
influence complex multifaceted biological events such as tumor invasion. To investigate 
whether CTAB affects the invasive capacity of NDRG1 deficient cells, we performed a 3-D 
spheroid invasion assay. Our data demonstrate that NDRG1 deficient PCa cells exhibit 
collective migration on a 3-D collagen matrix, which gets significantly inhibited after CTAB 
treatment. These results, combined with the antitumor activity of CTAB in HNC as indicated 
by Ito et al.17 urge further exploration of CTAB for its use in cancer therapy.
In summary, this study identifies cetrimonium bromide (CTAB) and irinotecan as clinically 
established compounds that selectively inhibit NDRG1 deficient PCa cells. This study gives 
leads for future studies about the function of NDRG1 and pathways in which this protein 
is involved, our results suggesting that NDRG1 might have a functional relationship with 
topoisomerase I. Future in vivo and clinical studies need to be performed to assess whether 
administration of CTAB or irinotecan to patients with NDRG1 deficient PCa is clinically 
beneficial. If these studies confirm the preclinical data presented here, CTAB or irinotecan 
could potentially be used in personalized medicine in combination with conventional or new 
PCa treatment methods, to prevent invasion of tumor cells in patients with NDRG1 deficient 
advanced PCa.
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Background: Cyclin-dependent kinase 5 (CDK5) is a potential target for prostate cancer 
treatment, the enzyme being essential for prostate tumor growth and metastases formation. 
In the current study, we identified agents that target prostate cancer cells based on CDK5 
expression.
Methods: CDK5 activity was suppressed by transfection of PC3 prostate cancer cells with 
a dominant-negative construct (PC3 CDK5dn). PC3 CDK5dn and PC3 control cells were 
screened for compounds that selectively target cells based on CDK5 expression, utilizing 
the Johns Hopkins Drug Library. MTS proliferation, clonogenic and 3-D growth assays were 
performed to validate selected hits.
Results: Screening of 3360 compounds identified rutilantin, ethacridine lactate and 
cetalkonium chloride as compounds that selectively target PC3 control cells and a tilorone 
analog as selective inhibitor of PC3 CDK5dn cells. A PubMed literature study indicated that 
tilorone may have clinical use in patients. Validation experiments confirmed that tilorone 
treatment resulted in decreased PC3 cell growth and invasion; PC3 cells with inactive CDK5 
were inhibited more effectively.
Conclusions: Tilorone selectively targets PC3 cells based on CDK5 expression. Future studies 
are needed to unravel the mechanism of action of tilorone in CDK5 deficient prostate cancer 
cells and to test combination therapies with tilorone and a CDK5-inhibitor for potential use 
in clinical practice.




Although novel therapies have recently been introduced into clinical practice for the 
treatment of advanced prostate cancer, prostate cancer has remained the second deadliest 
cancer in men in the United States in 2014.1 New therapeutic targets and strategies are 
urgently needed to further improve the clinical outcome of patients with prostate cancer.
One promising potential therapeutic target is cyclin-dependent kinase 5 (CDK5). CDK5 is a 
serine/threonine kinase structurally similar to other CDKs.2 CDK5 does not appear to have 
a major role in cell cycle regulation.3, 4 It has been well characterized for its dominant role 
in the development of the central nervous system, including roles in neuronal migration, 
differentiation and adhesion.5, 6 We and others subsequently showed that CDK5 plays 
an important role in cancer development and metastasis.7-12 In prostate cancer cells, we 
demonstrated that CDK5 was critical for cytoskeletal integrity, cell migration and invasion, 
and, in vivo, for metastasis.7 In pancreatic cancer, CDK5 is intrinsic to KRAS signaling 
through the centrally important Ral signal transduction pathway, thus providing a potential 
“druggable” target for mutant KRAS tumors.8 Together, these studies indicated that inhibition 
of CDK5, alone or in combination with other agents, may provide an effective therapeutic 
strategy for these and other cancer types.
In the current study we set out to identify agents that would be particularly effective in 
combination with CDK5 inhibition in prostate cancer cells. Therefore, we performed a screen 
of the Johns Hopkins Drug Library (JHDL). The JHDL is a collection of 3360 pharmaceutical 
compounds that have successfully completed safety testing in humans for a variety of 
applications.13, 14 This library has been used successfully for repurposing of compounds for 
cancer therapy, including identification of digoxin as an HIF-1α inhibitor,15 and itraconazole as 
an angiogenesis inhibitor.16 We have previously employed the JHDL to identify cetrimonium 
bromide and irinotecan as compounds with increased antitumor activity against prostate 
cancer cells expressing low levels of the metastasis suppressor gene N-myc downregulated 
gene 1 (NDRG1).17 Here, we performed a similar JHDL screening with prostate cancer cells 
which differ in CDK5 activity. Tilorone was identified as a compound with in vitro synthetically 
lethality in CDK5 deficient prostate cancer cells.
Materials and methods
Cell culture
PC3 prostate cancer cell lines were obtained from ATCC. These cells are derived from a bone 
metastasis from a 62-year old prostate cancer patient. Human prostate fibroblasts, kindly 
provided by dr. J. Isaacs, were obtained from a prostate biopsy on a 62-year old prostate 
cancer patient with a Gleason score of 4. Both cell lines were grown and maintained in 
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RPMI-1640 (Invitrogen) media supplemented with 10% fetal bovine serum. Cells were 
cultured in a humidified incubator at 37°C in a 5% CO2 atmosphere. 
Creation of PC3 CDK5dn cell line
Loss of CDK5 function was accomplished in PC3 cells by transfection of a dominant-negative 
construct containing a D144N mutation, kindly provided by dr. L.H. Tsai (Harvard Medical 
School).18 The protocol used has been described previously.7 In brief, the construct was 
subcloned in a bidirectional Tet vector, pBI-EGFP (BD Biosciences), which had a zeocin 
resistance gene added for selection (kindly provided by dr. K. Schuebel, Johns Hopkins 
University School of Medicine). pBI-EGFP empty vector or pBI-EGFP CDK5dn vector 
were transfected into PC3 cells which contained a Tet-Off promoter construct, pTTa (BD 
Biosciences).
Western blotting
Western blotting was performed as described previously.19 Ten micrograms of protein were 
loaded on the gel. Primary antibodies were dissolved in blocking buffer (5% milk in TBST (100 
mM Tris-HCl pH 7.4, 0.1% Tween 20, 150 mM NaCl in H2O)). A 1:1000 dilution was used for 
anti-CDK5 (Sigma-Aldrich); anti-vinculin (Millipore (Upstate) was diluted 1:4000. Secondary 
antibodies were diluted at a 1:4000 dilution. Normalization of band intensity was done with 
the housekeeper protein vinculin. Developed blots were scanned using a Microtek scanner.
Wound healing assay
Wound healing assays were performed with confluent PC3 control (containing the empty 
pBI-EGFP vector) or PC3 CDK5dn cells. A rubber-tipped scraper was used to scrape off an 
area of cells. Light microscopic images were taken immediately and 24 h after scraping.
Small-molecule library screening
The JHDL library has been described previously.13, 14, 17 Storage and screening of JHDL 
compounds was done as described previously.17 Briefly, PC3 control and CDK5dn cells were 
seeded in 96-well plates (1x103 cells per well) and allowed to adhere overnight. Then, 5 μl 
of drugs, stored as stock solutions of 200 µM in DMSO/H2O, was added to complete RPMI 
media, so that cells were treated at a final concentration of 10μM. After 48 h of treatment, 
20 µl MTS reagent from the CellTiter 96™ AQueous Non-Radioactive Cell Proliferation Assay 
(a reagent containing 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium (MTS) and phenazine methosulfate (PMS); Promega) was added 
to each well for a duration of 2-4 h at 37°C. Plates were analyzed using a SoftMax Pro plate 
reader (Molecular Devices). Proliferation of treated cells was compared with proliferation of 
DMSO-treated PC3 control or CDK5dn cells (proliferation index). Proliferation indices of PC3 
CDK5dn cells were compared to proliferation indices of PC3 control cells. A PubMed study 
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was performed to assess the clinical use of potential hits.
MTS assays
MTS assays were performed to measure the antiproliferative effect of tilorone treatment. 
Tilorone dihydrochloride (Sigma-Aldrich) was stored as a 10 mM stock solution in DMSO 
at -20°C. One thousand PC3 cells were plated in 96-well plates containing 100 μl complete 
RPMI media. At circa 50% confluence, tilorone dihydrochloride was administered. For 
experiments the compound was diluted in complete RPMI media to obtain the desired final 
concentration. After treatment for 72 h (tilorone monotherapy), MTS reagent was added, 
and absorption at 490 nm was determined using a SoftMax Pro plate reader (Molecular 
Devices). Proliferation indices were calculated; untreated PC3 control or CDK5dn cells were 
used as a control. Student’s t-tests were performed to assess p-values.
Clonogenic assays
Clonogenic assays were performed to assess long-term survival after tilorone treatment. 
Prostate cancer cells were plated in 60 mm dishes and allowed to adhere. At 50-60% 
confluency, cells were treated with tilorone for 72 h. Subsequently, 1x103 cells from each 
dish were plated in triplicate in 60 mm dishes and incubated in complete RPMI media for 
12 days. Colonies were fixed and stained with a solution containing 90% methanol and 10% 
crystalviolet solution (2.3% crystal violet, 0.1% ammonium oxalate and 20% ethylalcohol; 
Sigma). Colonies were scanned with a computer scanner (Microtek) and counted manually. 
Student’s t-tests were performed to evaluate whether differences between cell lines were 
statistically significant.
3-D growth assay
3-D growth assays were performed utilizing the same protocol described previously.17 In 
short, spheroids were generated by culturing PC3 cells for 16 h as a hanging drop over a 
humidified plate in a CO2 incubator in complete RPMI media containing 0.5% methylcellulose. 
Spheroids were embedded in collagen matrix (BD Biosciences), treated with tilorone, and 
imaged using a Nikon Eclipse Ti microscope (Nikon) on the day of treatment and six days 
after treatment start. Spheroid and total (spheroid plus sprouts) areas were measured with 
ImageJ. Fold increases were calculated by dividing the spheroid/total area at day 6 by the 
spheroid/total area on day 0 for each individual spheroid. For each cell line and time point, 





Suppression of CDK5 activity
PC3 prostate cancer cells were chosen for the JHDL compound screen due to their highly 
metastatic potential and androgen independence, thereby resembling aggressive metastatic 
castrate-resistant prostate cancer. CDK5 activity was inhibited by transfection and selection 
of a dominant-negative mutation (CDK5 144N). These PC3 CDK5dn cells had a higher protein 
level of total CDK5 as compared to PC3 control cells (PC3 cells transfected with an empty 
vector) (Fig. 1A). A wound healing assay confirmed that CDK5 was functionally inactive in 
these cells: unlike the PC3 control cells, PC3 CDK5dn cells did not have the ability to invade 
the scraped surface area (Fig. 1B). 
Library screen for compounds targeting PC3 cells based on CDK5 activity
A high-throughput screening assay was performed to select compounds that target PC3 
cells based on CDK5 activity. PC3 control and CDK5dn cells were treated with all compounds 
of the JHDL at 10 µM for 48 h. To identify hits that selectively target PC3 cells based on 
CDK5 expression, we selected all compounds in which the proliferation index ratio (CDK5dn/
control) was below 0.5 or above 1.5 (Fig. 2A). Furthermore, hits had to inhibit cell proliferation 
of PC3 cells by at least 10%, as we were specifically interested in compounds that inhibited 
cell growth (horizontal and vertical line in graph). We also selected all compounds that 
inhibited cell proliferation in PC3 cells by more than 70% (bottom left corner of graph), as 
we were interested in identifying potential highly effective antitumor agents. In total, 41 hits 
were selected for further evaluation.
Figure 1. Suppression of CDK5 activity by transfection of a dominant-negative construct. A) PC3 cells were transfected 
with a pBI-EGFP vector with or without a CDK5 dominant-negative construct; clones in which transfection was 
successful were selected. A Western blot for CDK5 was performed with these PC3 CDK5dn and control cell lysates. 
B) Wound healing assay with PC3 CDK5dn and control cells to confirm CDK5 inactivity in PC3 CDK5dn cells.
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A secondary screen was performed in which selected hits from the primary screen were 
added at 10 µM for 48 h to PC3 control and CDK5dn cells in triplicate, to weed out false 
positive results (Fig. 2B). Cutoff values were slightly less strict than in the primary screen: 
compounds were considered a hit when the ratio of proliferation indices (CDK5dn/control) 
was below 0.7 or above 1.4. This resulted in the identification of three compounds that 
selectively target CDK5-expressing PC3 cells: rutilantin, ethacridine lactate and cetalkonium 
chloride (Fig. 2C). These compounds have not been used as antitumor agents, and their 
potential clinical use as intravenous antitumor agents seems limited.20-23 Another compound, 
tilorone analog R9536-DA, was highly effective in inhibiting both isogenic PC3 cell lines 
(>70% inhibition), but inhibited proliferation of PC3 CDK5dn cells somewhat more effectively 
(ratio CDK5dn/control: 0.687). Tilorone and its analogs have antiviral activity, acting at least 
in part as interferon inducers,24-26 and have been shown preclinically and clinically to have 
antitumor activity too.27, 28
Tilorone selectively targets PC3 cells with low CDK5 activity
We continued our experiments with freshly dissolved tilorone dihydrochloride. After 72 h of 
tilorone treatment at various concentrations, its IC50 was established in MTS assays at 8-12 
µM in PC3 CDK5dn cells and 15 µM in PC3 control cells (Fig. 3A). At 8 µM, proliferation activity 
was decreased by 24% and 47% in PC3 control and CDK5dn cells, respectively (p=0.001). To 
assess toxicity of tilorone in normal prostate cells, MTS assays were performed with tilorone 
treatment of human prostate fibroblasts (Fig. 3B). Sensitivity of these cells to tilorone was 
similar to that of PC3 control cells. 
The inhibitory effect of tilorone in PC3 cells was further assessed by performing clonogenic 
assays (Fig. 3C). PC3 CDK5dn cells were also significantly more sensitive than PC3 control 
cells to tilorone in this assay. Treatment with 10 µM tilorone resulted in clonogenic survival 
of 40% in PC3 CDK5dn cells, and 72% in PC3 control cells (p=0.002). 
A spheroid growth assay was performed to assess 3-D tumor growth and invasion of PC3 cells 
upon tilorone treatment (Fig. 4). Both PC3 control and PC3 CDK5dn cells had comparable 
increases in spheroid size over six days. However, total size (the size of spheroids plus 
sprouts) had a higher fold increase in PC3 control cells, confirming that untreated PC3 
CDK5dn cells had a decreased invasive potential as compared to PC3 control cells. When 
tilorone was administered at 5 µM, PC3 control spheroids had a similar growth and invasive 
pattern as untreated PC3 control cells (p=0.59) (Fig. 4B left graph). However, when tilorone 
was administered at the same concentration to PC3 CDK5dn cells, a significant decrease in 
both spheroid size and total size was observed (p<0.01), suggesting that tilorone successfully 
inhibits spheroid growth and invasion of PC3 CDK5dn cells when administered at 5 µM (Fig. 
4B right graph). At 10 µM, both isogenic cell lines had a decreased invasive potential.
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Figure 2. Screening of the JHDL identifies four 
compounds targeting PC3 cells selectively based on 
CDK5 activity. A) Primary screen with 3360 compounds 
of the JHDL, by performing MTS assays after 48 h of 
treatment at 10 µM. Compounds were selected when 
the proliferation index ratio CDK5dn/control was <0.5 
or >1.5. Compounds were excluded as a hit when 
not resulting in a decreased cell proliferation of 10% 
in one cell line compared to DMSO-treated controls. 
Compounds inhibiting cell proliferation by >70% were 
selected too. B) Secondary screen by performing MTS 
assays in triplicate with PC3 cells treated with 41 hits 
from the primary screen. Compounds were selected 
when the proliferation index ratio CDK5dn/control 
was below 0.7 or above 1.4. C) The four compounds 
selected in the secondary screen. 
Figure 3. Validation of tilorone dihydrochloride as a 
compound that selectively targets PC3 cells based on 
CDK5 activity. A) MTS assays performed after treating PC3 
CDK5dn and control cells for 72 h with tilorone. B) MTS 
assays performed after 72 h treatment of healthy human 
prostate fibroblasts with tilorone to determine toxicity 
of tilorone in healthy cells. C) Clonogenic survival assays 
performed after 72 h treatment of PC3 cells with tilorone, 
further validating the screening results. 




The JHDL, a library of well characterized pharmaceutical compounds, was developed to 
facilitate drug repurposing studies.29 The extensive in vivo toxicity and pharmacokinetic 
profiles of compounds in the library allow rapid subsequent development of these 
compounds. Several compounds from the JHDL have been advanced to clinical trials for 
cancer and other therapeutic applications.13, 14, 16, 17, 30-32
In the current study we screened the JHDL for compounds that differentially inhibit cancer 
cell growth in the presence of CDK5 inhibition; tilorone and a tilorone analog were identified 
as agents that selectively target CDK5-deficient PC3 prostate cancer cells. Tilorone (Amixin 
IC) is employed clinically in some countries as an orally active antiviral agent.25 Tilorone has 
been tested in humans for the treatment of cerebral gliomas, laryngeal papillomatosis and 
breast cancer.28, 33, 34 Although antitumor efficacy was reported, interest in tilorone for cancer 
therapy has subsided. Recently, Zhou et al. reported new tilorone analogs with improved 
Figure 4. 3-D hanging drop growth assay performed to assess 3D spheroid growth and invasive potential of PC3 
cells upon tilorone treatment. A) Representative images of PC3 control (left) and CDK5dn (right) cells at day 0 and 
day 6, either untreated or treated with 5 µM tilorone. B) Fold increase in spheroid and total size after six days of 
tilorone treatment at various concentrations. 
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anticancer activity.35 These analogs may be promising to examine, especially in combination 
with CDK5 inhibition.
In addition to the possibility that tilorone may be promising in combination with CDK5 
inhibition, the identification of tilorone as an agent that selectively targets cells with inactive 
CDK5 suggests potential classes of drugs to potentiate the efficacy of CDK5 inhibition. Tilorone 
has been characterized as an interferon inducer.24 This suggests that interferon itself, or an 
alternative interferon inducer such as a TLR agonist, may be useful in combination with a 
CDK5 inhibitor. Nevertheless, other mechanisms may be involved. For example, tilorone is 
a DNA intercalating agent as well,24 and one may envision that it may modulate chromatin 
structure and gene expression. Other functions of tilorone, including signaling pathway and 
transcription factor interactions,36, 37 may also be involved. Further studies are needed to 
unravel the exact mechanism of action by which tilorone selectively targets CDK5-negative 
prostate cancer cells.
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Prostate cancer has the highest incidence of all cancers in men in the Netherlands.1 Its 
incidence rises with age. Virtually all mortality caused by prostate cancer occurs after the 
tumor has become metastatic and castrate-resistant (mCRPC). At this stage, prostate cancer 
treatment is strictly palliative. However, only 10-20% of all prostate cancer patients reach this 
disease stage within five years after diagnosis.2 Therefore, a majority of patients dies with 
prostate cancer, but not because of the disease. Nevertheless, due to its high prevalence 
in the population, prostate cancer is still the second deadliest cancer in men, being only 
surpassed by lung cancer.3, 4 In this thesis, multiple approaches to improve mCRPC outcome 
were studied, focusing on novel chemotherapies for mCRPC patients.
Until 2004, mCRPC patients were treated with mitoxantrone, which improves quality of 
life but has not shown to extend overall survival.5 That year docetaxel was introduced as 
first-line therapy for mCRPC patients. This taxane extended median overall survival by 2.4 
months compared to mitoxantrone treatment in the TAX-327 trial.6 Docetaxel targets cells 
by stabilizing microtubules. Its mechanism of action results in a variety of antitumor effects 
in the cell, such as mitotic arrest, inhibition of transnuclear localization of the androgen 
receptor, and p53 induced apoptosis.7, 8 However, docetaxel is not specific for cancer cells, 
and as microtubules play essential roles in healthy cells too, docetaxel treatment may 
result in severe adverse events, such as polyneuropathy and bone marrow suppression. 
Furthermore, only about half of mCRPC patients respond to docetaxel treatment, and 
eventually all tumors become docetaxel resistant.6 Therefore, additional research aims to 
further improve survival and quality of life of mCRPC patients.
Over the past few years, various novel second-line mCRPC therapies have been introduced 
into the clinic, such as cabazitaxel (a second-generation taxane),9 abiraterone acetate (an 
inhibitor of the enzyme cytochrome P450 c17 (CYP17)),10, 11 and enzalutamide (an androgen 
receptor antagonist)12. These agents have been studied or are being studied as first-line 
therapy as well; however, currently known results from studies such as COU-AA-302, a 
phase III study assessing abiraterone in asymptomatic or minimally symptomatic mCRPC 
patients, have not resulted in a change in policy regarding first-line mCRPC therapy in the 
Netherlands, one reason being that the control-arm received prednisone, which is not 
standard of care in the Netherlands.13
As multiple second-line mCRPC therapies have received approval, it has become unclear 
what therapy sequence is preferred after docetaxel therapy. In Chapter 4, we studied therapy 
outcome in mCRPC patients receiving cabazitaxel and abiraterone after docetaxel therapy. 
Differences in survival were minimal and non-conclusive, also as patient characteristics 
were not completely equal between groups due to the retrospective nature of the study. 




treated with abiraterone than in patients who received cabazitaxel before abiraterone; 
nevertheless, some patients still had clinical benefit by treatment with cabazitaxel. In patients 
treated with abiraterone after cabazitaxel, abiraterone was only slightly less effective than 
in patients receiving abiraterone prior to cabazitaxel. Future studies are needed to evaluate 
the cause of this decreased antitumor efficacy in more advanced mCRPC patients. As a final 
note, the CAST-study confirmed that toxicity caused by cabazitaxel, some life-threatening, 
remains a considerable issue with cabazitaxel therapy. 
In the CAST-study, abiraterone and particularly cabazitaxel had a decreased antitumor 
efficacy when administered in the third-line compared to second-line therapy. Similar 
results were reported in patients receiving enzalutamide after docetaxel and abiraterone, 
abiraterone after docetaxel and enzalutamide, and docetaxel after abiraterone.14-18 These 
findings may simply be a consequence of the patients having more advanced disease. 
Alternatively, cross-resistance between various mCRPC therapies may occur, e.g. as all 
therapies interact in some way with the androgen receptor pathway. Early preclinical 
studies indicated cross-resistance between taxanes and abiraterone.19 However, this theory 
currently lacks a thorough scientific basis: aforementioned results need to be confirmed 
and mechanisms for cross-resistance would need to be identified. Thirdly, these therapies 
may only target a subgroup of prostate cancer cells, while other critical cancer cells are 
not inhibited by the therapy. E.g., stem cell-like prostate cancer cells may not be targeted 
by these therapies, resulting in proliferation and differentiation of these cells and acquired 
resistance.20 It has also been suggested that epithelial-to-mesenchymal transition (EMT) 
may result in docetaxel resistance through reduced expression of miR-200C and miR-205, 
while such mesenchymal cells are prone to metastasize.21
Apart from aforementioned considerations regarding treatment sequence, the optimal 
time to initiate and end treatment needs more investigation. Another limitation of the COU-
AA-302 study is that it is unclear whether treatment at this early stage has an advantage 
over treating patients once they have become symptomatic. As all therapies are palliative 
and have adverse events, it would be best to postpone treatment as long as possible, unless 
clinical outcome would be worse. Until this has been studied more extensively, it seems 
rational to avoid treatment in non-symptomatic patients.
Treatment is currently discontinued once patients start progressing on their tumor. 
Furthermore, taxane treatment is generally discontinued after ten cycles. However, it is 
unknown whether this is the best moment to discontinue treatment. Increasing treatment 
duration may invoke an extra delay for therapies with improved antitumor efficacy, 
particularly now that multiple therapy options are available for mCRPC patients. On the 
other hand, even when patients have minimal progressive disease, e.g. slowly increasing 
PSA levels while no progression is observed during radiographic assessments, patients may 
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still be benefitting from this therapy.
Currently, mCRPC patients are being viewed as a homogenous population when making 
therapy decisions, while cancer is a heterogeneous disease. As discussed in chapter 2, 
race may be one factor in tumor heterogeneity in prostate cancer patients. Since prostate 
cancer prevalence and mortality differs across races, the importance of recruiting a patient 
population in clinical trials whose racial demographics adequately represent the average 
patient population in clinic is stressed in this chapter. Furthermore, markers that identify 
mCRPC patient populations that will respond better to therapy need to be identified. This 
has become more crucial now that multiple therapies are available: by treating patients 
with ineffective therapies, other, potentially effective therapies are being delayed, while 
toxicity of the ineffective therapy may be severe. Results from the Dutch compassionate 
use program with cabazitaxel (chapter 3) and the CAST-study (chapter 4) suggest that 
patients who respond well to docetaxel, i.e. completed at least 10 cycles of docetaxel, have 
a better response to cabazitaxel therapy than patients who had receive less than 10 cycles of 
docetaxel. Others have found that Gleason-score predicts docetaxel response.22 In chapter 
9, we report that nuclear Eg5-expression may be a biomarker predicting docetaxel response 
as well. Additional research is needed to identify predictive markers for therapy response, as 
well as markers that are able to follow therapy response more accurately during treatment. 
Such markers would prevent overtreatment and may aid in determining what therapy to 
initiate in an individual patient.
Nuclear Eg5-expression may not only be a marker for docetaxel response, but our results 
indicated that nuclear Eg5-expression may predict tumor aggressiveness too. While Gleason-
score is now most frequently used to assess tumor aggressiveness, this assessment is limited: 
patients with a Gleason 6 or higher may have highly indolent disease, while others with a 
Gleason 6 progress rapidly into highly aggressive mCRPC. Results from multivariate analyses 
in our study suggested that nuclear Eg5-expression is a biomarker of tumor aggressiveness, 
independent of Gleason-score. If our results can be confirmed in an independent larger 
study population, determination of Eg5-expression in biopsies taken from patients may aid 
in determining whether a patient can be treated more conservatively or needs aggressive 
treatment, such as treatment with taxanes at an earlier disease stage.
Due to the success of taxanes, researchers hypothesized that inhibitors of proteins that 
play essential roles during mitosis, commonly overexpressed in cancer, may be effective 
while causing fewer side effects. This rationale led to the development of amongst others 
Eg5-, polo-like kinase 1 (Plk1-) and aurora kinase-inhibitors (Chapter 5 section A). Early 
clinical studies with these inhibitors had disappointing results, amongst others as toxicities 




researchers, this casts doubt whether such therapies may be effective at all.23 In short, it 
was argued that mitotic inhibitors may have been unsuccessful as tumor cells in patients 
divide at a slower pace than tumor cells in vitro and in vivo. Due to the differences between 
preclinical models and tumors in patients, it was expected that mitotic inhibitors will have 
limited antitumor efficacy in humans. In Chapter 5 section B, we explain that such statements 
are too simplified. We argue that while the proteins have originally been identified due to 
their role in mitosis, they seem to play a more extensive role in tumor progression, such as 
regulation of the androgen receptor pathway.24-26 Considering the wide overexpression of 
these proteins in (prostate) cancer compared to healthy tissue,27-30 we think their roles as 
oncogene need to be investigated in more detail, and their clinical potential more thoroughly 
explored. The development of mitotic inhibitors is currently in full swing for a wide variety of 
cancers, among others prostate cancer.
Improvement of the antitumor effect of mitotic inhibitors in prostate cancer patients can be 
achieved by selecting patients based on the expression of the targeted protein in the tumor. 
For example, Eg5 and Plk1 are overexpressed in about half of prostate cancer patients; 
therefore, a priori selection of these patients would prevent overtreatment in about half of 
patients.27, 28 Since all mCRPC patients have had prostate biopsies taken and/or underwent 
prostate surgery, tumor tissue is readily available, hence this assessment would be non-
invasive. Increased specificity of antimitotic agents may decrease toxicities. Intracellular 
levels in the tumor may be improved by developing agents that have low affinity to pumps 
such as P-glycoprotein, which transports docetaxel and other agents out of the tumor cell, 
limiting their efficacy.31 Combination therapy may enhance antitumor efficacy. 
Similar to breast cancer, colorectal cancer and other cancer types, it is expected that in the 
future treatment of mCRPC will not consist of monotherapy but a combination of antitumor 
agents, due to the heterogeneity of the disease and as (stem cell-like) cancer cells have 
the ability to bypass pathways in order to survive. To speed up the clinical development of 
such combination therapies and to prevent unnecessary phase II studies with combination 
therapies that will not have an enhanced antitumor effect, we developed and tested Analysis 
of Functional Annotation (AFA) as an objective strategy to create a rationale for combination 
therapies (Chapter 6). Based on our AFA results with histone deacetylase inhibitors (HDACIs), 
we hypothesized that combinations of mitotic inhibitors with HDACIs would have an 
enhanced antitumor effect. In Chapter 7 and Chapter 8 we show that combination therapies 
of HDACIs with Plk1- and aurora kinase-inhibitors, respectively, indeed have synergistic 
antitumor effects in preclinical studies. This combination therapy could potentially be tested 
in humans, and may reduce bone marrow suppression and other adverse events, as lower 
concentrations can be used to accomplish similar antitumor effects.
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Research is ongoing to identify additional targets for prostate cancer therapy. As most 
morbidity and mortality from prostate cancer is caused by metastases, patients may benefit 
from therapies that exclusively target metastases. Recently it has been reported that 
radium-223 extends the median overall survival of mCRPC patients by solely targeting bone 
metastases, underlining the importance of metastases-targeting agents (Chapter 10).32 
Two targets to prevent or treat metastases are NDRG1, a metastasis-suppressor gene in 
prostate cancer (Chapter 11 section a), and CDK5, an enzyme necessary for prostate cancer 
metastases.33, 34 In Chapter 11 section b, we identify irinotecan and cetrimonium bromide 
as agents that selectively target NDRG1-deficient prostate cancer cells; tilorone selectively 
targets CDK5-deficient prostate cancer cells (Chapter 12). Furthermore, other targeted 
therapies may improve antitumor efficacy too, such as therapies that prevent epithelial-
mesenchymal transition (EMT) or stimulate mesenchymal-epithelial transition (MET), 
therapies that target the microenvironment of the tumor, and therapies that prevent/
target angiogenesis so that the tumor is deprived of its necessary oxygen and nutrients to 
grow and survive. Therapies that specifically target stem cell-like prostate cancer cells may 
be crucial, as these cells are resistant to most of the currently available therapies, while 
recent research suggested that such cells (the castration-resistant cells expressing the NK3 
homeobox 1 (Nkx3-1) (CARNs)) may initiate mCRPC after castration.35, 36 Future research 
will need to identify and establish the clinical benefit of therapy aimed at these specific 
molecular/cellular targets. 
Over the past years, significant progress has been made regarding the treatment of mCRPC 
patients. Multiple novel therapies have been introduced into clinical practice: cabazitaxel, 
abiraterone, enzalutamide and radium-223. Other therapies are at advanced stages 
of clinical development, such as ipilimumab, tasquinimod, custirsen and cabozantinib. 
Additional molecular targets and its targeted therapies are slowly but steadily identified in 
preclinical studies. Although the development of new therapies with increased efficacy and/
or decreased toxicity remains of high importance, due to this progress it has become crucial 
that studies optimize the use of existing therapies, so that maximum clinical benefit can 
be accomplished in mCRPC patients with existing therapies. Therefore, research assessing 
the optimal treatment strategy with available therapies and the development of improved 
biomarkers, both for therapy response and tumor aggressiveness, has become of high 
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Prostaatkanker is de meest voorkomende kanker in Nederlandse mannen. De incidentie 
van prostaatkanker stijgt met de leeftijd. Prostaatkanker leidt vrijwel alleen tot sterfte 
wanneer de tumor castratie-resistent en gemetastaseerd (mCRPC) is. Dit palliatieve stadium 
wordt door slechts 10-20% van alle prostaatkankerpatiënten binnen vijf jaar bereikt. De 
meerderheid van prostaatkankerpatiënten overlijdt dan ook aan andere aandoeningen 
dan de tumor. Desondanks is prostaatkanker na longkanker de dodelijkste kanker onder 
Nederlandse mannen. Gezien dit hoge sterftecijfer is het van belang om therapeutische 
opties voor mCRPC patiënten te verbeteren. In het afgelopen decennium zijn deze opties 
reeds aanzienlijk verbeterd. Was voorheen alleen symptoomverlichting mogelijk om de 
kwaliteit van leven te verbeteren, sinds 2004 zijn er systemische therapieën (o.a. docetaxel, 
cabazitaxel, abiraterone acetaat, enzalutamide) beschikbaar gekomen die de mediane 
overleving van patiënten met enkele maanden verlengen. Echter, omdat niet alle patiënten 
een respons op deze systemische therapieën hebben en uiteindelijk alle patiënten 
tumorprogressie hebben ondanks behandeling, is het noodzakelijk verder onderzoek te 
doen naar therapieën voor mCRPC patiënten. In dit proefschrift wordt vanuit verschillende 
invalshoeken dit vraagstuk nader onderzocht.
Prostaatkanker is een heterogene ziekte. Dit komt onder andere tot uiting in de 
demografische spreiding van de ziekte: terwijl Aziaten en Indianen over het algemeen 
minder prostaatkanker krijgen dan blanken, hebben mensen met een donkere huidskleur 
juist relatief vaak prostaatkanker. Daarnaast leidt prostaatkanker in de Verenigde Staten 
vaker tot sterfte in de Afro-Amerikaanse en Indiaanse bevolkingsgroepen. Het is daarom 
goed voorstelbaar dat de werking van een therapie bij blanke Europeanen/Amerikanen 
anders is dan bij andere bevolkingsgroepen. In hoofdstuk 2 wordt onderzoek gedaan naar 
de deelname van minderheden in klinische studies die bij de United States Food and Drug 
Administration ingediend zijn voor de markttoelating van nieuwe therapieën. Hierbij wordt 
geconcludeerd dat in deze studies minderheden over het algemeen ondervertegenwoordigd 
waren. Daarnaast is de deelname van minderheden niet toegenomen over de laatste twee 
decennia. Dit wordt mogelijk veroorzaakt door toenemende rekrutering van patiënten in 
landen waar deze minderheden in minder grote aantallen aanwezig zijn (zoals landen in het 
voormalige Oostblok), maar ook lijken pogingen tot verbeterde deelname van minderheden 
in Westerse landen niet succesvol. Door verbeterde deelname van minderheden in klinische 
studies, zal het begrip van de werkzaamheid van therapieën in minderheden verbeteren, 
zodat ook deze patiënten de optimale therapieën krijgen.




docetaxel behandeld. Deze chemotherapie grijpt aan op microtubuli in cellen. Hiermee 
voorkomt docetaxel onder andere dat cellen succesvol kunnen delen, maar grijpt het ook in 
op andere tumor-gerelateerde processen, zoals regulatie van het tumorsuppressorgen p53 
en de androgeen receptor. Echter, microtubuli spelen ook een belangrijke rol in gezonde 
cellen, taxanen maken hier geen onderscheid tussen. Daarom resulteert behandeling met 
docetaxel in soms aanzienlijke bijwerkingen, zoals polyneuropathie en beenmergsuppressie. 
Daarnaast reageert slechts ±50% van de patiënten op docetaxel, en ontwikkelen uiteindelijk 
alle patiënten resistentie tegen behandeling. Sinds enkele jaren hebben patiënten die 
behandeld zijn met docetaxel keuze uit verschillende andere therapieën, waaronder een 
ander taxaan, cabazitaxel, of hormoontherapie, abiraterone acetaat. 
In hoofdstuk 3 worden de resultaten van het Nederlandse compassionate use programma 
samengevat, waarin mCRPC patiënten met cabazitaxel behandeld zijn. Dit programma werd 
in Nederland gestart naar aanleiding van de resultaten van de TROPIC-studie, een fase III 
studie waarin cabazitaxel behandeling werd vergeleken met mitoxantrone in patiënten die 
progressie hadden tijdens of na docetaxel behandeling. Een compassionate use programma 
geeft patiënten, voor wie geen reguliere (levensverlengende) behandeling mogelijk is, de 
mogelijkheid om een nieuwe behandeling te krijgen die nog niet door de verzekeraars 
vergoed wordt, maar waarvan wel verwacht wordt dat dit in de nabije toekomst zal 
gebeuren. Inclusie in dit programma vindt in een beperkt aantal centra plaats, in het geval 
van cabazitaxel in vijf ziekenhuizen; de veiligheid van de behandeling moet geregistreerd en 
gerapporteerd worden. Uit de gegevens van het compassionate use programma blijkt dat 
cabazitaxel beter getolereerd werd in de klinische setting dan verwacht zou worden op basis 
van de resultaten van de TROPIC-studie. Verder suggereren onze resultaten dat patiënten 
die goed reageren op docetaxel over het algemeen ook een betere respons op cabazitaxel 
hebben. In juni 2011, een jaar na de start van dit programma, werd besloten dat cabazitaxel 
door Nederlandse verzekeraars vergoed zal worden.
Enkele maanden na deze beslissing werd op basis van de resultaten van de COU-AA-301 
studie besloten om abiraterone te vergoeden voor mCRPC patiënten met progressie tijdens 
of na docetaxel. Dit betekent dat momenteel cabazitaxel en abiraterone dezelfde indicatie 
hebben. Echter, welke volgorde het beste aangehouden kan worden, is niet bekend. Om deze 
reden werd de CAST-studie opgezet, waarvan de resultaten beschreven zijn in hoofdstuk 
4. In deze retrospectieve studie zijn in het totaal 326 Nederlandse patiënten gevolgd die 
met cabazitaxel en/of abiraterone behandeld zijn. Een eerdere studie suggereerde dat 
docetaxel na abiraterone een verminderd antitumor effect heeft. Ook in de CAST-studie is 
de respons op cabazitaxel na abiraterone kleiner dan wanneer cabazitaxel voor abiraterone 
wordt gegeven, hoewel sommige patiënten nog steeds goed reageren op cabazitaxel na 
abiraterone. Deze verminderde werking wordt in mindere mate ook bij abiraterone voor en 
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na cabazitaxel gezien. Verder blijkt uit de CAST-studie dat ondanks de toenemende ervaring 
met cabazitaxel, bijwerkingen van deze therapie ernstig kunnen zijn; bij een paar procent 
leiden de bijwerkingen zelfs tot het overlijden van de patiënt. Deze bevindingen kunnen 
artsen een handvat bieden wanneer gekozen moet worden tussen cabazitaxel en abiraterone 
ter behandeling van mCRPC patiënten na docetaxel. Toekomstige studies moeten uitwijzen 
of resistentie van de tumor tegen abiraterone ook tot resistentie tegen cabazitaxel leidt, of 
dat andere oorzaken tot de verminderde werking van cabazitaxel in de derde lijn leiden.
Het succes van de taxanen in mCRPC patiënten heeft geleid tot een zoektocht naar 
behandelingen die eiwitten remmen die noodzakelijk zijn voor succesvolle celdelingen, in 
de hoop een behandeling te vinden die meer selectief prostaatkankercellen remt. Zoals 
beschreven in hoofdstuk 5 sectie a heeft dit onder andere geleid tot de ontwikkeling van 
kinesin spindle protein (Eg5-), polo-like kinase 1 (Plk1-) en aurora kinase (AK-)remmers. 
De eerste klinische studies met dit soort medicijnen hadden niet het gewenste resultaat, 
o.a. omdat beenmergsuppressie door de therapie verhinderde dat hogere en effectievere 
concentraties gebruikt konden worden. Dit leidde tot twijfel bij sommige onderzoekers of 
kankerpatiënten überhaupt baat zullen hebben bij dit soort therapieën. In hoofdstuk 5 
sectie b wordt uigelegd waarom deze twijfel voorbarig is, en waarom te verwachten is dat 
in de toekomst deze behandelingen mogelijk wel in de kliniek toegepast zullen worden. 
Momenteel is de ontwikkeling van Plk1- en AK-remmers als kankerbehandeling in volle gang 
in preklinische en klinische studies.
Op dit moment worden mCRPC patiënten alleen met systemische monotherapieën 
behandeld. Echter, het is de verwachting dat het remmen van verscheidene oncologische 
processen door combinatietherapie meer effect heeft dan behandeling met monotherapie. 
Daarom is het onderzoek naar combinatietherapieën groeiende. In hoofdstuk 6 wordt 
Analysis of Functional Annotation (AFA) beschreven als een methode om op rationele 
wijze nieuwe combinatietherapieën te ontwikkelen. Voor deze analyse is gebruik gemaakt 
van prostaatkankercellen behandeld met histon deacetylase remmers (HDACIs). HDACIs 
moduleren transcriptie van genen door remming van histon deacetylases, enzymen die 
het DNA strak rond histonen wikkelen waardoor dit DNA niet afgelezen wordt. Hierdoor 
beïnvloeden HDACIs de expressie van vele (oncologische) processen, en leiden ze onder 
andere tot herexpressie van genen die tumorgroei onderdrukken. Hoewel HDACIs al worden 
toegepast voor de behandeling van lymfomen, viel het antitumor effect in solide tumoren tot 
nu toe tegen. Echter, gezien de talrijke cellulaire veranderingen die HDACIs teweeg brengen 
en relatief weinig bijwerkingen van HDACIs, vormt deze chemotherapie een uitstekende 
kandidaat voor combinatietherapie. Uit onze AFA blijkt dat HDACIs mogelijk gebruikt kunnen 
worden vóór behandeling met immunotherapie (zoals sipuleucel T of ipilimumab, beide in 




analyse dat HDACIs in combinatie met remmers van mitotische eiwitten mogelijk tot een 
verbeterd antitumor effect leiden.
In hoofdstuk 7 en hoofdstuk 8 wordt geconcludeerd dat de combinatie van HDACIs 
met respectievelijk Plk1-remmers en AK-remmers inderdaad leidt tot een synergistisch 
antitumor effect in vitro en in vivo. Echter, cellijnen reageren verschillend op deze 
combinatiebehandeling, zowel qua gevoeligheid als qua intracellulaire veranderingen. 
Verder onderzoek zal uitgevoerd moeten worden om vast te stellen of combinatietherapie 
ook een positief antitumor effect in de kliniek heeft, en welke eigenschappen van tumoren 
en patiënten tot een beter resultaat van deze combinatietherapie leiden.
Zoals eerder genoemd, vormen prostaatkankerpatiënten een heterogene populatie. Deze 
heterogeniteit komt tot uiting in demografische verschillen, maar ook in de aggressiviteit 
van de tumor en de reactie van de tumor op chemotherapie: terwijl in sommige patiënten 
langdurige regressie wordt bereikt na chemotherapie, zijn tumoren in andere patiënten 
compleet ongevoelig voor chemotherapie. Echter, omdat momenteel niet bekend is welke 
patiënten wel en niet zullen reageren op therapie, worden patiënten momenteel als een 
homogene populatie behandeld. Op zoek naar een marker voor therapie-respons zodat wel 
onderscheid tussen patiënten valt te maken, wordt in hoofdstuk 9 de hypothese getest dat 
Eg5 mogelijk een marker is voor de gevoeligheid van prostaatkankercellen voor docetaxel. 
Eg5 is een enzym dat aangrijpt op de microtubuli. Uit onze studie blijkt dat tumoren met 
nucleaire Eg5-expressie beter reageren op docetaxel. Daarnaast blijkt Eg5 een marker voor 
tumor-aggressiviteit: patiënten met tumoren die Eg5 tot expressie brengen in de nucleus, 
hadden bij diagnose aggressievere tumoren. Verder grootschalig onderzoek moet uitwijzen 
of Eg5 inderdaad als biomarker in de kliniek gebruikt kan worden, waarbij patiënten met 
tumoren met nucleaire Eg5 expressie mogelijk gebaat zijn bij eerdere behandeling met 
docetaxel.
De meeste morbiditeit en sterfte van prostaatkanker wordt veroorzaakt door metastasen. 
Patiënten zouden daarom baat kunnen hebben bij het selectief behandelen en/of 
voorkomen van metastasen. Deze theorie is recentelijk bevestigd door radium-223 chloride: 
deze radionuclide behandelt alleen botmetastasen, maar verlengt de overleving van mCRPC 
patiënten met enkele maanden (hoofdstuk 10). Sinds februari 2014 is deze behandeling 
beschikbaar voor Nederlandse mCRPC patiënten. Echter, meer onderzoek is nodig naar de 
lange termijngevolgen van radium-223, alsmede naar de plaats van deze behandeling in 
het reeds bestaande therapiespectrum. Daarnaast zijn studies nodig om de effectiviteit van 
radium-223 in andere tumoren waar botmetastasen een groot deel van de morbiditeit en 
mortaliteit veroorzaken, zoals borstkanker, te onderzoeken.
Eerder onderzoek heeft aangetoond dat het gen NDRG1 een metastase suppressor gen in 
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o.a. prostaatkanker is (hoofdstuk 11 sectie a), terwijl expressie van CDK5 juist noodzakelijk 
is voor de metastasering van prostaatkanker. In hoofdstuk 11 sectie b en hoofdstuk 12 zijn 
tumor-cellijnen gecreëerd die volledig identiek zijn, op de expressie van respectievelijk 
NDRG1 en CDK5 na. Gebruikmakend van een bibliotheek met medicijnen die voor 
uiteenlopende aandoeningen gebruikt worden, de zogenaamde Johns Hopkins Drug Library, 
is onderzoek gedaan naar medicijnen die selectief tumorcellen remmen gebaseerd op de 
expressie van deze genen. Uit deze studies blijken dat irinotecan en cetrimonium bromide 
selectief prostaatkankercellen remmen die weinig NDRG1 tot expressie brengen. Tilorone 
remt selectief prostaatkankercellen die weinig CDK5 tot expressie brengen.
Ten slotte worden in hoofdstuk 13 de eerdere hoofdstukken samengevat en in een 
toekomstig perspectief geplaatst. Geconcludeerd wordt dat met de introductie van 
cabazitaxel, abiraterone, enzalutamide en radium-223 chloride de afgelopen jaren veel 
vooruitgang is geboekt qua behandelopties voor mCRPC patiënten; de verwachting is dat 
in de nabije toekomst meer behandelingen voor mCRPC patiënten op de markt zullen 
komen. Deze snelle ontwikkelingen leiden tot een verschuiving van prioriteiten in mCRPC 
onderzoek: waar voorheen in onderzoek voornamelijk gefocust werd op de ontwikkeling 
van nieuwe, verbeterde therapieën, een prioriteit die overigens blijft bestaan, wordt het 
steeds belangrijker om therapieën beter af te stemmen op de individuele eigenschappen 
van de patiënt. Dit kan bereikt worden door betere biomarkers die zowel vóór als tijdens 
behandelingen voorspellen bij welke therapieën mCRPC patiënten het meeste baat zullen 
hebben. Een verbeterd begrip van mechanismen waardoor prostaatkankercellen resistent 
worden tegen bepaalde therapieën, kan ertoe leiden dat behandelingen waarvoor de 
tumor resistent is (geworden), niet (meer) gegeven worden. De behandelvolgorde is 
mogelijk van invloed op het te behalen klinische voordeel, afhankelijk van de individuele 
eigenschappen van de tumor en patiënt. Combinatietherapieën zijn mogelijk effectiever dan 
monotherapieën. Ten slotte moet verder onderzocht worden wat het optimale moment is 
om van behandeling te wisselen en wanneer de bijwerkingen van de behandeling niet meer 
opwegen tegen de te behalen gezondheidswinst. Hoewel mCRPC nog niet te genezen valt, 
kunnen verbeterde therapieën de kwaliteit van leven van patiënten aanzienlijk verbeteren 
en mogelijk de ziekte dusdanig uitstellen dat prostaatkanker in plaats van een dodelijke 
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